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Abstract 
The use of Raman spectroscopy in the detection and classification of malignancy within 
the human larynx and lymph nodes of the head and neck has been evaluated. Currently 
histopathology is considered the diagnostic gold standard. The potential for Raman 
spectroscopy to be used as an in vivo diagnostic tool in the detection of dysplasia and 
malignancy has been demonstrated. A consensus opinion from three expert 
histopathologists has been obtained and spectral diagnostic models developed by 
correlation with these results. 
 
The ability of Raman spectroscopy to differentiate between disease entities and normal 
tissue within the larynx has been shown. Raman spectroscopy was able to identify non-
neoplastic vocal cord mucosa (sensitivity 85 %, specificity 95%) from laryngeal mucosa 
showing neoplastic change (sensitivity 95 %, specificity 85%) with an increase in 
sensitivity to 89% for the non-neoplastic tissue and a reduction to73% in tissues 
showing neoplastic changes after cross-validation. For the first time benign changes in 
the structure of vocal cords such as those exhibiting hyperkeratosis and hyperplasia, 
where also identified with sensitivity of 97.9% for tissue exhibiting 
hyperplasia/hyperkeratosis and 100% for normal squamous cell epithelium. Research 
into the ability of Raman spectroscopy to interrogate lymphoid tissue in order to 
differentiate reactive nodes (sensitivity 90 %, specificity 88%) from those containing 
cancer (sensitivity 88 %, specificity 90%) was successful and fully independently 
validated. This work was further developed and the efficacy of Raman spectroscopy in 
differentiating between squamous cell carcinoma (sensitivity 76%, specificity 95%), 
adenocarcinoma (sensitivity 93 %, specificity 99%), Hodgkin‘s lymphoma (sensitivity 
80%, specificity 90%) and reactive lymph nodes (sensitivity 81%, specificity 88%) was 
shown. This model was also independently cross-validated by node producing further 
improvements to give a spectral performance of sensitivity/specificity for SCC of 
75/97%, adenocarcinoma 100/99%, Hodgkin‘s lymphoma 83/92% and reactive lymph 
nodes 85/86%. 
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Chapter 1:  Introduction  
The work presented in this thesis is a programme of rigorous in vitro studies 
investigating the possible application of Raman spectroscopy in the study of biological 
tissues obtained from the head and neck. The potential of Raman spectroscopy to act as 
an objective, non-invasive technique capable of identifying focal biochemical changes 
is explored, particularly the progression of benign disease towards malignancy within 
the human laryngopharynx and in lymph nodes.  
 
This chapter discusses the demographics of cancer with the emphasis on those which 
occur in the throat and lympho-reticular system. The context of the research described 
in the thesis is placed within the wider picture of resource allocation for cancer services. 
Raman spectroscopy is introduced as one of several optical diagnostic techniques that 
have potential for use in this area. The objectives of this research are summarised and 
the chapter concludes with an outline summary of the structure of this thesis as a whole. 
1.1 Context of Research 
1.1.1 Overview 
Medicine has been described as primarily an art rather than a science. This is never 
more apparent than in surgery. Despite extraordinary advances in technology there is no 
machine that can discriminate between the subtle shades and textures that allow us to 
find the correct plane in which to operate in order to avoid a frustrating procedure 
performed in an ever-increasing field of blood. To watch a really gifted surgeon is to be 
in no doubt that surgery truly is an art however increasingly there is an appropriate call 
for the justification of practices based on science and research. This is particularly true 
in the emotive areas of cancer diagnosis and treatment. 
 
Histopathology has historically been the gold standard in the assessment of disease 
within biological tissue however it is still haunted by difficulties of time and 
subjectivity. The basic workload of histopathologists is enormous and increasing. 
Technological advances allow for more tests, on more specimens and this is coupled 
with an increase in public and professional expectations on the speed of service delivery 
and accuracy of results. 
 
It is envisaged that this research will contribute to progress in the development of 
Raman spectroscopy as an effective, efficient technique used in support of histological 
diagnosis; the ultimate goal of which is the development of a diagnostic and surgical 
tool to be used as a new gold standard. 
1.1.2 Demographics of Cancer 
Statistics published by the World Health Organization (WHO) estimate that in 2005 of a 
total of 58 million deaths worldwide 7.6 million were due to cancer. Of these more than 
70% were in countries where incomes are classified to be in the low or middle brackets 
and where the provision off cancer services is considered poor. The WHO has predicted 
that by 2015 there will be 9 million deaths from cancer per year and by 2030, 11.4 
million (WHO, 2007).  
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In England between 1971 and 2004 the age standardized incidence of cancer increased 
by approximately 41% in women and 21% in men. The vast majority of cancers occur 
in the elderly with less than 0.5% of registered cancers diagnosed in children under the 
age of 15 (National Statistics Online, 2006a). The mortality rate from cancer has 
broadly remained the same with one in four people in the United Kingdom (UK) dying 
from cancer during the period 1950 to 2004 (National Statistics Online, 2006b).  
 
The highest incidence of laryngeal cancer within the UK occurs in Scotland (Table 1.1). 
To place this in the context of the overall incidence of cancer diagnoses made in 
Scotland studies have shown that 26, 400 new cancer diagnoses were made per annum 
over the period 1996-2000 and the prediction has been made that this will rise to 33, 
700 per annum in the period 2016 - 2020. This represents an increase of 28% in cancer 
diagnoses as a whole over the next 20 years, 1.4% per year. In actual patient numbers 
approximately an extra 650 newly diagnosed cases in the under 75 age group and a 
further 1200 cases in the over 75s per annum. This increase is not due primarily to an 
increase in the individual risk of developing a particular cancer type, although the 
incidence of some cancers are predicted to increase, but is mainly due to an aging 
population (Cancer Incidence Projections for Scotland, 2001-2020).  
Table 1.1: Number of new cases and rates of laryngeal cancer, UK, 2004. (Cancer 
Research UK, 2007) 
 England Wales Scotland N. Ireland 
Cases 
Males 1,424 91 234 40 
Females 269 24 71 13 
Persons 1,693 115 305 53 
Crude rate per 100,000 population 
Male 5.8 6.3 9.6 4.8 
Female 1.1 1.6 2.7 1.5 
Persons 3.4 3.9 6.0 3.1 
Age-standardised rate (European) per 100,000 population 
Males 5.0 5.1 8.3 4.9 
CI95% 4.8 5.3 4.0 6.1 7.3 9.4 3.4 6.4 
Females 0.8 1.1 2.0 1.4 
CI95% 0.7 0.9 0.7 1.5 1.6 2.5 0.7 2.2 
Persons 2.8 2.9 4.9 3.0 
CI95% 2.7 2.9 2.4 3.5 4.4 5.5 2.2 3.9 
 
Cancer of the larynx has historically been associated with smoking and alcohol 
consumption, particularly spirits. In all regions of the UK men have a significantly 
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greater risk of developing the disease compared to women. The peak age range at which 
a diagnosis of laryngeal cancer is made in men is 60 - 64 years and for women slightly 
older 65 - 69 years. In 2004 there were a total of 2,166 new cases diagnosed in the UK 
of these 1789 (82.6%) were in men and 377 in women (17.4%). Age-standardised 
mortality rates for laryngeal cancer in the UK between 1971 and 2005 show that from 
the early 1990‘s there has been a decline in mortality for men  and from 2000 there has 
also been a decline for women but this has been less pronounced (Cancer Research UK, 
2007). 
 
Cancers which affect lymph nodes can be either primary or due to secondary, metastatic 
spread from other sites. Of the lymph nodes cancers classified as primary lymphoma is 
the most common. Hodgkin‘s lymphoma makes up approximately 0.5% of all cancers 
presenting each year. In 2004 there were 1519 new cases diagnosed, of these 844 
(55.6%) were in men and 675 (44.4%) in women (Table 1.2). There are two age periods 
were presentation occurs most frequently 15-29 years and 75-84 years. Within these age 
groups different disease subtypes predominate. Hodgkin‘s Lymphoma ranks as the 6th 
most common cancer occurring in children under 15 years of age.  
Table 1.2: Number of new cases and rates of Hodgkin’s lymphoma within the UK, 2004. 
(Cancer Research UK, 2007) 
 England Wales Scotland N. Ireland 
Cases 
Males 697 45 79 23 
Females 560 27 71 17 
Persons 1,257 72 150 40 
Crude rate per 100,000 population 
Male 2.8 3.1 3.2 2.7 
Female 2.2 1.8 2.7 1.9 
Persons 2.5 2.4 3.0 2.3 
Age-standardised rate (European) per 100,000 population 
Males 2.7 2.9 3.2 2.7 
CI95% 2.5 2.9 2.1 3.8 2.5 3.9 1.6 3.9 
Females 2.1 1.8 2.6 2.0 
CI95% 2.0 2.3 1.1 2.4 2.0 3.2 1.0 2.9 
Persons 2.4 2.3 2.9 2.3 
CI95% 2.3 2.6 1.8 2.8 2.4 3.3 1.6 3.0 
 
Over the period 1970-1980 the age-standardised incidence rates for Hodgkin‘s 
lymphoma in the UK appeared to decrease. This is felt to be a reflection of 
reclassification of some disease as Non-Hodgkin‘s Lymphoma. From the mid 1980s to 
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2003 the age-standardised incidence rates have remained basically unchanged at 
approximately 3 per 100, 000 male and 2 per 100, 000 for females. 
 
Non-Hodgkin‘s lymphoma accounts for approximately 4% of all cancer that present per 
annum, in 2004, 8316 new diagnoses were made in England (Table 1.3). A significantly 
higher incidence of non- Hodgkin‘s lymphoma is found in persons over the age of 50 
and 69% of diagnoses being made in the over 60s. 
Table 1.3: Number of new cases and rates of Non-Hodgkin lymphoma within the UK, 
2004. (Cancer Research UK, 2007) 
 England Wales Scotland N. Ireland 
Cases 
Males 4,417 283 453 135 
Females 3,899 242 427 147 
Persons 8,316 525 880 282 
Crude rate per 100,000 population 
Male 18.0 19.7 18.6 16.1 
Female 15.3 15.9 16.3 16.8 
Persons 16.6 17.8 17.4 16.5 
Age-standardised rate (European) per 100,000 population 
Males 15.6 16.3 16.1 16.0 
CI95% 15.2 16.1 14.7 18.5 14.8 17.8 13.7 19.2 
Females 11.4 10.8 11.8 13.4 
CI95% 11.0 11.7 9.4 12.1 10.7 12.9 11.2 15.6 
Persons 13.3 13.4 13.8 14.6 
CI95% 13.0 13.6 12.2 14.5 12.9 14.7 12.9 16.3 
 
1.1.3 Utilisation of Cancer Resources 
The 58
th
 World Health Assembly (WHA) resolution on cancer prevention and control in 
May, 2005 called upon all member states to ‗intensify action against cancer by 
developing and reinforcing cancer control programmes.‘ The WHA suggested this be 
done using a framework of: 
 
 Prevention 
 Early Detection 
 Diagnosis and Treatment 
 Palliative Care 
 
As the population of the UK ages the number of people diagnosed with cancer also 
increases and with this the amount of funding required to diagnose, treat and support 
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patients. The planning of provision for the management of patients with cancer is 
challenging. Trends in population growth, cancer incidence along with variations in 
survival as a consequence of new treatment regimes must all be taken into 
consideration. The NHS Cancer Plan published in July 2000 outlined the governments‘ 
strategy for investment and reform within the cancer services network. The stated aims 
were to improve the ‗speed, quality and equality of cancer services.‘ The cancer plan 
outlines the strategies for improving cancer services in all areas not just those related to 
waiting times. It prioritises the provision of a unified, comprehensive cancer service 
focusing on service reorganisation, provision of equipment for diagnosis and treatment, 
improved levels of appropriately trained staff, facilities and research. To support these 
targets the government has undertaken a significant programme of additional 
investment in the NHS (The NHS Cancer Plan, 2000a & 2000b); 
 
£280 million in 2001-2002 
£407 million in 2002/2003  
£570 million in 2003/2004  
By 2003, £20 million each year towards the infrastructure of cancer research the aim 
being to match the investment made by the voluntary sector. 
£50 million towards palliative care 
 
Waiting list targets specified that by 2005 there would be a maximum wait of two 
months from receipt of an urgent referral to treatment of cancer and a one month 
maximum wait from diagnosis to treatment. The ultimate aim being that there was a 
maximum wait of one month from urgent GP referral to the commencement of 
treatment of all cancer patients by 2008 (The NHS Cancer Plan, 2000c). In order to 
make a diagnosis of laryngeal cancer or lymphoma patients usually require surgical 
removal of tissue for histological review. A technique that is significantly less 
expensive and could be used in the outpatients‘ clinic would be enormously 
advantageous in improving the speed of primary diagnosis and efficacy of screening for 
recurrence after treatment. This would ultimately help move clinical practice to a 
position where by it can offer a management plan for cancer sufferers that meets the 
criteria laid out in the NHS Cancer Plan. This work investigates the potential for Raman 
spectroscopy to be used as such a diagnostic technique. 
1.2 Research Objectives 
The primary aim of this work is to evaluate the potential of Raman spectroscopy as a 
tool capable of being used alongside histopathology techniques in the diagnosis of 
disease, specifically cancer occurring in tissues of the laryngopharynx and in lymph 
nodes. 
 
In order to achieve this hypotheses listed below will be tested; 
 
  Raman spectra obtained from biological tissue can be used to develop models 
capable of assigning pathological disease entities correctly for tissue obtained 
from the laryngopharynx and lymph nodes. 
 When used to formulate diagnostic algorithms for diseases in these anatomical 
areas Raman spectroscopy processes both the sensitivity and the specificity to 
compare with that of the gold standard, histopathology. 
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 Raman spectroscopy can be used to distinguish diseased and normal vocal cord 
tissue. 
 
Surgical skills and core medical knowledge have been maintained throughout the period 
of research as all tissue samples used were acquired during operations done by the 
author of this thesis. 
1.2.1 Laryngopharyngeal Study 
The aim of this study is to assess the ability of Raman Spectroscopy to differentiate 
between normal and diseased tissue in the laryngopharynx. If Raman Spectroscopy is 
found to be a viable tool in this respect it could be developed for use in the outpatient 
clinic. Using a thin flexible probe passed down the side port of a nasendoscope it may 
be possible to obtain an ‗optical biopsy‘ to assess if cancer is present, if recurrence    
diagnostic accuracy and give a reduction in the number of biopsies required. This is 
particularly important as the cohort of patients who present with cancer of the larynx 
often have significant co-morbidity resulting in higher risks associated with receiving a 
general anaesthetic. 
1.2.2 Lymph Node Study 
The aim of this work is to assess the ability of Raman spectroscopy to differentiate 
between normal and diseased lymphoid tissue in the neck. If Raman spectroscopy is a 
viable tool in this respect then it may be possible to use this technique to introduce a 
Raman probe by means of a needle obtaining an ‗optical biopsy‘ of enlarged lymph 
nodes in the neck without surgery. Work has begun on the development of an in vivo 
probe; however, there is a need to both clarify the validity of the technique when 
applied to this type of tissue and to formulate a baseline set of spectra for different 
lymphoid diseases. 
1.3 Thesis Structure 
Chapter 2 contains a review of the relevant literature. It begins with a section 
summarising the history and theory of Raman spectroscopy followed by a discussion of 
the characteristics required in an ideal diagnostic technique for the detection of 
malignancy and the positive attributes that Raman spectroscopy shows in this respect. A 
summary follows outlining the component parts of a classical Raman system and how 
Raman spectroscopy instrumentation has developed over time to give the system used 
in this work. A description of other relevant spectroscopic techniques is included and a 
discussion of various applications of Raman spectroscopy with particular emphasis on 
biomedical uses. The general theory of cancer development is then summarised along 
with clinical information relevant to this research. This includes a basic outline of 
anatomy and its influence on disease progression also the classification, aetiology, 
staging and treatment options for malignant diseases in the two anatomical areas 
studied. A discussion of the clinical relevance of Raman spectroscopy as a diagnostic 
tool in the investigation of disease in these areas concludes each of these sections. 
Chapter 3 details the materials and methods used including details of system 
calibration. The results of this work, along with a discussion of the findings are 
contained in Chapter 4. Chapter 5 summarises the conclusions drawn and discusses 
areas of future study. 
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Chapter 2: Literature Review 
2.1 Raman Spectroscopy 
After a brief outline of the historical context of the discovery of Raman spectroscopy 
the theoretical basis by which it is explained is discussed. The main emphasis is placed 
on the classical theory and only a brief description of the quantum theory is given. 
2.1.1 History of Raman Spectroscopy 
The possibility of inelastic scattering of light was first postulated in 1923 (Smekal, 
1923). Sir Chandreskhara Venkata Raman C.B.E (1880-1970) and K.S. Krishnan 
observed the Raman effect in 1928. Their work was carried out at the University of 
Calcutta and the Indian Association for the Cultivation of Science (IACS) and published 
in Nature the same year (Raman & Krishnan, 1928). This discovery was also 
independently reported by Russian physicists (Landsberg & Mandelstam, 1928). 
Raman‘s experiment used sunlight as the source of incident radiation. This light was 
focused using a telescopic lens onto samples of either gases or dust free vapours. A 
further lens and series of optical filters were placed beyond the sample at an angle to the 
direction of the incident beam of sunlight. Initially the naked eye then photographic 
plates were used to record the presence of the scattered radiation. This processed an 
altered frequency compared to that of the incident beam – the basic fundamental finding 
underpinning the theory of Raman spectroscopy and called by Raman and Krishnan ‗a 
new radiation.‘ Raman was knighted in 1928 and awarded the Nöbel prize in 1930. His 
other major scientific interests were in the physics of sound and theory of harmonics. 
Since the first observations of Raman peaks within the spectra obtained from the 
exposure of a chemical compound to incident monochromatic light there have been 
enormous developments in this technique. These advances will be discussed in more 
detail later, however, it is noted that they have resulted in an increasing number of 
biomedical and industrial applications for the technique of Raman spectroscopy. 
2.1.2 Theoretical Basis of Raman Spectroscopy 
When monochromatic light shines on a molecule it can pass through unchanged or 
interact with it in several ways undergoing either undergoing an absorption such as that 
which occurs in infrared (IR) spectroscopy or the light can be scattered as seen in 
Raman spectroscopy. Both IR and Raman spectroscopy are classified as vibrational 
spectroscopic techniques. In the case where no absorption reaction takes place the 
polarisability and the vibrational state of the molecule can change producing two 
distinct effects, Raman and Rayleigh scattering. The majority of photons undergo elastic 
scattering where the wavelength of the scattered light remains unchanged, this is called 
Rayleigh scattering. The energy of the incident photon and emitted photon are 
connected by a quantum of energy hence the interaction can be regarded as a single 
photon event rather than the type of two photon event, absorption followed by emission 
seen in IR spectroscopy (Nafie, 2001). A much smaller proportion of photons undergo 
inelastic scattering where energy is exchanged and the wavelength of the light is altered, 
this is called Raman scattering. Raman scattered light undergoes a frequency shift 
corresponding to the vibrational energy gained or lost by the change in the vibration 
motion of the molecule. Raman spectroscopy can be defined as an inelastic scattering, 
vibrational spectroscopic technique. It exploits a change in frequency in monochromatic 
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light occurring as a result of the interaction of incident photons with a test substance 
which results in the molecules within the test substance undergoing an alteration in their 
vibrational or rotational states. The signal obtained from Raman scattering is much 
weaker than that of Rayleigh scattering. If a million molecules are present 
approximately 100 000 will undergo an absorption reaction, 900 of these will undergo 
vibrational changes and of these only one will show the Raman effect. In Raman 
spectroscopy the speed of interaction between molecule and light is of the order of 
picoseconds. In absorption spectroscopy, such as infrared spectroscopy, the timescale 
over which absorption or fluorescence occurs is much slower nanoseconds. This allows 
the interaction seen in Raman spectroscopy to be thought of as a perturbation rather than 
an absorption reaction (Stone, 2001a). A Raman spectrum, such as that seen for 2-
propanone (acetone) in Figure 2.1, is a plot of scattered light intensity as a function of 
the energy difference between the incident and scattered photons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Raman spectrum of acetone 
The efficiency of scattering increases as the fourth power of the frequency of the 
incident light used. The energy gained or lost by the photon equals the change in energy 
of the molecule and is called the Raman shift and is measured in wavenumbers (cm
-1
). 
The position of peaks within a Raman spectrum is independent of the wavelength of the 
excitation photons; the more intense the peak the greater the number of Raman 
scattering events has occurred for that particular vibrational mode. The more energy 
required to produce a perturbation reaction within a molecule the larger the Raman shift. 
This energy is not used to initiate an electronic transition but to alter the conformational 
shape of the molecular bonds by setting up a vibration, stretch or bending motion that 
reflects the orientation of the atomic nuclei and arrangement of the chemical bonds 
within the molecule. This provides a highly specific method by which molecular 
vibrations can be probed and allows the attainment of a vibrational spectral finger print 
for each molecule species. 
 
Figure 2.2 shows the Raman spectrum of cyclohexane, the Raman peaks are narrow and 
correlate well with the vibrations of specific bonds within the molecules. 
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Figure 2.2: Raman spectrum of cyclohexane. 
Biological tissues are very complex and often highly heterogeneous; this can result in 
significant energy absorption and emission in the form of fluorescence. This has always 
been a problem limiting the scope of Raman spectroscopy in the analysis of biological 
tissue. Raman spectroscopy for in vivo analysis of biological tissue also requires the use 
of low power density lasers as the excitation light source in order to avoid tissue 
damage. Most biological molecules are Raman active and can provide their own 
spectral fingerprint, there is considerable cellular and molecular information contained 
within these spectra. Recent advances in instrumentation and improvements in data 
analysis have brought Raman spectroscopy to the forefront of the search to find a tool 
that can provide a viable, real time optical biopsy of tissue in vivo that differentiates 
between normal tissue and that which shows neoplastic change. 
2.1.3 Models Explaining Raman Spectroscopy 
The classical theory of Raman scattering is based on the wave theory of light. This 
approach has also been complemented by quantum theory, which reflects the nature of 
vibrations as being made up of discreet packets of energy - photons.  
Classical model 
Monochromatic light such as that of a laser beam is an electromagnetic wave whose 
field strength fluctuates with time. This fluctuating electric field can interact with that of 
a molecule and in so doing induces an oscillating dipole moment, made up of multiple 
harmonic components, within the target molecule. This elevates the molecule to a short 
lived, unstable ‗virtual state‘ whose energy is determined by the frequency of the 
incident light. The resultant oscillating dipole emits light in all possible directions at the 
frequency of each component of this oscillation. The electron cloud of a molecule is 
relatively light compared to the mass of the nucleus and as a consequence the energy 
change, hence the frequency change, of the light scattered by these molecular 
components is small. Whilst interacting with the electric field of the incident light 
should the molecule being studied undergo some internal motion i.e. of the nucleus such 
as bending, rotation or vibration then the primary oscillating dipole will have a further 
oscillation superimposed relating to each of these internal modes. The energy of the 
scattered light will differ from the incident beam by one vibrational unit (Smith & Dent 
2005a). This is Raman scattering and is considered inelastic. There are two forms 
depending on which vibrational state the molecule is in at the time of interaction. If the 
molecule is in the lowest vibrational state and as a result of an interaction with the 
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incident light electric field gains energy and is elevated into a higher vibrational state 
Stokes scattering occurs. A proportion of molecules will already be in an elevated 
vibrational state and the interaction of the electric field with these will result in a 
transfer of energy to the scattered photon and a fall in the molecules vibrational state, 
this is called anti-Stokes scattering. Whilst the convention in Raman spectroscopy is to 
record Stokes scattering there are occasions when measuring anti-Stokes scattering can 
be useful. Where fluorescence occurs it often does so at a frequency lower frequency 
than that of vibrational excitation. In these circumstances recording anti-Stokes 
scattering to avoid fluorescence interference may be helpful. 
 
At room temperature there are relatively few molecules in the higher vibrational states 
and Stokes scattering predominates. Anti-Stokes scattering will be weak and become 
weaker as the frequency of the vibration increases. One way to increase the amount of 
anti-Stokes scattering is to increase the temperature. The relationship between the 
number of molecules in the higher vibrational state and temperature is expressed in the 
Boltzmann equation. 
 Nv / No = exp (- Ev / kT)  Eq. 2.1 
 
Where; 
 
Nv = the numbers of molecules in the excited vibrational state.  
No= the numbers of molecules in the ground state. 
Ev = the energy in the vibrational state. 
K = Boltzmann constant. 
T = absolute temperature. 
 
Light of any frequency can induce a Raman effect however the cross section for the 
inelastic scattering process is proportional to λ in 
-4
 where λ in is the wavelength of the 
incident photon. For example incident light of wavelength 200nm will have a cross 
section of inelastic scattering 16 times that of light of wavelength 400nm. This 
important feature allows the energy level of the incident photons to be lower than that 
required for a molecular transition into a higher electronic state where resonance effects 
and fluorescence may come into play. The ease with which the dipole moment 
associated with a molecule can be distorted by an external electric field is called 
polarisability (α). The intensity of a Raman band is dependent on the degree to which 
the polarisability of the electron cloud around the molecule is changed by the vibration. 
Symmetrical vibrations will give the greatest change and so produce the most intense 
Raman bands. Unlike Raman spectroscopy in infrared absorption spectroscopy it is the 
change in dipole moment, maximal in asymmetric vibrations, that give the most intense 
peaks. Not all vibrations of a molecule will be both infrared and Raman active. Figure 
2.3 shows the Raman and infrared spectra of phenylaniline. The intensities of the 
spectral signals vary considerably and these two spectroscopic techniques are 
considered complementary. 
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Figure 2.3: IR and Raman spectra obtained from phenylaniline. 
Centrosymmetric molecules are those where a reflection of any point through the centre 
of the molecule produces an identical configuration e.g. C2 H6 (Figure 2.4). These 
molecules abide by a rule of mutual exclusion which states that in centrosymmetric 
molecules no band can be both Raman and infrared active. 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: A centrosymmetric molecule in 3 dimensions - Ethane (C2 H6). 
Molecular vibrational model. 
As previously discussed the frequency at which a molecular vibration occurs is 
dependent on the mass of the atoms and their bond strength and this determines the 
position of the bands within the spectra. The bond between nuclei can be approximated 
to a spring which obeys Hooke‘s Law (Eq 2.2). Hooke's Law describes the relationship 
between a force applied to an unstretched spring and the amount the spring will stretch 
when that force is exerted. It states that the resultant extension or compression of a 
spring is directly proportional to the loading force. The negative sign shows that the 
force exerted by the spring is in a direction opposite to that of the displacement. 
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 F=-kX  Eq. 2.2 
Where; 
F = force (N). 
K = spring constant (Nm
-1
) 
X = the distance moved by the object from its position of equilibrium 
 
Whilst a molecule remains in one electronic energy level the energy it processes can be 
expressed in terms of ‗degrees of freedom.‘ Translation in space accounts for three 
degrees of freedom and a further 3 describe rotational movement for all except linear 
molecules. Thus the dynamics of a molecule can be expressed in terms of its‘ nuclei. A 
molecule with N nuclei will have a total of 3N degrees of freedom. For non -linear 
molecules subtraction of rotational and translation degrees of freedom will result in 3N - 
6 degrees of internal freedom, 3N - 5 degrees for a linear molecule. 
 
The degree, to which polarisation and dipole changes occur and hence changes in the 
strength of the signals in the Raman or IR spectra, is dependent on the type of 
vibrational mode. A symmetrical stretching vibration will cause the largest change in 
polarisability hence the strongest Raman band. In this vibrational mode the dipole 
moment change will be very small and so the infrared band if seen at all will be very 
weak. The deformation mode of the molecule will produce the reverse as the change in 
dipole moment is comparatively large compared with the change in polarisability. 
 
Diatomic Molecules  
Symmetrical diatomic molecules e.g. Oxygen (O2), were N = 2, have 1 degree of 
internal freedom; linear stretch. This vibration will produce a change in polarisability 
but not in dipole so the resultant band will be present in the Raman spectrum but not in 
the infrared spectrum. 
 
Asymmetrical diatomic molecules e.g. nitric oxide (NO) also have one degree of 
freedom but in this case a simple stretch will result in both a change in polarisability 
and dipole hence the vibration will result in a single band but this will appear in both the 
Raman and infrared spectra. 
 
Triatomic Molecules 
Linear tri-atomic molecules e.g. carbon dioxide (CO2) were N = 3 have four modes of 
vibration (Figure 2.5), non- linear tri-atomic molecules such as water have three (Figure 
2.6). 
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Figure 2.5: Vibrational modes of carbon dioxide (CO2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Vibrational modes of water (H2O). 
Quantum  theory model 
To look in more detail at the relationship between molecular properties and Raman 
scattering for a particular molecular entity quantum mechanics can be used. Whilst 
detailed analysis of Raman spectroscopy based on these principles is beyond the scope 
of this work the basic grounding of this theory with respect to Raman spectroscopy is 
outlined below. 
 
If a photon of energy E = hν collides with a molecule the collision may be either 
perfectly elastic, and the photon of energy will be detected unchanged (Rayleigh 
scattering), or the collision may be inelastic (Raman scattering). In quantum mechanics 
if an inelastic collision occurs energy (ΔE) is exchanged between photon and molecule. 
The molecule may only loose or gain energy equal to the difference between two 
allowed energy states (Eq 2.3-2.5). Only transitions involving Δν = +/- 1 are allowed for 
a harmonic oscillator in quantum mechanics. If the molecule struck gains energy the 
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photon will be scattered with energy hν – ΔE, (Stokes scattering). If the molecule looses 
energy to the photon of radiation it is scattered with a higher frequency (anti-Stokes 
scattering). This can only occur if the molecule is in an excited vibrational or rotational 
state to begin with. 
 Eout = Ein (+/- Evib)  Eq. 2.3 
 hνout = hνin +/- hνvib  Eq. 2.4 
 νout = νin +/- νvib  Eq. 2.5 
When Evib equals zero elastic (Rayleigh) scattering has occurred. 
 
Where; 
 
Eout and Ein = the values for the energy of the emitted and incident radiation. 
Evib = the energy absorbed or emitted in order to alter the vibrational state. 
h = Planck‘s constant. 
νout and νin = the frequency of the emitted and incident radiation.  
νvib = the frequency of the energy absorbed or emitted in order to alter the vibrational 
state. 
 
A rigorous application of Quantum mechanics would necessitate that both the incident 
radiation and target molecule were treated as quantum particles. A good approximation 
can be made if the incident radiation is considered to be a perturbation of the wave 
function of the scattered molecule. This is considered valid, as the applied external 
electromagnetic field is small in comparison to the electromagnetic fields within the 
molecule. Deeper analysis using Quantum mechanics is beyond the scope of this thesis. 
2.2 Raman Spectroscopy as an Optical Diagnostic Technique 
The characteristics of the ideal spectroscopic technique used to diagnose disease are 
discussed, as are the advantages and disadvantages of Raman spectroscopy with 
particular reference to the detection of malignancy in biological tissues. The component 
parts of a classical Raman system are described, as are landmark developments in 
Raman instrumentation. 
2.2.1 Characteristics of the Ideal Optical Diagnostic Technique.  
The scope of applications for optical diagnostic techniques is vast both as a ‗stand 
alone‘ procedure and as part of a series of investigations aimed at confirming a 
diagnosis with maximum speed, sensitivity and specificity. The assessment of disease 
without the need for an invasive or surgical procedure is the ultimate goal. Where 
outpatient assessment of the disease is purely subjective, for example in dysplasia of the 
larynx, improved diagnostic specificity would be of great benefit. At present multiple 
biopsies are often required to monitor disease progression and repeated excision of 
vocal cord tissue can significantly damage voice quality. Intra-operative, real time 
accurate assessment of surgical resection margins would be an invaluable tool for all 
surgeons. This would reduce the need for secondary procedures which occur when 
histological review suggests resection margins are too close to tumour. It would 
improve morbidity and in some cases the mortality associated with these procedures 
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whilst reducing surgical lists and hence costs. The ideal optical diagnostic technique 
would allow real time mapping of disease as an outpatient procedure with accurate, 
highly specific, reproducible results. It should be non- or minimally invasive and not 
require the use of a general or local anaesthetic. The acquisition of the spectra should be 
over the shortest time frame possible to reduce the risk of thermal damage to tissue and 
make the technique attractive to clinicians. Tissue penetration is wavelength dependant 
and should be optimised in order that extension of disease beyond the mucosal layer 
may be identified. The ideal system should produce a small signal from water. The 
proportion of water in biological tissue is high and the signal it gives should not be 
allowed to obviate the signal from other molecular species. The spectra obtained should 
be molecular specific with sharp peaks providing excellent quantitative information and 
no fluorescence unless fluorescence spectroscopy is being utilised and vice versa. The 
spectra obtained should be consistent enough to allow standardisation over different 
systems in order to compile a comprehensive and generic spectral library for normal and 
diseased tissue. Of paramount importance is that the system is safe. It should use the 
lowest power laser possible, be stable over a wide range of ambient temperatures and 
high detector sensitivity should not be at the expense of specificity.  An inexpensive, 
portable system that is compatible with current endoscopic and monitor technology 
would be a great advantage to the speed, scope and cost of introduction into clinical 
practice. 
2.2.2 Why Raman Spectroscopy? 
Raman spectroscopy as a diagnostic technique for the detection of malignancy fulfils 
many of these criteria. Progress in instrumentation has allowed more rapid spectral 
acquisition times and the future commercial production of the Raman probe is likely to 
be suitable for use in the outpatient setting. For many epithelial cancers a reasonably 
comprehensive spectral library now exists and its content is constantly expanding. 
2.2.3 Component Parts of a Classical Raman System. 
At present most groups use one of two basic systems. The first has a UV, visible or near 
infrared laser as the excitation source, a dispersive spectrometer containing a 
monochromator or series of filters and a charge coupled device for detecting scattered 
light. The alternative uses a near infrared laser combined with a system based on an 
interferometer with Fourier-transform analysis of the scattered light signal recorded by 
an indium-gallium-arsenide (InGaAs) detector sensitive to NIR radiation (FTRS).  
2.2.4 Developments in Raman Spectroscopy Instrumentation. 
The original experiment undertaken by C.V Raman and K.S Krishan (Raman, 1928) 
used the sun as an illuminating light source, simple blue-violet filters, a prism as a 
spectrometer, highly purified liquid samples, the naked eye and photographic plates as 
detectors. Much of the early Raman work was limited by fluorescence and poor 
instrumentation particularly in the detection of the inherently weak Raman signal. 
Advances in optical diagnostic instrumentation combined with better understanding of 
disease processes and how they relate to changes at a molecular level have allowed 
Raman spectroscopy to move forward towards clinical relevance. Portable instruments 
small enough to gain access to key anatomical areas are now under development 
(Boppart, 2005). The Raman probe used in part of this work can fit within the biopsy 
port of a flexible nasendoscope; these instruments can be passed into the larynx, without 
any form of anaesthetic. The Raman probe is also small enough to pass through the 
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lumen of a 21 gauge needle. This size of needle is routinely used in the outpatients 
department for obtaining fine needle aspiration cytology specimens from enlarged 
lymph nodes percutaneously. The major steps taken in key areas of instrument 
development to bring us to this point are summarised below. 
2.2.4.1 Excitation Light Source 
Visible light Raman spectroscopy using sunlight as an illuminating light source was 
almost immediately superseded by the use of a mercury lamp combined with filters to 
produce monochromatic light. The Toronto mercury arc lamp became the mainstay 
excitation light source until the development of lasers in the 1960s (Maiman, 1960). 
From that point on, the work to produce an ideal light source has centred on laser 
technology.  
 
In the 1970s visible light Raman spectroscopy studies on biological tissue were done 
using continuous-wave noble gas ion lasers (Goheen, 1978). Argon lasers (351.1-
514.5nm) were used to produce intense monochromatic light, the scattered light was 
separated into different frequencies using a monochromator and a series of filters to 
isolate photons of a particular frequency. A photomultiplier was used to improve the 
signal to noise ratio and measure the light intensity over the chosen frequency range 
(Yu, 1975). In laser systems a noble gas is contained within an externally cooled plasma 
tube to improve the signal to noise ratio. A high current is passed through the tube and 
the gas ionises moving atoms to an excited state capable of lasing. For emission in the 
visible range the ends of the plasma tube are closed off by windows made of silica 
which are orientated at specific angles. Mirrors reflect the emission back and forth 
within the system providing indirect amplification and a prism can be used to select a 
specific wavelength. The prism can be removed if several laser transmissions are 
required for example in dye lasers. 
 
Pulsed lasers such as the neodymium-yttrium-aluminium-garnet laser, Nd:YAG , 
(1064nm) were developed in the late 1960s and early 1970s. Nd:YAG lasers emit over 
the blue-green range and gives excellent tissue penetration with minimal absorption by 
water and little fluorescence (Hirschfield, 1996). The YAG portion of the system carries 
the Nd
 
ions. Early versions were initiated with flash lamps this was subsequently 
superseded by arrays of diode lasers (800-900nm). In the 1970 to 80s development of 
tuneable dye lasers such as the Ti-sapphire laser allowed laser line emission over a wide 
range of frequencies. Driven by commercial applications diode lasers have now come to 
the fore. Characteristics such as modest cost, small size and high efficiency to power 
and cooling ratio has enabled them to be used extensively in information technology 
systems. Diode lasers produce emissions at the junctions of semiconductors. Their main 
limitation is one of beam instability with a tendency for the wavelength of light they 
produce to drift over time. In diode lasers the cavity is the actual silicon chip itself and 
the edges of the chip act in a similar way to the mirrors seen in early systems. As the 
silicon chip heats it undergoes a changes in size which is then reflected in a drift in the 
wavelength of the laser light emitted. 
 
Many characteristics of lasers make them ideally suited for use in spectroscopy. They 
can produce excellent power profiles; continuous wave lasers have a range of 1 to 2 
watts, pulsed lasers 10 to 100 megawatts and a wide range of wavelengths are available 
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particularly if dye lasers are used. The light produced has superb monochromisity and 
any small amounts of light of different frequencies can be removed easily. The 
illuminating light beam produced by lasers can be focused to a small spot size and this 
characteristic in combination with microscopy allows volumes as small as 2μm3 to be 
studied (Ferrano, 2003b). 
Choice of  frequency for excitation source. 
Raman scattering is weak and the intensity of the scattered light produced is related to 
three factors; laser power, the fourth power of the frequency of the excitation light and 
the polarisability of the molecular species studied (Smith & Dent, 2005b). The choice of 
which region of the electromagnetic spectrum to use to probe a molecular vibration, 
near infrared (NIR), visible (Vis) or ultraviolet (UV) light, is not straight forward each 
has advantages and disadvantages; the ultimate choice is invariably a compromise.  
 
At first glance to optimise the intensity of the Raman signal produced lasers emitting in 
the UV range would seem the best choice as light from this region of the 
electromagnetic spectrum has a higher frequency than that from the NIR region. 
However NIR excitation sources produce less fluorescence than UV excitation when 
used to investigate biological tissues. Another significant disadvantage of using UV-
radiation is that many biological molecules absorb UV light more strongly than visible 
light altering the appearance of their Raman spectra. Energy absorption can also cause 
photo and thermal degradation of the sample being studied, because of this and the 
potentially mutagenic effect on biological tissue, lasers emitting in this region are less 
applicable to in vivo applications (Wang, 2001; Runger, 2008). Ultraviolet radiation has 
very short penetration depth (Coohill, 1987) and systems require high specification 
optics and tend to be relatively expensive. Development of UV laser technology, driven 
by commercial applications, continues to make this form of Raman spectroscopy 
attractive however in vivo applications at present look very limited. 
 
Visible light lasers are widely available, they are small and inexpensive. Their main 
disadvantages over lasers using NIR and UV excitation is the degree of fluorescence 
they stimulate. Fluorescence can also occur below the molecular excitation energy of 
the main molecule being studied if other species are present which process energy 
transitions near the value of electronic absorption, producing near Raman resonance and 
masking Stokes Raman scattering. The energy of the photons emitted from visible light 
lasers can cause thermal and photo degradation effectively reducing the power profile 
available to the spectroscopist. Even at lower power values the fluorescence stimulated 
from the sample and contaminants can completely mask the Raman spectrum  
 
Near-infrared (785-860nm) lasers are now used extensively in Raman spectroscopy; 
they optimise signal to noise ratio and have fast integration times as a result of reduced 
tissue fluorescence and high sensitivity. FTRS uses NIR lasers for example the Nd
:
YAG 
laser. This laser excites at a frequency of 1064nm which is a great advantage as there 
are very few molecules which process excited states low enough in energy to fluoresce 
at this wavelength. As the fourth power of the frequency of the excitation radiation 
determines the intensity of Raman scattered light, NIR radiation produces relatively 
weak Raman scattering compared to that seen with visible and UV light. Higher laser 
powers are achievable compared to those obtained from visible light lasers because 
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excitation energy is lower in photons from the NIR region and these photons are 
minimally absorbed by most biological molecules. One disadvantage for NIR lasers 
(785-860nm) is that they operate right at the limit of CCD efficiency; other detectors 
such as InGaAs detectors are sensitive to photons from this region however they are 
more expensive. 
2.2.4.2 Collection and Amplification of Raman Scattered Light  
To optimise the signal detected from Raman scattered light it is imperative to remove 
the more prominent Rayleigh scattered light and all other forms of extraneous light such 
as that from specular reflection. 
Prisms and grating monochromators 
Prisms were first used for this purpose but were superseded by single and then multiple 
monochromators. When a single grating monochromator is used the frequency shifted 
Raman scattered light is seen to separate out however some stray light still persists, 
mainly undiffracted light scattered from the surface of the grating. A second and even a 
third monochromator will act to further isolate the Raman scattered light. These systems 
produce excellent separation of peaks close to the laser-line, an advantage over some 
filter systems. Systems using monochromators rather than notch filters can be tuned to a 
range of excitation frequencies. Disadvantages include the need to keep 
monochromators at a constant temperature to avoid variation in band width position. 
Grating characteristics such as size and density of surface grooves affect spectral 
resolution as do slit width and the speed of scanning. Triple monochromators are 
generally no longer used, they do produce very high spectral resolution, but only permit 
small amounts of light to be transmitted and hence require much higher acquisition 
times than the single monochromator systems. For Raman systems which use 
monochromators and single detectors, the scattered radiation is focused onto a 
photomultipler tube for amplification of the Raman signal. 
2.2.4.3 Wavelength Selection 
Optical filters are used to remove specific frequencies of light for example the laser-
line; light of frequency equal to that of the excitation source. They are imperative in 
order to eliminate any stray light which might otherwise saturate the detecting system. 
Holographic notch filters 
Holographic notch filters are interference filters made by a holographic process. They 
are a very effective tool used to filter out elastic scattered radiation. Characteristically 
they have a narrow spectral bandwidth and high optical density however they contain 
gelatin and the optical properties of this can decay over time. This allows variation in 
the frequency of light passing through the filter and hence variation in the spectra 
obtained. Holographic notch filters have the advantage over edge filters in allowing 
Stokes and anti-Stokes spectra to be measured. If a change in the excitation frequency is 
required a disadvantage of holographic notch filter systems is that the filter must be 
removed and replaced with one that will remove the new laser- line. Holographic notch 
filters do not allow the measurement of Raman scattering as close to the laser-line as 
multiple monochromator systems but they are small, efficient and very effective when 
used to collect and focus scattered light onto a monochromator 
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Edge filters 
Edge filters are metal oxide filters and are generally more robust than holographic notch 
filters. The pattern of signal noise seen in these systems can be altered by changing the 
angle of the filter however they are limited by the fact that they can only measure anti-
Stokes spectra. 
Band-pass filters 
Band-pass filters allow only the signal recorded over a specific band of frequencies. 
2.2.4.4 Detectors 
Photographic plates were used in the early Raman work however these were 
cumbersome and required long exposure times to record the weak Raman signal. For 
efficient detection both amplification systems and specialised detectors were developed. 
Photomultiplier tubes 
Spectrometers which utilise monochromators use photomultiplier tubes (PM) to amplify 
the Raman signal. PM tubes convert photons into an electrical signal. Each individual 
photon hitting the photocathode of a PM tube releases one or more electrons which in 
turn are attracted to a second dynode where each stimulates the release of more 
electrons. Successive dynodes are progressively less negatively charged and the 
resulting cascade effectively amplifies the signal. PM tubes require thermoelectric 
cooling to reduce ‗dark current‘. Dark current is that produced by emission from 
components of the system themselves. A further drawback is the need for the tubes to 
be dismantled and serviced regularly in order to dry out condensation in the lens system. 
There are two methods by which the amplified Raman signal can be quantified. In early 
systems the electron stream was averaged over time and the direct current amplified and 
measured. The second method, photon counting, is considered more sensitive and 
produces a better signal to noise ratio however the speed at which individual photons 
producing electron pulses can be counted is the rate determining step. Photomultipler 
tubes are single channelled and very sensitive however detecting Raman signals for 
each individual frequency in the range being studied was time consuming so 
multichannel photon detectors, called photoarrays, were developed to address this 
problem. 
Photoarrays 
Multichannel photon detectors are made up of a collection of small devices which are 
photosensitive. They can change an optical signal into a charge pattern which can then 
be read as a Raman spectrum. They have the advantage over single channel systems as 
they can detect the Raman signal over the entire frequency range simultaneously and as 
a consequence have much shorter acquisition times. This is of particular benefit in the 
study of unstable compounds  
Charge coupled devices (CCDs) 
Driven by advances in information technology and camera imaging CCDs have been a 
huge step in the development of more widely accessible and efficient detector systems. 
A CCD is a semiconductor based on silicon containing an array of pixels. When struck 
by photons each one of the photosensitive elements produces an electric charge 
proportional to the number of photons striking it and a charge transfer process allows 
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the pixels to be read. Time-resolved spectra are obtained by shifting a horizontal section 
of the CCD vertically as a function of time. There are no gratings and the component 
parts do not have to move allowing CCDs to be small and robust. They generate very 
little noise and have a superb signal to noise ratio. CCDs are very sensitive to light in 
the range of frequency used in Raman spectroscopy. They detect efficiently in the 
wavelength range 120-1000nm hence a CCD coupled with dye or diode lasers can be 
used to measure Raman signals from highly fluorescent compounds. Over 1000nm their 
sensitivity drops however other detectors which cover this region are available such as 
Indium-Gallium-Arsenic (InGaAs) detectors. 
Indium-Gallium-Arsenic (InGaAs) detectors 
InGaAs detectors are thermally stable and can be used at room temperature, they have a 
lower signal to noise ratio than CCDs however some improvement is seen when the 
system is cooled. These detectors are used in FTRS where the excitation light used is in 
the IR region but are limited in detecting spectra above 3000 cm
-1
. They produce 
minimal dark current and fluorescence and can record from a wide variety of samples in 
different states. 
2.2.5 Refinements 
Fourier-transform Raman spectroscopy (FTRS) 
Conventional Raman spectroscopy also known as dispersive Raman spectroscopy 
measures scattered light intensity against frequency or wavenumber whereas FTRS, also 
known as time-domain spectroscopy, measures light intensity against wavenumber over 
all frequencies simultaneously. Computer processing by Fourier transform converts the 
data obtained into a conventional spectrum. The development of Michelson 
interferometers (Michelson, 1920) allowed visible light Raman spectroscopy to be 
superseded by FTRS as a technique to probe biological tissue (Chantry & Gebbie, 
1964). Both visible light and NIR-FT systems are used however commonly FTRS 
systems use a continuous-wave Nd
:
YAG solid state laser (1064nm). The power range is 
1 to 10 watts with most systems operating at the lower end. Using NIR light 
significantly lowers the intensity of the Raman signal compared to that which would be 
obtained using lasers emitting visible light so the use of filtering optics to remove stray 
light is imperative. Holographic notch filters have been used extensively. Systems often 
incorporate a reference Helium-Neon (He-Ne) laser however the detectors used are 
sensitive to radiation of this frequency and so it must also be filtered out. FTRS has 
good acquisition times and signal to noise ratios. Large surface areas can be studied 
without loss of spectral resolution; however a disadvantage is that the spectral noise 
signal is split between all spectral components 
Micro-Raman spectroscopy  
Delhaye developed the first micro-Raman spectrometers 1974 (Delhaye, 1974). A year 
later Rosasco developed the first Raman microprobe (Rosasco, 1975). The spatial 
resolution of Raman scattered light was greatly improved by the development of micro-
spectroscopy systems. General advances in the technical specifications of the 
component parts, particularly detectors and distal end optics continue to improve this 
technique. Micro-Raman spectroscopy is based on the characteristic that light from 
lasers emitting in the visible region can pass through samples and then can be focused 
by a lens. Optical channels for excitation and reflected light are separated and 
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extraneous light such as specular reflectance is minimised with careful alignment of the 
excitation beam and sample. Maximum signal is detected by using the largest collection 
angle possible and a large collector aperture. Light can be focused to a very small spot 
size increasing the power density over the area studied and this allows a relatively low 
powered laser to be used. Spatial resolution is also dependant on the spot size. This 
technique gives excellent imaging of tissue epithelial surfaces, but is limited in the 
submucosa, deeper tissue and in the assessment of heterogeneous samples. This latter 
point is a great disadvantage to the development of this technique as a useful clinical 
tool. 
Confocal microspectroscopy 
In confocal microspectroscopy scattered light is collected from the area of the sample in 
focus only, off-axis light is removed. In confocal microscopes the X-Y mapping plane is 
extended to the z direction allowing focusing at different depths. A confocal microscope 
contains what is effectively a pin hole in the focal plane of the microscope. In some 
cases two separated slits at right angles are used, one in the microscope the other in the 
spectrometer. These block all light except that which is in the focal plane. The 
development of this refinement to Raman systems has allowed depth profiling and 
Raman signals to be obtained from well defined, small volumes. (Rosasco, 1980; 
Delhaye, 1990; Baldwin, 2001). 
Mapping and imaging Systems 
Much of the Raman spectroscopy work to date has utilised data from single point 
analysis; this remains a very valuable tool however motorised stage systems are now 
widely used to map larger areas. Two dimensional mapping involves mounting a sample 
on a mobile X-Y stage. The sample is moved in the X-Y plane by incremental amounts 
and after each movement a point measurement is taken. Mapping can also use an XYZ 
stage to obtain three dimensional images. Comprehensive mapping is a time consuming 
process and it is this problem which has been one of the major drawbacks encountered 
with this technique however it is excellent at identifying substances accurately and for 
showing the distribution of other components within the specimen. Recent 
developments may greatly reduce the time required for mapping. Systems such as the 
Renishaw Streamline system look very promising. In this system spectral measurements 
are taken whilst the stage is moving. It is a much quicker technique however it is limited 
by the small amount of scattered light captured compared to that seen with conventional 
mapping (Hutchings, 2008)). Each frequency of scattered light is focused at a specific 
point along a line on a CCD; alternatively a series of filters allows only one frequency 
of light through that corresponds to a particular vibrational excitation in the molecules 
being studied. In both these cases the detector can act like a camera and a Raman image 
of the specimen is obtained. 
Probe and portable Systems 
In 1988 technological advances were made in the development of fibreoptic probes to 
be used for in situ Raman spectral measurements (Hendra, 1988). The development of 
fibreoptic technology has allowed samples to be analysed remotely from spectrometers 
(Lieber, 2004). CCDs, developed in the video and digital camera commercial world, 
have helped to make systems more portable, as have miniature gratings based on 
fibreoptic interfaces and solid-state semiconductor lasers. The design of Raman in vivo 
probe systems is an active area of research (Utzinger & Richards-Kortum, 2003). Many 
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prototype probes are based on a ring of collecting optical fibers surrounding an 
illuminating fibre. Problems associated with these systems include the low intensity of 
Raman signal and the high signal to noise ratio from both the Raman system and the 
endoscope optics (Mahadevan-Jensen, 1998a). Systems such as the Visonex probe have 
beveled fibres to maximise the capture of scattered light and other recent advances 
include band-pass filters which allow only laser light through and remove the Raman 
silicon signal which emanates from the illuminating fibre optics. 
2.2.6 Limitations and Hazards Associated with Raman Spectroscopy 
Very slight biochemical changes must be detected in order that successful early 
diagnosis of disease can be made through analysis of Raman spectra. This, in 
conjunction with an inherently weak Raman signal, is the crux of the technical 
challenge faced in the development of medical diagnostic Raman spectroscopy. To 
optimise a Raman spectroscopy system a balance must be struck between the need for 
high laser power, a sensitive detector and the practicalities of whether these components 
are readily and inexpensively available. Much of the research in Raman spectroscopy 
has addressed these technical aspects. Raman spectroscopy has a great many useful 
properties. It can be used to probe molecular vibrational motion at much lower 
frequencies than IR spectroscopy i.e. less than 400cm
-1
 and has a spatial resolution of 
1m x 1m compared to that of IR which is in the order of 20m x 20m, although 
FTIR in mapping mode can produce higher resolution than this. Raman spectral bands 
are usually narrower than those obtained from IR excitation allowing better peak 
resolution and more accurate assignment to specific molecular vibrational entities. The 
water content within biological tissue is high resulting in stronger IR absorption 
compared to that seen when Raman spectroscopy is used. This gives Raman 
spectroscopy an advantage over IR in the assessment of some biological tissues. There 
are however some major drawbacks in the in vivo use of Raman spectroscopy for the 
study of these types of tissue. Biological tissue is often heterogeneous and absorbs light 
from the whole UV-Visible range producing a strong fluorescence emission which can 
swamp the much weaker Raman signal; this is largely overcome by the use of NIR 
excitation. The choice of excitation source has been discussed in detail and whist UV 
light has many advantages and it has been used in vitro studies extensively it can be 
mutagenic (Pfeifer, 2005). It is considered unsafe for in vivo applications and 
consideration of energy transfer to tissue producing both thermal and photo degradation 
must be considered. 
 
There are national and international guidelines for the acceptable levels of exposure of 
biological tissue to laser light. This data give the maximum permissible exposure (MPE) 
for skin but to date there are no values for the larynx or lymph nodes. The British 
guidelines (BS EN 60825, 2007) give the MPE for different wavelengths of light. For 
light of 790nm the limit of exposure is 95μW for a spot diameter of 200μm, for 830 nm 
the MPE is equivalent to 114 μW. If these MPEs were adhered to it would not be 
possible to obtain adequate Raman spectra however work on tissue in vitro suggests 
much higher levels of exposure can be used without thermal damage being caused 
(Puppels, 2001). Shim has not only published work on the effects on Raman spectra 
from different handling of ex vivo mammalian tissue (Shim, 1996) but has also more 
recently investigated the thermal effects of laser light (Shim, 2000). Using an 830nm 
laser, giving 250mW of power focused into a spot size of 500μm for 60 seconds no 
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thermal damage was detected. In the use of Raman spectroscopy there continue to be 
problems with optimisation of signal to noise ratio and reduction of dark current, 
although detector cooling has resulted in an improvement in this area. Progress has been 
made in compilation of molecular spectral databases which do not contain spectra 
contaminated with instrument signals or signatures but a truly standardised database is 
some way off. Despite great advances much work is still required for the development 
of a truly portable and clinically relevant system that can be used in vivo and which is 
affordable. 
2.3 Current Applications for Raman Spectroscopy 
An outline of the development of Raman spectroscopy as a biomedical diagnostic tool is 
given in this section. A more detailed overview for applications relating to specific 
anatomical areas is also listed and the section concludes with a synopsis of selected 
non-clinical uses. Multiple reviews of the biomedical applications of Raman 
spectroscopy have been undertaken in the past (Mahadevan-Jansen, 1996; Fulljames, 
1999; Hanlon, 2000, Wilson, 2007) so the aim of this chapter is to highlight the 
development and scope of this technique. 
2.3.1 General. 
In 1970 the first Raman spectra of proteins were obtained from cellular lysozymes using 
a He: Ne laser (Lord, 1970). A study done in 1974 (Larsson & Hellgren, 1974) was the 
first to highlight the possible value of Raman spectroscopy in the detection of disease. 
Raman and fluorescence spectroscopy were performed on the plasma component of 
blood from patients with a variety of diseases. The plasma from healthy patients showed 
Raman peaks attributed to the presence of carotenoids and aromatic amino acid side 
chains; these were not visible in the spectra obtained from the plasma of patients with 
disease. These spectra also showed a greatly increased fluorescence signal. 
Spectroscopy was shown to be able to distinguish between health and diseased plasma 
better than the standard measurement of erythrocyte sedimentation rate (ESR) but was 
not able to separate out the different disease entities. Instrumentation development in 
the 1970s (Delhaye, 1975) combined a dispersion Raman spectrometer with a 
microscope. This system allows Raman spectroscopy to be used for studies at a cellular 
level. From the mid 1970s to late 1980s much work was done on the analysis of 
individual proteins e.g. within the eye lens (Yu, 1974) and to study the RNA and DNA 
content of viruses (Hartman, 1973). Early work also included the study of foreign 
inclusion bodies, material that can become embedded within biological tissues and 
which the body has no way of removing e.g. asbestos and silicon particles. The first 
study analysed silicon inclusion bodies in vitro within lymph nodes (Abraham, 1979). 
Inclusion bodies generally give strong, distinctive spectral signals and work continued 
on refining Raman spectroscopy in order that it might be used to detect the small 
changes found in the biochemical profile of tissue that accompanies the pathological 
disease process. The advantage of visible light Raman spectroscopy used in studies 
undertaken at a cellular level is that it produces less fluorescence than that seen in 
studies of complete tissues. Even so technical advances such as the development of 
Confocal Raman microscopy have allowed more detailed work on cellular proteins to be 
undertaken (Puppels, 1990). Throughout the 1990s studies done using cultured cell lines 
yielded information on cellular structure (Sureau, 1990) and on protein conformation 
and concentration (Yazdi, 1999). As Raman spectroscopy evolved and was used to 
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study more complex tissue so fluorescence was increasingly a limiting factor. In the 
early 1990s skin studies using NIR and visible Raman spectroscopy showed good 
correlation between peak assignments obtained from in vitro and in vivo experiments 
(Williams, 1993 & 1994). In 1993 Alfano et al applied for a patent to cover the use of 
Raman spectroscopy in cancer diagnostics. Through the analysis of cellular constituents 
and metabolites a great deal has been learnt and extensive spectral library data bases 
now exist. Early work on individual cells was of fundamental importance in establishing 
the use of Raman spectroscopy as a tool for the detection of malignancy by showing 
that changes such as cytoplasm to nuclear ratio could be demonstrated in the presence of 
malignancy. Beyond oncology Raman spectroscopy has also been used as a tool for 
microbiological analysis and has been used successfully to classify strains of bacteria 
(Maquelin, 2000) and quantify the presence of viruses in cells (Wu, 2000). 
2.3.2 Clinical 
Larynx/pharynx 
Much progress has been made in the use of Raman spectroscopy in the study of 
epithelial cell changes in different anatomical sites (Stone, 2002). Yang et al used a 
series of spectroscopic investigations, including FT-IR and Raman spectroscopy, to 
study molecular changes that occur in the presence of squamous cell carcinoma within 
head and neck tissues (Yang, 1998). In 2000 preliminary studies showed that Raman 
spectroscopy could be used to discriminate between normal, dysplastic and malignant 
changes in squamous epithelial cells of the larynx (Stone, 2000; Kendall, 2000). An 
excitation wavelength of 830nm was used and 5 -12 spectra obtained from each sample, 
multivariate statistical methods – principal component and linear discriminant analysis 
were performed on the data to maximise spectral differences. These were most 
pronounced in the 850- 950 cm
-1
 and 1200-1350 cm
-1
 range. Peaks were identified that 
corresponded to conformational changes in proteins and stretches in the C-H bonds 
found in nucleic acid bases. As disease progressed towards malignancy the relative 
intensity of the peaks relating to nucleic acids increased. Cross validation of the 
discriminant model gave excellent specificities, 94%, 91% and 90% and good 
sensitivities 83%, 76% and 92% for normal, dysplastic and squamous cell carcinoma. 
This study was limited by a small sample number and part of the work contained in this 
thesis expands on these results. Stone et al extended their work to other anatomical 
sites; tonsil, oesophagus, stomach, bladder and prostate and using Raman spectroscopy 
classified normal and diseased epithelial tissue with similar sensitivities and 
specificities as that obtained from laryngeal tissue (Stone, 2002). A study published in 
2005 used slightly larger sample numbers than seen in the preceding studies and looked 
at the ability of Raman spectroscopy to discriminate between normal, malignant and 
laryngeal tissue infected with the human papilloma virus (Lau, 2005). Sensitivities of 
89%, 69% and 88% and specificities of 86%, 94%, and 94% were obtained for normal, 
laryngeal carcinoma and papilloma infected tissue respectively. 
Lymph nodes 
Raman studies of lymph nodes have been limited and most have been in association 
with the investigation of breast disease. Studies to date have shown the ability of Raman 
spectroscopy to interrogate lymph nodes for the presence of silicone in patients who 
have undergone breast augmentation with silicon implants (Feng, 2004; Katzin, 2005). 
More recently in vivo mice experiments have been undertaken to assess if Raman 
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spectroscopy can discriminate between normal and breast cancer metastatic disease in 
regional lymph nodes (Kast, 2008). 
Breast 
FT-Raman was first used to study breast cancer in 1991 (Lui, 1991) and has now been 
successfully used in vitro to detect the presence of lymph node metastases from breast 
cancer (Smith, 2003 & 2005). More recently in vivo experiments have been undertaken 
on mice using Raman spectroscopy to differentiate between normal breast tissue and 
that infiltrated with tumour (Thakur, 2007; Kast, 2008). Kast et al extended their study 
to also investigate metastatic disease in regional lymph nodes groups. Spectral 
classification of normal, tumour and inflammatory tissue correlated well with that 
obtained from histology. 
Lung 
Several review articles (Kraft, 2006; Zeng, 2004) have summarised the evidence in 
support of the application of spectroscopic techniques, such as Raman spectroscopy, in 
the diagnosis of lung malignancies. Raman spectroscopy has also been used for the 
study of the mechanism by which lung surfactants work (Vincent, 1991; Levin, 1993) 
and in the diagnosis of non-malignant pulmonary diseases such as alveolar proteinosis 
lung disease (De Silva 1999). Raman spectroscopy has been used to identify inhalation 
toxins such as ricin and sulphur mustard gas and it has been successfully used to assess 
pulmonary cell viability post exposure to these gases (Notingher, 2004). In the 
assessment of cells and subcellular components Raman spectroscopy has been used to 
identify the morphological changes associated with apoptosis in lung fibroblasts (Krafft, 
2006). Novel uses of Raman spectroscopy include the identification of foreign material 
in lung parenchyma biopsies (Bayder, 2005). In this study bisphenol-A-polycarbonate 
was identified in a granulomatous pulmonary lesion. This material is thought to have 
originated from an indwelling medical catheter which had degraded. More recently 
Raman spectroscopy has been used to assess the toxicity of inhaled nanoparticles 
(Baker, 2008) and the efficacy of drug delivery systems and pulmonary inhalation 
aerosols (Mansour, 2007). 
Thyroid 
Raman spectroscopy systems were initially used in the development of thyroid 
stimulating hormone immunoassays (Rohr, 1989), more recently they have been used in 
the assessment of thyroid stimulating hormone in rats (Medina-Gutierrez, 2005). In the 
study of thyroid disease Schultz et al used a combination of infrared and Raman 
spectroscopy, including in vitro fibre optic probe studies, to examine the cellular 
components of the thyroid gland and thyroid specific molecules such as thyroglobulins 
(Schultz, 2000). The first study to show the ability of Raman spectroscopy to 
differentiate between benign and malignant pathology in the thyroid was published in 
2000 (Manfait, 2000) and a more recent summary of the changes associated with 
malignancy in several tissues including the thyroid has also been published (Lui, 2005). 
Significant differences between normal thyroid tissue and thyroid follicular carcinoma 
samples were identified in particular Raman spectral bands at 1585 and 1634 cm
-1
 were 
found to be absent in samples containing carcinoma. 
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Vascular 
An enormous amount of work has been undertaken using Raman spectroscopy to study 
vascular lesions and several comprehensive reviews have been published (Yu, 1996; 
Naghavi, 2001; Landini, 2003). Salenius et al have used Raman spectroscopy to analyse 
the structure of the human arterial wall for lipid and calcium salt content (Salenius, 
1998). Whilst Buschman et al have demonstrated the use of Raman spectroscopy in vivo 
on the arterial wall in sheep (Buschman 2000). The use of Raman spectroscopy in the 
characterisation of vascular plaques, in particular determining those features which flag 
a lesion as unstable has been extensive (de Romer, 1998; Korte, 2000; Ozer, 2005) 
Gynaecological (cervical) 
Most of the work using Raman spectroscopy in gynaecology has concentrated on the 
spectral characteristics of cervical neoplasias and the changes that occur in the 
progression from carcinoma in situ to invasive disease (Mahadevan-Jansen, 1998; 
Utzinger, 2001; Krishna, 2006), some in vivo studies have also been completed (Chang, 
2002; Robichaux, 2002). Correlation with the biochemical changes which occur during 
cervical disease progression have now been made (Lyng, 2007). More recently Raman 
spectroscopy has been used to show the presence of cells expressing the human 
papilloma virus (HPV) 16 E7 gene. The cellular effects of infection with this virus 
identified at a biochemical level, even in fixed tissue samples, suggests it may be a 
useful and compatible adjunct to current screening programmes (Jess, 2007). 
Transvaginal sonography is a common way of screening for ovarian cancer however 
although this technique is good for detecting an abnormal mass it discriminates poorly 
between benign and malignant disease. A definitive diagnosis requires open biopsy 
however studies assessing the efficacy of Raman spectroscopy for the diagnosis of 
ovarian cancer have been promising (Leiber, 2000). 
Brain 
Raman spectroscopy is taking an increasingly valuable rôle in the investigation of the 
mechanisms by which neurological diseases occur and it has also been used in the 
assessment of many neuro-oncological conditions. Mizuno et al suggested that near-
infrared FT-Raman spectroscopy might be able to differentiate between rat brain grey 
and white matter (Mizuno, 1992) and later spectral analysis of human brain tissue 
showed that solvents applied to brain tissue removed nucleic acid and lipid components 
inducing conformational changes in proteins which could be followed using Raman 
spectroscopy (Sajid, 1997). Raman spectroscopy has been used to differentiate 
glioblastoma from necrotic tissue and mooted as a possible means of defining resection 
margins during stereotactic surgery (Koljenovic, 2002). It has also been used for the 
characterisation of brain tissue lipids in the hope that detection of their presence and 
variations in concentration profile might also be used as a diagnostic tool in 
neurological diseases (Krafft, 2005a, 2005b & 2006). Tumour maps have also been 
complied for glioma, meningeoma and schwannoma tissue (Krafft, 2006). A review of 
neuro-oncological applications of optical spectroscopy was published by Toms et al in 
2006 (Toms, 2006). 
 
The mechanism by which Alzheimer‘s disease occurs is still poorly understood however 
Raman spectroscopy is beginning to play an important rôle in Alzheimer research. It has 
been used in the confirmation of the importance of adequate Cu (II) levels which 
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competitively inhibit Zn (II) and reduce the aggregation of amyloid β-peptide, a key 
step in the development of the disease (Suzuki, 2001). More recent studies have looked 
at the ability of Raman spectroscopy to differentiate between Alzheimer‘s disease, 
normal brain tissue and other neurological diseases such as Huntington‘s chorea 
(Sudworth, 2005), this work has been further refined by utilising more sophisticated 
Raman systems (Archer, 2007). 
 
Advances in Raman technology have allowed a fibre-optic Raman probe to be used to 
characterise and differentiate between different anatomical areas within pig brain tissue 
(Koljenovic, 2007). In a fascinating study a Raman spectroscopy-based biosensor was 
combined with an image-guided surgery system. The Raman probe was connected to a 
passively articulated mechanical arm which was able to correctly classify a number of 
objects within a ‗phantom skull‘ (Reisner, 2007). This represents a further step towards 
a system which combines intraoperative diagnosis and the delineation of surgical 
resection margins by Raman spectroscopy combined with stereotactic surgery using 
image guidance systems.  
 
Raman spectroscopy has also been used to study the effects of radiation on rat neural 
tissue. Such exposure can produce changes some distance from the actual site of injury 
and the authors have used this evidence to support the hypothesis that radiation 
exposure produces systemically released protective factors (Lakshmi, 2002). This may 
be of importance to the use of Raman spectroscopy in the study of recurrent neoplastic 
disease in the head and neck where one of the primary treatment modalities is 
radiotherapy.  
 
The assessment of the severity of brain trauma and monitoring the progress of brain 
injured patients can be very difficult. A rat model has been developed were brain tissue 
ischaemia is used as a damage model and surface-enhanced Raman spectroscopy used 
to analyse the rat neural tissue ex vivo. This work has shown a correlation between 
Raman spectra features and areas of ischaemia (O‘Neal, 2000) and may be useful in the 
detection of highly vascularised tumours some of which occur in the head and neck. 
Cerebral oedema can be a life threatening complication of head trauma and is also of 
concern in patients with intracranial neoplasms. Raman spectroscopy has been mooted 
as a possible technique for measuring water concentration in brain tissues directly 
(Wolthius, 2001). After head injury damaged neurons release excitatory amino acids 
and these are thought to be associated with a risk of acquiring a secondary injury. 
Surface-enhanced Raman spectroscopy has been used in rats to investigate the 
possibility of rapid quantification of these compounds as a measure of the risk of further 
deterioration and assessment of the need for pharmacological intervention (O‘Neal, 
2003). Over the last ten years there has been an increase in the recorded incidence of 
prion disease and the neurodegenerative disorders it produces which in turn has 
stimulated an enormous amount of research. Surgical instrument cleaning has been 
greatly influenced by this and there is now a general move towards disposable 
instruments particularly in operations such as neurosurgery and tonsillectomy were it is 
necessary to resect tissue which processes an increased risk of containing prions. Raman 
spectroscopy has been used to investigate the affinity and binding properties of the 
precursor forms of the infectious isoform of prion particles for Cu (II) ions and how this 
binding alters with pH. It has been suggested that the presence of specific Cu(II) 
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bridged forms of the protein may be important in the aggregation of prion protein in its‘ 
pathogenic form and that the formation of these Cu(II) bridges can be influenced by the 
pH of the micro-environment of the neural tissue (Miura, 1999 & 2005).  
Skin 
The use of Raman spectroscopy for the in vivo study of skin (Williams, 1992 & 1993; 
Caspers, 2001) and skin lesions occurred early in the modern development of Raman 
spectroscopic techniques (Sterenborg, 1993). Raman spectroscopy has been used to 
show that the essential building blocks of skin from the 5200 year old ‗Similaun man‘ 
have remained essentially unchanged through time (Williams, 1995). The non-
destructive nature of this technique and the ease of access to skin has facilitated great 
progress in the assessment of protein structure, lipids and water content (Gniadecka, 
1998) and this has led to a clearer understanding of skin diseases,  such as psoriasis 
(Bernard, 2007), vitiligo (Schallreuter, 2008) and basal cell carcinoma (Nijssen, 2007). 
In 1998 the mode of action of salicylic acid with verrucae was studied using Raman 
spectroscopy (Lawson, 1998) and in the following year the first work towards clarifying 
the mechanism by which simple compounds are absorbed transcutaneously was 
published (Williams, 1999). A comprehensive review of methods available for the 
assessment of transcutaneous drug availability including Raman spectroscopy was 
published in 2008 (Herkenne, 2008). There has been a great commercial drive to find 
topical products that reduce the signs of aging and this has facilitated advances in the 
use of Raman spectroscopy in this field. Of particular interest has been changes seen in 
lycopenes and carotene derived compounds by external factors such as diet (Darvin, 
2007), ultra violet light (Hata, 2000; Darvin, 2006) and the effectiveness of absorption 
of topical moisturisers (Seig, 2006) and sun screens (Lademann, 1999). 
Bladder 
Work published by Stone et al summarised Raman studies outlining diagnostic 
algorithms for the classification of epithelial cancers and precancers in different 
anatomical areas including the bladder (Stone, 2002). The five group bladder model 
developed gave sensitivities of 78-98% and specificities of 96-99%. In the same year it 
was shown that Raman spectroscopy could be used to identify in vitro the different 
layers of the bladder wall in guinea pigs and that the spectra obtained from urothelium 
showed a particularly strong lipid signal (De Jong, 2002). In vitro studies of the Raman 
spectral characteristics of human bladder urothelium have shown that normal, 
inflammatory and malignant tissues can be differentiated. Within the malignant subset 
containing transitional cell carcinomas it has also been shown that it is possible for the 
grade and degree of invasion of to be correctly assigned paving the way for in vivo 
cystoscopic studies (Crow, 2004). Studies have now been published which outline the 
possible applications of Raman spectroscopy in the diagnosis of interstitial cystitis 
(Hsieh, 2007) and in the determination of the biochemical basis for disease in the 
prostate (Stone, 2007). 
Mineralised Tissue (Bone & Teeth) 
Raman spectroscopy has been used extensively to analyses bone and its‘ 
biocompatibility with prosthetic devices, particularly those used in dentistry and 
orthopaedics (Carden, 2000; Dippel, 1998; Bertoluzza, 1992). There have been some 
novel uses for this technique in the study of mineralised tissue including the study of the 
human remains of a seventh century cist burial in Anglesey (Edwards, 2007). In what 
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the paper describes as ‗a complex and dynamic environment‘ the forensic evaluation of 
the archaeological human remains by Raman spectroscopy showed that the environment 
surrounding the remains in which the tissue degraded played a part in the final 
composition of the tissue . Raman spectroscopy has also been put forward as a possible 
alternative to the use of dual x-ray absorptometry in the evaluation of osteoporosis. A 
recent study has suggested analysis of sulphation and the integrity of disulphide bonds 
in keratin, a protein contained in nails may correlate with changes in bone chemistry 
(Towler, 2007). Raman spectroscopy has also been used to investigate the link between 
the characteristics of mineral crystals and the mechanical properties of bone 
(Yerramshetty, 2008). An ongoing area of research is the effect of weightlessness on 
human physiology. Prolonged periods of weightlessness result in loss of bone mass and 
renal stones. Drugs to minimise these problems are given prophylactically to astronauts 
however their metabolism is also affected by weightlessness and as a consequence the 
reliability of earth based studies are limited. Standard analytical techniques employed 
on earth are not feasible in space and Raman spectroscopy has been investigated as an 
alternative (Inscore, 2006). From the 1990s Raman spectroscopy has been used in the 
study of human tooth enamel and the biocompatibility and penetration of resins used in 
dentistry (Suzuki, 1991). The differences in the Raman spectra obtained in the presence 
of caries has been studied (Hill, 2000; Ko, 2006) and Raman spectroscopy used to 
differentiate between normal teeth and resin restorations (Hill, 1997).Raman 
spectroscopy has also been used to study dental calculus; spectra obtained showed 
marked differences from those obtained from dentin. These spectral changes did not 
appear to alter with the age of the calculus (1 to 6 months). At the interface between 
calculus and saliva or dentine the Raman spectra were almost unchanged and it is 
thought that the distribution within dental calculus of the major constituent minerals 
does not alter significantly along the axis of growth (Tsuda, 1993). A detailed analysis 
of the internal vibrational modes obtained from Raman spectroscopy of human tooth 
enamel crystallites was published in 2002 (Leroy, 2002). UV resonance Raman 
spectroscopy has been used to study the impact of age on dentine and bone. An increase 
in the amide I peak was noted when teeth from donors aged 23 to 73 years were studied 
(Ager, 2006). 
Ophthalmic 
The eye is made up, in part, by media through which light is transmissible. This 
property makes the eye particularly amenable to study using Raman spectroscopy. 
Some of the earliest work utilising Raman spectroscopy in biomedical research was 
done using animal eye models (Rinai, 1970; Yu, 1982). Early applications mainly 
concentrated on the diagnosis of cataracts. In 1987 multichannel Raman spectroscopy 
was used to study the human lens in vitro (Ozaki, 1987). Since that time much work has 
been carried out to characterise lens pigmentation and opacities (Nei, 1990; Kellar, 
1994; Yu, 1996; Duidam, 1998; Furic, 2005). The association between UV light 
exposure and the development of cataracts instigated the use of Raman spectroscopy in 
a novel application to assess the degree of penetration of UV light through contact 
lenses (Bergbauer, 1993). Macular degeneration is a common eye disease related to 
increasing age. It is the leading cause of irreversible blindness in the elderly and is 
associated with a decrease in macular carotenoid pigments. Raman spectra of human 
lenses, in vivo, show a linear relationship between spectral peak size and carotenoids 
concentration. In addition Raman signal strength can be demonstrated to decline with 
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increasing age (Gellermann, 2002; Bernstein, 2004; Ermakov, 2005; Obana, 2008). 
Raman spectroscopy of the eye has also been used to determine concentrations of 
glucose (Lambert, 2005) and drugs such as Amphotericin B and other antibiotics (La 
Via, 2006; Sideroudi, 2006 & 2007). 
Upper gastrointestinal tract - Oesophagus 
Much progress has been made building on important early work using Raman 
spectroscopy to investigate the characteristics of the epithelium from several different 
tissues, including tissue from the upper gastro-intestinal tract. A NIR (850nm) 
dispersion spectrometer was used and a difference between the glycogen content of 
normal and diseased oesophageal tissue (Barrett‘s oesophagus) shown (Bakker-Schut, 
1997; Wolthius, 1999). Raman spectroscopy was also used successfully to assign 
classifications to the three main groups of tissue; normal, Barrett‘s and adenocarcinoma. 
Work published by Shim et al investigated the effects of ex vivo handling of biological 
tissue such as drying and snap freezing (Shim, 1996). It has also been shown that a 
250mW laser focused to a spot size of 500μm does not produce a rise (< 1oC) in the 
temperature in the tissue sample being examined (Shim, 2000). Detailed work has been 
published discussing the ability of Raman spectroscopy to classify epithelial cancers 
and pre-cancers, including those found in the oesophagus (Stone, 2002). This work also 
drew attention to the fact that it was difficult to spectroscopically differentiate tissue 
exhibiting early changes related to the development of cancer e.g. dysplasia from those 
that could be unambiguously be classified as neoplasia. Subsequent work has shown a 
great improvement in the ability of these models to classify disease when they are 
developed using consensus pathology reporting (Kendall, 2003). Stone et al have taken 
their work forward using the lessons learned and have shown it is possible to correctly 
assign pathological groups to epithelial tissue samples from different anatomical areas 
using a commercially available Raman microspectrometer (Stone, 2004). In another step 
forward Raman mapping studies have been used to clarify the possible biochemical 
changes, particularly in levels of glycogen and DNA, present during the development of 
adenocarcinoma of the oesophagus (Shetty, 2006). The hollow, tube like structure of the 
gastro-intestinal tract enables the passage of endoscopic instruments and this facilitates 
the use of fibre-optic Raman probes. Boere et al published work in 2003 that outlined 
the results of experiments using a Raman probe to study the characteristics of ex vivo 
Barrett‘s oesophagus from rats (Boere, 2003) and work continues towards in vivo 
human studies. 
Lower gastrointestinal tract – Colon/Rectum 
The incidence of colorectal carcinoma is increasing however treatment protocols are 
improving and one of the key factors in their success is early diagnosis. Raman 
spectroscopy has been investigated as a technique to fulfil this rôle. Initially UV 
resonance (Manoharan, 1995; Boustany, 1999) and NIR Raman spectroscopy (Feld, 
1995) were both used and review papers have discussed the advantages and 
disadvantages of these different modalities (Manoharan, 1996; Zonios, 1998). More 
recently studies with larger sample numbers, ex and in vivo, have explored the use of 
Raman probes in the diagnosis of different types of colonic polyps (Molckovsky, 2003). 
Several reviews outlining the use of Raman spectroscopy in the diagnosis of colonic 
lesions have been written (Da Costa, 2005; Dekker, 2005). In 2007 a study was 
published in which laser-induced fluorescence spectroscopy (LIF) and Raman 
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spectroscopy were used to investigate the presence of markers within serum that are 
associated with an increased risk of colorectal cancer (Li, 2007). 
2.3.3 Non Clinical 
Gemstones 
The 11
th
 century reliquary Heinrich‘s Cross has been examined in situ with the aid of a 
Raman probe. Not all the gems contained in the cross were unambiguously identified 
but of those that were it was shown that they were mainly glass quartz and paste. Some 
precious stones such as rubies were found but it is unclear if the non-precious stones 
were original or replacements (Reiche, 2004). Raman spectroscopy can be used for both 
the identification of gemstones and gemstone treatments. Emerald fissure can be treated 
with oil to improve the clarity of the stone and brown diamonds can be treated with a 
high temperature and pressure process that can render them almost colourless. 
Gemstones which have undergone either of these processes can be detected by Raman 
spectroscopy (Kiefert, 2000). 
The food industry 
Raman spectroscopy has been used in the assessment of the content of amylose in rice 
(Ootake, 1998), a compound which is closely related to stickiness. It has also been used 
in the study of soils. Over a prolonged period (22years) areas of soil were treated with 
different substances one of which was cattle manure. This work showed that the 
composition of the soil organic matter varied considerably between areas (Francioso, 
2000). It was suggested that in soil that had been ‗amended‘ with cattle manure the 
organic matter was made up of material that might prove more resistant to 
decomposition. Significant amounts of perchlorate from fertilisers have been found to 
have leached into drinking water sources in the USA and this has caused concern. 
Raman spectroscopy studies of perchlorate levels in water and vegetables have 
highlighted its‘ potential as a possible monitoring technique (Williams, 2001). Studies 
have also identified Raman spectroscopy as a possible way of analysing pesticides on 
and in fruit. The current world food crisis is likely to focus research on techniques 
which allow rapid and inexpensive methods for the assessment of plant components in 
order that the strongest specimens can be selected for cultivation. Raman spectroscopy 
has been shown to be a viable tool in these assessments and potentially also in the 
quality control of raw food materials and their end products (Schulz, 2007). 
Sport 
Raman spectroscopy has been put forward as a possible means of non-invasive 
evaluation of muscle fitness by the detection of lactic acid levels (Williams, 2001). It 
has also been used to detect substances banned in sport (Perez, 1998) and as previously 
discussed can now be used to detect and monitor a wide range of drugs which can be 
identified from human plasma and urine samples. 
2.4 The Pathogenesis of Cancer 
Cancer evolves as a result of a complex, multi-factorial sequence of events. There are 
many contributing factors related to both the individual patient and the external 
environment. Aetiological factors relating to both the host and environment are outlined 
briefly in this chapter. The mechanism by which carcinogensis occurs has been 
elucidated greatly by research in these areas and a summary is given. More detailed 
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studies of aetiological factors specifically relevant to diseases of the larynx and lymph 
nodes are to be found in Sections 2.5 and 2.6.  
2.4.1 Theory of Cancer Development 
Host Factors 
Genetic predisposition for the development of certain tumours has been clearly 
demonstrated in many neoplasms for example the breast and in the colon (Weatherall, 
1987). Familial polyposis coli is an autosomal dominant condition where multiple 
premalignant polyps are found in the colon and invariably transform to become 
malignant. In this disease in addition to the genetic predisposition there is also a loss of 
a tumour suppressor (antioncogene) gene. Although there are cancers that 
predominately occur in children such as retinoblastoma and certain leukaemias most 
neoplasia occurs in adults. Whilst increased age is certainly a risk factor the exact 
changes that cause this are still unclear, exposure to carcinogens may be accumulative 
and changes in hormones with age may also play a part. Immunosuppression is also 
known to increase the risk of neoplasia either acquired as a result of poor nutrition or 
resulting from an infective process such as Acquired Immunodeficiency Syndrome 
(AIDS) (Scheifele, 2005, Robbins, 1989a). Approximately a third of patients with AIDS 
develop the neoplasia Karposi’s sarcoma. Other systemic diseases can result in an 
increase in cancer risk such as atropic gastritis seen in pernicious anaemia patients 
which is associated with carcinoma of the stomach. 
Environmental factors 
Environmental factors such as geography and racial influences have been extensively 
studied. Geographic influences are considered mainly attributable to exposure to 
environment factors. The incidence of certain stomach cancer in Japan is  much greater 
than that seen in the United States of America however the children of Japanese 
immigrants living in the USA have a similar risk to those not of Japanese origin. 
Cultural influences can also play a part in the development of cancer for example 
chewing beetle nut, common in South America, increases the risk of carcinoma of the 
oral cavity. Cancer risk can be increased by exposure to carcinogens either chemical, 
infective or as a result of radiation. Chemical carcinogens can be divided into those that 
act to initiate and promote carcinogensis (complete) and those that can only fulfil one of 
these functions (incomplete). Some carcinogens occur naturally in the environment such 
as aflatoxin B1. This compound is produced by Aspergillus flavus found on poorly 
stored grain and it is a strong hepatocarcinogen. It is also an example of a procarcinogen 
as it requires metabolic activation by liver enzymes to give the ‗ultimate‘ carcinogen; 
dihydrodiol epoxide. Synthetic compounds can act directly or indirectly as carcinogens. 
Chemotherapeutic agents such as cyclophosphamide and chlorambucil are weak 
alkylating agents but never the less do act to damage cellular DNA, cyclophosphamide 
is also a very powerful immunosuppressant and it is these characteristics that cause its‘ 
carcinogenic properties. Indirect carcinogens require metabolic activation; there are an 
enormous number of these compounds. Aflatoxin B1 has been discussed but food 
additives have also been shown to act as indirect carcinogens. Azo dyes, used in the past 
to colour food e.g. margarine are metabolised in humans by urinary glucuronidase. The 
carcinogen produced predisposes to the development of bladder cancer (Robbins, 
1989b). Many infective agents, particularly viruses, both DNA and RNA have been 
shown to be oncogenic and their study has led to many breakthroughs in the 
27 
 
understanding of carcinogenesis. Infection with the Epstein-Barr virus, particularly in 
the presence of malaria increases the risk of Burkitt‘s lymphoma, hepatitis C virus is 
associated with hepatocellular carcinoma and certain strains of human papilloma virus 
(HPV 16 and 18), cervical carcinoma. The RNA virus human T cell leukaemia virus 1 
(HTLV-1) is implicated in the development of adult T cell leukaemia and lymphoma 
(ATLL). The correlation between radiation exposure and cancer has been clearly 
demonstrated. Ultraviolet light exposure and skin cancer have a strong correlation and 
there is an increase in the incidence of many different cancers in populations exposed to 
radiation after nuclear explosions. The ability of ionising radiation to produce 
mutagenic changes in DNA depends on the type and strength of the radiation, the 
duration of exposure and the nature of the tissue for example the thyroid is particularly 
radiation sensitive as are children compared to adults. 
The Mechanism of Cancer Pathogenesis 
Carcinogensis represents a series of steps beginning with initiation then promotion to 
produce a focal proliferative lesion. The cells of this lesion become autonomous, 
independent of normal homeostatic control. A cancer does not occur as the result of a 
single cellular event but as a consequence of a number of mutagenic events thus 
explaining the spectrum of disease seen from benign through precancerous lesions to 
true malignancy. Figure 2.7 is a diagrammatic representation of the steps involved. 
There can be a genetic predisposition to cancer however many carcinogens can also 
cause abnormal gene expression. Malignant neoplasias must develop certain 
characteristics; autonomy of growth, invasiveness and the ability to metastasize. It is in 
these areas that oncogenes and tumour suppressor genes have a rôle. The presence of 
mutations does not necessitate their expression and the body has developed both local 
and systemic controls utilising the immune system. Many tumours are weakly antigenic 
and vaccinations which protect against the development of certain cancers now exist. A 
vaccination against the human papilloma virus to reduce the risk of developing cervical 
carcinoma has proved very effective in clinical trials. Certain tumours have been shown 
to regress spontaneously. The degree to which the immune system can influence the 
development of neoplasia has, and still is, hotly debated. There is evidence to support 
the idea of T cell surveillance. Neoplasia induced by exposure to chemicals would 
appear to stimulate the formation of antigens that are unique. Tumours induced by 
exposure to viruses produce antigens that share characteristics with the virus itself. 
Certain antigens present in the embryo but not in adults are found to be re-expressed 
when neoplasia is present for example carcino-embryonic antigen (CEA) in the 
presence of carcinoma of the colon. These antigens are used to assess the presence of 
disease and response to treatment. Both natural and adaptive immunity play a part in the 
response to cancer. Natural immunity involving activated natural killer cells and 
macrophages can inhibit tumour cell growth and on occasions kill tumour cells by the 
release of compounds such as tumour necrosis factor. Adaptive immunity with the 
production of antibody is more likely to be effective against free cells such as those 
found in leukaemia than in solid mass tumours. Cell-mediated immunity against tumour 
cells by cytotoxic T cells has been shown to eliminate tumours in animal experiments 
and suppressor T cells can inhibit cytotoxic T cell function and stimulate tumour 
growth. This is seen in patients with Burkitt‘s lymphoma were high levels of an 
antibody similar to that found in infectious mononucleosis are found. It is felt that a 
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concomitant disease, in this case malaria, suppresses the normal cytotoxic T cell 
response allowing proliferation of the virus infected B cells (Robbins, 1989c). 
 
Figure 2.7: Pathogenesis of cancer (Adapted from Robbins, 1989d) 
2.5 Diseases of the Laryngopharynx 
A basic understanding of the anatomy of the larynx, and lymphoid system is extremely 
important to the understanding of the context of this work. The scope of the diseases 
that occur, their spread and treatment protocols all influence the type of diagnostic 
techniques that will be of use. It is the nature and anatomical configuration of the larynx 
and lymphoid system which dictate the type of diseases that occur and the ease and 
efficacy by which these diseases can be investigated, diagnosed and treated. 
2.5.1 Relevant Anatomy 
The structure of the pharynx and larynx plays has an intimate relationship with the way 
disease manifests in these areas and spreads beyond them. The three dimensional 
anatomy is complex so a simplified explanation of the main points is given in this 
section in order to place aspects of this research work in context and to clarify the 
references made to anatomical structures in the classification and staging protocols for 
laryngeal disease. 
 
The pharynx is a tube like structure approximately 12cm in length. It begins at the base 
of the skull and extends caudally to the level of the sixth cervical vertebra were it is 
contiguous with the oesophagus. It contains a series of defects anteriorly that allow for 
communication with the nose and mouth, distally it also communicates with the larynx 
via the laryngeal inlet. The walls of the pharynx are fibromuscular and are made up of 
four layers. When examined from inside to out; a mucosal, submucosal, muscular and 
fascial layer. The pharynx is divided anatomically into three parts, nasopharynx, 
oropharynx and laryngopharynx as seen in Figure 2.8. The nasopharynx extends from 
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the base of the skull to the level of the soft palate, the oropharynx from this point to the 
upper edge of the epiglottis, where the laryngopharynx begins. This lower portion ends 
at the point where the oesophagus starts. The cricopharyngeus muscle acts as a sphincter 
at the entrance to the oesophagus. The pharynx from the laryngeal inlet to 
cricopharyngeus may be referred to as the hypopharynx. In this part, on either side of 
the opening to the larynx, lie the piriform recesses. These recesses are obliterated as the 
wedge shaped hypopharynx narrows towards the cricopharyngeus muscle. Lying 
anteriorly at the level of the laryngopharynx the pharynx communicates with the trachea 
via the larynx and becomes contiguous with it at the same level as the laryngopharynx 
does with the oesophagus behind i.e. the sixth cervical vertebra which is also the level 
of the cricoid cartilage. 
 
 
Figure 2.8: Schematic diagram of the pharynx and larynx. 
The larynx is classified as a respiratory organ, in humans it has developed into the organ 
that is used for phonation but its primary rôle is to act as a sphincter to protect the 
airway. The larynx has a cartilaginous framework, the thyroid, cricoid and pair of 
arytenoids cartilages are composed of hyaline cartilage whilst the epiglottic and pairs of 
corniculate and cuneiform cartilages are made up of fibroelastic tissue. All cartilage 
elements of the larynx play an important rôle as attachments for the laryngeal ligaments 
and muscles but they also act as a structure over which the inner most mucosal lining of 
the larynx is draped allowing support for the vocal cords and the formation of a series of 
spaces. The thyroid cartilage lies a little higher than the cricoid cartilage and has two 
laminae which lie anteriorly meeting at the midline to form the laryngeal prominence; 
the Adam‘s apple. The cricoid cartilage is the main cartilaginous building block of the 
larynx and is the only complete cartilaginous ring. Its shape, articulation with the 
arytenoid cartilages and relationships to the thyroid cartilage are shown in Figure 2.9. 
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Figure 2.9: Anatomy of Thyroid and cricoid cartilages. 
The cricovocal membrane is the name given to the upper part of the cricothyroid 
ligament. The vocal folds, or cords, are formed from the free edges of the cricovocal 
membranes, one from each side. These membranes slant upwards from the inner surface 
of the arch of the cricoid cartilage and have an anterior attachment to the inner surface 
of the thyroid cartilage at the level of the laryngeal prominence. The arytenoid cartilages 
articulate with the cricoid cartilage posteriosuperiorly and are the posterior attachment 
of the vocal folds. The gap between the folds is called the rima glottis and is a V shaped 
space in the horizontal plane with the apex of the V lying anteriorly (Last, 1995). The 
drawings in Figure 2.10 show lateral views of the larynx. In these figures the lateral 
wall of the larynx, above the level of the cricoid cartilage has been cut away to show the 
inner part of the larynx at the level of the vocal folds and rima glottis. 
 
The space that exists between the laryngeal inlet below and the vestibular folds above is 
called the vestibule. There is a second space between the vestibular and vocal fold on 
each side which is slit like and projects laterally; these are called the laryngeal 
ventricles. Whilst diseases of the vocal cords themselves usually present early with 
symptoms of a hoarse voice disease present in these spaces can remain occult until 
directly visualised. 
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Figure 2.10: Human larynx - Line diagram and operative drawing of lateral view with 
outer wall cut away. 
2.5.2 Aetiology  
The development of epithelial cell tumours is thought to be multifactorial involving a 
series of steps underpinned by genomic instability and exposure to environmental risk 
factors (Hittelman, 2001). Koufman et al have presented a multifactorial model for 
carcinogenesis of laryngeal mucosa (Koufman, 1997). 
Genetic and molecular biology 
Both genetic and mutagenic factors are thought to have a rôle in the aetiology of head 
and neck squamous cell carcinomas (HNSCC), much work has been done to investigate 
the expression of molecular markers for premalignant laryngeal lesions with clinical 
prognosis and to establish genetic factors that determine susceptibility. There have been 
several review articles that summarise this work (Cattaruzza, 1996; Maier, 1997; Sadri, 
2006). Genetic predisposition can be investigated using the bleomycin sensitivity assay 
(BSA) which assesses chromosomal instability and hence the risk of developing a 
laryngeal cancer associated with exposure to environmental risks. Broadly speaking the 
risk of induced mutagenic changes from environmental exposure to carcinogens appears 
to decrease from the oral cavity caudally through the aero-digestive tract towards the 
larynx (Szekely, 2005). Studies of polymorphism in carcinogen-metabolising enzymes 
such as glutathione-S-transferase and cytochrome P-450 have shown an association 
with genetic predisposition to development of laryngeal carcinoma, but not pharyngeal 
carcinoma (Jahnke, 1996; Matthias, 1998). Other gene polymorphisms have been 
investigated as possible markers for genetic susceptibly (Varzim, 2003). In this study 
the presence of the CYP1A1 NcoI HT genotype was associated with a 2.3 fold increase 
in the risk of developing laryngeal cancer especially in smokers who had inherited 
certain genotypes. Known molecular alterations associated with tobacco smoking and 
resulting in an increased risk of developing laryngeal cancer now include mutations of 
the p53 tumour-suppressor gene, loss of heterozygosity (LOH) in chromosomal loci 
encoding for the p53, p16 genes (Szyfter, 1999; Lewensohn-Fuchs, 1994) and other 
tumour suppressor loci (Sasiadek, 2001). Over expression of the cyclin D1 gene 
(CCND1) is found in approximately 20% of laryngeal carcinomas. The three main 
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subgroups of head and neck squamous cell carcinoma are, oral, pharyngeal and 
laryngeal. Studies have demonstrated that specific differences exist in the pattern of 
genetic alterations between these anatomical sites and hypotheses have been formulated 
as to the most important initiating chromosomal events and the oncogenetic tree models 
complied for tumour progression (Huang, 2002). 
Smoking and Alcohol 
Since the early 1970s studies have correlated the increased risk of developing laryngeal 
cancer with cigarette smoking. It was established early that subjects smoking unfiltered 
cigarettes, particularly cigarettes containing high tar content had a relatively increased 
associated risk of developing laryngeal cancer (Wyder, 1979). A large, case-controlled 
study has shown an overall increase in the risk of developing cancer in the upper aero-
digestive tract in patients with significant alcohol consumption and to a lesser degree in 
smokers. In this study alcohol consumption was associated much more strongly with 
oral cavity, pharyngeal and extrinsic laryngeal tumours whereas smoking without 
excessive alcohol consumption increased the risk of developing intrinsic laryngeal 
carcinoma (Elwood, 1984). Different types of alcohol appear to confer differing risks 
with red wine and strong spirits causing the greatest increase in risk (De Stefani, 1987). 
Smokers have an increased risk of developing a carcinoma throughout the whole aero-
digestive tract however the risk appears to decline in those subjects who stop smoking 
(Choi, 1991). In male smokers the risk at all sites increased with increasing duration of 
smoking and increased consumption per day. Alcohol consumption also linearly 
increased risk, 15-fold for oral cavity cancers and 11-fold for the pharynx and larynx. 
Overall alcohol was felt to be a weaker risk factor in the larynx than smoking but that a 
synergistic effect existed. DNA damage and mutations in the p53 gene have been shown 
to be related to inhalation of tobacco smoke (Pfeifer, 2002). 
Diet 
In 1981 variation in the dietary intake of vitamins was associated with changes in the 
risk of developing laryngeal carcinoma with reduced intake of vitamins A and C 
increasing the risk 2-fold (Graham, 1981). Investigations into the possible effects of 
dietary iron and zinc have been inconclusive. Subjects who reported a diet high in these 
elements appeared initially to have a reduced risk however after further study with 
analysis of nail clippings no actual increase in the concentration of iron or zinc in tissue 
was detected. A case-controlled study of salted meat consumption has shown that high 
intake has a significant association with an increased risk of developing laryngeal 
cancer and that this is compounded by smoking in a synergistic way. Fresh meat also 
showed this trend however after the consumption of fresh meat was accounted for the 
results for salted meat persisted (De Stefani, 1995). A multi-centre European study 
published in 1996 noted cancers of the larynx were less prevalent in subjects who had a 
diet rich in vitamin C and A, fruit, vegetables, vegetable oils and fish along with low 
intake of butter and processed meat (Esteve, 1996). Using a case-control study it has 
also been shown that consumption of raw tomatoes and other lycopene containing foods 
is strongly associated with a reduced risk of development of upper aero-digestive tract 
neoplasia. (De Stefani, 2000). More recent epidemiological studies have evaluated and 
confirmed the generally perceived protective influence of a Mediterranean diet against 
these types of cancers (Bosetti, 2002 & 2003) in addition increased risk was observed 
with higher consumption of eggs, red and processed meats, sugars and mixed seed oils. 
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Gastro-oesophageal Reflux Disease (GORD) 
 In the 1980s attention was drawn to the possibility that GORD might be a risk factor 
for the development of laryngeal disease (Morrison, 1988). This study was limited by a 
small sample number as was a more recent retrospective review of patients with GORD 
(Freije, 1996). Both these studies looked at patients who lacked the generally accepted 
common risk factors however there are larger studies, using pH monitoring within the 
oesophagus, which cast doubt on this association (Chen, 1998; Pellicano, 2000) 
Occupational and Radiation Exposure 
A large case-controlled study published in 1984 investigated some of the possible 
occupational risks that might be associated with the development of laryngeal cancer, 
particularly nickel and chromium (Olsen, 1984). A positive correlation was 
demonstrated for unskilled and semiskilled workers, particularly those exposed to dust 
and those working in the cement and port industries. The study found no support to 
implicated chromium however exposure to nickel was felt to significantly increase the 
risk of developing laryngeal cancer. More recent case-controlled studies have confirmed 
the risk conferred by cement dust exposure (Dietz, 2004). Hypopharyngeal cancer has 
also been shown to be associated with exposure to coal dust and formaldehyde 
(Laforest, 2000). A study in Sweden seeking to correlate increased risk in meat workers 
did not concluded that the apparent increased risk associated with employment as a 
butcher could be explained when other lifestyle choices were taken into consideration 
such as smoking and alcohol consumption. It did however postulate that the increased 
risk demonstrated in other meat industry workers might be due to exposure to 
nitrosamines and polycyclic hydrocarbons (Boffetta, 2000). Exposure to aluminium and 
lead has been implicated in the development of precancerous lesions such as laryngeal 
papillomatosis and laryngeal cancer (Olszewski, 2006). 
Asbestos 
Stell et al first noted the association of asbestos exposure and laryngeal carcinoma in 
work published in 1973 (Stell, 1973). Since then there have been several studies but the 
situation remains unclear and more recent review articles have cast doubt on this 
association (Griffiths, 2003). 
HPV 
This association was first noted in 1983 and shortly after a case study was published of 
a 6 year old child with recurrent laryngeal papillomatosis. At post mortem area of 
laryngeal mucosa were shown to have undergone malignant transformation (Solomon, 
1985). This association has been extensively investigated but the rôle of infection with 
the human papilloma virus (HPV) in the aetiology of laryngeal cancer remains 
controversial. A study has shown that the p53 genetic mutation is associated with the 
integration of HPV-11 in malignant lesions (Rady, 1998). HPV DNA has been detected 
in cancers of the head and neck and in patients with respiratory papillomatosis however 
viral subset profiles differ and increased levels of oncogenic HPV are not universally 
present in patients with laryngeal carcinoma and leucoplakia (Major, 2005). After 
correction for smoking and alcohol consumption patients with HPV infection do show 
an increased risk of developing laryngeal cancer (Smith, 2000).More recent work has 
investigated the link between the presence of HPV and transfusion transmitted virus 
(TTV) in the aetiology of laryngeal disease concluding that co-infection with genogroup 
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1 TTV and HPV was associated with more rapid laryngeal tumour progression 
(Szladek, 2005). 
Immune Deficiency 
Oral, pharyngeal and laryngeal carcinomas have been shown to arise more commonly in 
immunosuppressed patients such as those that have undergone liver transplantation  and 
appear also develop at a much earlier age in patients infected with the human 
immunodeficiency virus (HIV) (Scheifele, 2005). 
Novel Ideas 
Mitomycin C has been used topically within the larynx to reduce scarring however a 
case report has been published suggesting that its use may be implicated in the 
development of a laryngeal carcinoma (Agrawal, 2006) 
2.5.3 Classification and Staging of Disease 
2.5.3.1 General classification 
The classification of disease within a specific anatomical area can be done in many 
ways. The most widely used and practical concept used by surgeons is called the 
‗surgical sieve‘. A clinician will approach the diagnosis of a lesion in a step-wise 
fashion with all the possibilities assigned under a heading that link them such as 
vascular, infective, inflammatory or neoplastic. These possibilities are then narrowed 
down in light of the clinical picture and results of investigations. For example a lesion 
that appears to fall into the neoplastic group may be either benign or malignant and may 
also be subclassified in relation to the type of cell from which it originated. The most 
common neoplastic lesion found within the larynx is squamous cell carcinoma; it is 
malignant and originates from squamous epithelial cells. Figure 2.11 summarises part of 
this surgical sieve and more full describes the differential diagnoses of neoplasms found 
within the larynx. It must be emphasised that the largest contribution by far in the 
section classifying possible malignancies are SCCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Part of the 'surgical sieve' used to classifiy diseases of the larynx. 
 Traumatic 
o Vocal cord nodules 
 Inflammatory 
o Rienkes oedema 
 Infective 
o TB 
o HPV virus 
 Neoplasic 
o Benign 
 Papillomas 
 Haemangiomas 
 Cartilageous tumours 
 Schwannomas 
 Neurofibroma 
 Granular cell myoblastomas 
 Paragangliomas 
 
o Malignant 
 SCC 
 Verrucous 
carcinoma 
 Adenocarcinoma 
 Fibrosarcoma 
 Carcinoid 
tumours 
 Mucoepidermoid 
tumours 
 Adenoid cystic 
carcinoma 
 Rhabdomysarcom
a 
 Plasmacytoma 
 Malignant 
synovioma 
 Kaposi‘s sarcoma 
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2.5.3.2 Staging 
Aims of Staging 
Staging is a process by which cancers are divided into groups which behave in a similar 
ways. The grade of a specific tumour is defined as the degree of differentiation present 
in the cells and it is convention to grade a tumour with respect to the area with the most 
advanced disease. There are correlations between tumour grade and prognosis but they 
are considered weak, tumour stage has a much more significant prognostic value. The 
first defining staging parameter is the anatomical site of the primary tumour, 
additionally histological type, size and extent of the tumour, particularly in respect to 
haematological and lymphatic spread, are important. With progress in areas such as 
molecular biology other parameters are now beginning to play an important rôle in 
defining the stage of some diseases. This is particularly important for some neoplasms, 
notably in lymphomas were the natural history of the diseases are such that they do not 
lend themselves to this classical view of staging; this will be further discussed in 
Section 2.6.2. 
 
Staging is primarily used as a guide to treatment and as part of the assessment of 
suitability for adjuvant therapy. A patient presenting with a small vocal cord carcinoma 
requires a completely different treatment plan to that of a patient presenting with a large 
invasive tumour and regional lymph node metastases. Staging is also used as a guide to 
prognosis; this is of immense importance to the patient and also to the clinician and 
researcher. For laryngeal disease clinical stage and anatomical subsite still offer the 
strongest practical predictors of outcome although the presence of molecular and 
cellular markers such as apoptosis index, p53 aberration and angiogenesis may play a 
rôle in the staging of laryngeal neoplasia in the future (Teppo, 2003). Staging also 
allows the results of different treatment protocols to be compared between groups of 
patients with the same stage of disease. This is imperative in the assessment of new 
techniques and to allow accurate audit and comparison of results between treatment 
centres. 
Criteria for staging laryngeal malignancy 
There are two principle staging classifications for head and neck cancer One published 
by the American Joint Committee on Cancer (AJCC) and the second by the Union 
Internationale Contre le Cancer (UICC). The most recent handbooks published by these 
organizations are The Manual for Staging Cancer, Ed 6 (AJCC) and the TNM 
Classification of Malignant Tumours, Ed 6, (UICC). To establish uniformity between 
these two classifications a supplementary publication is available; The TNM 
Supplement: A Commentary on uniform use, 3rd Ed. For the purposes of this thesis the 
TNM staging classification has been used for all neoplasias of the head and neck, 
excluding lymphomas. 
TNM Classification of Malignant Tumours- Larynx 
This classification was developed between 1943 and 1952 by Prof Pierre Denoix at the 
Institute Gustave-Roussy in France. It is anatomically based and records the site of the 
primary tumour (T), any regional lymph node involvement (N) and the presence or 
absence of metastases (M). To simplify the number of permutations the different 
categories are grouped. These groups are designated as stages and given Roman 
numerals, stage I, II, III and IV. The system can be used to assign a pre and post-
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surgical clinical stage as well as a pathological stage (pTNM). The former are 
anatomically based relying on clinical examination, imaging, laboratory tests and 
biopsy results and is determined before any treatment is given. The latter utilises 
additional information obtained from pathological examination of the tumour after 
resection. Both systems are of practical use, the clinical TNM stage is used to formulate 
an initial management strategy and the pathological TNM stage is used to help 
determine what adjuvant therapy and follow-up will be required. The full TNM 
classification of laryngeal carcinoma can be found in Appendix B, Figure 2.12 is a 
summary for the glottis. 
 
 
Summary—Glottis 
 
T1 
Limited to vocal cord(s), normal mobility  
a.  one cord 
b.  two cords 
 
T2 Supraglottis, subglottis, impaired cord mobility 
T3 Cord fixation, paraglottic space, thyroid cartilage erosion 
T4a 
 
Through thyroid cartilage; trachea, soft tissues of neck: deep/extrinsic muscle of 
tongue, strap muscles, thyroid, oesophagus 
T4b Prevertebral space, mediastinal structures, carotid artery 
 
 
Figure 2.12: Summary of the TNM classification of malignant disease of the glottis. 
2.5.4 Non-spectroscopic Diagnostic Techniques for Laryngeal Disease 
2.5.4.1 General 
Accurate outpatient assessment of the larynx in patients presenting with laryngeal 
disease is imperative. A great many patients are referred for otolaryngological 
assessment with altered voice but in many cases these symptoms are not due to cancer. 
In those cases were suspicious areas of mucosal change are found a simple, accurate and 
acceptable procedure aids early diagnosis, subsequent follow-up and ultimately 
improves prognosis. 
2.5.4.2 Optical 
Indirect Laryngoscopy 
In the past outpatient examination of the larynx was by indirect laryngoscopy. This 
technique involved placing a mirror behind the uvula at an angle resulting in an image 
that could be viewed per orally. The great advantage of this technique is its simplicity; 
the only equipment needed was a mirror, light source and swab to hold the tongue. The 
disadvantages are that the view is often limited particularly if the patient has an over 
hanging epiglottis or a sensitive throat and cannot tolerate the procedure. 
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Nasendoscopy 
In the developed world indirect laryngoscopy has been superceded by the use of the 
flexible nasendoscope, Figure 12.13. This technique involves passing a fine, flexible 
endoscope through one side of the nose, the post nasal space and over the superior 
aspect of the soft palate to view the laryngeal inlet below. By asking the patient to say 
certain vowel sounds an assessment of the vocal cords may be made. This procedure is 
often done without anaesthetic but if required this can be applied using a nasal spray. 
Whilst this procedure is usually tolerated very well there are a very few patients in 
whom it is not or in whom the anatomical configuration does not allow an adequate 
view. In these patients, were there is any suspicion of malignancy, a formal endoscopy 
is performed under general anaesthetic. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Flexible nasendoscopy; equipment, technique and view of normal vocal cords.  
Stroboscopy 
Laryngostroboscopy has been used for many years and remains an extremely useful tool 
in the assessment of the vocal cords for the presence of invasive malignancy 
(Bigenzahn, 1998). Even superficial lesions of the cords that invade the muscle below 
produce interruptions in the stroboscopic signal. 
Contact Endoscopy 
Contact endoscopy of the larynx has been used in the past to help delineate areas of 
mucosal change in the larynx but is no longer widely practiced; it is a form of 
chromendoscopy. A compound, for example toluidine or methylene blue, was applied to 
the area of the vocal cord under investigation with malignant tissue showing an 
improved uptake of the dye (Thomsen, 1975). Whist the results suggested that this 
technique might be useful the practical problems encountered during its use such as 
leaching of dye has limited uptake of the technique. 
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2.5.4.3 Histopathology 
General 
The larynx is considered part of the respiratory tract and for the most part it is lined with 
pseudostratified columnar ciliated epithelium, however the stratified squamous 
epithelium which covers the anterior epiglottis can project onto its posterior surface and 
by varying amounts can creep caudally onto the aryepiglottic folds and into the 
vestibule of the larynx. Areas of squamous metaplasia can also be found within the 
ciliated epithelium of the vestibule however the normal mucosa over the vocal folds is 
always stratified squamous and is firmly attached to the vocal ligaments. Scattered 
mucous glands can be found throughout the larynx but these are generally concentrated 
in the saccule. The step wise progression of disease change within the larynx, 
particularly on the vocal cords is one of the reasons Raman spectroscopy might offer a 
viable diagnostic tool. The criteria for histological classification of laryngeal disease, 
including grades of dysplasia are summarised in Appendix C. 
 
Cytology has been used in the past to assess cells removes from the vocal cord by 
brushing during microlaryngoscopy (Lundgren, 1982) but this is no longer regularly 
practiced. Certain cell markers namely mini-chromosomal maintenance protein-2 and 
Ki67 found in laryngeal squamous epithelial lesions may improve the diagnosis by 
increasing objectivity and reliability of disease grade when used in conjunction with 
confocal microscopy to assess expression patterns. Flow cytometric analysis has 
recently been used to diagnose carcinoma occurring in the head and neck (Abou-
Elhamd, 2007). In this study DNA image cytometry was used to assess if DNA ploidy 
could predict clinical outcome. Imprint cytology has also been mooted as future 
diagnostic technique (Loncar, 2007). The results of this study appeared very promising 
however the inherent drawbacks of cytology, inter-observer error and error induced by 
poor handling and preparation of the tissue, remain problematic. 
 
There has been a great deal of interest in the use of molecular biology in the study of 
head and neck cancers. Investigation of tumour biology has concentrated on analysis of 
treatment results and the search for prognostic indicators. This is a huge area of ongoing 
work and as yet no single test has been found to be predominant however there is a 
great deal of work on the expression of the p53 gene. It is known that over expression of 
p53 at the edges of resected laryngeal cancers which macroscopically appeared free 
from disease reflects a similar poor prognosis to those specimens resected with positive 
margins (Brennan, 1995). Similarly the assessment of dysplastic lesions using 
immunohistochemical markers for differentiation such as cytokeratins and involucrin 
(Mills, 2008) 
2.5.4.4 Imaging 
Computed Tomography Scanning (CT) and Magnetic Resonance Imaging (MRI) 
In the past patients with laryngeal cancer underwent chest x-ray to detect the presence 
of concomitant bronchial tumours or the presence of lung metastases. This investigation 
has now been superceded by the use of computed tomography scanning (CT). CT 
scanning also gives good visualization of thyroid cartilage infiltration form laryngeal 
tumours. Comparative studies of CT scanning with other investigative modalities were 
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done in the 1980s (Charlin, 1989).This study compared the abilities of CT and 
endoscopy to stage laryngeal malignancy and found them to be complementary. CT is 
both low in cost and widely available and with the advent of spiral-CT scanning which 
allows three dimensional reconstruction it may in the future be utilised further (Xu, 
2007). One way to achieve this may be the development of a computer tomography 
virtual endoscopy (CTVE), (Sanuki, 1997; Gallivant, 1999). MRI and CT have 
historically been seen as competitors. MRI facilitated multiplanar imaging earlier than 
CT scanning and produces better delineation of soft tissue (Casselman, 1992). Its ability 
to delineate the extent of disease allows for accurate staging and improved operative 
planning. In 2006 a preliminary study assessed the ability of diffusion-weighted MRI to 
evaluate the larynx after patients had been treated with radiotherapy (Vandecaveye, 
2006). This type of scanning is non-invasive and probes tissue by determining the 
movement of water. This study had a very small sample size however it is likely this 
will be an area for future investigation and may offer an alternative to Positron 
Emission Tomography (PET). 
Positron Emission Tomography (PET) scanning 
PET scanning is based on the detection of a radioactive tracer which is introduced to the 
body intravenously and can be varied depending on which tissue is under 
investigation.PET scanning can be used to assess physiological function such as blood 
flow and metabolism. Using a fluorine 18 radioactive glucose analogue, 18-
fluorooxyglucose, the rate of cellular glucose consumption can be measured and used to 
distinguish between malignant and benign tissue in the head and neck (Foehrenbach, 
2002; Israel, 2007). This type of scan is not widely available and the cost of the 
equipment is large however it is now used in specific areas such as the detection of 
occult head and neck malignancy particularly in patients who have radionecrosis and/or 
surgical scarring and in whom clinical assessment can be very difficult. The lack of PET 
scanners in the UK means many suitable patients still undergo CT scanning as an 
alternative. 
 
The efficacy of different imaging modalities for the detection of metastatic lymph node 
disease arising from a primary tumour in the larynx has been studied (Kau, 2000). In 
this study CT and MRI scanning were felt to be superior to neck palpation. Ultra sound 
examination also appeared slightly better, PET scanning and ultrasound guided fine 
needle aspiration cytology gave the best results. 
Scintigraphy and Super-imposed Dual Isotope Scanning (SPECT) 
99mTc-tetrofosim scintigraphy has been investigated as a possible way of staging 
laryngeal cancer (Fattori, 2005). This study compared the results of scintigraphy with 
those obtained from CT scanning. Both modalities were found to be equally sensitive 
(96%) for identification of the primary tumour. CT was significantly more sensitive in 
detecting lymph nodes containing metastatic disease (100% vs. 50%) however the 
specificity of 99mTc-tetrofosim scintigraphy was much higher than CT scanning (100% 
vs. 56%). The invasion of thyroid cartilage is normally assessed with CT initially then 
with histology from a resected specimen. In 2004 a study investigated the use of isotope 
scanning with dual-isotope SPECT images obtained from tumour being superimposed 
onto SPECT bone scans which were taken simultaneously. Although the numbers in this 
study were small the results were encouraging. 
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Colour Duplex Echography 
Colour duplex echography is not widely used in the UK but is in the United States as a 
way of assessing blood flow (Leuwer, 1997). This study assessed the ability of colour 
duplex echography to help distinguish the margins of malignant tissue within the head 
and neck by analysis of blood flow. It was noted that the central portion of tumours 
where relatively poorly vascularised compared with those seen at the periphery of the 
lesion and it was felt that this technique would only be a useful adjunct to other staging 
procedures. 
Endolaryngeal high-frequency ultrasound 
This technique has also be used in the assessment of diseases of the head and neck 
(Arens, 1998) but has not as yet borne out its‘ early potential because of the availability 
of less invasive and more cost effective procedures. 
2.5.5 Treatment 
The treatment of laryngeal cancer is currently undergoing great change. Treatment of 
primary tumours and metastatic spread to regional lymph nodes has been based around 
three modalities; surgery, radiotherapy and chemotherapy. Generally the TNM stage of 
a tumour has determined which of these, or which combination of these, should be used 
however technology is advancing and so too are surgical techniques and this in turn is 
greatly influencing options for treatment. The ideal aim of treatment is cure however 
where this is felt to be impossible then local control is of paramount importance. The 
guidelines for the treatment of cancer of the head and neck are published by the British 
Association of Otorhinolaryngologists and Head and Neck Surgeons (BAO-H&N). 
Carcinoma of the larynx at the in situ, T1 or T2 stages have a 80-90% chance of cure 
independent of the treatment modality; surgery or radiotherapy (Marioi, 2006), and until 
recently early cancers of the larynx have been treated with radiotherapy ensuring voice 
preservation. The disadvantage of this approach has always been the fact that there is a 
limit to the radiation tissue can be exposed too. This has meant that should a recurrence 
or another primary tumour of the head and neck occur salvage surgery has been the only 
treatment available for local control. This type of surgery is technically very difficult as 
it is done on a background of tissue radiation damage which destroys anatomical 
landmarks, can make haemostasis difficult and healing poor. Surgery for small primary 
laryngeal cancers has changed enormously over the last few years with the advent of 
laser surgery. Cancers up to T3 can be removed using a CO2 laser and this opens up the 
possibility of retaining radiotherapy as a second line management strategy. 
2.5.6 Clinical Relevance of Raman Spectroscopy 
There are a large range of techniques available, both spectroscopic and non-
spectroscopic for the diagnosis and staging of laryngeal malignancy. The key in 
treatment is early detection but the progression of cellular changes through the disease 
spectrum is continuous. Determination of the cut off points for histological grading are 
difficult to make and interpret consistently. Definitive diagnosis is reliant on histology 
from tissue resected from the larynx. This procedure is not without risk as it involves 
manipulation of the airway and the patient requires a general anaesthetic. 
Nasendoscopic evaluation of the larynx is highly subjective but is the mainstay of 
outpatient clinic assessment, both at presentation and during follow-up. A way of 
objectively assessing the degree of dysplasia present on a vocal cord in clinic or at the 
edge of a laser resection of a vocal cord lesion during surgery would be a tremendous 
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step forward. It is hoped that Raman spectroscopy will, in time be able to fulfil these 
rôles. 
2.6 Diseases of the Lymphoreticular System  
The lymphatic system comprises of all lymphoid tissue in the body and the lymphatic 
vessels connecting them. Section 2.6.1 gives an explanation of the structure and 
function of the different components of this system. 
2.6.1 Relevant Anatomy 
2.6.1.1 Lymphatic vessels 
These vessels are analogous to those found in the vascular system but are smaller and 
contain lymph not blood. In subcutaneous tissue they generally run alongside veins and 
in deeper tissue arteries. The two systems, lymphatic and vascular are intimately related 
but not directly connected except via the thoracic duct. Hydrostatic pressure and 
electrolyte differences allow the transfer of fluid from vascular capillaries through the 
tissue interstitum into lymphatic vessels which then form a plexus present in all tissues. 
Groups of lymph nodes are scattered throughout the body and are usually related to 
larger blood vessels. Lymph nodes contain both afferent and efferent lymphatic vessels 
and the route lymph takes after passing through a node can vary enormously depending 
on which efferent vessels it chooses. The only lymphoid organs that do not have 
afferent lymphatic vessels are the thymus and spleen. Lymph fluid eventually returns to 
the circulation via the thoracic duct which joins the vascular system at the confluence of 
the left subclavian artery and internal jugular vein in the root of the neck. The lymphatic 
system is generally considered ‗one-way‘ as larger lymph vessels contain valves 
however despite this the clinical spread of disease by the lymphatic system, infective 
and neoplastic, does not always follow a strict anatomical progression. Lymph nodes 
can be by-passed, alternative efferent vessels used and distal increases in pressure, for 
example as a consequence of obstruction, can compromise lymph valves and cause back 
flow. One of the consequences of the vast number of interconnections within the 
lymphatic system is that surgeons can tie off the thoracic duct with impunity and lymph 
will always find a path which allows it to recirculate back into the vascular system. This 
is one of the mechanisms by which ‗surveillance‘ information can be shared with other 
areas of the body where immune mediators are produced. 
2.6.1.2 Lymph 
Lymph is the name given to the fluid which circulates in lymphatic vessels and is an 
ultra-filtrate of blood. It contains proteins and cells such as B and T lymphocytes, 
macrophages and antigen-presenting cells (APCs) which mediate in the response to 
disease. The body has several defence systems the most basic being the physical barrier 
provided by skin however it can also mount a defence against attack by using non-
specific mechanisms to recognise, engulf and destroy foreign material - phagocytosis. 
The immune response is a more specific defence mechanism reacting to foreign 
particles and micro-organisms. 
 
There are two types of immune response, humoral and cell-mediated, both require 
lymphocytes. All lymphocytes arise from a common stem cell and before birth they are 
produced by the embryological liver and the yolk sac, after birth by the bone marrow. 
Lymphocytes that settle and proliferate in the thymus are called T lymphocytes as they 
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are dependent on the thymus for development. After maturation they are released into 
the blood stream and colonise lymphoid organs. T lymphocytes are responsible in part 
for the cell-mediated immune response where by cells which circulate in the blood 
destroy and facilitate the destruction by phagocytosis of organisms and antigens 
perceived as foreign. Several subsets of T cells exist such as T helper cells, T killer cells 
and T suppressor cells. The second type of lymphocyte is the B cell, these are formed 
and mature in the bone marrow and are responsible for the humoral immune response. 
Normal B cells migrate from bone marrow into secondary lymphoid tissues such as 
lymph nodes and when exposed to an antigen they form germinal centres, proliferate 
and mature. B cells can develop into B memory cells or plasma cells and plasma cells in 
turn can produce protein molecules called immunoglobulins which attach to antigens 
allowing the combination of the two to be recognised and destroyed. B cells are not 
named after bone marrow but from the Bursa of Fabricus an organ in chickens in which 
the humoral antibody response was first noted. 
2.6.1.3 Lymphatic organs 
Lymphoid follicle 
Lymphoid follicles, also called lymphoid nodules are made up of a spherical collection 
of lymphocytes. The central area of the follicles is paler as the lymphocytes here are less 
densely packed together. Isolated lymphoid follicles can be found throughout the 
respiratory and gastrointestinal system mucosa and submucosa; those found in the ileum 
are known as Peyer‘s patches. 
Bone Marrow 
This is where B lymphocytes are produced and mature and its function with respect to 
the lymphoid system is described in Section 2.6.1.2. 
Thymus 
The thymus, as previously described, is where T cell lymphocytes are produced and 
mature. Its‘ structure is dissimilar to the other lymphoid organs as it is formed from 
several lobules and rather than having spherical follicular concentrations of 
lymphocytes they are arranged as a band around the outer cortex of the lobules. 
Lymph nodes 
The primary functions of lymph nodes are to act as filters and to facilitate 
lymphopoiesis and its related functions. Lymph nodes have simple connective tissue 
capsules, afferent and efferent lymphatics and contain the classical spherical 
arrangement of lymphoid follicles arranged around their periphery within the cortex of 
the node. The afferent lymphatics enter the node at its outer edge and continue through 
the paracortical areas via a series of anastomosing sinusoids which join together 
forming the medullary sinuses. They leave the node as the efferent lymphatic vessels at 
the hilum of the node. Sinusoids are lined with macrophages which filter material 
perceived as foreign and help in the initiation of specific immune responses. All cells 
within a lymph node work together but in certain types of response different cells which 
mediate in the response to disease will dominate. T cells are found in the deeper 
paracortical areas and will proliferate in response to organisms such as viruses 
otherwise most of the lymphocytes within lymph nodes are B lymphocytes, contained 
within primary follicles. Secondary follicles are those in which a germinal centre has 
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been formed and in which B cells are proliferating and this occurs in response to 
bacterial infections. Where there is enlargement of lymphoid follicles and increased 
production of B cells the term follicular hyperplasia is used. The structure of a normal 
lymph node is illustrated in Figure 2.14 and Figure 2.15 shows how they are classified 
to levels within the neck. 
 
 
 
 
 
 
 
 
 
 
 Figure 2.14: Sectioned lymph node and explanatory diagram of structure. 
 
 
 
 
 
 
 
 
 
 
Figure 2.15:Lymph node levels in the neck. 
Spleen 
The spleen is analogous to lymph nodes in many ways however it has a thicker 
connective tissue capsule and has blood rather than lymph passing through it. It plays a 
more prominent rôle when an antigen passes into the blood stream and acts by trapping 
organisms and stimulating immune cell proliferation. 
Tonsils 
The tonsils, both the palatine and pharyngeal are very similar to lymph nodes but differ 
from them in one major way. Both types of structures are encapsulated however the 
tonsil capsule is lined by stratified squamous epithelium which dips inwards forming 
crypts. This is an important point as it differentiates between lymph nodes and tonsillar 
tissue and means that a primary squamous cell carcinoma of the tonsil can occur where 
as it can only be found as metastatic disease within lymph nodes. 
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2.6.2 Classification and Staging of Disease  
The general classification of diseases which affect lymph nodes can be done in a similar 
way to those of the larynx using the ‗surgical sieve.‘ The most common neoplastic 
lesions found in lymph nodes are metastatic cancer arising from a different primary site 
and lymphoma. In neck lymph nodes metastatic disease is usually squamous cell 
carcinoma originating from the upper aero-digestive tract however a smaller number of 
other cancers do on occasions spread to nodes in this region for example 
adenocarcinoma. Lymphomas are a primary malignancy occurring in lymph nodes and 
are considered to be haematological malignancies manifest as solid tumours and include 
any tumour which arises from a lymphoid cell line. 
 
In 1971 a meeting was held in Ann Arbor in order to formulate a clinical classification 
for Hodgkin‘s disease (Carbone, 1971). This classification replaced the Rye histological 
classification and has been adopted by both the AJCC and UICC. It was later slightly 
modified to take into account disease bulk and number of sites affected; the Cotswold 
modification (Lister, 1989). The Ann Arbor classification has now been extended to 
include non-Hodgkin‘s lymphoma (NHL). Although the classification of lymphoma is 
complex there are very clear clinical and histological distinctions between the two 
groups. Hodgkin‘s lymphoma is comparatively amenable to treatment compared to the 
more resistant NHL and histologically NHL can be very hard to interpret. NHL appears 
to be a series of distinct diseases and clear delineation between them often requires 
sophisticated immunohistological diagnostic techniques and prediction of outcome has 
historically been based on an overview of several prognostic indicators.  
 
The clinical staging classification of lymphoma is primarily determined by the location 
of the tumour. This is then modified depending on the presence of additional symptoms 
which are subdivided into an A and B classification. Pathological staging follows the 
same criteria but in addition uses information gleaned from a laparotomy. If a full 
pathological stage is to be assigned the spleen must be removed for evaluation and liver, 
lymph node biopsies and a bone marrow trephine results included. The full Revised 
European American Lymphoma classification (REAL) and WHO classifications can be 
found in Appendix D. 
 
The classification of NHL has been a cause of great debate and the REAL classification 
is now widely used for the diseases that collectively make up NHL. It is based on a 
combination of clinical features, morphology and immunophenotyping (Harris, 1994). 
The REAL classification has also been the basis on which a World Health Organisation 
classification has been developed in the hope of unifying and developing an overall 
consensus document (Harris, 1999). Changes in the emphasis of the newer 
classifications have allowed these diseases to be subdivided on the basis of their clinical 
picture rather than just histological features. The division of NHL into low-grade and 
high-grade NHLs is commonly used and is based on the natural history of the diseases. 
Low-grade NHLs are generally considered less aggressive, responding well to treatment 
initially but with ultimately a fairly poor cure rate. High-grade NHLs are more 
aggressive initially but have good long term survival if the patient responds well to 
primary treatment. 
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2.6.3 Aetiology 
Hodgkin‘s lymphoma can present at any age but most commonly in young adults. The 
cervical lymph nodes are involved in 60-70% of patients (Hoffbrand, 2006a) and are 
usually enlarged, firm and rubbery to palpate. NHL is a group of diseases that have very 
diverse presentations however all lymphomas are malignancies that originate from a 
genetic aberration of a single bone marrow or lymphoid tissue cell. The remainder of 
this section and Section 2.6.4 summarises the principal aetiological and prognostic 
factors. Familial factors seem to play only a small part in the risk of developing 
lymphomas as does exposure to radiation, organic solvents and certain drugs. There is 
clear evidence of an increased risk in patients who also suffer from specific infections, 
for example malaria and Epstein-Barr virus (EBV). EBV is associated with the 
development of Burkitt‘s lymphoma, a high-grade, B-cell NHL. Other infections that 
have been implicated include the human immunodeficiency virus (HIV), human T-
lymphotropic virus type 1 and the herpes viruses. Bacteria such as Helicobacter pylori 
have an association with lymphoma of the gastro-intestinal tract. Patients with primary 
Sjögren‘s disease, a chronic autoimmune disorder of salivary glands, are at increased 
risk of developing non-Hodgkin's lymphoma (Hoffbrand, 2006b). 
2.6.4 Prognostic Factors in Lymphoproliferative Disease 
Hodgkin’s lymphoma 
Hodgkin‘s disease is highly amenable to treatment; prognostic indicators are used to 
determine what levels of intervention are required and to predict their chance of success. 
In stages I and II the extent of disease is felt to be a major prognostic indicator as is the 
volume of disease within an individual region. The presence of B symptoms is also felt 
to be a poor prognostic indicator as they are an indirect reflection of disease bulk. In a 
similar way haematological parameters such as anaemia, decreased serum albumin and 
elevated erythrocyte sedimentation rate (ESR) are also felt to predict a poor outcome. 
Older patients have generally been thought to have a poorer prognosis but it is now felt 
that early diagnosis in the older patient with early disease negates this and is a strong 
point in favour of the development of early, accurate diagnostic techniques. Patients 
with immunodeficiency appear to have a poorer prognosis as do males. Certain 
histological features are also regarded as prognostic indicators and it was on this that the 
Rye classification was based. Race has not been found to be a clear prognostic indicator 
for early disease but access to sophisticated diagnostic and treatment regimes have been. 
In stages III and IV the bulk of disease is much harder to evaluate. The number of sites 
involved, the amount of disease below the diaphragm, within the spleen and in the 
mediastinum are all considered important. In addition elevated, alkaline phosphatase 
and a reduction in white cell count, particularly in lymphocytes, are poor prognostic 
indicators. 
NHL 
In NHL the immunophenotype of the tumour is particularly important in determining 
prognosis. The majority of NHLs are B-cell in origin and these patients general fair 
better than those with tumours which have a T-cell phenotype. Tumour bulk is again a 
major prognostic indicator as are the presence of B symptoms, elevated serum LDH, on 
occasions elevated serum calcium and malnutrition. There are now many 
haematological, biochemical and molecular markers which can act as prognostic 
indicators and some of these are highly specialised for example the amount of protein 
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found in the cerebro-spinal fluid (CSF) of patients with primary brain lymphoma. Older 
age is an adverse prognostic indicator in all NHLs and seems to be related to the degree 
of tolerance that patients over 60 exhibit to treatment. Gender seems to be only related 
to poor outcome for males with early NHL. Immunocompromised patients do 
particularly badly with NHL the second commonest malignancy in patients with HIV. 
2.6.5 Non-spectroscopic Diagnostic Techniques for Lymphoproliferative Diseases 
Staging lymphoma is imperative in order to help choose the correct treatment modality 
for a patient, over and above a detailed clinical examination certain tests outlined below 
are usually carried out for accurate staging.  
Haematological and Biochemical Tests 
Haematological and biochemical tests used for staging include full blood count (FBC), 
erythrocyte sedimentation rate (ESR), liver function tests, lactate dehydrogenase (LDH) 
and C-reactive protein measurements. Surgery at present is mandatory before treatment 
to obtain a definitive diagnosis through histological and immunohistological analysis of 
affected lymphoid tissue although in some cases a tru-cut biopsy of a prominent lymph 
node may be done. Fine needle aspiration cytology will not confirm the diagnosis of 
lymphoma but can be used to confirm the presence of metastatic squamous cell 
carcinoma in a lymph node. In the past for full pathological staging a bone marrow 
trephine was taken from the iliac crest and diagnostic laparotomy done with 
splenectomy. Clinical assessment is thought to underestimate the amount of abdominal 
involvement in a large percentage of patients with clinical stage (CS) I and II of 
Hodgkin‘s disease but there is no recorded improvement in survival in patients who 
have undergone staging with laparatomy so this has now been abandoned (Carde, 
1993). 
Imaging 
Imaging plays a vital rôle in staging at all points during diagnosis, treatment and follow-
up. CT scanning of the chest and thorax has largely superceded the use of chest x-ray 
and is done for both staging and to monitor response to treatment. MRI scanning is 
commonly utilised and in certain centres full body PET scanning is used in the staging 
of both non-Hodgkin‘s and Hodgkin‘s lymphoma. It is particularly useful in 
combination with CT for the detection of small residual tumour masses post treatment. 
Bone scans can also be useful in detecting extralymphatic deposits. 
Histopathology and Immunohistochemistry 
Lymphoma cannot be reliably diagnosed from tissue frozen sections and requires 
paraffin sections. The definitive diagnosis of lymphoma is made on assessment of an 
excised lymph node and the histological feature which divides Hodgkin‘s lymphoma 
and NHL is the presence of Reed-Sternberg cells which are found in Hodgkin‘s 
lymphoma. 
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There are five sub-groups of Hodgkin‘s lymphoma defined histologically; 
 
 Nodular-sclerosing (NS) 
 Mixed cellularity (MC) 
 Lymphocyte depleted (LD) 
 Lymphocyte rich (LR) 
 Nodular lymphocyte-predominant. (LP) 
 
The majority of early Hodgkin‘s lymphoma is of the nodular-sclerosing (NS) and 
mixed-cellularity (MC) types. There is now scope within this classification for the 
presence of a lymphocyte predominant (LP) subgroup which in the early stages has an 
excellent response to treatment. Histological definition of NHL subgroups is difficult 
and immunohistochemistry is very useful in determining phenotype. If certain markers 
are present for example κ or λ light chains the presence of NHL is confirmed 
differentiating the node from a purely reactive one. This is off great importance 
particularly in children who often present with non-specific lymphadenopathy. Analysis 
of tumour cell antigens, immunoglobulin and T-cell receptors may also be useful. 
Cryogenetics, the study of specific chromosomal translocations is a relatively new and 
exciting field, certain translocations may be important in the diagnosis and prognosis of 
NHL (Hoffbrand, 2006c). 
2.6.6 Treatment 
Treatment of Hodgkin’s disease 
Patients with early stage Hodgkin‘s lymphoma are treated with either radiotherapy or 
combined radio and chemotherapy. Patients with early disease, particularly the LP sub-
group, are often treated with external beam radiotherapy alone. Fractionation and new 
ways of planning and delivering radiotherapy are making this an even more valuable 
form of treatment helped in some cases by the addition of chemotherapy which has led 
to a decrease in the amount of radiation required. Radiotherapy can be used to reduce 
the size of bulky tumours which are causing pressure effects and in the treatment of 
painful isolated bone deposits. Chemotherapy is used as the primary treatment modality 
in stages III and IV and also in patients with early disease but who have B symptoms, 
bulky disease or have relapsed after radiotherapy. In patients who relapse different 
combinations of chemotherapy can be used and autologous stem cell grafting. Stem cell 
transplantation involves the obliteration of the patient‘s immune and haemopoietic 
systems by chemotherapy, radiotherapy or both then the reintroduction of stem cells 
either from another person (allogenic) or a previously harvested set of cells from the 
patient which have been treated to allow re-colonisation to be successful (autologous). 
Treatment of Non-Hodgkin’s Disease 
It is impossible to generalise the treatment options for NHL as they constitute such a 
diverse group, however the low-grade NHLs diseases such as lymphocytic lymphoma 
are often very slowly progressing and require little treatment. Others such as follicular 
lymphoma can also have a benign course presenting in middle to old age with only a 
few cases transforming to the more aggressive form. The early localised stages of these 
diseases are often treated by radiotherapy alone; however the treatment of disseminated 
disease can vary from conservative management to chemotherapy and stem cell 
transplantation. The high-grade NHLs are generally more aggressive but with rapid, 
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targeted treatment patients have a good chance of long term survival. Treatment regimes 
for these diseases include radiotherapy, chemotherapy and stem cell transplantation with 
the main modality usually being chemotherapy. For example, diffuse large B-cell 
lymphoma is treated with an extended period of chemotherapy of 6 to 8 courses. 
2.6.7 Clinical Relevance of Raman Spectroscopy 
The development of lymphadenopathy is by no means pathognonic of lymphoma and in 
many cases is due to a response to infection. The need to clearly and simply 
differentiate between the two is imperative. This is true in all age groups but is 
particularly relevant in children as some of the investigative procedures such as fine 
needle aspiration cytology are very poorly tolerated. The pressure to undertake lymph 
node excision can be great however in children and in some adults this will often 
necessitate a general anaesthetic with its inherent risks as well as the risks to other vital 
structures in the neck and the inevitable resultant scarring. The greatest factor at play to 
support the development of Raman spectroscopy in this field is that the major 
prognostic factor for the response to disease in lymphoma is the extent of the disease at 
presentation. This presents a compelling argument for investment in the development of 
accurate, sensitive and minimally invasive diagnostic techniques, such as Raman 
spectroscopy
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Chapter 3: Materials and Methods 
3.1 Materials 
3.1.1 Laser and Static Spectrometer System  
The aim of using the system whose configuration is described below was to obtain good 
quality spectra with high signal-to-noise ratio and the lowest laser power possible to 
avoid damage to the biological tissue specimens. It was also hoped that by using a 
configuration consistently between different research work comparisons between results 
could be made. This was particularly true of the work carried out on lymph nodes from 
the head and neck where squamous cell carcinoma and lymphomas predominate 
compared to those obtained from the axillae and areas adjacent to the upper 
gastrointestinal tract where adenocarcinomas are most common.  
 
A customized Raman spectrometer system based on the commercially available 
Renishaw System 1000 microspectrometer coupled with an excitation source and 
confocal, polarized light, microscope (Leica DML) was used in this work. A labelled 
schematic diagram of this system can be seen in Figure 3.1 and a summary of the major 
components are given in Table 3.1. The path of the laser light before illumination of the 
specimen is nominally drawn in red and after illumination in green. A photograph of the 
Renishaw spectrometer and experimental configuration used for obtaining point spectra 
is shown in Figure 3.2. Further pertinent details on individual parts of the system 
configuration are contained in the remainder of this section. 
 
 
 
Figure 3.1: Schematic diagram of Renishaw System 1000 microspectrometer (reproduced 
by kind permission of Renishaw spectrometer division). 
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Table 3.1: Major components of experimental configuration. 
Key Component Technical Detail 
1 
Excitation 
radiation source 
Diode Laser 
2 Mirror Directs laser light into the horizontal plane 
3 Steering mirror 
Direct laser light onto the laser-line rejection apparatus 
(4/7). 
 
4a & 4b 
Laser-line 
rejection filter 
apparatus 
This is made up of two parts (4a) a fixed mirror which is 
aligned to reflect only light of the laser-line towards the 
microscope (5) and (4b) an edge filter which removes any 
light with wavelength equal to that of the laser-line from 
the scattered radiation; allowing only light with an energy 
shift greater than 150cm
-1 
from the laser-line to pass 
through. 
 
5 
Lieca confocal 
microscope 
Light passes through the microscope and illuminates the 
specimen after which it is collected and redirected back 
horizontally towards the laser-line rejection filter 
apparatus. The laser-line light is reflected off the 
horizontal axis and the remainder of the scattered light is 
allowed to pass forwards in this plane towards the 
focusing lens (7) 
6 
Specimen 
presentation stage 
A motorized, computer controlled x-y-z translational 
stage used to allow accurate movement of the sample by 
computer control. This in turn allowed large numbers of 
spectra to be obtained with detailed signal positioning, of 
particular importance in mapping studies. 
7 Focusing lens 
Focuses the collected light onto an entry slit in the 
monochromator (8) 
8 
Monochromator 
entry slit 
Removes any scattered light which is out of focus from 
the sample volume. This improves spatial resolution and 
removes any fluorescence contribution from the tissue. A 
slit width of 50μm was used throughout these 
experiments. 
9 
Beam expanding 
lens 
 
10 Prism mirror 
A prism mirror with two reflective surfaces which allows 
light to be both directed towards a grating (11) and then 
collected from the grating after it has been dispersed into 
its‘ constituent wavelength components. 
11 Dispersion grating 
A single dispersion grating containing 300lines/mm used 
to separates the light into its‘ constituent wavelengths and 
allows it to be directed towards the CCD focusing lens 
(12). 
12 
CCD focusing 
lens 
This lens focuses the dispersed light onto  the CCD array 
detector (13) 
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13 
CCD array 
detector 
Sensitive to NIR radiation. 
 
14 
Control and 
analysis systems 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Renishaw spectrometer and experimental configuration for point spectra 
experiments. 
General points 
The laser system was bolted to a laboratory bench and the environment closely 
monitored and kept at 23
o
C. This was to reduce inaccuracies that might be caused in 
calibration and spectra signal by vibration and changes in ambient temperature. 
Excitation Source (1) 
The excitation source used was a high power, tuneable (750 to 950nm) Argon ion 
(Stabilite 2017, Spectra Physics) pumped Ti: Sapphire laser (3900S Spectra Physics). 
When NIR radiation is used as an excitation source it is unlikely to produce electronic 
absorptions and hence fluorescence within biological tissue. Using a radiation source 
with longer wavelength has the disadvantage of being within a range less efficiently 
detected by a CCD. This is because Raman scattering cross-section is inversely 
proportional to the fourth power of the wavelength of the excitation source used and as 
a consequence very high sensitivity detectors are needed. Work has shown that using 
this system 830nm is the optimum excitation source wavelength for measuring the 
Raman spectra from biological tissue such as that obtained from the larynx (Stone, 
2001a; Kendall, 2002b) and from lymph node tissue (Smith, 2005). This wavelength 
allows for optimisation of the Raman signal with minimisation of interference from 
fluorescence and was used in this work. A 300 lines/mm grating and a pair of edge 
filters (Semrock) were used to separate the Raman from the elastically scattered light 
and to disperse the spectrum across the deep depletion CCD detector. This was Peltier 
cooled to -70oC to reduce thermal noise. The beam of laser light was launched into the 
53 
 
spectrometer through a series of delivery optics which included the initial alignment 
mirror (2). 
Microscope (5) 
A confocal, polarizing light microscope was used with a x80 ultra-long-working-
distance objective. Both reflectance and transmission white light images could be 
recorded and the Raman signal was collected in backscattering geometry. Each 
component of the laser system absorbs energy and reduces the power available at the 
surface of the specimen (Stone, 2001b). When a x80 (Olympus) ultra-long-working-
distance (ULWD) objective is used in conjunction with a 500mW power output from 
the Ti: Sapphire laser 60mW power is detected at the sample (Kendall, 2002c). The 
choice of objective used was a balance. The numerical aperture (NA) is a way of 
describing the collection angle of a lens and is related to the refractive index of the 
material surrounding the lens and the maximum angle of collection from the optical axis 
of the lens. For the x80 ULWD objective NA=0.75, the maximum collection angle is 
48.6
o
 and collection efficiency 16.9%. The collection efficiency of this objective is 
greater than that of a x20 objective (4.2%) and whilst this reflects a greater ability to 
collect photons of light by the x80 objective the corresponding larger numerical aperture 
reduces the working distances and depth of field. This is an important consideration as 
the depth at which a Raman signal can be collected by different objectives will be very 
important in the design of equipment used clinically. In the larynx, malignant changes 
occur within the surface layer epithelium which is approximately 500 microns thick. 
This epithelium consists of layers of cells 10-20 microns in diameter and work 
analyzing the depth intensity profile for a Raman signal using different objectives has 
shown that has shown that the x80 objective has a poorer depth of field than a x50 
objective and this in turn is poorer than a x20. As a consequence using a x80 objective 
the Raman signal from only a depth of 2 to 3 cell will be obtained but for a x20 
objective this is increased by at least ten-fold however the background Raman signal 
seen with a x80 ULWD objective is lower than that from a x20 ULWD lens (Kendall, 
2002d). The objective chosen for use in the point studies in this work was the x80 
ULWD lens. 
Specimen presentation stage (6) 
The x-y-z stage used allowed specimens to be moved along all axes in pre-designated 
step sizes. 
Dispersion grating (11) 
Although the use of a single dispersion grating is advantageous in that it allows high 
signal through-put, its disadvantage is that it is inefficient at removal of stray light. The 
use of a single grating is made possible by the laser-line rejection apparatus, which 
contains edge filters (4b) and is placed in a position earlier in the system. The dispersion 
grating is mounted on a stage that allows for precision rotation and as a consequence 
permits selection of the spectral range studied. The grating was made up of 300 
lines/mm and this allowed signals up to 1980cm
-1
 to be recorded when the grating was 
static. 
CCD Array Detector (13) 
A peltier cooled depletion charge coupled device (CCD) was used which was sensitive 
to light in the NIR range of the electromagnetic spectrum. The CCD was made up of a 
54 
 
384 x 576 pixel array and the silicon wafer kept cooled to -70
o
C to reduce thermal 
noise. 
Control and Analysis Systems (14) 
The laser system was controlled using a Hewlett Packard Pentium II Vectra PC which 
allowed system configuration, calibration and data acquisition via a CCD interface card 
installed in the computer. The software used was Galactic GRAMS/32 (Graphic 
Relational Array Management System) and WiRE (Windows based Raman 
Environment), version 1.3.15. Galactic Grams software is a stand- alone 32 bit data 
processor software package designed to facilitate the analysis, display and storage of 
large datasets from spectroscopy. It also allows for automatic file conversion whereby 
foreign type data files are treated as having a SPC format. The WiRE software was 
designed by Renishaw for use with their spectrometers specifically and it provides all 
the basic instrument controls, calibration, data acquisition and analysis functions. 
3.1.2 Probe System 
This section is included for completeness and refers to work in which a portion of each 
lymph node sample underwent investigation using a Raman probe. The experimental 
work has been completed and data analysis is ongoing. A 2mm diameter (GASER level 
10), reusable Visonex fibreoptic probe was used in this series of experiments. The 
GASER scale is used to define depth of field with lower values indicating a longer 
working distance and larger depth of field. This probe consists of a central delivery fibre 
(400µm diameter) surrounded by seven collection fibres (300µm diameter) the actual 
experimental configuration is shown in Figure 3.3. 
 
Each probe fibre has a numerical aperture of 0.22 and is capable of sampling a volume 
of 1mm
3
 to a depth of 500µm (Crow, 2004).The delivery fibre commences at the laser 
excitation source and the collection fibres finish at the spectrometer. These two sets of 
fragile fibres are combined and held surrounded by a metal jacket for protection; this in 
turn was held by a retort clamp placed above the sample to be measured. The proximity 
of the sample could be finely adjusted in the vertical plane by using a movable stage on 
which the mounted sample was positioned. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Experimental configuration using Visonex Raman fibreoptic probe. 
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3.1.3 Tissue 
Laryngopharynx study 
Micro-biopsies, approximately 2mm in diameter, were taken from the vocal cords 
including those that appeared macroscopically normal. Specimens were also acquired 
from other sites within the laryngopharynx when areas of suspicion where identified. 
Where ever possible a biopsy was taken from the contralateral side in order to act as an 
‗internal‘ control.  
Lymph node study 
For the lymph node study biopsies were obtained from lesions presenting as masses in 
the neck and obtained by open neck dissection. The dimensions of the neck masses 
excised varied enormously from approximately 0.5cm to 14cm. In some cases the mass 
proved to be multiple lesions in close proximity which had on external manual palpation 
appeared to be one. The size of biopsies taken from the main operative specimens for 
research purposes were 0.25cm to 1.5 cm in diameter. 
3.2 Methods 
3.2.1 System Calibration 
Renishaw static system. 
Raman spectrometers measures light intensity as a function of wavelength and both 
these parameters need to be calibrated accurately. Where calibration error remains 
constant throughout the development of a model analysis of the spectra will not be 
affected, however if a different system is used or an instrument drift occurs the model 
may produce spurious results. Instrument calibration allows spectra acquired at different 
times and using different systems to be compared as knowledge of the calibration error 
in wavelength and light intensity measurements allows their influence to be calculated 
and removed from the Raman spectra measured. Calibration of wavenumber and light 
intensity can be thought of as full and daily. 
 
The full wavenumber calibration for the modified Renishaw system is necessary should 
changes in the excitation wavelength or system alignment occur. Full wavenumber 
calibration of the Renishaw spectrometer used in point spectra studies was done using a 
Neon-Argon atomic emission lamp standard, Figure 3.4 (Renishaw Plc). 
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Figure 3.4: Raman spectrum obtained from Neon-Argon emission lamp standard. 
To perform a full calibration, several atomic emission lines within the spectral range to 
be studied are selected and their absolute position defined by a line file. Using a x20 
objective, an entrance slit of 10-20µm and acquisition time of 20 seconds the emission 
from the Neon-Argon lamp is measured over the range 10 000 -12 100 wavenumbers 
(cm
-1
). The grating is moved in 25cm
-1
 steps over this wavenumber range and the 
emission spectrum recorded at each point. The WiRE software supplied by Renishaw is 
then used to fit the peaks measured to those in the line file which contains the absolute 
peak positions. For the daily calibration of wavenumber, Silicon was used as the test 
substance to test peak position. Cyclohexane (Sigma Chemicals) held in a UV-grade 
quartz cuvette (Jensons) shows standard peaks that when recorded over time allows 
calibration drift to be measured. Equal alteration of all peak positions suggests a 
variation in laser wavelength has occurred. Other standard substances used in the daily 
calibration of this system were a plastic pipette tip and the diffuse output from the 
Neon-Argon lamp. 
 
The efficiency by which a Raman signal is detected is wavenumber dependent as a 
result of the fact that both the efficiency of the scattered light detector and the system 
optics are both wavenumber dependent. Therefore the shape of any spectrum measured 
depends not only on the molecular composition of the test specimen but also on the 
intrinsic response profile of the spectrometer. In these experiments the energy 
calibration relies on the measurement of a substance with a spectrum of standard, 
known shape. By comparing the ratio of the emitted light from the measured and 
standard spectra an instrument response profile can be developed and used to correct 
spectra obtained from tissue specimens. The energy calibration of this system was done 
using a tungsten-filament lamp whose spectral output was calibrated by the National 
Physics laboratory (Teddington, UK). Laser light was shone at a barium fluoride disc 
which was orientated at 45
o
 to the axis of the illuminating source. This causes the light 
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to be scattered almost completely diffusely which has the advantage of reducing any 
effects from beam geometry. 
3.2.2 Specimen Collection 
All tissue used in this work was obtained by myself, assisted by Mr. M Thomas, 
consultant ENT surgeon, Gloucestershire NHS Trust (GNHST) during surgical 
procedures. These procedures were performed on patients under general anaesthetic in 
accordance with an approved ethical proposal (Appendix H). Prior to surgery the aims of 
this research were explained to each patient by me and a written explanatory leaflet 
given. The patient was then allowed time to read the leaflet and decide if they wished to 
participate after which they were asked to sign a consent form in triplicate; one copy 
was retained in the patient‘s notes, another given to the patient and the final copy kept 
by myself in their research file. At all times the General Medical Council (GMC) 
guidelines on good clinical practice were followed. No patients declined to participate. 
Laryngopharynx study specimens 
After administration of a general anaesthetic the first step of the surgical procedure was 
an assessment of the neck and base of tongue done by manual palpation. Figure 3.7. 
 
After this the patient‘s head was repositioned with the neck extended to help obtain an 
adequate view of the larynx. A gum shield was then inserted to protect the teeth and a 
thorough initial visual assessment of the laryngopharynx made using a hand held 
laryngoscope. After this a suspension apparatus was used to hold the laryngoscope in 
place allowing the surgeon to have both hands free to use other instruments (Figure 
3.7). Pictures of the standard laryngoscope and the microlaryngoscopy instruments used 
during these procedures are shown in Figure 3.5. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Standard laryngoscope and microlaryngoscopy instruments. 
An operating microscope was wheeled into position and orientated to allow the rest of 
the surgery to be carried out under magnification, Figure 3.6. A typical view of the 
vocal cords seen through the microscope is seen in Figure 3.7. 
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Figure 3.6: Operative configuration for microlaryngoscopy. 
 
Figure 3.7: View of vocal cords with SCC on right as seen through operating microscope. 
Each patient had a micro-biopsy taken from the suspicious area of vocal cord epithelium 
and a further biopsy taken from the macroscopically normal cord. This biopsy was 
taken in an area that was not adjacent to the first biopsy to avoid complications such as 
laryngeal web formation. No adrenalin was applied to either vocal cord for haemostasis 
before these biopsies were taken in order to avoid specimen contamination. Each 
specimen was then carefully placed on acetate paper and oriented so that the epithelial 
surface could be clearly identified by placing this surface adjacent to a mark on the 
paper. This was imperative for further processing of the specimens and to allow 
comparison between H&E slides prepared for regular histopathological assessment and 
the results obtained from the Raman studies. The mounted specimens were then placed 
in a cryo-vial labelled with the date, coded patient identification and sample number for 
example 1LP1 corresponds to the first sample taken from patient number 1, 1LP2 the 
second sample. The vial was then placed in liquid nitrogen, snap frozen and stored at 
minus 85
o
C. At the time of surgery a card was written detailing the exact position of the 
biopsies and this was added to the research file kept for each patient. A written 
comment was also made on the histopathology request form used for the main operative 
samples that further biopsies had been taken and from which positions. 
Lymph node study specimens 
During open neck dissection, biopsies were taken of all neck masses presenting in 
patients recruited to this study, in many cases multiple masses could be delineated and a 
research biopsy was taken from each. All operations were done under general 
anaesthetic and local anaesthetic infiltration was confined to the area of the skin incision 
and if near to the mass was superficial to it. Only specimens located away from areas 
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where bipolar diathermy had been used for haemostasis were included. The patient was 
positioned prone with the head resting in a gel ring or pillow and turned towards the 
unaffected side if the lesion was unilateral or held centrally for bilateral lesions (Figure 
3.8). 
 
Figure 3.8: Operative position for neck dissection. 
A skin incision was marked and local anaesthetic infiltrated. Research biopsies were 
obtained from as many separate nodes as possible and each assigned a side and 
anatomical level. Figure 3.9 shows a photo of a lymph node resection from a neck. 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Photographs of a neck lymph node excision.  
The research biopsies were placed on acetate paper and wherever present the capsule of 
the node was placed uppermost next to a mark on the paper in order that orientation 
could be maintained throughout processing. Each specimen was placed in a cryo-vial 
labelled in the same way as for the laryngopharyngeal study except that the letters 
assigning the sample to a particular study were changed from LP to NN, for example 
1NN1 was the label given to the first sample from patient number one recruited to the 
lymph node study. The specimens were snap frozen and stored in the same way as that 
done for the laryngopharyngeal study. A card was written at the time of surgery 
identifying the exact location on the main specimen from which each biopsy had been 
taken and placed in the patient‘s research file. A comment was also written on the 
histopathology request form sent with the main specimen(s) to keep the reporting 
pathologist informed. After processing to give H & E slides, each research specimen 
from the lymph node study was bisected. This was to allow two studies on the same 
node, one using point spectra and one using the fibreoptic Raman probe. 
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Probe Study Specimens 
The remaining portion of the bisected lymph node specimens were used in these studies 
in order that the results could be compared with the results from point spectra obtained 
using the Renishaw static configuration. Larger bisected specimens were divided in half 
again in order that they could be studied using the Visonex probe. In time the remaining 
specimens will be used in a comparison study of the Visonex probe and a needle probe 
that our research group hopes to develop. 
3.2.3 Specimen Processing  
Details of all samples collected were entered into databases developed for each study 
and specimens assigned a unique identifying code as described above. Other 
information contained within these databases included, hospital number, patient age, 
number and collection date of spectra; number, type and location of samples and 
research specimen pathology assignments from each histopathologist and those deduced 
from the histopathology report issued on the main operative specimen(s). 
 
For every specimen histological tissue cross sections were obtained and H&E slides of 
the frozen section made. Distortion of spectra from the contamination that occurs during 
normal histological processing (Sajid, 1997) was avoided by obtaining H&E slides from 
the frozen sections using a freezing microtome. The acetate paper on which the 
specimen was mounted in the operating theatre acted not only to orient the sample but 
also allowed the specimens to adhere to the microtome chuck without the need for 
cutting agents. Ice crystal artefact was avoided throughout by snap freezing the 
specimens using liquid nitrogen. Figure 3.10 shows the order in which the histological 
sections were obtained. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Tissue sectioning. 
The freezing microtome was used to first obtain a flat specimen surface then a 7 micron 
section was cut and mounted on a plain glass slide for H&E staining. If the specimen 
had been selected as a possible candidate for mapping studies at a later date a thicker 
section (15 microns) was then cut and mounted onto a calcium fluoride (CaF2) slide and 
a further 7 micron section taken for a second H&E slide. This slide was used to compare 
with the one obtained from above the mapping section in order to confirm consistency 
of tissue structure above and below the mapping section. All H&E slides were assessed 
by three histopathologists independently. The blocks of tissue remaining and mapping 
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specimen mounted on CaF2 slides were stored at -85
o
C and before being used in any of 
the Raman experiments were allowed to passively thaw at 23
o
C. 
3.2.4 Specimen Presentation and Acquisition of Spectra 
The following sections describe how the specimens were presented for each study and 
experimental parameters used in spectra acquisition. 
Point Spectra Studies 
Specimens were individually mounted in their anatomical position on CaF2 slides and 
held oriented in the correct position by two other pieces of CaF2 (Figure 3.11). 
 
 
 
 
 
 
 
 
Figure 3.11: CaF2 mounted block specimens. 
CaF2 was used for this purpose as it has a well defined spectrum with only one Raman 
peak at 323cm
-1
, a peak which falls outside the main wavenumber range being studied 
(400-1800 cm
-1
). The CaF2 unit was placed on the microscope presentation stage and by 
moving the stage up or down a basic focus was achieved which was fine tuned by using 
the microscope manual controls. Multiple point spectra were obtained in a step wise 
progression across the specimen by moving the presentation stage. The microscope 
fitted with the x20 objective was used to focus the laser prior to the acquisition of each 
spectrum. The excitation source used provided light with a wavelength of 830nm, the 
spectra acquisition time was set at 10 seconds. The range over which scattered light was 
detected was 400-1800 wavenumbers (cm
-1
). 
3.3 Histopathology 
The main operative specimens from which the research biopsies were taken underwent 
standard histopathological assessment and in some cases immunohistochemistry where 
lymphoma was suspected. Each research biopsy had histological frozen sections taken 
and H&E slides produced as described in Section 3.2.3. A consensus approach was 
taken to the assessment of these slides with three senior consultant pathologists making 
independent assessments of each one. Each pathologist was blinded to patient details, 
type of tissue presented and other relevant histological reports. The histopathologists 
used for these studies were Dr Christie-Brown (GNHST), Dr Keith McCarthy (GNHST) 
and Dr Simon Rose (Royal United Hospital, Bath).  
 
In the assessment of the H&E slides from each research biopsy histopathologists were 
invited to comment on the homogeneity of the samples, type of tissue present and to 
give a diagnosis based on their findings. Where laryngeal epithelium exhibited any 
degree of dysplasia the pathologists were asked to assign a grade in accordance with 
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specific criteria (Appendix B2). One area of difficulty in the assessment of the H&E 
research biopsy slides is in the diagnosis of lymphoma. Lymphoma cannot be reliably 
diagnosed from H&E slides of frozen sections and requires assessment of formalin 
fixed specimens however certain histological features seen in the H&E slides of frozen 
sections can arouse suspicion. These features were used to assign a diagnosis from H & 
E slides of frozen sections and these results were analysed latter to formulate a majority 
consensus result which was also compared to the definitive report given for the main 
operative specimen. The results of these two studies are contained in Section 4.1. In 
both studies all slides on which the diagnosis differed between different pathologists 
and the cases in which specimens were poorly predicted by the relevant diagnostic 
models were looked at in more detail. 
 
Only the standard histological and supplementary immunochemistry reports of the main 
operative specimen(s) are available to clinicians when patients attend postoperatively 
for discussion of their diagnosis and treatment plan. It was felt important to investigate 
the efficacy of a model based on these reports as well as the reports of the specific H&E 
slides obtained from research biopsies. The standard reports were obtained at the end of 
the study and the research biopsies assigned a diagnosis solely from these reports by 
correlation with positional data recorded at the time of surgery. 
3.4 Data Processing 
The data processing used in this work is discussed below and summarised in Figure 
3.12. 
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Figure 3.12: Data processing. 
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3.4.1 Database development 
From the outset of this work an excel database has been built for each of the two main 
areas of work; laryngopharynx and lymph nodes.. Each database contains information 
under identical headings and this facilitated the use of similar Matlab processing scripts 
for most of the studies. A text file was made from each complete excel database and 
used within the Matlab data loading script. For each spectrum a corresponding H&E 
slide of the tissue sample from which it was obtained was reviewed by three expert 
consultant histopathologists. A diagnostic numerical code called the ‗pathology code‘ 
was then assigned to each consultant opinion and recorded in the database against each 
sample and spectra. The databases were used to generate and record a consensus 
pathology decision for each sample from the three individual consultant opinions. 
 
A surgeon relies greatly on the written histopathology report, compiled after 
examination of the origin resected surgical specimen, to make a management plan for 
the treatment of the patient. Whilst there are inherent difficulties in comparing the 
diagnoses made by consultant consensus of individual slides and the original pathology 
report it was considered interesting to examine the similarities and differences and so a 
further consensus was formulated between consultant opinions and the diagnosis given 
in the original pathology report. 
 
Within each of the three main study areas  ‗mini-models‘ were developed by comparing 
different groupings of diseases, each disease having been assigned its‘ own numerical 
‗pathology code‘. For ease of computer programming each of these groupings were also 
given a further numerical ‗study group code‘. For example in the larynx study mini-
model, L2a, was developed by comparing squamous cell carcinoma made up of 
pathology groups 12, 13 and 14  (poorly, moderately and well differentiated SCC) 
against a group made up of normal laryngeal mucosa taken from the vocal cords and 
given pathology codes 7 and 15 respectively. Pathology codes 12, 13 and 14 were given 
a study group code of 1 whilst 7 and 15 were assigned the study group code 5. A 
summary of the pathology and study group numerical codes is recorded at the beginning 
of the relevant results sections and also in Appendix D.2. 
3.4.2 Pre-processing 
Conversion of spc to prn files 
The original data for each spectrum was saved as a spc file however in order to use 
Matlab for data analysis these files required conversion to a prn format. 
Removal of cosmic rays and fluorescence spectra 
The ability of the models developed to separate different disease entities relies on the 
accuracy of the information used to build the model. In order to achieve a clean and 
accurate dataset spectra containing cosmic rays and those in which fluorescence 
obscured signal from tissue components were discarded from the larynx and lymph 
node point spectra dataset before any analysis was undertaken.  
Baseline correction 
To adjust for variations in Raman system throughput two corrections were made to the 
experimental data. A correction was made to account for the effects of variation in the 
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baseline of spectra (y axis). For this an absolute green glass reference and daily green 
glass calibration spectra were used and each spectrum individually corrected with 
reference to the corresponding green glass spectrum. 
 
It was noted that after undergoing green glass correction when all sample normalised 
mean spectra were plotted together they had an x axis offset manifest as the appearance 
of double peaks seen particularly prominently for the major phenylaniline peak at or 
near 1001.5 cm
-1
. To correct for this an adjustment was made during data loading which 
gave all phenylaniline peaks an x coordinate of 1001.5cm
-1
 exactly. 
Interpolation 
Interpolation was done between 350 and 1850cm
-1
 wavenumbers during data loading 
but after baseline correction. 
Smoothing/filtering 
Before undergoing green glass correction the experimental data produced spectra which 
where relatively smooth however it was noted that after green glass correction the 
spectra appeared much noisier. The green glass calibration spectra themselves did show 
more noise than the actual dataset and this noise appeared to be passed to the 
experimental data during correction and so was removed from the green glass spectra 
only, by smoothing using a savgol function. 
3.4.3 Empirical Spectral Analysis 
3.4.3.1 Spectra Mean Analysis 
Mean and normalised spectra 
Within each study group the mean spectra was determined and each of these spectra 
where normalised so certain comparisons could be made between the mean spectra of 
different groups such as peak height and area ratios. 
Difference spectra 
Difference spectra were generated in each mini model by subtracting the mean spectra 
from each other. For example in mini- model study L1 the mean spectra representing 
non-malignant tissue was subtracted from that for squamous cell carcinoma. The 
resulting difference spectrum is constructed about a y axis value of 0 and shows both 
positive and negative peaks. Positive peaks represent tissue constituents that are present 
in greater amounts in the squamous cell carcinoma group and negative peaks those that 
are more prevalent in the non-malignant tissue group. This technique allowed a visual 
representation to be used to pick out those peaks, and hence tissue constituents, that 
might be significantly different between the two groups and subsequently allowed more 
focused investigation to be undertaken. 
3.4.3.2 Spectra Peak Analysis 
Spectral peak comparisons-peak height, intensity and peak area ratios 
Using customised Matlab scripts prominent peaks particularly those present in the 
difference spectra were identified and marked on the normalised, mean spectra of each 
study group. Ratios of peak heights, intensities and areas were calculated and entered 
into a database. This formed a representation of the similarities and differences between 
the groups not unlike that shown by difference spectra but in a numerical form. 
Peak assignment to tissue constituents 
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This proved to be the most difficult part of the data analysis as the complex structures 
found in biological tissue produce peak assignments that in many cases overlap. 
Standard tables of some biological tissue peak assignments now exist and the table used 
in this work was compiled by Catherine Kendall (Kendall, 2002e) and a copy can be 
found in Appendix E. 
Mean centering of spectra 
This technique is used before PCA is undertaken and helps ensure that the first PC is 
not simply a reflection of the variance about the mean. 
3.4.4 Multivariate Statistical Analysis 
Multivariate analysis was used in this work to identify and quantify differences in 
spectra. It has a major advantage over the univariate analytical techniques described 
above as it uses all the data measured and also allows inspection of very small 
differences in spectra more easily. 
Principal component analysis (PCA) 
PCA allows extraction of spectral components which best describe the variance over the 
entire dataset. This allows reduction and optimisation of the number of dimensions of 
the original variables to a minimum value which is capable of adequately describing the 
variance of the original dataset and can then be used in linear discriminant analysis of 
promising models. Two things are generated during PCA; loads, also called 
components, and scores. The first principal component (PC) represents the spectral 
features which best represents the variance over the whole dataset and as the number of 
the PC increases the degree to which it does this reduces. Each group‘s mean centred 
spectrum is broken down into a series of PCs and a score allocated depending on the 
degree to which it is represented in that individual spectrum. The sum of each principal 
component multiplied by its score should reproduce the spectrum. 
Analysis of variance (ANOVA) 
ANOVA is used to compare the means where more than two groups exist and allows 
the effects of multiple interrelated factors to be assessed simultaneously. For example it 
can be used to determine whether more than two independent samples originate from 
the same group. In this work it is used to identify diagnostically significant PCs. An F 
statistic is formulated which is the ratio of the mean square of the variance between the 
groups to the mean square of the variance within the groups; the greater the difference 
between the groups the greater the F value. A critical F value (Fcrit) is the value over 
which a particular PC score represents true variance within the dataset and is dependent 
on the level of significance the investigator has chosen. 
Linear discriminant analysis (LDA) 
This is a technique in which information on the origin of the samples is applied to the 
analysis and is an example of a ‗supervised‘ technique as information relating to the 
samples in the training set is used for the analysis and the number of groups in the study 
is specified rather than found as a result of the analysis. Using spectral data LDA allows 
identification of the dimension of maximal variance between a designated number of 
groups within the dataset. The scores for selected PCs are used as the input data and the 
groups correspond to the study group codes each one representing a group of samples 
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containing one or more pathology codes. The results of LDA are presented as the 
proportion of spectra correctly predicted by the model as belonging to a specific group. 
Cross-validation 
Once a classification model has been developed by using data to train the model it is 
usually tested by using a different validation dataset. When the results of analysis of the 
two datasets are the same or very similar the model can be thought of as robust. When 
no independent validation data is available a ‗leave one out‘ cross validation technique 
can be used. This is where one piece of data is withheld, a multivariate model made 
from the remaining data and the process repeated. In this work the type of data withheld 
could have been either a single spectrum, the data relating to a single sample or that 
relating to a single patient. A leave one out (LOO) cross validation was chosen and the 
data relating to a single specimen in each cycle was removed. This allowed optimisation 
of validation whilst ensuring each analysis ran in a reasonable time. 
3.4.5 Summary 
The use of empirical methods such as comparison of normalised mean spectra allows a 
simple overview that helps focus further analysis and by producing difference spectra 
from the SGs normalised mean spectra the main wavenumber areas where a difference 
is present can be clearly seen. Difference spectra are produced by subtraction of the 
normalised mean spectra and utilise all data from these plots. The intensity of the 
difference spectra at a particular wavenumber reflects the absolute difference in the 
amount of the compound(s) present that are responsible for that particular signal. If 
spectra B is subtracted from spectra A and no peaks are seen compound A and B must 
be the same. If a positive peak is seen the molecular entity/entities responsible for it are 
present in a greater amount in compound A, and this amount is directly proportional to 
peak height. The difficulty in interpretation of Raman spectra in general is that more 
than one entity can be attributed to the Raman signal at a certain wavenumber. This is a 
limiting factor in the conclusions that can be drawn from empirical analysis. 
 
The other main interrogative tool used in the empirical analysis is peak intensity ratios 
(PIRs). This technique compares the data between study groups in a different way. 
Firstly the values for the main peaks within a normalised mean spectrum are ratioed to a 
single peak that occurs in that spectrum and in the spectra of the other study groups. For 
each study group a set of ratio values is produced, one for each peak, that describe the 
relative amounts present of the entity/entities responsible for the peak signals in that 
study group alone. The pattern of ratios can be compared within a study group to give 
clues as to the molecular construction of the sample and between study groups to assess 
how this composition may differ between them. The difference in the PIRs between 
study groups can be calculated giving values that reflect the difference in the proportion 
of the constituents; they do not reflect absolute values. In both cases a single ratio taken 
in isolation is less useful than a pattern of the ratios or ratio differences between study 
groups as peaks may have more than one molecular assignment. One drawback with 
this technique is that only a relatively small amount of the data is used. The power of 
interrogation can be increased by also considering the peaks that do not occur in the 
spectra of all the study groups in the mini model. These peaks may in fact be of 
enormous importance because by definition they are absent in at least one of the study 
groups and if they can be given a peak assignment there is potential to learn a great deal 
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about that group, again this information is given more power if it can be linked with a 
pattern of ratio changes. 
 
Multivariate analysis treats the data as a whole and is a very powerful tool. However it 
is not as useful as empirical analysis in helping determine molecular composition in a 
study group or molecular differences between them. Multivariate analysis does enables 
the variance across the data set to be analysed in detail and gives a clear objective 
assessment of the ability of a model to discriminate between groups of samples. 
 
Each tool within the empirical and multivariate analyses has a part to play and this is 
demonstrated in the diagnostic mini model results. Section 4.2.3.7 contains the results 
for mini model L4 and this mini model is a good example of how all these techniques 
can be combined to maximally interrogate the data. 
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Chapter 4: Results and Discussion 
This chapter is divided into three main sections, consensus studies relating to the 
histopathological classification of tissue samples and two sections relating to diagnostic 
models; larynx and lymph node studies. 
 
The results and discussion for the two diagnostic model studies are organised in a 
similar way with the first section in each summarising general information relating to 
the data and how this data is organised to form the diagnostic ‗mini models‘. This is 
followed by a section outlining findings related to the spectra from tissue samples of 
individual pathology codes and for the combinations of these that are used to form study 
groups. The section that follows contains a detailed look at the data for each diagnostic 
mini model and is divided into three parts; results obtained from the empirical and 
multivariate analysis and finally a discussion section. 
 
To avoid repetition the results and discussion section for mini model L1 is written in the 
most detail as it aims to show the systematic approach by which the models and studies 
developed. 
4.1 Consensus Studies 
Three consultant histopathologists independently assessed H&E slides of frozen 
sections for all tissue samples used in these experiments. Each pathologist was blinded 
to the history of the patient, the site of surgery and the opinion of the other pathologists. 
They were also unaware of the histopathology report given for the main operative 
specimen. Table 4.1 is an example of how data relating to the histological classification 
of tissue samples was recorded. Columns 2 to 5 contain the numerical pathology codes 
representing the opinion of each consultant as to the type of tissue and any disease 
process present. Column 2 refers to the diagnoses gleaned from the histology report of 
the main operative specimen and columns 3 to 5 are coded A, B and C to identify 
clearly the relevant histopathology consultants. The codes for the histopathology 
diagnoses for the larynx study are summarised in Table 4.2 and in Table 4.3 for the 
lymph node study. 
Table 4.1: Example of data compiled in order to obtain a consultant majority consensus on 
histological classification of H & E slides of frozen sections obtained from each tissue 
sample. 
Sample Report A B C Consultant Consensus
Consultants 
Agree/Disagree
Count of Agree
Count of 
Disagree
10L1 7 7 7 7 7 All Agree 1 0
11L1 9 7 7 7 7 All Agree 1 0
11L2 7 7 7 7 7 All Agree 1 0
12L1 15 15 15 15 15 All Agree 1 0
12L2 15 15 15 15 15 All Agree 1 0
13L1 17 17 17 17 17 All Agree 1 0
13L2 17 17 17 17 17 All Agree 1 0
17L1 7 7 7 7 7 All Agree 1 0
17L2 7 7 7 7 7 All Agree 1 0
17L3 1 1 1 1 1 All Agree 1 0
18L1 1 1 1 1 1 All Agree 1 0
18L2 13 13 11 11 11 Someone  Disagrees 0 1  
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A majority consensus histological classification (consensus) was then used to build a 
series of mini models within the two main studies; larynx and lymph node. The 
consensus classification was kept as detailed as possible so that combinations of related 
codes and hence related histological findings could be used. For example codes 16 to 20 
in the lymph node study all refer to types of Hodgkin‘s lymphoma. In the future as more 
specimens are added to the study this data may be used to test the ability of Raman 
spectroscopy to interrogate specimens of Hodgkin‘s lymphoma further to ascertain if 
subgroups can be identified. 
Table 4.2: Pathology codes assigned to different histological diagnoses in larynx study. 
 
Pathology 
Code
Description
1 Laryngeal polyp
2 CT/Stroma
3 Muscle
4 Tonsil/Lymphoid Tissue
5 Papilloma
6 TB
7 Controls - Hyperplasia/Hyperkeratosis
8 V/C Dysplasia - mild
9 V/C Dysplasia - moderate
10 V/C Dysplasia - severe
11 Carcinoma in situ
12 SCC Poorly differentiated
13 SCC Moderate differentiated
14 SCC Well differentiated
15 Controls - Normal squamous epithelium
16 Not used
17 Reactive lymph node
01 Cleaned SCC Well differentiated
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Table 4.3: Pathology codes assigned to different histological diagnoses in lymph node 
study. 
Pathology 
Code
Description
1 Reactive Lymph node
2 Branchial cyst
3 Fibrous connective tissue
4 Normal squamous epithelium
5 Fat
6 Parotid salivary tissue
7 Normal thyroid tiassue
8 SCC - Poorly differenciated
9 SCC - Moderately differentiated
10 SCC - well differentiated
11 Adenocarcinoma
12 Pleomorphic adenoma
13 Poorly differentiated carcinoma
14 Thyroid - papillary carcinoma
15 Thyroid - follicular carcinoma
16 Hodgkin's lymphoma (HL) - mixed cellularity 
17 HL - nodular sclerosing
18 HL - follicular cell
19 HL - classical lymphocyte predominant
20 HL - Non-classical 
21 Non-Hodgkin's lymphoma (NHL) - diffuse large B cell
22 NHL - Low grade malignant
23 NHL - MALT type  
4.1.1 Results and Discussion - Consultant consensus study. 
As expected there was a range of diagnoses given to different tissue samples and to the 
diseases which affected them. Tables 4.4 and 4.7 summarise the consensus for tissue 
samples from the larynx and lymph node studies respectively. There are very important 
limitations on the interpretation of these results as much larger numbers of samples 
would be needed for a rigorous analysis of the variation in histopathology classification 
between consultants however there are some interesting features in the results of this 
work that might prove helpful in directing future studies. 
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Table 4.4: Histopathology consultant majority consensus for larynx study tissue samples. 
PathologyC
ode
Name
Instances All Consultants Agree with 
Consensus
Instances Some 
Consultants Disagree with 
the Consensus
1 Laryngeal polyp 2 0
2 CT/Stroma 3 0
3 Muscle 0 0
4 Tonsil/Lymphoid Tissue 6 0
5 Papilloma 1 0
6 TB 0 0
7 Control V/C - Hyperplasia/Hyperkeratosis 13 0
8 V/C Dysplasia - mild 1 0
9 V/C Dysplasia - moderate 0 1
10 V/C Dysplasia - severe 1 0
11 Carcinoma in situ 1 1
12 SCC Poorly differentiated 7 2
13 SCC Moderate differentiated 15 0
14 SCC Well differentiated 0 5
15 Control - Normal  Squamous epithelium 10 0
16 Not used 0 0
17 Reactive lymph node 14 0
74 9
83  
 
Variation in the histological classification of laryngeal disease has always been a 
concern particularly in the classification of dysplasia and carcinoma in situ and also in 
the assignment of the degree of differentiation of a squamous cell carcinoma. In this 
work the classification of the experimental tissue samples was even more challenging as 
it was done on H&E slides prepared from frozen sections. Table 4.5 shows an example 
of the classifications given by different consultants for a tissue sample were a 
disagreement exists. Overall the degree to which consultants agreed on the histological 
classification of specimens in the larynx study was excellent, 74 specimens out of 83 
(89.1%) had complete agreement. 
Table 4.5: Larynx study tissue samples were a disagreement in consultant histological 
classification exists. 
 
 
The diagnosis of moderate dysplasia and carcinoma in situ evoked some disagreement 
as might have been expected. One specimen was classified by A as mild dysplasia 
whilst the other two consultants felt this to be moderate dysplasia. The operative 
specimen was classified as exhibiting moderate dysplasia. Of the two specimens the 
consensus classified as showing the presence of carcinoma in situ one was agreed on by 
all consultants and one specimen had a single consultant (A) disagreement were a 
classification of a moderately well differentiated squamous cell carcinoma (SCC) was 
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given. This classification was supported by the histology report of the main operative 
specimen. 
 
Of the 9 samples classified by consensus as exhibiting features of poorly differentiated 
SCC seven were agreed by all consultants and 2 were classified by A as moderately 
differentiated SCC, the same classification as given in the main specimen histology 
report. Interestingly the histology reports for the main operative specimens correlating 
to the seven fully agreed experimental tissue samples were very interesting. Whilst two 
agreed with the consensus five did not and of these, the reports classified the main 
operative specimens as showing features of reactive lymph nodes in 4 cases, the 
presence of papilloma in one case. 
 
The diagnosis of well differentiated squamous cell carcinoma was not agreed by all 
consultants for any of the samples. Table 4.6 shows the breakdown of consultant 
opinion. For all five samples two out of three consultants assigned a classification of 
well differentiated squamous cell carcinoma (SCC). The third consultant assigned a 
classification of moderately well differentiated SCC in 4 out of the five cases and 
poorly differentiated SCC for the remaining sample. Interestingly the reports from the 
operative specimen classified them all as showing moderately well differentiated SCC. 
Table 4.6: Break down of the individual diagnoses for samples which ultimately had a 
consensus diagnosis of well differentiated squamous cell carcinoma in the larynx study. 
 
 
In all cases of disagreement between consultants, apart from that of carcinoma in situ, 
the discrepancies between classifications was slight and related to the degree of 
expression of a disease and was not a disagreement in the fundamental nature of that 
change. In the single case of carcinoma in situ this also held true but rather than one 
degree of change between the consensus and the disagreeing consultant in this case the 
disagreement suggested the changes noted by the consultant were two degrees more 
advanced than the consensus classification. The view of the disagreeing consultant was 
upheld by the full histology report and as the patient treatment plan is always based on 
the histology report of the main specimen no under treatment resulted. The difference in 
the slide preparation between the experimental and main operative specimens may 
account from some differences in classification as might variation between the weights 
consultants put on certain histological features when assigning the degree of 
differentiation. Whilst consultants all reviewed the same slide for each experimental 
specimen the slides prepared from the main operative specimen will not have been 
prepared from exactly the same tissue. As the disease process may not be uniformly 
expressed over the whole of the diseased area variations in histology classification 
between the main operative specimen and the experimental specimens may arise. This is 
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particularly true where tissue samples were taken from large main operative specimen 
such as those obtained from total laryngectomy patients or where the tissue samples 
themselves were large, increasing the possibility of disease variance over the sample 
itself. 
Table 4.7: Histopathology consultant majority consensus for lymph node study tissue 
samples. 
Pathology Code Name
Instances Consultants 
Agree with Consensus
Instances Consultants 
Disagree with their 
Consensus
1 Reactive Lymph node 55 0
2 Branchial cyst 0 1
3 Fibrous connective tissue 5 1
4 Normal squamous epithelium 8 0
5 Fat 0 0
6 Parotid salivary tissue 8 0
7 Normal thyroid tiassue 5 0
8 SCC - Poorly differenciated 6 0
9 SCC - Moderately differentiated 8 10
10 SCC - well differentiated 0 0
11 Adenocarcinoma 8 0
12 Pleomorphic adenoma 1 2
13 Poorly differentiated carcinoma 8 0
14 Thyroid - papillary carcinoma 0 5
15 Thyroid - follicular carcinoma 7 0
16 Hodgkin's lymphoma (HL) - mixed cellularity 2 0
17 HL - nodular sclerosing 4 0
18 HL - follicular cell 0 1
19 HL - classical lymphocyte predominant 4 0
20 HL - Non-classical 1 1
21 Non-Hodgkin's lymphoma (NHL) - diffuse large B cell 8 0
22 NHL - Low grade malignant 0 0
23 NHL - MALT type 0 0
CheckSum 138 21
159  
 
The consensus between the consultants who reviewed the H&E slides of the frozen 
section specimens entered into the lymph node study was also excellent; 138 samples 
out of 159 (86.8%) had complete agreement. Most tissue samples included in this study 
were larger than those in the larynx study. The homogenicity of the samples and hence 
H&E slides of the lymph node study specimens were also better. The diseases present in 
the tissue samples used in the lymph node study do not tend to show the same step wise 
progression from normal to invasive cancer that SCC of the larynx shows and all these 
points would suggest that the consensus for the lymph node study should be better than 
that for the larynx study. 
 
There are some general difficulties in the classification of the type of specimens used in 
the lymph node study which might explain the slightly poorer consensus result. 
Lymphoma frozen sections are notoriously difficult to interpret and are in fact never 
used as a definitive diagnostic technique for these diseases. The classification of 
moderately differentiated SCC showed some disagreement between consultants and this 
is summarised in Table 4.8. In all these samples the diagnosis of SCC was made but it 
was in the classification of the degree of tumour call differentiation that differences 
arose. This is a common occurrence and reflects the subjective nature of the histological 
classification process. In the one case were there was no agreement between any 
consultant; the full report on the operative specimen confirmed the presence of 
moderately differentiated SCC. In the other cases the diagnosis was still one of SCC but 
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classification of the degree of differentiation assigned was different. In six samples one 
consultant made a classification of poor differentiation in four cases a single consultant 
thought the samples well differentiated. In the latter case the full histology reported 
moderately differentiated SCC whilst for the former the report classified the disease as 
poorly differentiated. Whilst the prognosis of the patient may be affected by the degree 
of differentiation of tumour cells the initial treatment plan for these patients would not 
have been altered. 
Table 4.8: Majority consensus for lymph node study tissue samples classified as 
moderately differentiated SCC but where a disagreement in classification exists. 
 
 
The consensus relating to classification of thyroid tissue was very interesting. In the 5 
cases classified by consensus as papillary carcinoma one case was reported by 
pathologist A as poorly differentiated carcinoma and this classification agreed with that 
given for the main operative specimen. In the four other cases where a consultant 
disagreed with the consensus the classification was by consultant B who felt the 
samples possibly represented a pleomorphic adenoma. These tumours are aggressive 
locally invasive neoplasias usually affecting the parotid gland in the head neck. The 
main histology for these 4 specimens classified 3 of them as papillary carcinoma and 
one as a normal lymph node. The latter classification suggests that the section of the 
operative specimen examined was of a normal lymph node however the diagnosis was 
not missed as the large specimen had multiple areas examined and the diagnosis of 
papillary carcinoma was made from these. Some tissue in or near the parotid was 
entered into the study from a formal parotidectomy. The full histology report classified 
this tissue as showing a pleomorphic adenoma in two cases and in one as showing fat. 
Two consultants felt that two samples showed a pleomorphic tumour in all three cases. 
One consultant thought this true of one of the samples and that the other two showed 
features of a poorly differentiated carcinoma. Table 4.9 shows the consensus 
classification result for the samples designated as pleomorphic adenoma. 
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Table 4.9: Samples classified as pleomorphic adenoma by majority consensus in lymph 
node  
 
 
The degree to which the consultants were able to reach full agreement was recorded 
using pivot tables and the results have been illustrated in Figures 4.1, 4.2, 4.3 and 4.4 in 
the form of histograms. Percentage plots have been shown but it is noted that in some 
cases actual pathology numbers are small. 
 
 
 
Figure 4.1: Consultant consensus for histopathological classification of tissue specimens in 
the larynx study - expressed as a percentage. 
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Figure 4.2: Consultant consensus for histopathological classification of tissue specimens in 
the lymph node study - expressed as a percentage. 
4.1.2 Results and Discussion –Comparison of consultant consensus and 
histopathology report issued for main operative specimen. 
The histopathological classification assigned to the main operative specimen was 
obtained and a comparison made to the histopathology consultant majority consensus 
for the experimental tissue samples for both the larynx and lymph node studies. 
 
The larynx study dataset contained tissue samples unrelated to the main operative 
specimen (pathology codes 7 and 15/study group 5) and so no meaningful comparison 
could be made between the consultant consensus and the histology report for the main 
operative specimen for these larynx samples. In order to make a valid comparison of the 
consensus histology and the operative specimen histology reports these tissue samples 
were removed from the analysis for this section only. For the larynx the consultant 
consensus agreed with the main histology report in 40 out of 53 specimens (75.5%) and 
in the lymph node study in 115 out of 159 samples (72.3%). 
 
Tables 4.10 and 4.11 compare the agreement/disagreement between consultant 
consensus and main specimen histology report. Figure 4.3 compares the 
agreement/disagreement between consultant consensus and main specimen histology 
report expressed as a percentage for the larynx study patients. Figure 4.4 does this for 
the lymph node study. In some cases where there was also a disagreement within the 
consultant consensus comments and discussion relating to these samples may have 
already been included in Section 4.1.1.  Agreement between the consensus and the 
histology report for the main operative specimen is, as expected much lower that for 
that of the consensus alone. The most obvious problem is that the full histology report is 
based on the review of slides that may not have any direct spatial relation to the samples 
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taken for consensus review. This is more of a problem where the operative specimen is 
large but does highlight a difficulty for both traditional histology and Raman 
spectroscopy. How do we ensure that enough of the specimen is reviewed to ensure no 
areas of disease are missed? In histology large number of slides are prepared and 
reviewed which is enormously time consuming, expensive and potentially open to error. 
In Raman spectroscopy probing at depth is still a problem, as is limitation of speed that 
makes the scanning of areas in real time clinically challenging. For small areas of 
disease such as those found on vocal cord this may be less of a problem but if Raman 
spectroscopy was applied to large pieces of tissue which might only contain foci of 
disease then these concerns increase. 
Table 4.10: Comparison between consultant consensus and histopathology report issued 
on main operative specimens in larynx study. 
Pathology Code Name
Instance Consultant 
Consensus Agrees with 
Report
Instance Consultant 
Consensus Disagrees with 
Report
1 Laryngeal polyp 2 0
2 CT/Stroma 0 3
3 Muscle 0 0
4 Tonsil/Lymphoid Tissue 5 1
5 Papilloma 1 0
6 TB 0 0
8 V/C Dysplasia - mild 0 1
9 V/C Dysplasia - moderate 1 0
10 V/C Dysplasia - severe 0 1
11 Carcinoma in situ 1 1
12 SCC Poorly differentiated 4 5
13 SCC Moderate differentiated 9 6
14 SCC Well differentiated 0 5
16 Not used 0 0
17 Reactive lymph node 6 8
29 31
60
 
With smaller areas of tissue it would have been expected that the consensus and main 
reports might be more in agreement for the larynx rather than for the lymph node study 
however this is not the case and it appears that two reasons are the difficulties in 
classifying dysplasia and differentiation of SCCs. For the three cases the consensus 
classified as connective tissue/stroma the full histology picked up a poorly differentiated 
squamous cell carcinoma. This case was carefully reviewed and the two sets of slides 
had quite different appearances and SCC was not thought to appear in the study slides 
so no adverse clinical incident occurred. The one case of discrepancy relating to 
tonsil/lymphoid tissue showed that the main specimen whist containing lymphoid tissue 
also had sections showing normal squamous epithelium. The cases of severe dysplasia 
and carcinoma in situ reported by consensus that did not agree with the full histology 
report did so because full histology classified them as moderately well differentiated 
SCC. Severe dysplasia and carcinoma in situ are difficult to assess and often there is 
great debate as to the best way forward clinically, treat/intervention or a watchful 
waiting approach. If the latter were adopted these patients would often undergo repeat 
endoscopy and likely biopsy usually within a few weeks of the original procedure. The 
treatment of moderately differentiated SCC is very different and requires significant 
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surgery so this difference in opinion for these cases has real clinical significance and is 
an example of the diagnostic difficulties were grades of disease can coexist. All samples 
classified by consensus as showing moderately differentiated SCC and this disagreeing 
with report was because the report graded the tumour as a poorly differentiated SCC.  
 
The lymph node specimens included in the larynx study were obtained from en bloc 
laryngectomy dissections and where a discrepancy exists this is due to the slides used in 
the study being from different areas of the large specimen compared to the ones used for 
the main report and in some cases the level at which the lymph node was obtained was 
reported as containing reactive lymph nodes where the main specimen showed SCC. 
 
 
Figure 4.3: Comparison between consultant consensus and histopathology report issued 
for main specimens in larynx study - expressed as a percentage. 
One of the very interesting points to note in relation to the consensus and its agreement 
with the reported main histology in the lymph node study is the surprising degree of 
accuracy the consensus shows for the diagnosis of lymphomas. As discussed the 
pathologists involved in reporting the consensus slides would never rely on them for a 
firm diagnosis but it is a reflection of their clinical judgement and experience that they 
had such good agreement when pressed hard to give their ‗best guess.‘ In the case of fat 
as a consensus all samples were reported by full histological examination as either 
showing lymph node or a SCC and this is a reflection of different tissue sampling. The 
disagreements between consensus and main histology report relating to the thyroid 
tissue have been discussed in Section 4.1.1 as have the disagreements relating to 
classification of SCCs. It is important clinically to note that there was a large 
disagreement for samples classified by consensus as reactive lymph nodes. The main 
histology specimens showed these patients as having lymph nodes at the same level as 
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the study samples positive for poorly differentiated SCC (4), moderately differentiated 
SCC (1), NHL (1) and Hodgkin‘s‘ lymphoma in one case. No complete lymph nodes 
were taken from the main specimens and these finding confirm that in these cases, other 
than the lymphomas, that lymph nodes either contained foci of disease or that some 
nodes at these levels did not contain disease. 
Table 4.11: Comparison between consultant consensus and histopathology report issued 
for main operative specimens in lymph node study. 
Pathology Code Name
Instance Consultant 
Consensus Agrees 
with Report
Instance Consultant 
Consensus Disagrees 
with Report
1 Reactive Lymph node 44 9
2 Branchial cyst 1 1
3 Fibrous connective tissue 2 3
4 Normal squamous epithelium 2 0
5 Fat 0 2
6 Parotid salivary tissue 7 0
7 Normal thyroid tiassue 5 0
8 SCC - Poorly differenciated 2 17
9 SCC - Moderately differentiated 12 1
10 SCC - well differentiated 0 0
11 Adenocarcinoma 8 0
12 Pleomorphic adenoma 2 0
13 Poorly differentiated carcinoma 8 1
14 Thyroid - papillary carcinoma 3 7
15 Thyroid - follicular carcinoma 0 0
16 Hodgkin's lymphoma (HL) - mixed cellularity 2 1
17 HL - nodular sclerosing 4 0
18 HL - follicular cell 1 0
19 HL - classical lymphocyte predominant 4 0
20 HL - Non-classical 0 0
21 Non-Hodgkin's lymphoma (NHL) - diffuse large B cell 8 0
22 NHL - Low grade malignant 0 0
23 NHL - MALT type 0 2
CheckSum 115 44
159
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Figure 4.4: Comparison between consultant consensus and histopathology report issued 
for main specimens in lymph node study - expressed as a percentage. 
4.2 Larynx Study 
4.2.1 Data summary 
The tissue sample dataset for the larynx study is summarised in Table 4.12. The number 
of patients recruited the number of samples with specific histopathology classifications 
and the numbers of spectra obtained are recorded. 
 
39 patients were recruited to the larynx study and from these patients 83 tissue samples 
were collected. In total 2422 individual point spectra were obtained. The mean number 
of spectra obtained from a sample being 29 (range 11 to 44). 
 
Tissue samples were each assigned to a pathology group. Pathology group 6 contained 
only specimens thought to be infected with TB. These specimens were not used as 
facilities for the processing of this type of sample were not available. A sample of 
muscle yielded no useful spectra as it was inadvertently defrosted and degraded as a 
result. No samples were assigned to group 16 which was held as a ‗spare‘ assignment 
throughout the analysis incase a more detailed breakdown of a pathology group was 
required. The pathology classifications were subdivided as far as possible in order to 
facilitate more detailed Raman modeling as the dataset is expanded. 
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Table 4.12: Numerical data for individual pathology coded specimens in larynx study. 
Pathology 
Code
Description
Number of 
Patients
Number 
of 
Samples
Number 
of 
Spectra
Average 
Spectra per 
Sample
Average 
Spectra per 
patient
1 Laryngeal polyp 1 2 63 31.5 63.0
2 CT/Stroma 1 3 59 19.7 59.0
3 Muscle 0 0 0 0.0 0.0
4 Tonsil/Lymphoid Tissue 3 6 185 30.8 61.7
5 Papilloma 1 1 28 28.0 28.0
6 TB 0 0 0 0.0 0.0
7 Controls - Hyperplasia/Hyperkeratosis 9 13 341 26.2 37.9
8 V/C Dysplasia - mild 1 1 26 26.0 26.0
9 V/C Dysplasia - moderate 1 1 11 11.0 11.0
10 V/C Dysplasia - severe 1 1 41 41.0 41.0
11 Carcinoma in situ 2 2 49 24.5 24.5
12 SCC Poorly differentiated 5 9 302 33.6 60.4
13 SCC Moderate differentiated 4 15 517 34.5 129.3
14 SCC Well differentiated 1 5 219 43.8 219.0
15 Controls - Normal squamous epithelium 4 10 251 25.1 62.8
16 Not used 0 0 0 0.0 0.0
17 Reactive lymph node 5 14 330 23.6 66.0
39 83 2422  
 
The number of laryngeal mucosal specimens is small compared to the number of 
specimens used in the lymph node study (83 to 159). In particular there is only one 
sample classified as showing each of the dysplasias and 5 samples from one patient 
which contained well differentiated SCC. Two patients gave one sample each of 
carcinoma in situ. This is a reflection of the throughput of patients requiring 
microlaryngoscopy and biopsy, time pressure on the operating lists and the nature of the 
operation meant only very small sample numbers could be obtained from a single 
patient. In the lymph node study larger neck dissection specimens often afforded the 
opportunity to retrieve multiple lymph nodes from a single patient. These specimens 
were generally larger and easier to handle affording less wastage during processing. 
 
Matlab scripts were written to combine sets of pathology codes into study groups (SGs). 
For example pathology codes 12, 13 and 14 all define SCCs, however pathology code 
12 is used to describe those specimens which are poorly differentiated; 13 moderately 
well differentiated and 14 well differentiated. Combined these three pathology codes 
make up study group 1 (SG1). A summary of the pathology codes which make up the 
sixteen study groups is contained in Table 4.13. 
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Table 4.13: Numerical data for combinations of pathology codes used to form larynx study 
groups. 
Study 
Group
Description Pathology Codes
Number 
of 
Patients
Number 
of 
Samples
Number 
of 
Spectra
1 SCC 12,13,14 10 29 1038
2 Mild Dysplasia 8 1 1 26
3
Controls - Hyperplasia 
Hyperkeratosis
7 9 13 341
4 Non-malignant
1,2,3,4,5,6,7,8,9,
10,11,15,17
29 54 1384
5 All Controls 7,15 13 23 592
6 Moderate Dysplasia 9 1 1 11
7 Abnormal Mucosa 8,9,10,11 5 5 127
8 Severe Dysplasia 10 1 1 41
9 Carcinoma in Situ 11 2 2 49
10
Controls - Normal 
squamous epithelium
15 4 10 251
11 SCC Poorly differentiated 12 5 9 302
12
SCC Moderately 
differentiated
13 4 15 517
13 SCC Well differentiated 14 1 5 219
14 Dysplasic Mucosa 8,9,10 3 3 78
15
Cleaned SCC Well 
differentiated
01 1 5 212
16 SCC + Abnormal Mucosa
12,13,14,8,9, 
10,11
15 34 1165
 
 
A comparison between different study groups forms the basis of the larynx study mini-
models, Table 4.14 summarises which SGs are used in each one. The models are used to 
work systematically through the different options for comparing pathology groups and 
the rational for investigating each one is summarised in the results section for that 
model. 
 
Appendix D contains tables and figures relating to results from the larynx studies. A 
summary sheet of the makeup of the different mini-models can be found in Appendix 
D.2. 
 
The organization of the lymph node study dataset has been done in a similar way as for 
the larynx.  
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Table 4.14: Laryngeal mini models – a comparison between different study groups. 
Mini 
Model
Description
 S
tu
d
y 
G
ro
u
p
Description
St
u
d
y 
G
ro
u
p
Description
St
u
d
y 
G
ro
u
p
Description
St
u
d
y 
G
ro
u
p
L1 SCC 1 Non-malignant 4
L1-1
SCC+Abnormal 
Mucosa
16 All Controls 5
L2a SCC 1 All Controls 5
L2b
Controls - 
Hyperplasia 
Hyperkeratosis
3
Controls  - Normal 
Sq epithelium
10
L2c SCC 1 All Controls 5
Abnormal 
Mucosa
7
L2c-1 SCC 1
Controls -
Hyperplasia 
Hyperkeratosis
3
Abnormal 
Mucosa
7
L2c-2 SCC 1
Controls - Normal 
Sq epithelium
10
Abnormal 
Mucosa
7
L2c-3 SCC 1
Controls - Normal 
Sq epithelium
10
Displastic 
Mucosa
14
L3 Mild Dysplasia 2
Moderate 
Dysplasia
6 Severe Dysplasia 8
Carcinoma in 
Situ
9
L4 Carcinoma in Situ 9
SCC Poorly 
Differentiated
11
SCC Moderately 
Differentiated
12
SCC Well 
Differentiated
13
L4-1
SCC Well 
Differentiated
13
Controls - 
Hyperplasia 
Hyperkeratosis
3
L4-2 Carcinoma in Situ 9
SCC Poorly 
Differentiated
11
SCC Moderately 
Differentiated
12
Cleaned SCC 
Well 
Differentiated
15
 
4.2.2 Pathology overview 
4.2.2.1 Normal laryngeal tissue 
The spectrum obtained from normal laryngeal mucosa is seen in Figure 4.5 and the 
main spectral peaks are summarised in Table 4.15. Many of the peak assignments are 
the same as those published previously (Stone, 2002). There are peaks which are present 
in both studies but which are very small (780, 1048, 1172, 1386 and 1617cm
-1
). Peaks 
which cannot be seen in Figure 4.5 but are noted by Stone et al are positioned at 725, 
899, 920, 1228, 1314, 1560, 1583, and 1601cm
-1
. No clear pattern emerges to explain 
these omissions. The peaks may in the spectrum obtained during this work but better 
resolution of the SG10 mean normalised spectrum may be needed to see them, also 
some variations in the Controls - ‗normal‘ squamous epithelium spectra are noted, this 
is more fully discussed in Section.4.2.3.4. One point is noted, the peak at 480 cm
-1
 
attributed to glycogen is less prominent in the spectra of ‗ normal‘ laryngeal mucosa 
compared to that of normal oesophagus or cervix. 
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Figure 4.5:.Raman spectra of ‘normal’ laryngeal mucosa. 
Table 4.15: Main spectral peak assignments for normal laryngeal mucosa (SG10). 
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4.2.2.2 Normalised spectra for single pathology codes 
Figure 4.6 is a plot of all the normalised spectra for a single pathology code i.e. tissue 
type. In this case tissue classified histologically by majority consensus as showing 
features of severe dysplasia (pathology code 10). The corresponding plots for the other 
pathology codes can be found in Appendix D.1. 
 
Figure 4.6:Normalised mean spectra for larynx study group 10 – normal vocal cord 
squamous epithelium. 
There are some interesting simple features seen in these plots. Data sets containing 
small numbers of spectra become obvious and the degree to which the spectra vary 
across their mean can be seen. To the experienced reviewer the sharpness and overall 
shape of some peak groups can give an idea as to the proportion of certain molecular 
constituents within a sample. Some plots show spectra that do not appear to fit the 
norm; for example in the plot for pathology group 13 (Appendix D.1). Here a single 
spectrum (red) stands out but prompted by unexpected findings in mini model L4 a 
closer examination showed other features which are discussed in the results section for 
this mini model. 
4.2.2.3 Normalised mean spectra for all study groups 
Figure 4.7 shows the normalised mean spectra for each of the study groups on one 
graph. Figure 4.8 the same plot but for SGs 4, 8 and 12 only, a review of this figure 
allows a very general assessment of the variation between the spectra and some 
interesting features have been noted. Even taking into account variations in the spectra 
baseline the relative ratios of some peaks appear quite different. When the two most 
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prominent peaks at 1444cm
-1
 and 1650cm
-1
 are considered it can be seen that the spectra 
from study groups 4, 8 and 12 exhibit different peak intensity ratios. 
 
Figure 4.7:Normalised mean spectra for each larynx study group. 
To clarify this section of the spectra has been magnified (Figure 4.9). The peak 
intensities at these wavenumbers for SG4 (non malignant tissue) appear to be very 
similar. For SG8 (severe dysplasia) the peak intensity at 1444cm
-1
 is greater than that 
for the peak at 1651cm
-1
 and this is reversed for SG12, poorly differentiated SCC. To be 
rigorous it is the difference in the PIRs that should be considered for each study group 
spectral pair. For each peak these are measured from a line between the two adjacent 
troughs rather than the x axes. The PIR values for these peaks are recorded in Table 
4.16. Whilst the absolute peak intensities, read from the x axis in Figure 4.9, for SG4 
appear almost equal the difference in the relative PIRs is quite large. This reemphasises 
the need to use PIRs for this type of paired comparison to minimise the error associated 
with factors such as baseline variation. 
Table 4.16: Laryngeal mini models – a comparison between different study groups. 
Column1 1444cm
-1
1651cm
-1
PIR - SG4 37.15 33.69
PIR - SG8 31.47 30.54
PIR - SG12 17.85 18.51  
 
 It can also be seen that the peaks in the spectra for SG 12(SCC) appear to be slightly 
shifted to the right, 1444cm
-1
 to 1446cm
-1
 and 1651 to 1655cm
-1
. There can be slight 
variation in the placement of the peak wavenumber assignment cursor when attaining 
these wavenumbers but the value of simply looking at the spectra when magnified as in 
Figure 4.9 is that it is clear that the spectrum for SG12 is genuinely offset slightly to the 
right. This is interesting in that the tissue samples involved were not measured together 
but on different days and randomly selected for acquisition of their spectra. The change  
may be a reflection of a change in secondary structure form α helix to ß pleated 
sheet/random coil as might be expected in cancer cells. 
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Figure 4.8:Normalised mean spectra for larynx study groups 4, 8 and 12. 
 
Figure 4.9:.Magnified normalised mean spectra for larynx study groups 4, 8 and 12. 
4.2.3 Diagnostic models 
4.2.3.1 L1 - SCC/Non-malignant tissue (SG1/SG4) 
Empirical analysis 
Figure 4.10 shows the normalised mean spectra for the two study groups examined in 
this model, their difference spectrum is shown beneath. Figure 4.11 contains two plots; 
the normalised mean spectra from both study groups overlaid and the difference spectra 
obtained from them is placed adjacent. Figure 4.11 has been included in addition to 
Figure 4.10 in order to show the development of the study from the simple normalised 
mean spectra. The difference spectra for all the larynx mini models can be found in 
Appendix D.3. 
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Figure 4.10: L1 - Normalised mean and difference spectra for SCC and non malignant 
tissue (SG1/SG4). 
 
 
 
Figure 4.11: L1 – Overlaid normalised mean and difference spectra. 
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The wavenumbers of major peaks present in the normalised mean spectra of each study 
group were recorded with the corresponding peak intensities and areas, these data sets 
can be found in Appendix D.5. Those peaks which occurred in all study groups within a 
particular mini model where separated out and the ratios of their peak intensities and 
areas calculated. The peak with the lowest wavenumber was used as the reference point 
from which all ratios were calculated. For each shared peak the two PIRs were 
subtracted to examine the degree to which the peak intensities and areas differed across 
the groups. Figure 4.13 shows these results as a histogram. 
 
Whilst the changes in the ratios of peaks is very interesting and gives objective evidence 
as to possible biochemical differences in the tissue samples from each group, of equal 
importance is the presence of isolated peaks not shared between study groups. This data 
is also recorded in Appendix D.5.1. Figure 4.14 records the difference in the area ratios 
superimposed on those of peak intensity and the same pattern is seen for both variables. 
This finding was consistent for all mini models and so only the variation in peak 
intensities ratios is discussed. 
 
Biochemical assignments, based on wavenumber, were given to the peaks where 
differences in peak intensity ratio existed in order to investigate the possible 
biochemical differences that might exist between the study groups. The main spectral 
peaks for individual SGs can be found in Appendix D.4 and a comparison between them 
for the SGs in each mini model, highlighting shared and unique peaks, in Appendix D.5. 
 
  
Figure 4.12: L1 – Peak intensity ratios for Study Groups 1 and 4. 
92 
 
-2
0
2
4
6
8
10
12
14
16
18
4
5
7
5
4
3
6
4
3
7
1
8
7
5
4
7
8
2
8
2
7
8
5
2
9
3
5
1
0
0
2
1
0
8
5
1
1
2
5
1
1
5
4
1
1
7
4
1
2
0
5
1
2
4
4
1
3
3
9
1
4
4
6
1
6
5
4
P
e
a
k
 I
n
te
n
s
it
y
 R
a
ti
o
 D
if
fe
re
n
c
e
Wavenumber cm1
SG4-SG1
PIRs (Non-Malignant - SCC)
 
Figure 4.13: L1 – Differences in peak intensity ratios for Study Groups 1 and 4. 
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Figure 4.14: L1 – Differences in peak intensity and area ratios for Study Groups 1 and 4. 
Multivariate analysis 
The results for the L1 multivariate analysis are detailed below. Figure 4.15 shows the 
mean centred data, followed by a histogram demonstrating the separation between study 
groups using LDA (Figure 4.16). Figures 4.17 and 4.18 detail the percentage correct 
classification for each SG and show the calculated sensitivity and specificity 
93 
 
 
Figure 4.15: L1 –. Mean centred data set. 
 
Figure 4.16: L1 – Histogram demonstrating the separation between study groups using 
LDA. 
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Figure 4.17: L1 – Classification of study group samples by multivariate analysis. 
 
L1 SG1 SG4 Sensitivity Specificity
SG1 889 149 85.6% 87.2%
SG4 177 1207 87.2% 85.6%  
Figure 4.18: L1 – Training classification performance 
Figure 4.19 is made up of the load plots for the 6 highest principal component scores 
out of a total of 25 PCs determined by ANOVA as statistically significant (p>0.001), 
and in addition the load plot for PC2 is also shown. 
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Figure 4.19: L1 – Plots of loads for 6 highest principal component scores out of a total of 
25 PCs determined by ANOVA as statistically significant (p>0.001), and in addition the 
load plot for PC2. 
Discussion 
Within the larynx study this mini model contains the greatest number of tissue samples 
and compares groups with the broadest range of diseases. SG1 contains samples of SCC 
where as SG4 is made up of many types of tissue with a single unifying property; none 
were felt histologically to show features of malignant change. As a consequence of the 
heterogenicity of tissue samples in SG4 it was expected that there might be some 
difficulty in separating these study groups. 
 
29 samples showing SCC were compared with 54 samples of non malignant tissue. 
From these samples 1038 spectra were obtained from the SCC tissue and 1384 from the 
non malignant tissue group. The non-malignant group includes a diverse range of tissue 
types including papilloma, muscle and connective tissue. Ideally small targeted mucosal 
biopsies would be sufficient to give a diagnosis without the need for removal of deeper 
vocal cord tissue or muscle but this can be very difficult and is not always possible. 
 
The aim of surgery is to obtain an adequate biopsy to definitively secure the diagnosis 
with one surgical procedure in a group of patients who often have considerable co 
morbidity. The success of this is dependent on the extent and type of disease and in 
some cases surgical ability. Another factor to consider is the presence of benign 
conditions such as hyperplasia and hyperkeratosis. These can visually mimic SCC, the 
upper most layers of cells can be very thick and the depth to which a biopsy is taken is 
very much a matter of individual judgement. It was with all these factors in mind that it 
was felt that the analysis in this mini model was clinically relevant. The inclusion of the 
papilloma sample was felt valid as infection of the larynx with Human Papilloma Virus 
(HPV) is not uncommon and can be difficult to irradiate. The presence of papilloma 
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tissue can lead to voice dysfunction, both as a result of the disease and from treatment, 
respiratory distress and airway obstruction. However it is the relationship between HPV 
laryngeal infection and neoplastic changes leading to the development of SCCs that 
gave reason for inclusion of this sample in the study. 
 
A simple visual inspection of Figure 4.11 was the first step in the analysis and shows 
that, even after variations in baseline intensity are taken into consideration, there are 
areas where peak intensity ratios (PIRs) e.g. 1444 and 1654 cm
-1
 and peak shapes are 
clearly very different. The different shapes of the spectra over the range 1220 to 1380 
cm
-1
 are very interesting. The spectrum from tissue classified as SCC shows a trough 
and that from non-malignant samples a plateau at 1280 cm
-1
. This wavenumber 
corresponds to Amide III/ phospholipid membrane. The phospholipid membrane is 
considered a basic building block for cell walls and a relative increase in this cellular 
constituent is more usually associated with the presence of cancer cells. However more 
generically it can be associated with an increase in any form of cell division, suggesting 
that SG 4 might contain cells which are either misclassified as non- malignant or that 
this study group might contain cells undergoing other types of proliferation. The peak at 
1085 cm
-1
 seen in the spectra of both SGs has also been attributed to phospholipids, but 
reflecting the difficulty of this type of analysis it is also seen in the spectrum of the 
amino acid phenylalanine. In order to investigate these spectra more closely the relative 
peak intensity ratios were calculated and compared. A summary of peak assignments 
referred to in this work can be found in Appendix E. 
 
Figures 4.12, 4.13 and 4.14 consider the peaks that are shared between the two study 
groups SG1 and SG4. The only peak showing a PIR greater in SG1 is the peak at 1174 
cm
-1
. Peaks at 1175 cm
-1 
and 1176cm
-1
 have been attributed to C-O stretching and the 
presence of amino acids tyrosine and phenylalanine. 
 
The largest difference between the SGs for peaks common to both is the peak intensity 
ratios at 1446cm
-1
 and 1654 cm
-1
. The peak at 1654 cm
-1
 has been assigned to Amide I 
(C=O stretch) with an α helix secondary structure and has also been seen in lipid. The 
peak at 1446 cm
-1
 represents δ (CH2) or δ (CH3) / deformation of CH3CH2 in collagen.  
 
The peak at 1244cm
-1
, common to both study groups, has a larger PIR in the SG4 
spectrum. The peak assignment for this wavenumber is given as Amide III with a 
random coil secondary structure but it has also been shown to be present as Amide III in 
disordered collagen from keratin. A further peak for Amide III (random coil) would be 
expected at 1238 cm
-1
 but this is absent from both spectra. Other peaks are present that 
are associated with keratin such as that seen at 935 cm
-1
. This peak is shared between 
SG1 and 4 but is again more prominent in the spectrum from SG4. It has been attributed 
to C-C skeletal vibrations in protein with an α helix secondary structure but also to C-C 
stretching within the backbone of collagen in skin and keratotic tissue. Peaks at 827, 
852 and 1002 cm
-1
have been found in spectra obtained from strateum corneum from 
skin and psoriatic plaques. 872cm
-1
 has been assigned to δ (CCH) aliphatic and 852cm-1 
to δ (CCH) aromatic and it is noted that both these wavenumbers have also been 
assigned to the amino acid tyrosine as has the peak both SGs share at 1002cm
-1
.  
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The peak at 1002cm-1 is sharp and consistent; it is  seen in the spectra of phenylalanine 
and has been attributed to a ν (CC) aromatic ring stretch of the phenylalanine residue in 
keratin. The peak at 852cm
-1
 has also been found in the spectra of glycogen and there 
are some other peaks present that could be attributed to this compound (935, 1085, 
1125cm
-1
) but the majority usually seen are not present in significant intensities. There 
are tiny peaks at 1047 and 481 cm
-1
 that could be attributed to glycogen in the spectrum 
obtained from SG4 and these are not seen in the spectrum obtained from SCC tissue 
(SG1). Both tyrosine and phenylalanine are significant constituents of keratin. 
 
Peaks are present at 1030, 1303 and 1339 cm
-1
, those at 1303 cm
-1
 and 1339 cm
-1
 are 
both seen in the spectra obtained from adenine and in addition 1303 cm
-1
is seen in CH2 
twisting, triglycerides and δ (CH2) in phospholipid membrane. The empirical analysis in 
the wavenumber range (1217 to 1363 cm
-1
) is very difficult to interpret particularly in 
SG4 as the shape of the plot becomes a plateau suggesting the confluence of several 
peaks resulting in considerable inaccuracies when peak baseline extremities are picked 
and hence in the calculation of intensity and area. A review of the difference spectra 
however show several large positive peaks suggesting SG4 has a proportionally greater 
amount of the molecular entities responsible for these Raman signals. 
 
The peaks that appear only in the spectrum of SG4 can be attributed to thymine (666 
cm
-1
), proline (898cm
-1) and δ (CH2) scissoring seen in the spectrum of strateum 
corneum (1438 cm
-1
). 
 
In histopathology an increase in the nuclear to cytoplasmic ratio is used as a marker of 
the progression of neoplastic change. The relative intensity ratios of peaks at 1336 cm
-1
 
and 1250 cm
-1 
have been used in a similar way. The peak at 1336 cm
-1
 is a reflection of 
nucleic acid content and the one at 1250 cm
-
1 the Amide III mode protein (random 
coil). The relative peak intensity ratios for the peaks with the wavenumbers closest to 
these in SGs4 and 1 (1339 and 1244 cm
-1
) give ratios of 0.40 and 0.38 for SG1 and SG4 
as would be expected. 
 
The multivariate analysis of the data from this model confirms that there is a 
statistically significant (p<0.001) difference between the two study groups tested. 
ANOVA determined significant principal component scores with values greater than the 
F crit. The value of this parameter alters for each model and they are summarised in 
Appendix D.5.11. The most statistically significant of the first 25 PC scores were 
calculated by ANOVA and the combination describes 99.9% of the variance across the 
dataset. Figure 4.19 shows plots of the 6 most significant scores. ANOVA is a test to 
determine how well the PCs discriminate between the groups alone. Linear discriminate 
analysis, a multivariate technique, then uses a combination of the diagnostically 
significant PCs to create the model. A single PC will not adequately describe the spectra 
however a plot of an individual PC load may highlight peaks that help towards an 
understanding of the molecular differences between the groups. The load plot of PC1 
shows the best representation of the variance across the dataset and as the PC number 
increases less variance of the dataset is described and more noise is seen (Figure 4.19). 
In the load plots for this model certain features stand out. The peaks that have been 
noted in the empirical analysis are also prominent in the load plots. However analysis of 
these plots can be of enormous help and an example is in the 1217 to 1363 cm
-1
 region. 
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This region was very difficult to analyse as it appeared in the normalised mean spectra 
as a confluence of peaks. In the PC load plots this area can be teased out. The load plots 
especially PC 2 show there to be peaks at1244 and 1280 cm
-1
 which can be attributed to 
proteins, 1244 cm
-1
 with a ß sheet secondary structure and 1280 cm
-1
 to Amide III. The 
peak seen at 1421 cm
-1
 may be due to δ (CH3) previous seen in keratin and those at 
1060 and 1634 cm
-1
 lipids and protein respectively. The load plot for PC1 is inverted 
suggesting the presence of high levels of protein and the sharp change in orientation of 
the peaks at 1280, 1454 and 1632 cm
-1
 suggests a change in lipid and protein structure. 
The peak at 1280 can be assigned to Amide III in phospholipid and that at 1654cm
-1
 to 
Amide I in the α helix form whilst the peak at 1001cm-1 can be due to several molecular 
entities but it can be due to proteins with a ß sheet structure. 
4.2.3.2 L1-1 – Controls – Normal squamous epithelium/Neoplastic tissue (SG5/SG16) 
This extra mini model was performed to address the question as to whether Raman 
spectroscopy can differentiate a sample of squamous epithelium from a vocal cord that 
had been assessed histologically as not showing features of neoplasia from those that 
did. 
 
Figures 4.20 and 4.21 show the overlaid mean normalised and difference spectra for the 
two study groups. These study groups are subdivided further in later mini models and a 
detailed empirical analysis has been done then. Figure 4.22 is a plot of the mean centred 
dataset and is followed by Figure 4.23 which is a histogram demonstrating the 
separation between SG5 (red – ‗normals‘) and SG16 (green - neoplastic) using LDA. 
The overall results of the multivariate analysis are summarised in Figures 4.24 and 4.25 
with those of the cross-validation found in Tables 4.17 and 4.18. 
Empirical analysis 
 
Figure 4.20: L1-1 – Overlaid normalised mean spectra. 
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Figure 4.21: L1-1 –Difference spectra. 
Multivariate analysis 
 
Figure 4.22: L1-1 – Mean centred data set. 
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Figure 4.23: L1-1 – Histogram demonstrating the separation between SG5 (red) and SG16 
(green). 
 
Figure 4.24: L1-1 – Classification of study group samples by multivariate analysis. 
L1-1 % Correct
SG16 95.2
SG5 84.6
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L1-1 SG16 SG5 Sensitivity Specificity
SG16 1109 56 95.2% 84.6%
SG5 91 501 84.6% 95.2%  
Figure 4.25: L1-1 – Training classification performance 
Cross validation 
Table 4.17:– L1-1 – Training performance. 
 
Training Performance 91%
Neoplasia (SG16) 95%
Normal Sq Epithelium (SG5) 84%  
 
Table 4.18:– L1-1 –Test performance. 
 
Test performance
Neoplasia (SG16) 73%
Normal Sq Epithelium (SG5) 89%  
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Discussion 
Mini model L1-1 is a comparison of SG5 and SG16. SG5 is made up of those samples 
of vocal cord mucosa classified by histopathology not containing evidence of neoplastic 
change, those in SG the opposite. SG5 contains 23 specimens gathered from 13 patients 
and from these 592 spectra have been obtained. SG16 has 34 samples, from 15 patients 
and 1165 spectra have been measured. 
The histogram demonstrating the separation between SG5 (red) and SG16 (green) 
shows the presence of a possible double peak in the plot for SG5 and this has been seen 
in other models e.g. L2a; it is investigated further in mini model L2b. This model 
predicts correctly for the neoplasia group (SG16 – 95.2%) better than the controls (SG5 
- 84.6%). This may suggest the control group is not truly homogeneous. 
In the cross-validation study (leave one sample out) the test performance for SG16 gives 
a sensitivity of 73% and for SG5 89%. 
4.2.3.3 L2a - SCC/Controls – All (SG1/SG5) 
Empirical analysis 
Figure 4.26 demonstrates the normalised mean spectra overlaid for SG5 and SG1, the 
difference spectrum is adjacent. The PIRs for the shared spectral peaks and lists those 
peaks which occur in only one of the spectra can be found in Appendix D5.2. The 
histograms in Figures 4.27 and 4.28 are used to more clearly to display this data. 
 
 
Figure 4.26: L2a – Overlaid normalised mean and difference spectra. 
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Figure 4.27: L2a – Peak intensity ratios for Study Groups 1 and 5. 
 
Figure 4.28: L2a – Differences in peak intensity ratios for Study Groups 1 and 5. 
Multivariate analysis 
Figure 4.29 shows the mean centred dataset and is followed by Figure 4.30 
demonstrating the separation of the SGs with multivariate analysis using LDA. The 
numerical results are summarised in Figures 4.31 and 4.32. 
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Figure 4.29: L2a – Mean centred data set. 
 
Figure 4.30: L2a – Histogram demonstrating the separation between study groups using 
LDA. 
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Figure 4.31: L2a – Classification of study group samples by multivariate analysis. 
 
L2a SG1 SG5 Sensitivity Specificity
SG1 982 56 94.6% 83.4%
SG5 98 494 83.4% 94.6%  
Figure 4.32: L2a – Training classification performance 
Discussion 
This mini model is a natural progression from L1 and compares the Raman spectra 
obtained from SCC against that of normal squamous cell epithelium. The inclusion 
criteria for the latter group were that tissue samples should be of squamous cell 
epithelium which exhibited no features of neoplastic change; SG5 – pathology codes 7 
& 15. 
 
L2a % Correct
SG1 94.6
SG5 83.4
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Specimens in pathology groups 7 and 15 were taken as control specimens and to the 
naked eye appeared to be normal squamous epithelium. Initially classified together as 
non-neoplastic squamous epithelium certain features found within the analysis 
prompted a further review. This showed that the samples making up SG5 could be split 
into two. This prompted a review of the histopathology reports and further subdivision 
of the samples. Resulting in the formation of SG3; containing samples exhibiting 
hyperplasia or hyperkeratosis (pathology code 7) and SG10 containing samples felt to 
represent truly normal squamous cell epithelium (pathology group 15). 
 
The striking feature of the empirical analysis in this mini model is that all the peaks 
shared in mini model L1 are also seen in this model however the pattern of difference in 
the peak intensity ratios is altered. The peaks seen at 1085, 1154, and 1030 cm
-1
can all 
be attributed to the presence of phospholipids and are seen in relatively greater amounts 
in SG1 (SCC). The peak at 718cm
-1
is associated with the presence of nucleotides and 
has a PIR greater for SG1. The peak at 1339 cm
-1
is larger for SG4 and this peak is also 
a feature of tissue containing nucleotides but can also be attributed to collagen. The 
peaks that can be attributed to keratin or specific residues present within keratin 
predominate in the spectrum of SG4 as might be expected. 
 
SG5 contains all the peaks that occur only in SG1, within the limits of the technique 
with which they can be selected. Peaks at 422 and 620 cm
-1
 are at wavenumbers similar 
to peaks attributed to δ (CCC) from strateum corneum and n(C-S) from phenylalanine 
in a psoriatic plaque. The peak occurring at 481 cm
-1
suggests the presence of glycogen 
and those at 898, 1547 and 1572cm
-1 
proline, tryptophan and nucleotides. 
 
The empirical analysis of such complex spectra is difficult and even more so when the 
cell populations exhibit similar properties and in cases such as this multivariate analysis 
comes into its‘ own and the findings seen on the PC load plots support those of the 
empirical analysis. 
 
Multivariate analysis confirmed the finding above and showed that whilst the two main 
study groups separated well, and somewhat better that that seen in L1, there does appear 
to be a large distribution of values / variance in SG5 because of the mixed pathologies 
included. Plots of the PC loads supported the findings of the empirical analysis. The 
percentage of SCC samples correctly classified by LDA in this model is 83.4 % and for 
the All – controls group 94.6%. 
4.2.3.4 L2b - Controls All / Control - Normal squamous epithelium (SG3/SG10) 
Empirical analysis 
The overlaid, normalized mean and difference spectra for this study are shown in Figure 
4.33. 
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Figure 4.33: L2b – Overlaid normalised mean spectra and difference spectra (SG3/SG10). 
PIR tables for the shared spectral peaks and details of unique peaks can be found in 
Appendix D5.3. Figures 4.34 and 4.35 show the data displayed as histograms for ease of 
analysis. For subsequent mini models tabulated PRI data and the corresponding 
histograms can be found in Appendix D5. 
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Figure 4.34: L2b – Peak intensity ratios for Study Groups 3 and 10. 
 
Figure 4.35: L2b – Differences in peak intensity ratios for Study Groups 3 and 10. 
Multivariate analysis 
Figure 4.36 shows the L2b mean centred data and the results of the multivariate analysis 
are summarised in Figures 4.37, 4.38 and 4.39. 
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Figure 4.36: L2b – Mean centred data set. 
 
Figure 4.37: L2b – Histogram demonstrating the separation between study groups using 
LDA. 
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Figure 4.38: L2b – Classification of study group samples by multivariate analysis. 
 
L2b SG3 SG10 Sensitivity Specificity
SG3 334 7 97.9% 100.0%
SG10 0 251 100.0% 97.9%  
Figure 4.39: L2b – Training classification performance 
Discussion 
This study was undertaken as a result of the findings in mini model L2a and was to 
further assess the separation of samples with pathology codes 7 and 15 and to 
investigate any specific features that might help understand the differences between 
them. 
 
L2b % Correct
SG3 97.9
SG10 100.0
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SG3 (hyperkeratosis/hyperplasia) contains 13 samples obtained from 9 patients and 
these samples afforded 341 spectra. SG10 contains 10 samples classified histologically 
as truly normal vocal cord mucosa. These came from 4 patients and produced 251 
spectra. The data from the two groups is reasonably well balanced. Specimens assigned 
to group 7 show either hyperplasia or hyperkeratosis. These specimens would not be 
considered as showing histological features of neoplastic change but their appearance to 
the eye and even under a microscope can be very similar to SCC. The clinical 
importance of this prompted mini-models L2c-1,-2 and -3 to be undertaken. The 
presence of hyperplasia implies that within the specimen there is a proliferation of 
normal squamous cells and where hyperkeratosis is seen layers of keratin have been 
deposited. The ability of Raman spectroscopy to differentiate non-neoplastic tissue and 
cancer relies on the presence and relative intensity of certain peaks for example peaks 
related to the presence of cellular constituents reflecting the expansion of a cell line in a 
neoplastic process. The Raman spectral features associated with this might also be seen 
in the presence of hyperplasia/hyperkeratosis and a more reliable interrogation strategy 
might prove to be the presence of Raman spectral changes associated with structural 
conformational changes in neoplastic tissue. 
 
A visual inspection of the overlaid normalised mean spectra for these two SGs shows 
great variation between the two plots. This is confirmed by the difference spectra where 
the mean normalised spectrum of SG10 is subtracted from that of SG3 (Figure 4.33). 
Positive peaks therefore reflect an increase in the amount of the molecular entity 
producing the Raman signal at that wavenumber in the samples making up SG3. There 
are small glycogen peaks at 480cm
-1
 in both spectra, these are less prominent than might 
be expected compared to this peak in other normal tissue from the oesophagus and 
cervix. The difference spectra has strong negative signals at 689, 733, 717, 780 cm
-1
 and 
again over the range 1488 - 1617 cm
-1
. There a large number of clearly positive peaks. 
The one at 620 cm
-1
 is noted as of possible particular significance in the L4 mini model 
analysis. Strong positive peaks at 826 and 854 cm
-1
 have been assigned to tyrosine and δ 
(CCH) aromatic determined from strateum corneum and interestingly the peak at 935, 
which is also positive is associated with CH3 rocking and C-C stretch in the α helix of 
keratin. The positive peak at 1122/1123 cm
-1
 may be due to glycogen or lipid but there 
is also a positive peak at 1372 that can be attributed to lipid. In the range 1470 to 1645 
cm
-1
 the peaks are negative and confluent and are likely to be due to nucleic acid bases, 
carotenoids and protein. There is also a negative confluence of peaks over the 689 to 
780 cm
-1
 range which is again likely to reflect the presence of nucleotides/DNA. 
 
The PIRs for SG10 look higher on the histogram relative to those for SG3 (Figure 4.34) 
however care must be taken in drawing general conclusions as this histogram only 
shows a sample of the peaks that are present. 
 
The multivariate analysis of this model gives an excellent separation of the two study 
groups with high scores over the lowest six PCs which agree with the findings of the 
empirical analysis. This mini model supports the findings from L2a; the presence of two 
separate groups with different biochemical spectral fingerprints within the All – controls 
(SG5) study group. It also shows there is some evidence that Raman spectroscopy can 
differentiate hyperkeratosis/hyperplasia of vocal cord mucosa but it would be helpful 
and important for the dataset relating to these findings to be expanded as the numbers 
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included in this study do not give data that is strong enough to support extensive cross-
validation or full independent testing. 
4.2.3.5 L2c mini model series 
This is a series of models exploring the ability of Raman spectroscopy to evaluate the 
effect of a possible lack of homogenicity in a collection of samples all consider not to 
display features of neoplasia (All-controls). It will also try to evaluate if Raman 
spectroscopy can distinguish between SCC, different subgroups of ‗normal‘ mucosa, 
tissue displaying dysplasia and carcinoma in situ. 
Summary of L2c models 
 L2c SCC/ Controls – All / Abnormal mucosa (SG1/SG5/SG7) 
 L2c-1 SCC /Controls – hyperplasia & hyperkeratosis / Abnormal mucosa 
(SG1/SG3/SG7) 
 L2c-2 SCC / Controls – normal squamous epithelium / Abnormal mucosa 
(SG1/SG10/SG7) 
 L2c-3 SCC / Controls – Normal squamous epithelium / Dysplastic mucosa 
(SG1/SG10/SG14) 
To avoid repetition the discussion relating to all the L2c models is done together after 
the results of the empirical and multivariate analyses for each mini model. 
Empirical analyses 
The overlaid, normalized mean spectra for these studies are shown in Figures 4.40 to 
4.43 and the PIR histograms in Figures 4.44 to 4.47. The individual difference spectra 
are recorded in Appendix D3.4 to D.3.7 and the tabulated PIR data and difference 
histograms in Appendix D.5.4 to D.5.7. 
 
Figure 4.40: L2c – Overlaid normalised mean spectra. 
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Figure 4.41: L2c-1 – Overlaid normalised mean spectra. 
 
Figure 4.42: L2c-2 – Overlaid normalised mean spectra. 
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Figure 4.43: L2c-3 – Overlaid normalised mean spectra.  
 
Figure 4.44: L2c – Peak intensity ratios for Study Groups 1, 5 and 7. 
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Figure 4.45: L2c-1 – Peak intensity ratios for Study Groups 1, 3 and 7. 
 
Figure 4.46: L2c-2 – Peak intensity ratios for Study Groups 1, 10 and 7. 
 
Figure 4.47: L2c-3 – Peak intensity ratios for Study Groups 1, 10 and 14. 
117 
 
Multivariate analysis 
The mean centred data for these mini models are shown in Figures 4.48, 4.50 and 4.52. 
Examples of scatter plots for each mini model are given in Figures 4.49, 4.51, 4.53 and 
4.54 the numerical results of the multivariate analysis are recorded, including 
sensitivities and specificities in Figures 4.55 to 4.62. 
 
Figure 4.48: L2c - Mean centred data set. 
 
Figure 4.49: L2c – Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.50: L2c-1 - Mean centred data set. 
 
Figure 4.51: L2c-1 - Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.52: L2c-2 - Mean centred data set. 
 
Figure 4.53: L2c-2 - Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.54: L2c-3 - Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.55: L2c - Classification of study group samples by multivariate analysis. 
 
 
Figure 4.56: L2c – Training classification performance 
L2c % Correct
SG1 91.8
SG5 84.3
SG7 77.2
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Figure 4.57: L2c-1 - Classification of study group samples by multivariate analysis. 
 
 
 
Figure 4.58: L2c-1 – Training classification performance 
L2c-1 % Correct
SG1 93.9
SG3 86.5
SG7 83.5
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Figure 4.59: L2c-2 - Classification of study group samples by multivariate analysis. 
 
 
Figure 4.60: L2c-2 – Training classification performance 
L2c-2 % Correct
SG1 93.7
SG10 90.4
SG7 89.0
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Figure 4.61: L2c-3 - Classification of study group samples by multivariate analysis. 
 
 
Figure 4.62: L2c-3 – Training classification performance 
Discussion L2C / L2c-1 / L2c-2 / L2c-3 
It is clear from the analysis of mini models L2a and L2b that pathology groups 7 and 15 
can be separated by Raman spectroscopy however for completeness the L2c mini model 
was performed with SG5 – all controls as it can be very difficult clinically to distinguish 
between normal, and hyperplastic mucosa, hyperkeratotic mucosa, SCC and carcinoma 
in situ. 
L2c-3 % Correct
SG1 94.7
SG10 94.8
SG14 82.0
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L2c compares SCC against all controls and also to the group labelled ‗abnormal 
mucosa.‘ This group contains all samples classified as showing dysplastic changes and 
also those displaying carcinoma in situ. Other mini models related to this study, L2c-1, 
L2c-2 and L2c-3, subdivide this model to account for the discovery that the original 
control group contained two discreet types of tissue. L2c-3 investigates if Raman 
spectroscopy can differentiate between SCC, truly normal vocal cord mucosa and 
dysplastic tissue. 
 
As the models are developed and the study groups subdivided, the numbers of 
specimens considered in each is reduced. The largest study group is SCC were 10 
patients gave 29 samples and from these 1038 spectra were obtained. This is a large data 
set compared to the abnormal mucosa study group which contained 5 samples and 127 
spectra. The number of spectra in the ‗All controls‘ group lies between the two other 
study groups and forms a reasonably large dataset of 592 spectra. Interestingly these 
spectra were obtained from 23 samples whereas many more spectra were collected per 
sample for the SCC group. This reflects the size of the samples which were generally 
larger in the SCC group and these samples were much easier to process. 
 
Visually inspecting the overlaid normalised mean spectra and taking into consideration 
the variation in the baselines, the plot for SCC still tends to sit alone in the L2c and L2c-
1 mini models (Figures 4.40 & 4.41). The spectra for ‗All controls‘ and ‗Controls – 
hyperplasia & hyperkeratosis seem very similar to that of ‗Abnormal mucosa‘. In L2c-2 
and 3 this trend is reversed with the spectra for SCC and Controls – normal squamous 
epithelium more closely associated (Figures 4.42 & 4.43). 
When the overlaid normalised spectra for all the samples in SG10 (pathology group 15) 
are looked at in detail and with the spectra magnified as shown in Figure 4.63 three 
distinct features are noted; there appears to be two spectral shapes, one drawn in blue 
and labelled A, and a second that has a broad peak between 630 and 800cm
-1
 with 
irregularities that look like peak vertices, the most prominent at 720 cm
-1
and labelled B. 
This range is most often attributed to Raman signal arising from DNA and in particular 
amino acids such as tyrosine and phenylalanine. The peak at 720 cm
-1
 has been assigned 
to nucleotides, the peak at 854cm
-1
, in the spectra whose shape is highlighted in red, can 
be attributed to both tyrosine and δ (CCH) aromatic from strateum corneum . The peak 
at 937 cm
-1 
that can be seen in Figure 4.64 can arise from a protein with an α helix 
secondary structure and this has been seen in the analysis of nails. All these factors 
combined suggest the possibility of a rise in keratin content. There are several 
explanations that may account for this; some samples may have been misclassified, are 
heterogenous, or Raman spectroscopy is detecting features at a molecular level before 
they are obvious histologically. 
 
The PRI trend in L2c (Figure 4.44) shows that for the shared peaks the PRI is generally 
smallest for the SCC samples and the PRIs for the other two groups again are generally 
larger with the greatest being in the lipid/protein range and at 1001cm
-1
. The PIR 
histogram for L2c-1 (Figure 4.45) shows a consistent trend with the PIRs increasing 
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from SG1 (SCC) to SG7 (Abnormal mucosa) to SG3 (Controls – hyperplasia & 
hyperkeratosis). This is a trend that correlates well with our knowledge of the nature of 
the disease which is understood to be a progression from normal through dysplasia to 
carcinoma in situ and then to SCC; SCC subdividing into well, moderate and poorly 
differentiated. The latter having the worse prognosis and being made up of cells 
morphologically most distinct from normal squamous cells. The pattern seen in the PRI 
histogram for L2c-2 is similar to that seen in L2c. Suggesting that the differences in 
molecular structure associated with SG10, normal squamous epithelium, predominates 
over those resulting in the PRIs for SG3 (controls - hyperplasia/hyperkeratosis). The 
histogram for L2c-3 is almost identical to that of L2c-2. This is likely to be due to the 
fact that the only difference between the two models is that in L2c-2 a comparison is 
made between SG1 (SCC), SG10 (Controls – normal squamous epithelium) and SG7 
(Abnormal mucosa) whereas in L2c-3 SG7 is replaced by SG14 (dysplastic mucosa). 
The latter, SG14, is the same as SG7 except that it does not contain the spectra from the 
carcinoma in situ samples. 
 
 
Figure 4.63: L2c-3 – Magnified section of normalised spectra for SG 10 (Controls - normal 
squamous epithelium). 
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Figure 4.64: L2c-3 – Further magnified section of normalised spectra for SG 10 (Controls 
normal squamous epithelium). 
The multivariate analysis of this series of mini models has been very useful in clarifying 
the advantages of further refining a model although this must be viewed in the light of a 
decreasing and more imbalanced dataset, the scatter plots do reemphasise these points. 
The colour coding of the data sets is consistent throughout with reference to the order 
the groups are compared, detailed in Table 4.14. The colours are assigned in the order 
green, blue, red and cyan for example in mini model L2c green codes SG1 (SCC), blue 
SG5 (All controls) and red SG7 (Abnormal mucosa). Reviewing the scatter plots even 
taking into account the discrepancy in spectra numbers SG5 (All controls) does again 
seem to be dividing into two (Figure 4.49). In Figure 4.51 the SCC group has a very 
definite area of maximal density but there is a distinct overlap group with the abnormal 
mucosa and hyperplasia/hyperkeratosis groups. 
 
Comparing L2c to L2c-1 where the all-controls group is replaced by one of its 
subgroups, SG3 (hyperkeratosis/hyperplasia), there is an improvement in the percentage 
of correctly predicted spectra for all study groups. The largest improvement is seen in 
SG7. That is some of those spectra wrongly predicted in L2c as belonging to SG7 
(Abnormal mucosa) are predicted correctly when SG5 (All controls) is replaced by SG3 
(hyperkeratosis/hyperplasia). 
 
Comparing L2c-1 and L2c-2; the difference between these is that SG3 
(hyperkeratosis/hyperplasia) is replaced by SG10 (Normal squamous epithelium). A 
significant improvement is seen in the ability of the model to predict both SG7 
(Abnormal mucosa) and also SG10 (Normal squamous epithelium) with very little 
change in the result for SG1 (SCC). 
The final mini model in this series replaces SG7 (Abnormal mucosa) with SG14 
(Dysplastic mucosa). Spectra of samples classified as carcinoma in situ have been 
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removed leaving only dysplastic mucosa spectra in SG14. Again there a further 
improvement in the prediction of samples classified as SG10 (Normal squamous 
epithelium) and a slight improvement in the result for SG1 (SCC). The ability of this 
model to predict SG14 (Dysplastic mucosa) is reduced compared to the prediction for 
SG7 (Abnormal mucosa) in mini-model L2c-2 however the imbalance in spectra 
numbers is the worst for this model  
4.2.3.6 L3 - Mild dysplasia / Moderate dysplasia / Severe dysplasia / Carcinoma in situ 
(SG2/SG6/SG8/SG9) 
Empirical analysis 
Figure 4.65 is a plot of the overlaid, normalized mean spectra for this model. With 4 
study groups there are 12 possible difference spectra and examples of these can be 
found in Appendix D.3.8. Figure 4.66 is the corresponding PIR histogram. 
 
Figure 4.65: L3 – Overlaid normalised mean spectra. 
 
Figure 4.66: L3 – Peak intensity ratios for Study Groups 2, 6, 8 and 9. 
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Multivariate analysis 
Figure 4.67 shows the mean centred dataset for mini model L3 and Figures 4.68 to 4.72 
the results of the multivariate analysis. 
 
Figure 4.67: L3 – Mean centred data set. 
 
Figure 4.68: L3 – Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.69: L3 – Scatter plot comparing linear discriminant functions 1 & 3. 
   
Figure 4.70: L3 – Classification of study group samples by multivariate analysis. 
L3 % Correct
SG2 96.1
SG6 100.0
SG8 100.0
SG9 100.0
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L3 SG2 SG6 SG8 SG9 Sensitivity Specificity
SG2 25 1 0 0 96.2% 91.8%
SG6 0 11 0 0 100.0% 96.3%
SG8 0 0 41 0 100.0% 98.8%
SG9 0 0 0 49 100.0% 100.0%  
Figure 4.71: L3 – Training classification performance 
ID Group Group2 Dot Product
A Mild dysplasia (SG2) Moderate dysplasia (SG6) 0.994
B Mild dysplasia (SG2) Severe dysplasia (SG8) 0.9925
C Mild dysplasia (SG2) Carcinoma in Situ (SG9) 0.991
D Moderate dysplasia (SG6) Severe dysplasia (SG8) 0.9933
E Moderate dysplasia (SG6) Carcinoma in Situ (SG9) 0.9916
F Severe dysplasia (SG8) Carcinoma in Situ (SG9) 0.9931  
 
0.9895
0.99
0.9905
0.991
0.9915
0.992
0.9925
0.993
0.9935
0.994
A B C D E F
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Figure 4.72: L3 – Results of dot product analysis. 
Discussion 
Differentiation between these groups is notoriously difficult both clinically and 
histologically and so it was felt that despite the small number of samples available it 
was important to begin the analysis of this dataset and use it as a pilot study on which to 
base future work. 
 
The main difficulty in this study is that the numbers of patients, samples and spectra are 
extremely small. Each of the dysplasia groups contains one patient and there are two in 
the carcinoma in situ group. 1 sample was obtained for both the mild and moderate 
dysplasia groups and from these 26 spectra obtained from the former and 11 from the 
latter. 41 spectra were obtained from the single sample showing severe dysplasia and 49 
from the two samples of carcinoma in situ. 
 
The carcinoma in situ overlaid normalised spectra show some unusual features, for 
example those labeled in Figure 4.73 and also shown in Figure 4.74, the latter has been 
magnified. 
 
Figure 4.73: L3 – Normalised spectra for pathology 11 (SG9) - Carcinoma in Situ. 
It is important when assessing a group of spectra that appear to vary significantly from 
the mean to appreciate the features that set them apart may simply be a reflection of the 
variance across the dataset. In this case there does appear to be distinct differences in 
the spectra shape and this can be seen in the 716 to 757cm
-1
 range.  
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Figure 4.74: L3 – Normalised spectra magnified for pathology 11 (SG9) - Carcinoma in 
Situ. 
Limited conclusions can be drawn from this data but it is interesting to note that the 
main shared peaks can be attributed to DNA (724cm
-1
), tyrosine (851 cm
-1
), lipids (1129 
cm
-1
), nucleic acids (1339 cm
-1
) and protein (1660 cm
-1
) with the largest PIRs in the 
lipid and protein ranges. The mild dysplasia group consistently has the lowest PIRs and 
those of moderate and severe dysplasia tend to be similar. The PIRs for dysplastic tissue 
at 1449cm
-1
 vary in a way that would be expected from our knowledge of the disease 
process to date as do those at 1339 cm
-1
, a peak which is related to nucleic acid content. 
 
Very little can be drawn conclusively from the results of the multivariate analysis in this 
mini model however the scatter plot Figures 4.68 does seem to show that in this model 
the spectra represented by green (mild dysplasia) and blue (moderate dysplasia) seems 
to relate to each other.  
 
An additional piece of data analysis was performed on the dataset from this model. 
Knowledge of the disease process would suggest that the molecular configuration of the 
tissue should change in a way that reflects the progression of disease from mild through 
moderate to severe dysplasia and finally to carcinoma in situ. Empirical analysis did not 
uphold this but only specific peaks were considered and a great deal of information 
from the spectra was not used. Whilst multivariate analysis improves on this it still 
breaks down the spectra into a limited number of PCs. In view of this a dot product 
analysis was applied to the data set after the background signal had been removed. This 
analysis calculates the cosine of the angle between the two datasets, in this case the 
normalised mean spectra. The cosine of the angle is the result of the dot product of the 
two spectra divided by the product of their size vectors. If the spectra are identical the 
angle between them will be 0 and the cosine of this is 1. If the spectra are maximally 
different the angle will be 90 degrees and the cosine of this is 0. In summary the closer 
the spectra are to each other the nearer the dot product will be to 1. The results of this 
analysis is summarised in Table 4.72. It can be seen that when the data is analysed in 
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this way the spectra that are most similar are mild dysplasia (SG2) and moderate 
dysplasia (SG6), moderate and severe dysplasia (SG6 & SG8) and severe dysplasia and 
carcinoma in situ (SG8 & SG9) which would agree with our knowledge of the disease 
and suggests that Raman spectroscopy may be used to differentiate these conditions but 
that studies containing larger sample numbers are required. 
4.2.3.7 L4 - Carcinoma in Situ / Poorly differentiated SCC / Moderately differentiated 
SCC / Well differentiated SCC (SG9/SG11/SG12/SG13) 
Empirical analysis 
This mini model utilises the relatively large number of spectra from SCC samples and 
begins to assess the ability of Raman spectroscopy to differentiate between different 
grades of SCC and carcinoma in situ. Figure 4.75 shows the overlaid, normalised mean 
spectra from the SGs, Figures 4.76 and 4.77 the PIR histograms for both L4 and L4-2 
models. Figure 4.78 shows the PIRs at two specific peaks and assesses their relationship 
to each other. Figure 4.79 shows the separation of the study groups in L4_1 and Figure 
4.80 demonstrates the mean centred data for L4. Scatter plots are demonstrated for both 
the L4 and L4-2 models in Figures 4.81 to 4.85 and the results of training classification 
performance for both are recorded in Figures 4.86 to 4.89. 
 
Figure 4.75: L4 – Overlaid normalised mean spectra. 
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Figure 4.76: L4 – Peak intensity ratios for Study Groups 9, 11, 12 and 13. 
 
 
Figure 4.77: L4-2 – Peak intensity ratios for Study Groups 9, 11, 12 and 15. 
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Figure 4.78: L4-2 – Peak intensity ratio comparison for Study Groups 9, 11, 12 and 13 at 
peak positions 1447 and 1656 cm
-1
. 
 
Figure 4.79: L4_1 – Histogram demonstrating the separation between SG3 and SG13. 
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Multivariate analysis 
 
Figure 4.80: L4 - Mean centred data set. 
 
Figure 4.81: L4 – Scatter plot comparing linear discriminant functions 1 & 2. 
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Figure 4.82: L4 - Scatter plot comparing linear discriminant functions 1 & 3. 
 
Figure 4.83: L4 - Scatter plot comparing linear discriminant functions 2 & 3. 
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Figure 4.84: L4-2 - Scatter plot comparing linear discriminant functions 1 & 2. 
 
Figure 4.85: L4-2 - Scatter plot comparing linear discriminant functions 1 & 3. 
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Figure 4.86: L4 - Classification of study group samples by multivariate analysis. 
 
L4 SG9 SG11 SG12 SG13 Sensitivity Specificity
SG9 48 0 0 1 98.0% 99.3%
SG11 0 274 8 20 90.7% 99.2%
SG12 1 4 487 25 94.2% 95.1%
SG13 6 2 20 191 87.2% 94.7%  
Figure 4.87: L4 – Training classification performance 
L4 % Correct
SG9 98
SG11 90.7
SG12 94.2
SG13 87.2
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Figure 4.88: L4-2 - Classification of study group samples by multivariate analysis. 
 
L4-2 SG9 SG11 SG12 SG15 Sensitivity Specificity
SG9 48 0 0 1 98.0% 99.3%
SG11 0 274 8 20 90.7% 99.4%
SG12 1 5 488 23 94.4% 94.8%
SG15 6 0 21 185 87.3% 94.9%  
Figure 4.89: L4-2 – Training classification performance 
Discussion 
L4 investigates the ability of Raman spectroscopy to differentiate between subgroups of 
SCC and also begins to assess if Raman spectroscopy can be used to solve the important 
clinical problem of differentiation of carcinoma in situ from SCC. 
L4-2 % Correct
SG9 98.0
SG11 90.7
SG12 94.4
SG15 87.3
142 
 
 
This mini model is very limited by small sample numbers particularly in the carcinoma 
in situ and well differentiated SCC groups. 49 spectra were obtained from 2 samples, 
provided by two patients for carcinoma in situ and 4 patients provided 15 tissue samples 
for the moderately differentiated SCC group. 219, 517 and 302 spectra were obtained 
from the well, moderately and poorly differentiated SCC samples There is a much better 
balance in the spectral data numbers when only the SCC specimens are included but it is 
important to note again that the number of patients providing these specimens varies 
with only one in the well differentiated group and 4 and 5 in the moderately and poorly 
differentiated groups respectively. Overall there is a large number of spectra from 
samples containing SCC and these are reasonably evenly spread between the three 
subgroups. Should the SCC subgroups separate this would help lend some confidence in 
that result. All these factors must be considered and must limit confidence in the results 
of the complete model however it is included as it shows the successful application of 
the empirical and multivariate analytical tools in directing the interrogation of the 
results as is noted further on in the discussion. 
 
The use of empirical techniques based on visualization of the overlaid spectra is 
difficult when there are four spectra however there appears to be differences between 
the spectra for carcinoma in situ and those of SCC at 1096 cm
-1
 a region associated with 
phosphate and DNA. There also appears to be a prominent shoulder in the carcinoma in 
situ spectra over the range 1510 to 1600 cm
-1
 and this may be attributed to amino acids 
such as tyrosine but interestingly it has also been shown to be present in heme. There is 
a broad set of positive peaks between 400 cm
-1
 and 500 cm
-1
 which may have a 
significant contribution from glycogen as there are also peaks attributable to this 
compound in the same orientation at1122 cm
-1
 and 1380 cm
-1
.The two positive peaks at 
1029 cm
-1
 and 1166 cm
-1
 are seen in the spectra of collagen. 
 
This model generates six difference spectra. The difference spectra resulting from 
poorly differentiated SCC subtracted from carcinoma in situ shows the most obvious 
differences (Appendix D.3.9). This is as would be expected as these two pathologies are 
the furthest apart in severity. A positive peak is present in the difference spectra at 1274 
and this wavenumber has been assigned to a Raman signal from heme. This combined 
with the finding noted from review of the overlaid spectra suggests the possibility that 
the carcinoma in situ sample may contain heme as a contaminant. There are negative 
signals over the 770-880 and 1410 to 1530 cm
-1
  ranges, the former is a range where 
DNA produces Raman signals and the latter mainly lipid and protein. 
 
A comparison of the PIRs for these study groups produced patterns that did not 
intuitively trend suggesting the possibility that the spectra from the well differentiated 
SCC group (SG 13) might be slightly unusual. This prompted a closer look at the 
original data. The data from SG13 was analysed against that from SG3 (mini model L4-
1), the latter group was arbitrarily chosen in order to assess if a histogram might show a 
double peak for the SG13 data as per the discovery made in L2a. Figure 4.79 shows that 
there might be the possibility of a double peak in the red histogram i.e. that of SG13 but 
this was by no means definitive and may be just indicative of missing data in a normal 
distribution.  
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The next step was that the plot containing all the normalised spectra for SG13 
(pathology group 14 – Well differentiated SCC) was carefully examined and there was a 
band of 7 spectra seen to be clearly different. All these spectra came from the same 
sample which had 35 spectra in total. The spectra were all collected on same day and 
were not recorded consecutively These seven spectra were removed from the data set 
and a new amended data set produced in addition to the original, this was called SG15. 
The normalised mean spectra from this new group (SG15/path 01) was subtracted from 
that of SG13 in the hope that the difference spectra might give some idea as to the areas 
in which the differences arose however this was unsuccessful. It is felt that the 
imbalance in spectra numbers and more importantly the fact that mean spectra were 
compared is likely to be the reason for this. 
 
The new data set was then used to rerun the model and the PIRs recalculated. The 
pattern of the PRIs altered to one that showed a gradation smoothly through carcinoma 
in situ, well, and moderate and poorly differentiated SCC as would be expected. The 
multivariate analysis also showed a marginal improvement. In this study PIRs 
histograms proved useful in detecting subtleties in sets of spectra and the detailed look 
at the histogram for L4-2 between 1447 and 1656cm
-1
shows a trend in PIRs that would 
be expected for these diseases and agrees with the findings noted by other authors 
(Stone, 2000) 
 
The multivariate analysis on the original data set of mini model L4 gives a scatter plot, 
when linear discriminant functions (ldf) 1 and 2 are compared, that shows a separation 
of the four groups (Figures 4.81, 4.82 & 4.83). Whilst the group containing specimens 
of carcinoma in situ (green) contains fewer spectra this group does appear to sit apart 
from those of SCC. In Figure 4.83 there is one spectrum from the moderately 
differentiated group that sits within the carcinoma in situ group but considering the 
great difficulty in consistently differentiating between these groups histologically it is 
encouraging that there is so little overlap and incongruous spectrum positions. The L4-2 
model has been shown to have better PRI correlation with disease and also shows better 
group separation on multivariate analysis scatter plots (Figures 4.84 & 4.85). These 
plots also show moderate and poorly differentiated SCC and well differentiated and 
carcinoma in situ groups sitting closer together again this would agree with our 
understanding of the spectrum of this disease. The percentage of spectra correctly 
predicted by model L4-2 is the same for carcinoma in situ and marginally better for all 
the SCC subgroups compared to the results for the basic L4 model. 
4.3 Lymph Node Study 
The variety of tissue samples collected and the range of diseases present necessitated a 
slightly different and simplified approach to the lymph node study work. The primary 
question of whether Raman spectroscopy is capable of differentiating lymph nodes 
within the neck that showed reactive changes from those which contained tissue 
exhibiting features of neoplastic change was addressed. The second question, which has 
equal importance to the clinician, is whether Raman spectroscopy can differentiate 
between SCC, lymphoma and adenocarcinoma. 
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4.3.1 Data summary 
Tables 4.19, 4.20 and 4.21 summarise the data organisation for these mini models in 
total 48 patients were recruited to take part in this work and from these patients 159 
tissue samples and 4549 spectra obtained. The mean number of spectra per patient was 
95 (range 15 to 242) and the mean number of spectra per sample 29 (range 15 to 44). 
The samples were generally much larger and. the range of diseases seen wider in the 
lymph node study compared to the larynx study. For studies N1 and N2 only part of the 
dataset was used; 86 spectra from the reactive lymph node (SG1) and 4 from the SCC 
(SG3) group, this resulted in two samples being lost from (SG1). This was due to a lack 
of phenylalanine peaks in these spectra meaning that they could not be corrected in the 
same way as the other spectra so were put to one side and will be looked at separately at 
another time to check they are not representing a subgroup of disease not 
accommodated for in the classification. For the four group model only spectra from 
samples containing Hodgkin‘s lymphoma (pathology codes16, 17, 19) were used for the 
main analysis, more samples are now available as detailed in the specimen summary 
(Table 4.19) and these will be used in the future to expand the spectra dataset and begin 
work on assessing the efficacy of Raman spectroscopy in differentiating subgroups of 
the disease.  During empirical analysis it was noted that the spectra for Non-Hodgkin‘s 
lymphoma shows some subtle but clear differences from both Hodgkin‘s lymphoma and 
the other study groups, this would also warrant further work in the future. 
Table 4.19: Numerical data for individual pathology coded specimens in lymph node 
studies. 
Pathology 
Code
Description
Number 
of 
Patients
Number 
of 
Samples
Number 
of 
Spectra
Average 
Spectra per 
Sample
Average 
Spectra per 
patient
1 Reactive Lymph node 18 55 1475 27 82
2 Branchial cyst 1 1 15 15 15
3 Fibrous connective tissue 3 6 134 22 45
4 Normal squamous epithelium 3 8 202 25 67
5 Fat 0 0 0 0 0
6 Parotid salivary tissue 1 8 226 28 226
7 Normal thyroid tiassue 1 5 78 16 78
8 SCC - Poorly differenciated 3 6 170 28 57
9 SCC - Moderately differentiated 4 18 622 35 156
10 SCC - well differentiated 0 0 0 0 0
11 Adenocarcinoma 1 8 242 30 242
12 Pleomorphic adenoma 2 3 132 44 66
13 Poorly differentiated carcinoma 2 8 251 31 126
14 Thyroid - papillary carcinoma 2 5 165 33 83
15 Thyroid - follicular carcinoma 1 7 187 27 187
16 Hodgkin's lymphoma (HL) - mixed cellularity 1 2 60 30 60
17 HL - nodular sclerosing 1 4 113 28 113
18 HL - follicular cell 1 1 34 34 34
19 HL - classical lymphocyte predominant 1 4 149 37 149
20 HL - Non-classical 1 2 62 31 62
21 Non-Hodgkin's lymphoma (NHL) - diffuse large B cell 1 8 232 29 232
22 NHL - Low grade malignant 0 0 0 0 0
23 NHL - MALT type 0 0 0 0 0  
 
The numerical data and combinations of pathology codes used to make up the lymph 
node study groups are detailed in Table 4.20 and 4.21. The best balance of data is for 
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mini model N1. The balance of data for N2 is less good and adenocarcinoma is the least 
well represented. 
Table 4.20: Numerical data for combinations of pathology codes used to form lymph node 
study groups. 
Study 
Group
Description Pathology Codes Number of Patients Number of Samples Number of Spectra
1 Reactive Lymph node 1 18 53 1389
2 Cancer
8,9,11,16,17,19, 21
12 50 1584
3 SCC 8,9 7 24 788
4 Adenocarcinoma 11 1 8 242
5 Hodgkin's Lymphoma 16,17,19 3 10 322
 
 
Table 4.21: Lymph node mini models – a comparison between different study groups. 
Mini 
Model
Description
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L1
Reactive Lymph 
node
1 Cancer 2
L2
Reactive Lymph 
node
1 SCC 3 Adenocarcinoma 4
Hodgkin's 
Lymphoma
5
 
 
4.3.2 Diagnostic models 
4.3.2.1 N1 Reactive tissue/Neoplastic tissue 
There can be difficulties in interpreting the spectral differences between two groups 
were one contains such a diverse range of tissue samples as the cancer group in this 
study so a simple two group model was formulated which aimed to address the question 
as to whether Raman spectroscopy could differentiate reactive lymph nodes from those 
containing cancer. 
 
A more detailed empirical look at the mean normalised spectra is discussed in Section 
4.3.2.2. 
 
25 statistically significant principal components determined by ANOVA were examined 
and Figures 4.91, 4.92 & 4.93 shows the load plots with those for PCs 5 and 6 shown in 
more detail. Linear discriminant analysis exhibited a clear separation between the study 
groups as is demonstrated in Figure 4.90. 
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Figure 4.90:.N1 – Histogram of lymph node two group model showing separation of 
reactive lymph nodes from those containing cancer. 
 
Figure 4.91:.N1 – LDA loads. 
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Figure 4.92:.N1 – PC load 5. 
 
Figure 4.93:.N1 – PC load 6. 
148 
 
These load plots can help tease out significant differences between study group spectra 
which may be obscured in the overlaid normalised mean spectra plot for example PC 6 
looks positive for the presence of collagen. 
 
This model was cross-validated and the results of this are summarised in Tables 4.22 
and 4.23. The results are very encouraging, for the two group model the cross-validated 
result showed 90% specificity for cancer and 88% for reactive nodes and the reverse for 
sensitivity. 
Table 4.22:– N1 – Spectral prediction performance for 2 group model (leave one sample 
out - cross validation). 
Histopathology Reactive Cancer +ve
Reactive 1245 144
Cancer +ve 192 1392
Sensitivity 90 88
Specificity 88 90
Spectral Prediction
 
 
It was interesting to note that cross-validation assessing spectral performance by node 
showed even better results. Assessment of the model by node could be viewed as 
somewhat closer to the clinical scenario and a help in negating somewhat the effects of 
aberrant spectra. 
Table 4.23:- N1 – Spectral prediction performance by node for 2 group model (leave one 
sample out - cross validation). 
Histopathology Reactive Cancer +ve
Reactive 49 4
Cancer +ve 7 43
Sensitivity 92 86
Specificity 86 92
Spectral Prediction
 
 
4.3.2.2 N2 Reactive Lymph nodes/ SCC/Adenocarcinoma/Lymphoma 
This mini model is a natural progression from N1. In the past it has been difficult to 
balance sample numbers in this type of study because of the paucity of reactive lymph 
node specimens. In this work the reverse is true and the numbers of samples from 
adenocarcinoma and lymphoma could be improved. The figures did allow cross-
validation on a leave one sample out basis to be performed. The results of the cross-
validation studies are summarised in Tables 4.24 and 4.25. 
Figures 4.94 and 4.95 show the normalised mean spectra for the study groups in this 
mini model with SG5 split into two; Hodgkin‘s and Non-Hodgkin‘s lymphoma. This 
split was prompted by knowledge of the difficulties that exist in the classification of 
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lymphomas. The thought being that Raman spectroscopy might be able to differentiate 
between the two types of lymphoma and in the future as the data set is expanded 
perhaps be able to subdivide them even further. 
 
Figure 4.94:.N1 – PC:Overlaid mean normalised spectra for individual pathology groups. 
 
Figure 4.95:.N2 – Normalised spectra for individual pathology groups 
The areas enclosed in the ovals show subtle differences in the spectra between the five 
different groups. In the mini model N2 Hodgkin and non-Hodgkin lymphoma groups 
are combined however it is interesting to note that there are distinct features within the 
spectrum for Non- Hodgkin‘s that distinguish it from the other groups. Even accounting 
for the variation in the baseline the feature labelled A shows that for SCC there appears 
to be a more prominent peak at 540cm
-1
. At B and just beyond there are some unusual 
features in the plot for Non-Hodgkin‘s lymphoma were it crosses those of Hodgkin‘s 
lymphoma and reactive lymph nodes (670cm
-1
). At 744cm
-1
 there is a small peak that is 
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seen in the spectrum for Non-Hodgkin‘s lymphoma and possibly in SCC but appears 
absent in the plot for adenocarcinoma. At 895cm
-1
 there is a broad peak that again is 
present in Non-Hodgkin‘s lymphoma and the spectrum for reactive lymph nodes. The 
feature at 540 cm
-1
 is likely to be a protein peak and that at 670 cm
-1
 can be attributed to 
the breathing of aromatic rings in purine bases (DNA). The peaks at 744 and 895 cm
-1
 
can be assigned to phosphate bonds in DNA and DNA backbone. 
Figure 4.96 shows the different linear discriminant functions for this model and Figure 
4.97 is a 3D representation of the separation of the study groups achieved. 
 
Figure 4.96:.N2 – Linear discriminate functions. 
The 3D plot of the linear discriminant functions shows diagrammatically that the 
separation of the groups is excellent and to further assess the dataset a cross-validation 
study was performed. 
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Figure 4.97:.N2 – 3D linear discriminate plot for 4 group model. 
Cross-validation 
Tables 4.24 and 4.25 summarise the results for the 4 group model (cross–validated). 
The model sensitivity is best for adenocarcinoma and worst for SCC with similar values 
for reactive nodes and lymphoma. Whilst no misdiagnoses, in particular false negatives, 
are acceptable the results show that the specificity of the model is very good for cancer, 
99, 95 and 90% respectively for adenocarcinoma, SCC and Hodgkin‘s lymphoma 
(Table 4.24)  
Table 4.24:– N2 – Spectral prediction performance for 4 group model (cross validation - 
leave one sample out). 
Histopathology Reactive Adenocarcinoma SCC Lymphoma
Reactive 1130 20 76 163
Adenocarcinoma 0 225 8 9
SCC 107 2 598 81
Lymphoma 86 0 23 445
Sensitivity % 81 93 76 80
Specificity % 88 99 95 90
Spectral Prediction
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Table 4.25:– N2 – Spectral prediction performance by node for 4 group model (cross 
validation - leave one sample out. 
Histopathology Reactive Adenocarcinoma SCC Lymphoma
Reactive 45 1 2 5
Adenocarcinoma 0 8 0 0
SCC 4 0 18 2
Lymphoma 3 0 0 15
Sensitivity % 85 100 75 83
Specificity % 86 99 97 92
Spectral Prediction
 
In the cross-validation of the spectral performance by node the sensitivity is improved 
for reactive nodes, adenocarcinoma and lymphoma and is reduced by 1% for SCC. The 
specificity of the model for cancer improves to give even better result; 92% 
(lymphoma), 99% (adenocarcinoma) and 97% SCC. 
4.4 Discussion summary 
4.4.1 Consensus studies 
The consultant consensus histology classification for both studies was excellent with 
complete agreement achieved for 89.1% of samples in the larynx study and 86.8% in 
the lymph node study. In no cases did all three consultants disagree. This level of 
concordance is unusual considering the inherent difficulties in the assessment of H&E 
slides derived from frozen sections and increases confidence in the results of the models 
developed in the larynx and lymph node studies. The comparison of the consultant 
consensus and the histopathology report from the main operative specimen showed 
lower levels of agreement as would be expected, 75.5% and 72.3% for the larynx and 
lymph node studies respectively; this is fully discussed in Section 4.1.2. The importance 
of this finding is that the study has sought where ever possible to reference experimental 
procedure to the clinical setting and it highlights a difficulty in the future development 
of Raman spectroscopy as a real time useful in vivo tool. It will be imperative that in 
heterogenous samples where foci of disease exists Raman spectroscopy is able to pick 
up the presence of disease either through the detection of field changes or by use in 
combination with other imaging techniques. The consultant consensus and 
consultant/histopathology report studies were also small enough that data could be 
looked at in great detail. Individual histopathology opinions were compared and if a 
discrepancy was noted this was thoroughly investigated by reference to the original 
patient notes and history. This ensured no adverse clinical decisions were made on the 
basis of the main operative specimen histopathology report where a different diagnosis 
had been assigned through consultant consensus of the experimental sample. 
4.4.2 Larynx studies 
The development of the diagnostic models created in the main larynx study was based 
on the need to investigate the efficacy of Raman spectroscopy in answering key clinical 
questions. Each step in the development of the studies aimed to push further the 
assessment of the ability of Raman spectroscopy to differentiate ever more specific 
disease entities. Table 4.14 details the different types of tissue samples compared in 
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each of the mini-models. This table is further expanded in Appendix D.2 to summarise 
the nomenclature used for pathology groups (tissue classified as one histopathological 
entity), study groups (different combinations of pathology groups) and also records the 
number of spectra obtained from each study group. A full break down of the numbers of 
patients, samples and spectra obtained from samples in each pathology group is 
recorded in Table 4.13. 
 
The first, most basic question addressed in mini model L1 was could Raman 
spectroscopy differentiate between tissue containing malignancy (SCC) and tissue that 
did not? Whilst the tissue in the latter group did not contain malignancy it did contain 
samples where neoplastic change such as dysplasia and carcinoma in situ had occurred. 
No tissue samples, other than those containing TB, where removed from this study in 
order assess Raman spectroscopy in as clinically relevant way as possible. L1-1 refined 
this basic but fundamental assessment further by interrogating tissue that exhibited 
neoplasia (SCC) or neoplastic changes, such as dysplasia and carcinoma in situ, against 
tissue from vocal cords that had been assessed as showing no evidence of any form of 
neoplastic change (All controls) histologically. The results for L1 showed 85.6/ 87.2% 
(sensitivity/specificity) for SCC and 87.2/85.6%% for tissue containing no evidence of 
true malignancy. In the L1-1study when Raman spectroscopy was used to identify tissue 
showing neoplastic change it did so with 95.2% sensitivity and 84.6% specificity which 
gave an overall training performance of 91%. This reduced to 81% after independent 
testing by cross-validation. The specificities obtained for this model where 84.6% for 
the tissue showing neoplastic change and 95.2% for the tissue that did not. The 
refinement of the model giving improved results for sensitivity in diagnosis of tissue 
exhibiting neoplastic change of all types compared to SCC alone and an improvement in 
the specificity of diagnosis for vocal cord tissue that did not exhibit any neoplastic 
change compared to the non-malignant group in L1. The latter result is encouraging and 
would be as predicted as the samples in the corresponding group in the L1 study where 
completely heterogenous in nature. L1-1 compares groups that correlate very closely to 
those that would be obtained during surgical biopsy for the investigation of a vocal cord 
lesion and answer positively the key clinical question ‗ To what extent can Raman 
spectroscopy differentiate between normal vocal cord tissue and tissue showing degrees 
of neoplastic change?‘ 
 
The L2 series of mini-models followed on initially as a refinement to the L1 study. L2a 
compared tissue containing SCC against ‗All controls‘; vocal cord tissue assessed 
histologically as showing no evidence of any form of neoplastic change. The results 
from L2a showed 94.6% sensitivity for SCC and 83.4% for ‗All controls‘. The 
specificity results were 83.4% for SCC and 94.6% for ‗All controls.‘ These results were 
rather disappointing but multivariate analysis results highlighted the possibility that the 
‗All controls group might be significantly heterogenous. This was confirmed by a closer 
look at the histology which showed that in fact this group contained samples exhibiting 
hyperplasia and perhaps more significantly hyperkeratosis. L2b was a study borne out 
of this observation and assessed if Raman spectroscopy could identify hyperkeratosis 
and separate it from genuinely normal vocal cord tissue. This study contained moderate 
numbers of samples and a reasonably well balanced number of spectra between groups. 
It gave excellent results with 97.9/100% (sensitivity/specificity) for hyperkeratosis and 
100/97.9% for normal squamous cell epithelium. As clinically hyperkeratosis can look 
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very similar to SCC this is a very positive finding and supports the eventual use of 
Raman spectroscopy as a diagnostic tool.  
 
The 3 group mini-models in the L2c study series work in a logical way through 
refinements to the L1-1 study by taking into account the findings of L2b that the 
original ‗All controls‘ group could be divided into two; tissue showing 
hyperkeratosis/hyperplasia and tissue exhibiting normal squamous cell epithelium. This 
series of mini-models also subdivides the L1-1 group which contains tissue classified as 
showing any neoplastic change into two further groups; tissue containing SCC and a 
second group in which the tissue exhibited dysplasia or carcinoma in situ (abnormal 
mucosa). The last mini-model in this series removes the tissue containing carcinoma in 
situ from the ‗abnormal mucosa ‗group and assesses the Raman spectroscopy 
classification of SCC/normal squamous cell epithelium and dysplastic mucosa (L2c-3). 
With the caveat that as the mini-models become more refined the number of samples 
used reduces and this will reduce confidence in results this series that the general trend 
is an increase in the sensitivity and specificity of results as the study groups used 
become more specific for one pathology. This is discussed in much more detail in 
Section 4.2.3.5. Multivariate analysis also shows very clearly that the separation 
between study groups agrees with that expected from our knowledge of the natural 
history of these diseases. This again supports the development of a clinical diagnostic 
application for this technique within the larynx in the future. 
 
There is considered to be a continuum of vocal cord neoplastic disease from normal 
through mild, moderate to severe dysplasia and from there to carcinoma in situ. From 
carcinoma in situ there is a key point where SCC develops, this is generally considered 
to progress in severity from well to moderately well and finally poorly differentiated 
SCC which has the worst prognosis. The mini- models in L3 and in the L4 series aim to 
investigate if Raman spectroscopy can differentiate between different grades of diseases 
such as the three grades of dysplasias (L3) and the three grades of SCC (L4) but they 
are also designed to investigate the degree to which carcinoma in situ can be separated 
from dysplasia (L3) and from SCC (L4). This latter point has great clinical significance 
as it is both histologically challenging and a key point at which treatment regimes 
change. The grades of dysplasia and SCC are notoriously difficult to consistently 
classify and particularly for SCC it can be of help in assessing patient prognosis. 
 
L3 assesses the differentiation between tissue showing the three degrees of dysplastic 
change and that showing carcinoma in situ. Patients with vocal cord dysplasia and 
carcinoma in situ are followed up in the outpatient clinic often every few weeks/months 
with biopsy under general anaesthetic periodically if the disease is thought to be 
progressing. The assessment of vocal cords in outpatients is purely subjective, this study 
was designed to assess if Raman spectroscopy could do this objectively. The results for 
sensitivity and specificity obtained in this study cannot be validated because of the 
small number of samples however the multivariate results from this study again 
correlate well with our knowledge of the progression of this disease and the group 
separation shown graphically is striking. In order for this study to be validated it will 
need to be expanded however this work shows that Raman spectroscopy is likely to be 
able to differentiate these disease states and for the first time that Raman spectroscopy 
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might in time be a viable outpatient screening tool for the different grades of pre-
malignant change seen in vocal cord tissue. 
 
The series of mini- models in L4 are designed to look at the ability of Raman 
spectroscopy to differentiate the different grades of SCC and carcinoma in situ. 
Inspection of the mean centred data for this model and the empirical analysis 
highlighted the possibility that some of the spectra in the well differentiated SCC study 
group might be unusual. L4-1 selected the hyperplasia/hyperkeratosis group to 
nominally compare to the SCC – well differentiated group to assess if on multivariate 
analysis a ‗double peak‘ could be seen in the LDA histogram for the SCC. This could 
not be seen and in retrospect this should have been expected as the number of spectra 
was small and the differences when averaged out would have made only a nominal 
difference. The spectra were so clearly different that they were removed and the model 
re-run (L4-2). This model would benefit enormously from increased numbers but the 
multivariate analysis clearly shows graphically in figures 4.81 to 4.85 that the groups 
separate and that they do so in a way that correlates well with our understanding of the 
disease. 
4.4.3 Lymph node study 
These two studies are used to assess for the first time the efficacy of Raman 
spectroscopy to differentiate between malignancies in lymph nodes obtained from the 
neck. Table 4.19 summarises the different tissues types by pathology codes, the 
numbers of patients from which they were obtained along with details of the 
corresponding number of samples and spectra. Table 4.20 details the combinations of 
pathology groups that are used to make up study groups which were then compared 
(Table 4.21). The results obtained for the mini-models in these studies are the best 
considered in this work and the large size of the dataset allowed for rigorous 
independent validation. 
 
N1 compares the Raman spectra obtained from samples of lymph nodes considered to 
show only reactive changes against those considered to show changes indicative of 
malignancy done with a similar rational to that of the L1 study. N2 develops the model 
further by breaking down the cancer group into SCC, adenocarcinoma and Hodgkin‘s 
disease. This has great clinical significance as the removal of an undiagnosed SCC from 
the neck by simple lymph node excision is a disaster and has enormous consequences 
for the patient, yet this may be all that is required for the diagnosis and selection of a 
treatment regime for lymphoma. There were a larger number of specimens and spectra 
used in these studies and the results have been fully cross-validated. The spectral 
performance for N1 showed that Raman spectroscopy could clearly differentiate 
between reactive lymph nodes and those containing cancer (Tables 4.22 and 4.23). The 
results for N2 show for the first time that Raman spectroscopy can differentiate superbly 
between reactive lymph nodes, SCC, adenocarcinoma and Hodgkin‘s disease; cross-
validated both by sample and by node (Tables 4.24 and 4.25). 
 
The work on the analysis of the lymph node study data has only really been touched 
upon but it has given excellent results for the groups compared to date and the initial 
empirical analysis for Non- Hodgkin‘s disease is also very exciting. The development of 
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this work to consider the ability of Raman spectroscopy to identify different subgroups 
of cancer with further modelling and data analysis is ongoing. 
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Chapter 5: Conclusions and Future Work 
5.1 Conclusions 
This work differs from that previously published in that the reasoning for the studies 
themselves and importantly the way in which these studies were developed was driven 
by clinical pragmatism. Throughout the needs of the clinician to make a diagnosis and 
those of the patient to have this done in an accurate and timely fashion have been the 
priority in the assessment of Raman spectroscopy as a diagnostic technique. The 
conclusions drawn from the results of the three main studies, particularly those for the 
larynx and lymph node studies are detailed in this context. 
5.1.1 Consensus studies 
In this work the consensus between histopathologists as to the classification of disease 
in the samples used for spectral analysis was good; 89.1% complete agreement for the 
larynx study and 86.8% for lymph node study samples. These results showed excellent 
concordance however it was felt unusual for the results for consultant consensus in the 
lymph node study to be poorer than those for the larynx as the larynx study specimens 
were generally smaller and more heterogeneous. There are several reasons this might 
have occurred, one of which is the fact that no specimens were removed from the 
analysis because of heterogenicity. This was felt to be imperative as a surgeon has no 
way of telling intra-operatively whether the biopsy or resection obtained is 
homogeneous or heterogenous. The tissue samples used in the lymph node study were 
generally larger than those of the larynx study and so the potential for mixed disease 
states coexisting was greater. In likely hood more importantly is the fact that diseases 
such as lymphoma are very poorly diagnosed from H&E slides of frozen sections. 
 
The possibility that one consultant histopathologist tended to grade the severity of 
disease slightly lower than the other consultants did arise. This was carefully examined 
and no changes in the clinical management of the patients would have resulted from the 
minor alterations in disease classification that could have ensued. Interestingly the 
classification afforded by this histopathologist generally agreed with that of the main 
operative specimen, suggesting that possibility that the other histopathologists might 
have tended to over-grade, again no material change in treatment would have occurred 
as a result. 
5.1.2 Laryngeal studies 
The spectra obtained during this work are consistent and reproducible. There are only a 
small number of studies to date that have investigated the use of Raman spectroscopy in 
the diagnosis of laryngeal disease and in particular to investigate the ability of Raman 
spectroscopy to differentiate between tissue showing neoplastic change and laryngeal 
mucosa which does not. This question was addressed in the two group mini model L1-1 
and the results, which were subjected to cross-validation, support the finding of other 
studies that Raman spectroscopy shows great promise as a diagnostic tool in this area 
provided that the practical problems relating to its‘ use can be overcome. 
 
The importance of empirical analysis cannot be over-emphasised. Whilst this technique 
uses only part of the data gathered in any one study it still allowed the pattern of change 
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between the spectra of different study groups to be assessed. This was used as the ‗step 
off‘ point in the development of the early hypotheses as to the biochemical changes that 
may exist between study groups, for example in the secondary structure of some 
proteins (L1). The main study published to date in this area by Stone et al (Stone, 2002) 
is discussed in the literature review; the findings in this work are very similar for SCC, 
dysplasia and normal laryngeal mucosa sensitivity and specificity. They are detailed in 
full in the discussion section for the L1 and L2 mini models. An improvement is present 
in some results however the drawback of this work, as it was in the previous study, is 
the small number of specimens/patients in some arms of the mini models. The results 
are encouraging but for the work to be validated a larger data set is required so that 
cross-validation can be done initially with a leave one sample out technique but in time 
ideally a leave one patient out technique should be used leading to optimized models 
and full independent testing. The difficulties in obtaining samples means that further 
work would be most successful if a multicentre approach was taken. It might also prove 
interesting to trace back the few spectra that appear to be misclassified and review their 
notes to see the progression if any of their disease. 
 
No tissue specimens were discarded and the power of this work is in its pragmatic 
approach; striving to keep the work as near to the clinical scenario as possible. It can be 
extremely difficult to target biopsies in the larynx and targeting tissue with the Raman 
probe in the future is likely to encounter many similar problems. It is hoped that by 
accepting all specimens into the study the validity of results supporting the effectiveness 
of Raman spectroscopy as a clinical tool will be upheld. Furthermore, it removes any 
errors introduced into studies where the full pathology mix is not included and real-
world performance therefore not tested. 
 
Yang (Yang, 1998) has investigated the use of Raman spectroscopy in the larynx where 
there is infection with Human Papilloma Virus. This is a very interesting area of study 
as prognosis in this disease can be very variable and there is an increased risk of the 
development of neoplastic change. Coupled with interest in vaccine development 
towards different HPV strains there maybe value in further work in this area. Whilst the 
disease is not common patients often require multiple debridements‘s affording the 
opportunity to harvest multiple samples and possibly map disease remission and 
progression and explore the reasons they occur. 
 
Accurate visual or microscopic assessment of diseased laryngeal tissue is very difficult, 
for example hyperkeratosis can be extremely difficult to differentiate from SCC. At 
present accurate intra-operative assessment of diseased laryngeal tissue is not possible 
and in this work Raman spectroscopy has been shown to be a highly sensitive tool in the 
detection of non-neoplastic variations in the normal structure of vocal cords. Samples 
exhibiting hyperplasia and hyperkeratosis can be separated from samples considered to 
be ‗true‘ normal histologically and this finding strongly supports the use of Raman 
spectroscopy as a clinical tool. 
 
It was hoped that mini model L3 would answer the question as to whether Raman 
spectroscopy could differentiate carcinoma in situ from dysplasia. The small sample 
numbers make it very difficult to draw any definitive conclusions however the results 
again look promising and further work is needed to increase the dataset. On the other 
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hand study L4 has shown that Raman spectroscopy is likely to be able to discriminate 
well between SCC and carcinoma in situ. This study would be improved by increasing 
the number of patients and in particular the number of samples in the carcinoma in situ 
group, however the results strongly support the conclusion that Raman spectroscopy can 
differentiate between different grades of SCC. Once again these studies where designed 
to assess the ability of Raman spectroscopy to act as a diagnostic tool in areas where 
there is currently great diagnostic difficulty such as in the discrimination between SCC, 
dysplasia and carcinoma in situ and the results to date are extremely encouraging. 
5.1.3 Lymph node studies 
This work is the first to undertake a rigorous investigation into the efficacy of Raman 
spectroscopy as a diagnostic tool in neoplastic diseases of lymph nodes within the head 
and neck. Some work has been published in the past but primarily relating to metastatic 
deposits from breast disease (Smith, 2003 & 2005). The dataset for this study is much 
larger and whilst ideally a more even distribution of samples and increase in the number 
of patients in the adenocarcinoma and lymphoma groups would be good the number of 
reactive nodes harvested provides a good basis for future work. This work shows that 
Raman spectroscopy can differentiate between SCC, adenocarcinoma, lymphoma and 
reactive lymph nodes in the head and neck with excellent specificity and sensitivity. 
Sections of the remaining lymph node samples have been analysed with a Raman probe 
and early results are very encouraging it is hoped that this work will be continued within 
the research group and a comparison made between it and the static Raman system 
results. This study has been well tested and that the results are likely to be rapidly 
implemented. Our research group has recently secured funding to explore needle Raman 
probes for identification of suspicious nodes in the head and neck, the remaining lymph 
node specimens will be used to forward this work 
5.2 Future work 
A study into the degree to which histopathological classification varies between the 
participating consultants using carefully selected slides that optimise discrimination 
would be helpful in giving confidence to the experimental classification results. These 
results suggest that ‗histopathology panels‘ for the classification of these types of 
samples might reduce the degree to which individual subjectivity influences outcome. 
 
The development of a spectral library for ‗normal tissues‘, in addition to those for single 
biochemical entities, would be extremely useful. During the collection of spectra the 
inclusion of a reference peak for the calculation of PIRs would be of help. 
 
For Raman spectroscopy to be a genuinely useful tool it must be able to differentiate 
between neoplastic and non-neoplastic tissue in the real clinical setting. The use of 
lasers in the operating theatre is increasing and this is particularly true within oto-rhino-
laryngology where the treatment of early vocal cord neoplasia has moved away from 
radiotherapy to primary laser resection. Operative margins are currently visually 
assessed by the surgeon with the use of a microscope and biopsies at the resection 
margin taken and send for analysis. These frozen sections are reported whilst the patient 
is in theatre anaesthetised, if positive further resection is undertaken and the process 
repeated. The development of Raman spectroscopy for intra-operative use in the 
delineation of resection margins would be a huge a step forward. In order for this to be 
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achieved data acquisition and processing time must be improved enormously and the 
development of systems such as those reliant on neural networks may be the way 
forward. 
 
The laryngeal studies undertaken in this work assessed tissue taken from patients who 
had all smoked. Smoking is such a strong aetiological factor in the development of 
laryngeal cancer further work to elucidate the affect of this carcinogen using Raman 
spectroscopy would be very helpful particularly if, as has been shown, Raman 
spectroscopy may be picking up biochemical changes in tissue before it is evident using 
conventional histological techniques. A difficulty inherent within these studies is that 
the vocal cords we consider normal have also been exposed to the same chemical 
carcinogen as the visually affected cords. Ideally a spectral data base from laryngeal 
tissue not exposed to smoke should be developed however biopsying the vocal cords of 
non-smokers in whom there is no indication for microlaryngoscopy is ethically 
questionable. As such this may be an area in the future where an animal model might be 
useful, not as a means of further supporting the aetiological connection but in assessing 
the ability of Raman spectroscopy to show the spectroscopic changes, and hence the 
possible biochemical changes present in the vocal cord tissue of smokers before a 
neoplasia becomes clinically evident. 
 
The maximum depth at which Raman spectroscopy can be used to probe diseased 
laryngeal tissue and still retain excellent sensitivity and specificity must be further 
assessed. This work could be usefully combined with the ongoing development of ‗deep 
Raman probing.‘ Validation of the use of the Raman probe in the larynx has already 
started but in order to acquire enough tissue to expand the spectral data base of samples 
analysed in vitro, prior to an in vivo study, a multicentre trial is required. This should 
concentrate on the assessment of Raman spectroscopy in areas where difficulty exists in 
clinical decision making and where there is histological debate with reference to the 
classification of diseased laryngeal tissue. 
 
One of the major challenges faced by Raman spectroscopy is its‘ use in the assessment 
of tissue which is not uniformly affected by disease such as in lymph nodes. This work 
clearly shows the excellent sensitivity and specificity with which Raman spectroscopy 
can be used to differentiate between SCC, adenocarcinoma and lymphoma in lymph 
nodes. This work would benefit for being expanded to include more adenocarcinoma. 
The practical question is how can Raman spectroscopy, which realistically can only 
sample limited volumes of tissue over real time guarantee to pick up the foci of disease 
within lymph nodes as well if not better than histopathology. It would seen unrealistic in 
the short term for Raman spectroscopy to be developed to the point where it can do this 
alone but in combination with image guidance systems to place the Raman probe 
accurately in areas of suspicion this problem may yet be overcome. Should Raman 
spectroscopy be shown to pick up early biochemical changes that affect whole lymph 
nodes in the presence of foci of disease this would add greatly to the potential for 
Raman spectroscopy to be a useful clinical tool in this area. 
 
Vibrational spectroscopy applied to disease diagnosis is a rapidly expanding field and 
many new devices for signal collection and methods of data analysis are making this 
approach easier to perform, more rapid and likely to be more accurate at making a 
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molecular diagnosis of disease in the future. The number and variety of tissue types and 
diseases represented within the lymph node study dataset means that much more work 
could be done on data analysis and with time many other areas in the head and neck 
where Raman spectroscopy may be of use could be explored. 
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74. Furić, K., Mohaček-Grošev, V., Hadžija, M. (2005). Development of cataract 
caused by diabetes mellitus: Raman study. Journal of Molecular Structure, 744-
747(SPEC. ISS.), p.169-177. 
75. Gallivan, R. P., Nguyen, T. H., Armstrong, W. B. (1999). Head and neck 
computed tomography virtual endoscopy: Evaluation of a new imaging technique. 
Laryngoscope, 109(10), p.1570-1579. 
76. Gellermann, W., Ermakov, I. V., Ermakova, M. R., McClane, R. W., Zhao, D., 
Bernstein, P. S. (2002). In vivo resonant Raman measurement of macular 
carotenoid pigments in the young and the aging human retina. Journal of the Optical 
Society of America A: Optics and Image Science, and Vision, 19(6), p.1172-1186. 
168 
 
77. Gniadecka, M., Nielsen, O. F., Christensen, D. H., Wulf, H. C. (1998). Structure 
of water, proteins, and lipids in intact human skin, hair, and nail. Journal of 
Investigative Dermatology, 110(4), p.393-398. 
78. Gniadecka, M., Nielsen, O. F., Wessel, S., Heidenheim, M., Christensen, D. H., 
Wulf, H. C. (1998). Water and protein structure in photo aged and chronically aged 
skin. Journal of Investigative Dermatology, 111(6), p.1129-1133. 
79. Goheen, S. C., Lis, L. J., Kauffman J. W. (1978). Raman spectroscopy of intact 
feline corneal collagen. Biochim Biophys Acta, 536(1), p.197-204. 
80. Graham, S., Mettlin, C., Marshall, J. (1981). Dietary factors in the epidemiology 
of cancer of the larynx. American Journal of Epidemiology, 113(6), p.675-680. 
81. Griffiths, H., Malony, N. C. (2003). Does asbestos cause laryngeal cancer? 
Clinical Otolaryngology and Allied Sciences, 28(3), p.177-182. 
82. Harris, N. L., Jaffe, E. S., Diebold, J., et al. (1999). World Health Organisation 
Classification of Neoplastic Diseases of the Haemopoietic and Lymphoid Tissues – 
A Progress Report. Am J Clin Path, 111, S8-S12. 
83. Harris, N. L., Jaffe, E. S., Stein, H., et al. (1994). A Revised European-American 
Classification of Lymphoid Neoplasms: A Proposal From the International 
Lymphoma Study Group. Blood, 85, p.1361-92. 
84. Hartman, K. A., Clayton, N. W., Tomas, G. J. (1973). Studies of virus structure 
by Raman spectroscopy. Biochemical and Biophysical Research Communications, 
50 (3), p.942-949. 
85. Hata, T. R., Scholz, T. A., Ermakov, I. V., McClane, R. W., Khachik, F., 
Gellermann, W., et al. (2000). Non-invasive Raman spectroscopic detection of 
carotenoids in human skin. Journal of Investigative Dermatology, 115(3), p.441-
448. 
86. Haußinger, K., Becker, H., Stanzel, F., Kreuzer, A., Schmidt, B., Strausz, J., et 
al. (2005). Autofluorescence bronchoscopy with white light bronchoscopy 
compared with white light bronchoscopy alone for the detection of precancerous 
lesions: A European randomised controlled multicentre trial. Thorax, 60(6), p.496-
503. 
87. Hendra, P. J., Ellis, G., & Cutler, D. J. (1988). Use of optical fibres in Raman 
spectroscopy, Journal of Raman Spectroscopy, 19, p.413-418. 
88. Herity, B., Moriarty, M., Bourke, G. J., Daly, L. (1981). A case-control study of 
head and neck cancer in the republic of Ireland. British Journal of Cancer, 43(2), 
p.177-182. 
89. Herkenne, C., Alberti, I., Naik, A., Kalia, Y. N., Mathy, F., Préat, V., et al. 
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(2005). The application of NIR Raman spectroscopy in the assessment of serum 
thyroid-stimulating hormone in rats. Spectrochimica Acta : Molecular and 
Biomolecular Spectroscopy, 61(1-2), p.87-91. 
173 
 
159. Michelson, A. A. (1920). The Vertical Interferometer. Proc Natl Acad Sci 
U.S.A, 6, p.473-474. 
160. Molckovsky, A., Wong Kee Song, L., Shim, M. G., Marcon, N. E., Wilson, 
B. C. (2003). Diagnostic potential of near-infrared Raman spectroscopy in the 
colon: Differentiating adenomatous from hyperplastic polyps. Gastrointestinal 
Endoscopy, 57(3), p.396-402. 
161. Morrison, M. D. (1988). Is chronic gastroesophageal reflux a causative factor in 
glottic carcinoma? Otolaryngology - Head and Neck Surgery, 99(4), p.370-373. 
162. Muller, M. G., Valdez, T. A., Georgakoudi, I., Backman, V., Fuentes, S., 
Kabani, S. (2003). Spectroscopic detection and evaluation of morphological and 
biochemical changes in early human oral cancer. Cancer. 97(7), p.1681-92. 
163. Nafie, L. A. (2001). Theory of Raman Spectroscopy. In: Handbook of Raman 
Spectroscopy, Edited by Lewis, I. R., Edwards, H. G. M. Marcel Dekker, New York, 
p.1. 
164. Naghavi, M., Madjid, M., Khan, M. R., Mohammadi, R. M., Willerson, J. 
T., Casscells, S. W. (2001). New developments in the detection of vulnerable 
plaque. Current Atherosclerosis Reports, 3(2), p.125-135. 
165. National Statistics Online. (2006). – Health.  http://www.statistics.gov.uk  
(accessed 28
 th
 September 2006). 
166. Nelson, D. B., Block, K. P., Bosco, J. J., Burdick, J. S., Curtis, W. D., et al 
(2000). High resolution and high magnification endoscopy. Gastrointest. Endosc. 
52, p.864-866. 
167. Nie, S., Castillo, C. G., Bergbauer, K. L., Kuck Jr., J. F. R., Nabiev, I. R., 
Yu, N. (1990). Surface-enhanced Raman spectra of eye lens pigments. Applied 
Spectroscopy, 44(4), p.571-575. 
168. Nijssen, A., Maquelin, K., Santos, L. F., Caspers, P. J., Bakker Schut, T. C., 
den Hollander, J. C., et al. (2007). Discriminating basal cell carcinoma from 
perilesional skin using high wave-number Raman spectroscopy. Proc SPIE, 12, 3  
169. Nishiyama, Y., Yamamoto, Y., Yokoe, K., Miyabe, K., Iwasaki, T., Toyama, 
Y., et al. (2004). Superimposed dual-isotope SPECT using 99mTc-
hydroxymethylene diphosphonate and 201Tl-chloride to assess cartilage invasion in 
laryngohypopharyngeal cancer. Annals of Nuclear Medicine, 18(6), p.527-532. 
170. Obana, A., Hiramitsu, T., Gohto, Y., Ohira, A., Mizuno, S., Hirano, T., et 
al. (2008). Macular carotenoid levels of normal subjects and age-related 
maculopathy patients in a Japanese population. Ophthalmology, 115(1), p.147-157. 
171. Olsen, J., Sabroe, S. (1984). Occupational causes of laryngeal cancer. Journal 
of Epidemiology and Community Health, 38(2), p.117-121. 
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Appendix A: Other Spectroscopic Techniques 
Raman spectroscopy is one of many optical techniques which have the potential for use 
in medical diagnostics. This section classifies and discusses the main alternatives and 
seeks to show how they inter-relate, their advantages, and disadvantages and how these 
techniques might be combined with Raman spectroscopy to produce more complete 
specimen analysis in the future. 
A.1 General classification of Spectroscopic Techniques 
Spectroscopy can be defined as the study of the interaction between radiation and 
matter. Historically, spectroscopy referred to a branch of science in which visible light 
was used for the qualitative and quantitative analysis of the molecular structure of 
matter. This definition has now broadened to encompass new techniques which utilise 
other forms of electromagnetic and non-electromagnetic radiation such as microwaves, 
radio waves, x-rays, electrons and phonons. Spectroscopy can be sub-classified 
according to the physical parameter measured or calculated; alternatively it can be 
classified according to the measurement process itself. The absorption, emission, and 
scattering of electromagnetic radiation by atoms or molecules are the fundamental 
processes in the spectroscopic techniques discussed in this section. When atoms or 
molecules absorb electromagnetic energy the incoming energy, if quantum matched, 
allows transfer of the atomic or molecular system to a higher energy level. Transfer of 
electromagnetic energy to the atom or molecule is called absorption. A transition from a 
higher energy level to a lower level were energy is transferred to the electromagnetic 
field is called emission. If a redirection of light occurs as a result of its interaction with 
matter the term scattering is used. Generally electrons are promoted to higher orbital 
states by excitation using ultraviolet or visible light; vibrations are excited by infrared 
light and rotation by microwaves. A general classification based on the measurement 
process used is outlined in Figure A.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1: A general classification of spectroscopic techniques. 
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A.1.1 Absorption Spectroscopy 
Absorption spectroscopy encompasses a range of different techniques and can be sub 
classified in two ways. Techniques can be defined with reference to the wavelength of 
the incident radiation e.g. ultraviolet-visible (UV-Vis) range, infrared (IR) and near 
infrared (NIR) spectroscopy or may be classified according to the direction of the 
radiation beam after it has interacted with the target specimen as shown in Figure A.2. 
Radiation that passes through the specimen and is detected in the 180
o
 arc based on a 
plane running perpendicular to the direction of the incident radiation beam is said to be 
detected in transmission. Radiation that exits the specimen behind this plane is said to 
be detected in remission and is made up of two entities, specular reflection where 
radiation exits at the same angle as that of the incident radiation and diffuse reflection 
where it occurs at all other angles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.2: Radiation detected in reflectance and transmission. 
Energy levels available within the target substrate determine the wavelength of radiation 
absorbed and the energy of the incident photon must match that required to move 
electrons to a higher electronic level. This allows selective probing of samples by 
varying the wavelength of the incident radiation. In absorption spectroscopy the 
absorbed photons are not re-emitted, energy which has been transferred to the target 
substrate is lost in other ways e.g. thermally. Absorption spectra can be obtained from 
matter in gas, liquid or solid states. The absorption spectrum obtained is expressed as a 
plot of radiation absorbance against wavelength and is a fundamental characteristic for 
that compound. At a given wavelength the measured absorbance is proportional to the 
molar concentration of the absorbing species and the thickness of the sample. For a 
specific specimen λ max is the wavelength of the most intense absorption line i.e. the 
wavelength at which maximum transmission occurs. Each component of a solution has 
its own λ max hence this parameter may be used qualitatively to identify the 
constituents of a solution. 
Ultraviolet (UV) and Visible (Vis) light spectroscopy 
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Ultra-violet (UV) spectroscopy has been used extensively as an analytical tool, several 
amino acids absorb in the ultraviolet range of the electromagnetic spectrum and the 
technique has been used to quantify concentrations of proteins and DNA. Recently UV 
resonance Raman spectroscopy has been used to detect 8-oxo-deoxyguanosine (8-oxo-
dG), an oxidative lesion in DNA which is responsible for cellular mutation (Kundu, 
2007). Ultraviolet-visible light spectroscopy (UV-Vis) uses incident radiation in the 
visible, ultraviolet or near infrared ranges of the electromagnetic spectrum. Samples 
tested are generally liquids although the technique can be applied to gases and solids.  It 
is routinely used for quantitative analysis of organo-metallic solutions containing 
transition metal ions and some innovative uses have been made within the ceramics 
industry (Masui, 2004). Solutions containing these elements absorb light in the visible 
range of the electromagnetic spectrum and so are coloured. Absorption is influenced by 
the presence of other ions, and these can alter the electronic state and hence the 
wavelength of the absorbed light. As previously noted the Beer-Lambert law applies 
hence absorbance of the solution will be directly proportional to the concentration of the 
substance tested. By using calibration curves, which show how quickly absorbance 
changes with concentration, the concentration of the solution can be determined and 
standard spectra produced which are independent of the device used. 
Infrared spectroscopy (IR) 
Infrared spectroscopy is also an example of absorption spectroscopy. The transition 
between molecular vibrational levels is within the mid-infrared range allowing Raman 
spectroscopy and mid-infrared spectroscopy to be complimentary in nature when used 
to probe biological molecules. The two techniques have fundamental differences; in IR 
the absorption effect occurs as a result of a change in the permanent molecular dipole 
whereas in Raman spectroscopy it results from scattering of light due to an induced 
dipole present round the molecule. IR exploits the fact that certain molecules have 
unique frequencies at which they can vibrate or rotate. In molecules with little or no 
symmetry the IR and Raman spectra have peaks at similar positions. As a gold standard 
the vibrational motion of a molecule can only be fully expressed by considering both IR 
and Raman spectra 
 
In infrared spectroscopy the incident radiation is polychromatic i.e. has a range of 
frequencies. It can only excite the molecule through vibrational transitions and 
absorption only occurs when the energy required by the molecule to move between 
vibrational levels equals that of the photons of incident light. In Raman spectroscopy 
the incident radiation is monochromatic and the scattered radiation measured differs by 
one vibrational unit of energy from the incident radiation thus no match is required 
between the energy of the incident radiation and the energy difference between the 
ground and excited electronic states (Smith & Dent 2005c; Ferrano, 2003c). Infrared 
absorption can be thought of as resulting from a direct resonance between the frequency 
of the incident radiation and the vibration frequency of that particular molecule. The 
increase in energy corresponds to the energy of the incident photon at the frequency of 
vibration resonance. This is a one-photon event in contrast to the changes that results as 
a result of Raman and Raleigh scattering which are considered two photon events and 
require much higher radiation energy (Nafie, 2001). 
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Electromagnetic radiation can be characterised by its‘ wavelength (λ). Energy is linearly 
related to frequency (ν) and wavenumber (ώ). The relationship between wavelength, 
frequency and energy (∆Ε) is shown below (Eq A.1-A.4) also that of absorbance, 
radiation intensity and transmission (Eqn A.5-A.13). 
 λ = c/ν  Eq. A.1 
 ν = ∆Ε / h  Eq. A.2 
 ώ = 1/ λ =  ∆Ε / hc  Eq. A.3 
 ∆Ε α 1/ λ  Eq. A.4 
Where; 
 
c = speed of light (3x10
8
ms
-1
) 
h = Planck‘s constant (6.626 x 10 -34 Js or 4.136 x 10-15 eVs) 
ώ = wavenumber (cm-1) 
 
Thus the highest energy absorption is associated with radiation of the shortest 
wavelength and highest frequency. 
 
The intensity of infrared absorptions can be expressed in several ways  
 
Absorbance =A 
Transmission =T 
% Transmission = T (%) 
 A = log10 (Io / I)  Eq. A.5 
 T = I / Io  Eq. A.6 
 T (%) = 100 T  Eq. A.7 
 Hence A = log10 1/ T  Eq. A.8 
Io is the intensity of the incident radiation and I the intensity of the radiation after it has 
passed through the sample. 
 
Absorbance is governed by the Beer-Lambert Law 
 
 A = ε b c  Eq. A.9 
Where; 
 
ε = the molar absorbtivity (Lmol-1cm-1) 
b = the cell length (cm). 
c = the concentration of the sample in solution (mol L
-1
) 
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 A = log10 (Io / I) = ε b c  Eq. A.10 
 I = Io е 
- ε b c
  Eq. A.11 
 Io / I = 1/ е 
- ε b c
  Eq. A.12 
In infrared spectra it is conventional to plot percentage transmission against 
wavenumber. 
 T (%) = (Io / I) x 100  Eq. A.13 
Equations A.12 and A.13 show that percentage transmission is not directly proportional 
to concentration so in quantitative work absorbance is used in preference (Ferraro, 
2003b). IR spectroscopy is simple and reliable. it can be used for both qualitative steady 
state and dynamic measurements. One practical point of note is that in aqueous 
solutions the broad absorbance signal resulting from water must be subtracted out of 
spectra to allow simpler assessment. 
 
Fourier–transform infrared spectroscopy (FT-IR) is an efficient method for processing 
spectral data obtained using interferometers. Nearly all IR and nuclear magnetic 
resonance spectroscopy are now performed using Fourier transforms as is much NIR 
Raman spectroscopy. Fourier-transform Raman spectroscopy has been discussed in 
more detail in Section 2.2.5. 
A.1.2 Emission Spectroscopy 
Theoretical explanation of emission spectroscopy led the way to the development of 
quantum mechanics. This form of spectroscopy examines the wavelength of photons 
emitted when an atom or molecule drops from a higher electronic state to a lower one 
and it is the structure of the sample that dictates the wavelength of the photons the 
sample can absorb and emit. The mechanism by which atoms or molecules are excited 
subclassifies this type of spectroscopy further. For example if electromagnetic radiation 
is used, fluorescence spectroscopy can result. Protons can produce particle-induced x-
ray emission, and if heat is applied to a sample causing an increase in collisions 
between particles flame emission spectra can be detected. In fluorescence spectroscopy 
the absorption of a quantum of energy by the target molecule allows a transition from 
the ground state to a higher electronic state in which there are several vibrational levels. 
Collisions between the sample molecules can result in a loss of a different quantum of 
energy as the molecule drops from one vibrational state to a lower one within that 
particular electronic state. A further quantum of energy can be lost if the molecule 
subsequently drops to its ground state. The energy emitted during each of these events is 
different and hence so are the frequencies and wavelengths of the emitted light. Two 
types of spectra can be obtained; where the excitation radiation has a single, constant 
wavelength the intensity of the emission is recorded and the spectrum produced is called 
an emission spectrum. If different wavelengths of excitation radiation are used a series 
of emission spectra can be recorded and the wavelength producing the maximum 
intensity of emitted radiation from each spectrum can be used to form an intensity 
profile for that specimen as a function of the excitation wavelength, this is called an 
excitation spectrum. 
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At low concentration the intensity of fluorescence is considered to be directly 
proportional to the concentration of the fluorophore present. In fluorescence spectra the 
Raman signal is always seen at a position which has a constant wavenumber difference 
relative to the excitation wavenumber. It has proved difficult to obtain standard spectra 
in fluorescence spectroscopy as the signal can be distorted in many ways. Factors 
related to instrumentation include variation in the intensity and wavelength of the light 
source. A light source which maintains the same intensity over all wavelengths has 
proved elusive as has a detecting system which maintains constant efficiency over time. 
Factors relating to the sample include; photodecomposition, scattering of light by 
Raman and Rayleigh effects and variation in the intensity of the radiation throughout 
the sample with photons of energy emitted through fluorescence sometimes being 
reabsorbed. 
A.1.3 Scattering Spectroscopy 
The mechanism by which spectra are obtained by scattering techniques has been dealt 
with in some detail with reference to Raman spectroscopy. Diffuse elastic and elastic 
scattering are also examples of this form of spectroscopy and considered further in 
Section A.2.2.2. Elastic scattering spectroscopy is also known as Raleigh or light 
scattering spectroscopy. 
A.1.4 Tri modal spectroscopy 
The combination of three spectroscopic techniques, Raman spectroscopy, 
autofluorescence and elastic scattering is gaining favour and has been used for the 
detection of cancer of the oral cavity (Muller, 2003). 
A.2 Field Classification of Spectroscopic Techniques 
In Figure A.3 the general classification described above can be further refined to 
emphasis those techniques which are predominant in the assessment of biological 
tissues. At a basic level techniques for the delineation of the macroscopic, microscopic 
and biochemical characteristics of biological tissue can be divided into imaging 
techniques and those that utilise spectroscopy. The area of tissue over which these 
differing modalities can be practically applied further broadly classifies them into those 
used over a wide field (cm
2
) and those used over much smaller areas, narrow or point 
fields (nm
2
). Wilson uses this type of classification to base a review paper describing 
the various spectroscopic and imaging techniques currently available (Wilson, 2007a). 
However with rapid technological advances this classification is becoming blurred with 
imaging techniques such as OCT being applied over very small fields and spectroscopic 
techniques over much larger areas with fast mapping techniques. The remainder of this 
chapter uses this classification but also seeks to clarify the interrelationships between 
the modalities described. The relationships between field and point techniques are 
illustrated in Figure A.3. Increasing work the combination of a ‗scanning‘ modality 
predominately utilising imaging field techniques with detailed examination of areas of 
suspicion by spectroscopic point techniques is being used; once again allowing optical 
medical diagnostics to achieve a further step towards clinical effectiveness. 
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Figure A.3: Inter-relationships between spectroscopic and imaging techniques 
predominantly used in the assessment of biological tissues. 
A.2.1 Wide Field Techniques 
A.1.1.1 Variations on White Light Endoscopy 
White light endoscopy (WLE) is used extensively in the routine surveillance of disease 
in many areas of the body. In laryngology nasendoscopy is used in all outpatient 
appointments where visualisation of the larynx is needed. In gastroenterology the upper 
and lower gastrointestinal tract have been successfully visualised by this means for 
many years. Areas of suspicion require biopsy and the tissue obtained undergoes 
histological assessment. Improvements in WLE have been driven by the need to localise 
these areas accurately to reduce unnecessary clinical intervention. 
High resolution endoscopy 
Instrument advances have made a great difference to WLE most recently with the 
advent of video endoscopes which are rapidly replacing fibre optic endoscopes. The use 
of high-density charge-coupled device (CCDs) detector arrays with 2 to 3 times the 
number of pixels (400 000-850 000) used in a standard WLE. High resolution 
(magnification) endoscopes with sophisticated optics can now focus down to close on 
the size of a cell, 10μm, (Nelson, 2000). At such high magnification this technique 
moves from a field to a point technique and at its‘ limit can be thought of as 
endocytology. 
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Chromoscopy 
The aim of this technique is to enhance the junction between normal and dysplastic 
tissue by the topical application of a stain. The stain can either bind to normal or 
abnormal tissue and can be classified into two groups; chromogenic or modifiers.  
Methylene Blue is an example of a chromogenic stain; it is absorbed onto cells and 
highlights mucosal architecture (Eberl, 2007). Another example is crystal violet, a stain 
that highlights the actual nuclear component of the cell. Lugol‘s Iodine has been used 
successfully to stain islands of squamous cells in the detection of Barrett‘s oesophagus 
(Takubo, 2005). Acetic acid is an example of a ‗modifier‘, this compound acts by 
breaking down the surface glycoprotein layer changing the refractive index of the tissue. 
It has been used very successfully in the detection of cervical neoplasia and in ‗screen 
and treat programs‘ for this disease used in developing countries (Denny, 2000). Whilst 
there is still some debate as to the efficacy of chromendoscopy to detect oesophageal 
dysplasia it is now well established as a technique for the delineation of sessile 
adenomas in the colon (Fujii, 2001). 
Narrow band imaging (NBI) 
The image obtained from a standard white light microscope is produced by 
recombination of the red-green-blue channels. In narrow-band imaging these channels 
are displayed separately. This results in the highlighting of micro vascular patterns and 
improves the contrast between different mucosal morphologies. The improvement in 
contrast is due to the different attenuations of these three spectral regions. More 
superficial layers of tissue are biased towards blue, deeper towards red. The 
combination of narrow-band imaging and autofluorescence endoscopy is of interest and 
may improve diagnostic specificity (Wilson, 2007a). A case report has been published 
outlining the use of narrow-band imaging in the detection of recurrent hypopharyngeal 
cancer in a piriform fossa after radiotherapy (Watanabe, 2007). 
A.1.1.2 Fluorescence Endoscopy (FE) 
The utilisation of fluorescence endoscopy as a diagnostic tool is long standing however 
it gained more attention in the 1960s when the first photodynamic therapy agent was 
developed, haematoporphyrin derivative (HpD). In the 1970s fluorescence endoscopy 
was used to localise photosensitizers with the earliest work being done on the detection 
of bronchial tumours (Profio, 1997).  
Autofluorescence endoscopy (AFE) 
Biological tissues often process endogenous fluorophores capable of autofluorescence 
such as tryptophan, NADH, collagen, elastin and flavins. AFE has been used to improve 
the effectiveness of WLE for example in the detection of nasopharyngeal carcinoma 
(Chang, 2002). In the gastrointestinal tract it has been shown to help differentiate 
between benign hyperplastic polyps and adenomatous polyps which have malignant 
potential (McCallum, 2008). It has also been used as an adjuvant to WLE in 
examination of the bronchus were loss of extracellular matrix reduces the collagen 
signal and allows an increase in the attenuation of green fluorescence from the 
submucosal layer (Haubinger, 2005). Several studies in the past have assessed the 
ability of autofluorescence spectroscopy to be used as a diagnostic tool in the larynx 
(Paczona, 2003; Palasz, 2003; Arens, 2004 & 2007). All these studies showed 
autofluorescence could delineate pathological entities in the larynx. Normal laryngeal 
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mucous will fluoresce green when illuminated by a xenon lamp however the presence of 
malignancy appears to reduce this fluorescence and in some cases change it to a red-
yellow colour (Zalesska, 2005). The use of indirect autofluorescence as a diagnostic tool 
for laryngeal disease has also been assessed (Arens, 2004 & 2007). In their first 
prospective study patients underwent autofluorescence which was compared to direct 
autofluorescence obtained during microlaryngoscopy. All these results were then 
compared to histological sections with excellent correlation. It was noted that the 
presence of inflammation, scarring and hyperkeratosis made assessment of the lesions 
more difficult. The aim of the study published in 2007 was to compare indirect 
autofluorescence laryngoscopy with 5-ALA-induced protoporphyrin IX (PPIX) 
fluorescence. Fluorescence was induced using a xenon arc lamp (375-440nm) and after 
initial investigation with autofluorescence laryngoscopy the 5-ALA was applied by 
inhalation, two hours later both investigations were performed again. The results of this 
study suggest that both these techniques are useful in the assessment of premalignant 
and malignant lesions however it is pointed out that autofluorescence has the advantage 
of not requiring the patient to have an exogenous substance however the changes seen in 
scarred laryngeal tissue using 5-ALA suggest it may be the more useful of the two 
techniques in this scenario. There are problems associated with AFE; where fibre optics 
instruments are used the signal at shorter wavelengths can be relatively poor. The 
advent of video endoscopes with autofluorescence capability may make this less 
problematic. Endogenous autofluorescence from moieties other than those of interest 
may also reduce specificity and sensitivity. 
Exogenous Fluorophores 
Exogenous fluorophores such as fluorescein applied to tissue have been shown to bind 
to certain biomolecular entities which can then be utilised in imaging techniques 
(Kiesslich, 2006). 
A.2.2 Point Field Techniques 
A.1.1.3 Point Imaging 
Endocytoscopy 
This technique can be seen as an extension of high resolution endoscopy. A contact 
endoscope with sophisticated optics allows in vivo images to be obtained with a cellular 
resolution is in the order of 2-4 µm. Endocytology can produce images of areas 100-
300µm wide and to a depth of 5-15µm (Wilson, 2007b). 
Confocal endoscopy 
Once the preserve of microscopy confocal imaging is now used in endoscopy. Unlike 
high resolution (magnification) endoscopy it allows depth scanning. Point scanning is 
performed on tissue in a plane at a specific depth (max 100µm) and a detector rejects 
any scattered photons not from this plane. The combination of contact endoscopy and 
fluorescence contrast enhancement has been used to study bronchial wall microstructure 
(Thiberville, 2007) and oesophageal disease (Kiesslich, 2006). Whilst much progress 
has been made in this area drawbacks do exist with this technique; specimens can suffer 
photobleaching and the equipment is still expensive. The combination of confocal 
endomicroscopy with the application of exogenous fluorophores is an area on ongoing 
research and hold promise for the future (Wilson, 2007b). 
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Optical coherence tomography (OCT) 
White light interferometry used as a technique for taking measurements optically has 
been used for many years however interest in this technique has under gone resurgence 
with the advent of optical coherence tomography (Huang, 1991). OCT is analogous to 
ultrasound but utilises electromagnetic radiation rather than sound. The basic difference 
between the practical application of ultra sound and OCT lies in the fact that reflected 
sound travels over distance and time on a scale that is easily measured (nanoseconds). 
Light travels at much greater speeds and to date there are no clinically applicable 
methods in which it can be recorded in a similar way to ultrasound. As a consequence 
the technology on which the two techniques are based differs a great deal. OCT systems 
can produce spatial resolutions in the range of 10µm however ‗ultra-high‘ resolution 
systems can now give images down to1µm (Barr, 2007) whereas that from ultra sound 
is in the region of 100µm. OTC utilises interferometry; a technique where by two or 
more waves of the same frequency and phase can be superimposed. A beam of light is 
split into 2 or more ‗coherent‘ parts one of which is used as a reference beam the other 
acts on the sample. The reflected beams are recombined with any small difference 
detected as ‗interference‘. If the superimposed waves are initially in phase the 
interference is constructive and increases the amplitude of the resultant wave or vice 
versa. Any changes in the phase of a beam will shift the interference from its maximum 
to minimum values making the system very sensitive to a factor that changes the phase 
of one of the reflected waves such as the refractive index of the specimen. An 
interference pattern is only generated if the two beams of light have travelled an optical 
distance less than the coherence length, areas of the specimen that reflect more light will 
create greater interference 
 
OCT has a significant number of biomedical applications. It was first demonstrated in 
this context in the in vitro examination of a retina (Huang, 1991). It can be used easily 
in the clinical setting and produce images over real time. It has better resolution than 
magnetic resonance imaging (MRI) and USS (Yaqood, 2006). However if the reference 
and sample scattered radiation are not aligned signal fading can occur. OCT has been 
used to assess the larynx and can identify disruption of the basement membrane and 
disease transitional zones (Armstrong, 2006) and has also been used in the evaluation of 
the paediatric airway (Ridgeway, 2007) and the larynx of an awake patient. At present 
OCT is limited by the need to strike a balance between the power and band width of the 
radiation source, resolution, coherence length, expense and portability.  It has good 
sensitivity as interferometry measures the field not the intensity of the scattered 
radiation and the relatively weak scattered signal can be amplified by the reference 
beam. At present the most serious drawback seems to be limitations in penetration depth 
particularly in the assessment of exophytic lesions. 
A.1.1.4 Point Spectroscopy 
Fluorescence spectroscopy 
Autofluorescence spectroscopy (AFS) can be used to determine the optimum spectral 
range over which to use autofluorescence endoscopy AFE and this technique has been 
relatively simple to implement in the clinical setting. This is because the fibre optic 
probe used can be inserted via the biopsy/instrument port of the endoscopes currently 
used in clinical practice. This arrangement is not without practical problems; where 
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several biopsies are required the process can takes some time. Where an instrument is 
used to hold tissue, removing it to insert a probe may alter the orientation of the sample 
and hence the spectra obtained. To overcome these difficulties multi channelled 
endoscopes can be used or instruments where biopsy forceps and probe are combined. 
Tissue can also be fixed with the use of a probe which applies pressure to the area; 
however this may alter the blood flow and result in a change in the attenuation of the 
light. The optimum angle at which the probe is applied is less of a problem in the larynx 
where the areas of concern are perpendicular to the tip of the probe, unlike in the 
oesophagus. In the oesophagus the areas which require biopsy are in a plane parallel to 
the long axis of the instrument and subject to a great deal variation in position due to the 
intrinsic peristalsis of the oesophagus and transmitted movement resulting from the 
heart beating. AFS is a relatively expensive technique requiring multiple CCD cameras 
and the spectra obtained can show considerable point to point and patient to patient 
variation however the use of time resolved modes may provide additional information 
that helps with this problem.  
 
The application of exogenous fluorophores can selectively highlight specific disease 
entities or can bind to molecules only present in normal tissue thus allowing the edges 
of surgical resection margins to be probed (Da Costa, 2007). In time a combination of 
AFE with AFS using exogenous fluorophores to probe tumour edges may allow a 
quantitative appraisal of the presence of tumour. The difficulties lie in the ongoing 
technical challenges of rapid spectroscopic scanning and the difficulties in isolating 
highly disease specific exogenous fluorophores.  
Reflectance spectroscopy 
This form of spectroscopy explores some of the micro morphological features that make 
up many of the criteria used in the histological diagnosis of dysplasia and cancer such as 
nuclear size and chromatin content. Reflectance spectroscopy is subclassified depending 
on its‘ ability to subtract the signal acquired from multiply scattered photons from the 
measured spectra in order to enhance the contribution made by photons which have 
undergone few scattering events. Reflectance spectra represent both the absorptive and 
scattering properties of the specimen examined (Wilson, 2007c). 
Diffuse reflectance spectroscopy /Light scattering spectroscopy (LSS) 
This technique has many similar features to that of fluorescence spectroscopy. It is 
differs from elastic scattering spectroscopy in that it is a measurement of the total 
spectrum of light scattered from the surface of the specimen. The light which is emitted 
after passing through deeper tissues and which will have undergone more interaction 
with the molecules of the specimen is filtered out by a polarizer. Only light which has 
been reflected back without undergoing any significant deeper collisions, i.e. were the 
polarisability is unaltered, and is collected.  
Elastic scattering spectroscopy (ESS) 
In ESS there is no change in energy between the incident and scattered radiation, hence 
no change in frequency. ESS produces spectra which are dependent on the wavelength 
of the excitation radiation. The scattering component in this form of spectroscopy is 
related to the optical index of refraction of the specimen and in biological tissue these 
changes occur as a result of the different densities of the cellular components; these 
areas are called scattering centres. ESS has been used to assess lymph nodes (Jerjes, 
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2005) and squamous epithelial tissue from the mouth Muller, 2003). It is fast, cheap, 
and reliable, giving good correlation with the key histological changes that alert to 
malignancy. It is successfully utilised is many areas such as the monitoring of 
chemotherapy drugs levels and the oxygenation of free-flaps (Swinson, 2006). 
A.1.1.5 Advanced Raman Spectroscopy Techniques 
A major drawback to the use of Raman spectroscopy in the study of biological tissues 
has always been the considerable fluorescence signal produced when visible excitation 
has been used. As a consequence visible Raman spectroscopy has been superseded by 
near infrared excitation; the techniques described in this section have been developed in 
part to try to overcome this problem. 
Resonance Raman spectroscopy 
Pre resonance Raman occurs when the energy of the excitation photon nears that 
required to stimulate an electron to reach a higher electronic state. In these 
circumstances the intensity of the Raman scattering significantly increases. If the 
excitation energy is sufficiently large to promote the chromophore to a higher electron 
energy state absorption of the photon can occur. Despite the whole molecule absorbing 
energy during an electronic absorption, in a mixed sample the molecules exhibiting 
resonance Raman will be preferentially enhanced. This is a great help in probing the 
individual chromophores of highly complex biological molecules however resonance 
Raman is only effective in certain coloured molecules and continues to have drawbacks 
relating to fluorescence interference and photo degradation of the sample. 
Surface enhanced Raman spectroscopy (SERS) and surface enhanced resonance Raman 
spectroscopy (SERRS) 
Since being first reported in the mid 1970s by Fleischman and later extensively 
developed (REF MRSp133), surface enhanced Raman spectroscopy (SERS) and 
subsequently surface enhanced resonance Raman spectroscopy (SERRS) have begun to 
play an ever increasing rôle in the development, understanding and utilisation of Raman 
spectroscopy. In this technique the tissue sample is held in a cell into which a metal 
electrode is inserted and the choice of metal can vary. Silver and gold are extensively 
used and the close proximity of the specimen to the roughened metal surface allows 
significant enhancement of the Raman signal. The voltage applied across the cell 
determines the size of the enhancement and relative peak intensities. SERRS combines 
the advantages of surface and molecular resonance enhancement. The substance being 
tested is usually a dye or molecule containing a dye and absorption of this dye onto the 
surface of the metal electrode quenches fluorescence. One of the great advantages of 
this technique is that although the intensity of the peaks can vary their positions are very 
similar to those seen in the resonance Raman spectra, or FT-Raman spectra if the 
substance is fluorescent. This makes the identification of the test substance and 
contaminants relatively straight forward. In SERRS the extra resonance enhancement 
seems to discriminate against contaminants which can improve the reliability of the 
results and is one of its advantages over SERS. SERRS can also be done using lower 
powered lasers and has reduced accumulation times making photodegradation less of an 
issue (Smith & Dent, 2005d). 
Non linear Raman spectroscopy 
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Pulsed lasers of high power densities are now available allowing for the possibility that 
at a particular moment in time a molecule may be hits by two photons producing a 
multi-photon event. Techniques which utilise this phenomenon are called non-linear 
Raman spectroscopy examples of which include hyper-Raman and coherent anti-Stokes 
Raman spectroscopy. These techniques require more than one laser excitation source 
and to date have proved expensive and difficult to use. 
Hyper-Raman Spectroscopy 
In hyper-Raman spectroscopy (HRS) molecules can be promoted to a virtual state at 
double the frequency of the excitation radiation. As well as expense there are some 
technical difficulties that must be addressed with all forms of non-linear Raman 
spectroscopy. In order that multiple photons interact at the same time the beams of 
incident radiation must be carefully phased. In HRS the frequency of the scattered light 
may not be in a range capable of detection by CCDs and difficulties in detection are 
compounded by the inherently weak signal. The high power of the pulsed lasers also 
produces more heat which may cause difficulties in probing bio molecules in vivo. 
Coherent anti-Stokes Raman spectroscopy (CARS) 
This technique requires several laser excitation sources, in the past three but more 
recently two. In the three laser system the first photon used is of a frequency that 
elevates the molecule to a virtual state the same as with conventional Raman 
spectroscopy. The second photon has a frequency equal to that which would be apparent 
if the molecule underwent spontaneous Stokes Raman scattering. The third photon has a 
frequency used to excite the molecule into a second virtual state from which it can fall 
to the electronic ground state. CARS can be used in conjunction with resonance 
enhancement and has the great advantage that it is an anti-Stokes event and hence does 
suffer from fluorescence interference. 
Time resolved Raman spectroscopy 
This is a very exciting development in Raman spectroscopy. A pulsed laser is split into 
two and the second beam is delayed by a fraction of a second; a nanosecond, picosecond 
or even less. The first beam initiates a photochemical event and the second beam probes 
it producing a Raman spectra. For each laser pulse there may only be a few Raman 
events but over time they can produce a significant accumulative signal provided that 
minimal photo degradation occurs. The Raman signal can be detected much more 
quickly than that of fluorescence so by subjecting a specimen to fast pulses of radiation 
this technique can be used for fluorescence suppression. In a converse fashion if longer 
is taken for the emitted radiation to be collected time resolved Raman spectroscopy can 
be used for depth probing (Baker, 2007) 
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Appendix B: Staging and Classification Criteria for 
Laryngeal Disease. 
B.1 TNM Staging 
Tumours involving two anatomical sites are classified according to the site in which the 
greater part of the tumour is located. In invasive tumours with an associated carcinoma 
in situ only the invasive component is considered for classification. Superficial 
extension to adjacent sites is not considered invasion of adjacent structures. In tumours 
extending to an adjacent site, differentiation between superficial extension and deep 
extension is necessary. In superficial extension the involvement is considered to be 
limited to the mucosa; in deep extension, muscles, bones or other deep structures are 
invaded. Deep extension to an adjacent site can be the result of vertical invasion of 
adjacent structures or the result of horizontal spread not limited to the mucosa but also 
involving muscles or bones. Such extension is classified as invasion of adjacent 
structures. 
 
In advanced lymphatic spread, one often finds perinodal tumour and the confluence of 
several lymph node metastases into one large tumour conglomerate. In the definition of 
the N classification, the perinodal component should be included in the size for isolated 
lymph node metastases; for conglomerates, the overall size of the conglomerate should 
be considered and not only the size of the individual lymph nodes. The pN classification 
is based on the size of the metastasis rather than the size of the lymph node. 
 
B.1.1 The cervical lymph nodes groups; 
Submental (Level IA) 
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscle 
and the hyoid bone. 
Submandibular (Level IB) 
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric 
muscle and the body of the mandible. 
Upper jugular group (Level II) 
Lymph nodes located around the upper third of the internal jugular vein and adjacent 
spinal accessory nerve, extending from the hyoid bone to the skull base. The posterior 
boundary is the posterior border of the sternocleidomastoid muscle, and the anterior 
boundary is the lateral border of the sternohyoid muscle. This group includes the 
jugulodigastric node, which is the most cranial jugular node. 
Middle jugular group (Level III): 
Lymph nodes located around the middle third of the internal jugular vein, extending 
from the carotid bifurcation superiorly to the omohyoid muscle or cricothyroid notch 
inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid 
muscle, and the anterior boundary is the lateral border of the sternohyoid muscle. 
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Lower jugular group (Level IV): 
Lymph nodes located around the lower third of the internal jugular vein, extending from 
the omohyoid muscle superiorly to the clavicle inferiorly 
Dorsal cervical nodes along the spinal accessory nerve (Level V) and Supraclavicular 
nodes (mostly Level IV):  
These two groups are combined and called the ―posterior triangle group‖ and comprise 
predominantly of the lymph nodes located along the lower half of the spinal accessory 
nerve and the transverse cervical artery. The posterior boundary is the anterior border of 
the trapezius muscle, the anterior boundary is the posterior border of the 
sternocleidomastoid muscle, and the inferior border is the clavicle. Most are in Level 
IV; some may occupy the most caudal component of Level V. 
Anterior compartment group (Level VI): 
Lymph nodes surrounding the midline visceral structures of the neck, extending from 
the level of the hyoid bone superiorly to the suprasternal notch inferiorly. On each side, 
the lateral boundary is the medial border of the carotid sheath. Located within this 
compartment are the perithyroidal lymph nodes, paratracheal lymph nodes, lymph 
nodes along the recurrent laryngeal nerves and precricoid lymph nodes. 
Prelaryngeal and paratracheal nodes 
These may be further subdivided as follows: 
 cranial - paratracheal (suprathyroidal), thyroidal (perithyroidal) 
 caudal - paratracheal (infrathyroidal, lateral tracheal) 
 prelaryngeal 
 pretracheal - near the thyroid isthmus (delphian) 
Retropharyngeal nodes 
Parotid nodes 
The parotid nodes may be subdivided into superficial i.e. in front of the tragus of the ear 
and on top of parotid fascia and deep parotid nodes. The latter are located underneath 
the parotid fascia and include intra-glandular nodes. The preauricular and infra-auricular 
nodes are assigned to the parotid nodes. 
The buccal (facial) nodes 
These nodes include the buccinator nodes located deep on buccinator muscle, the 
nasolabial nodes located underneath the nasolabial groove, the molar nodes located in 
the surface of cheek and the mandibular nodes located outside the lower jaw. 
Retroauricular (mastoid, posterior auricular) and occipital nodes. 
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B.1.2 Summary—Oropharynx  
 
T1 2 cm 
T2 >2 to 4 cm 
T3 >4 cm 
T4a 
Larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard 
palate, mandible 
T4b 
Lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, 
skull base, carotid artery, prevertebral fascia 
 
 
 
 A tumour extending from the oropharynx to the nasopharynx or to the 
hypopharynx or to the oral cavity or larynx and limited to the mucosa (without 
invasion of muscles, bones or other deep structures) is classified only according 
to size up to T3. 
 A tumour invading soft tissue of neck and paravertebral fascia/muscles is 
classified as T4b. 
 Invasion of the larynx is defined as invasion of the outer framework (thyroid 
cartilage, cricoid cartilage, pre-epiglottic space) or internal structures such as 
arytenoid and epiglottic cartilages. 
B.1.3 Summary—Nasopharynx  
 
T1 Nasopharynx 
T2 
Soft tissue 
  
T2a 
    Oropharynx/nasal cavity without parapharyngeal 
extension 
  
T2b     Tumour with parapharyngeal extension 
T3 Bony structures and/or paranasal sinuses 
T4 
Intracranial, cranial nerves, infratemporal fossa, hypopharynx, 
orbit, masticator space 
 
 
 
 Tumours not involving the oropharynx and/or nasal fossa, but with 
parapharyngeal extension are classified T2b. 
 The term ―postnasal space‖ corresponds to nasopharynx (C11). Invasion of 
vertebral bodies is classified T3. 
197 
 
B.1.4 Summary—Hypopharynx  
 
T1 2 cm and limited to one subsite 
T2 >2 to 4 cm or more than one subsite 
T3 >4 cm or with larynx fixation 
T4a 
Thyroid/cricoid cartilage, hyoid bone, thyroid gland, 
oesophagus, central compartment of soft tissue 
T4b Prevertebral fascia, carotid artery, mediastinal structures 
 
 
 
 The term ―laryngopharynx‖ corresponds to hypopharynx 
 For classification, the hypopharyngeal surface of the aryepiglottic fold (C13.1) 
belongs to the hypopharynx, while the laryngeal aspect of the aryepiglottic fold 
(C32.1) is part of the supraglottis. 
 Fixation of hemi-larynx is diagnosed endoscopically by immobility of the 
arytenoid or vocal cord. 
 The uncommon tumours limited to one subsite but with vocal cord fixation 
should be classified as T3. 
 Involvement of the arytenoid cartilage is classified as T3, not T4a 
 A tumour extending from the hypopharynx to oesophagus and limited to the 
mucosa (without invasion of muscles, bones or other deeper structures) is 
classified only according to size up to T3. 
B.1.5 Summary—Larynx 
Summary—Supraglottis 
 
T1 One subsite, normal mobility 
T2 
Mucosa of more than one adjacent subsite of supraglottis or 
glottis or adjacent region outside the supraglottis, without 
fixation 
T3 
Cord fixation or invades postcricoid area, pre-epiglottic tissues, 
paraglottic space, thyroid cartilage erosion 
T4a 
Through thyroid cartilage; trachea, soft tissues of neck: 
deep/extrinsic muscle of tongue, strap muscles, thyroid, 
oesophagus 
T4b Prevertebral space, mediastinal structures, carotid artery 
 
Summary—Glottis 
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T1 
Limited to vocal cord(s), normal mobility  
a.  one cord 
b.  two cords 
 
T2 Supraglottis, subglottis, impaired cord mobility 
T3 Cord fixation, paraglottic space, thyroid cartilage erosion 
T4a 
Through thyroid cartilage; trachea, soft tissues of neck: 
deep/extrinsic muscle of tongue, strap muscles, thyroid, 
oesophagus 
T4b Prevertebral space, mediastinal structures, carotid artery 
 
Summary—Subglottis 
 
T1 Limited to the subglottis 
T2 Extends to vocal cord(s) with normal/impaired mobility 
T3 Cord fixation 
T4a 
Through cricoid or thyroid cartilage; trachea, deep/extrinsic 
muscle of tongue, strap muscles, thyroid, oesophagus 
T4b Prevertebral space, mediastinal structures, carotid artery 
 
 
 
 For pathological classification concerning impaired mobility or fixation of vocal 
cords the information from the clinical T is used for the pathologic T.  
 For invasive carcinoma, the classification according to horizontal spread is 
based only on the invasive component. 
 To indicate the presence of associated carcinoma in situ (adjacent or separate) 
the suffix ―(is)‖ may be added to the respective T category of the invasive 
carcinoma, e.g., T2(is). The presence of an associated carcinoma in situ 
influences treatment of the invasive carcinoma and needs identification and 
separate analysis of such cases. 
 
B.2 Histological Classification 
The histological classification of laryngeal dysplasia, carcinoma-in-situ and SCC has 
historically been a difficult area in which to achieve consensus. Whilst the application 
of guidelines does leave great scope for inter-observer error there has been recent work 
to clarify areas of debate and it is this that is summarised below and these are the 
parameters used in the histological reports obtained for this work. This section contain 
extracts from a definitive text on this subject (Mills, 2008) 
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B.2.1 Keratosis (leucoplakia / erythroplakia) 
Mucosal Keratosis found in the head and neck and not associated with dysplastic 
change is very common and has certain distinct features which in combination help to 
separate it from both dysplasia and invasive SCC. The macroscopic features of keratosis 
are weaker than the microscopic features in this respect. 
Macroscopically 
 White, thickened mucosa 
 Visible increase in vascularity in underlying stroma at times 
 Strips easily especially from vocal cords usually at the junction of the basal cells 
and stroma 
 Intact basal cell layer – good differentiator from invasive SCC 
Microscopically 
 Normal or thickened layer of squamous mucosa 
 Prominent granular cell layer 
 Overlying layers of ortho-keratin often admixed with parakeratotic cells 
 Orderly cell maturation 
 Mitotic figures confined to the basal cell layer 
 No aberrant keratinisation of individual cells 
B.2.2 Laryngeal Dysplasia 
Many grading systems have been used to classify mucosal dysplasia found within the 
head and neck and these have usually been based on those applied to dysplastic lesions 
arising in the cervix. One of the major differences is that in the head and neck dysplastic 
lesions often retain a considerable number of keratinised cells even in high-grade 
lesions.  
 
In many systems a separate grade of carcinoma-in-situ is applied for lesions felt to have 
progressed beyond severe dysplasia but not to invasive SCC. In this system and for the 
purposes of the work these lesions are included with those classified as severely 
dysplastic. 
 
Squamous dysplasia can extend a considerable distance and involve the underlying 
seromucinous ducts. This must be carefully assessed to distinguish dysplasia from 
invasive SCC and this can be very difficult particularly in frozen sections. Key features 
of the extension seen in dysplasia is the sharp circumscription of the nests, the lack of 
surrounding stromal response and the presence nearby of more easily recognised 
seromucinous ducts. 
Mild dysplasia 
 Nuclear irregularity 
 Nuclear crowding, primarily in basal layer 
 Essentially normal nuclear chromatin 
Moderate dysplasia 
 Larger, irregular nuclei 
 Often peripherally condensed chromatin resulting in central clearing 
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 Focally prominent nucleoli 
 Increase in mitotic figures in basal cell layer but not extending to superficial 
layers 
Severe dysplasia 
 Aberrant cell maturation with dyskaryotic cells 
 Mitotic figures, some of which are atypical, present above the basal cell layer 
 Often in the setting of partial or complete maturation with keratinisation of the 
overlying surface mucosa. 
 At low power the presence of individual keratinised (dyskaryotic) cells is an 
important clue to the presence of significant dysplasia however surface 
keratinisation itself is not considered reliable in the assessment of laryngeal 
dysplasia 
B.2.3 Invasive Squamous Cell Carcinoma 
Well differentiated 
 Obvious squamous differentiation 
 Large, closely apposed cell nests 
 Prominent keratinisation 
Moderately differentiated 
 Smaller nests of more pleomorphic cells 
 Increased mitotic activity 
 Clear-cut but less prominent squamous differentiation 
 +/- prominent intra-lymphatic invasion 
Poorly differentiated 
 Highly mitotically active cells growing alone and in small nests 
 Showing ragged or diffuse rather than ‗pushing‘ infiltration 
 Squamous differentiation is focal and often poorly developed 
 +/- prominent intra-lymphatic invasion 
 
There is a particular situation where in certain SCCs are present but appear to ‗drop off‘ 
the basal cell layer and are overlain by essentially normal mucosa. In this situation 
endoscopic diagnosis is extremely difficult and biopsies must be taken with an adequate 
depth but they are not considered histologically as a separate entity. 
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Appendix C: Staging and Classification Criteria for 
Lymphoproliferative Disease. 
C.1 Staging 
At the present time it is not considered practical to propose a TNM classification for 
non-Hodgkin lymphoma and since no other convincing and tested staging system is 
available, the Ann Arbor or WHO classification is recommended with the same 
modifications as for Hodgkin lymphoma 
 
Summary 
 
Stage Hodgkin Disease Substage 
Stage I 
Single node region  
  
Localized single extralymphatic organ/site IE 
Stage II 
Two or more node regions, same side of 
diaphragm 
IIE 
  
Localized single extralymphatic organ/ site with 
its regional nodes, ± other node regions same 
side of diaphragm 
 
Stage III 
Node regions both sides of 
diaphragm ± Localized extralymphatic 
organ/site 
IIIE 
  
Spleen IIIS 
  
Both IIIE+S 
Stage IV 
Diffuse or multifocal involvement of 
extralymphatic organ(s) ± regional nodes; 
isolated extralymphatic organ and non-regional 
nodes 
 
All stages 
divided 
Without weight loss/fever/sweats A 
  
With weight loss/fever/sweats B 
 
 
Notes 
 
1. Right and left neck are considered separate lymph node regions. 
2. Single lymph node regions are: 
 Lymph nodes of head, face and neck 
 Intrathoracic lymph nodes 
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 Intra-abdominal lymph nodes 
 Lymph nodes of axilla or arm 
 Lymph nodes of inguinal region or leg 
 Pelvic lymph nodes 
3. Bilateral involvement of axillae/arm lymph nodes is considered as involvement 
of two separate regions. The same applies to bilateral involvement of inguinal 
lymph nodes. 
4. Direct spread of a lymphoma into adjacent tissues or organs does not influence 
classification. 
C.2 Classification  
C.2.1 Revised European-American Lymphoma Classification 
B cell neoplasms 
I. Precursor B cell neoplasms: B precursor lymphoblastic leukaemia/lymphoma 
II. Peripheral B cell neoplasms 
1. B cell chronic lymphocytic leukaemia / prolymphocytic leukaemia / 
small lymphocytic lymphoma 
2. Lymphoplasmacytoid lymphoma / immunocytoma 
3. Mantle cell lymphoma 
4. Follicle centre lymphoma  
5. Marginal zone B cell lymphoma 
6. Splenic marginal zone lymphoma 
7. Hairy cell leukaemia 
8. Plasmacytoma / plasma cell myeloma 
9. Diffuse large B cell lymphoma 
10. Burkitt lymphoma 
11. High-grade B cell lymphoma – Burkitt-like 
T cell and putative natural killer (NK) cell neoplasm 
I. Precursor T cell neoplasms: T precursor lymphoblastic leukaemia/lymphoma 
II. Peripheral T cell  and NK cell neoplasms Peripheral B cell neoplasms 
1. B cell chronic lymphocytic leukaemia / prolymphocytic leukaemia 
2. Large granular lymphocytic leukaemia, T and NK cell types 
3. Mycosis fungoides / Szary syndrome 
4. Unspecified peripheral T cell lymphoma 
5. Angiommunoblastic T cell lymphoma 
6. Angiocentric lymphoma 
7. Intestinal T cell lymphoma 
8. Adult T cell lymphoma / leukaemia 
9. Anaplastic large cell lymphoma 
10. Anaplastic large cell lymphoma – Hodgkin‘s – like 
 
Hodgkin’s disease 
I. Lymphocyte predominance 
II. Nodular sclerosing 
III. Mixed cellularity 
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IV. Lymphocyte depleted 
V. Lymphocyte-rich classical Hodgkin‘s disease 
 
C.2.2 WHO Classification of Neoplastic Diseases of the Haemopoietic and 
Lymphoid Tissues 
 
Precursor B cell neoplasms 
Precursor B cell neoplasms 
 B cell lymphoblastic leukaemia / lymphoma 
Peripheral B cell neoplasms 
B cell chronic lymphocytic leukaemia / small lymphocytic lymphoma 
Variant: monoclonal gammopathy / plasmacytoid differentiation; mu heavy chain 
disease 
Mantle cell lymphoma 
 Variant: blastic 
Follicular lymphoma 
 Variant: cutaneous follicular lymphoma 
Marginal zone B cell lymphoma of mucosa-associated lymphoid tissue 
 Variant: alpha heavy chain disease 
Nodal marginal zone lymphoma +/- monocytoid B cells 
Splenic marginal zone B cell lymphoma 
Hairy cell leukaemia 
Diffuse large B-cell lymphoma 
 Variants: Centroblastic 
Immunoblastic 
T cell or histiocyte rich 
Anaplastic large B cell 
Burkitt-like 
Lymphomatoid granulomatosis type 
Diffuse large B-cell lymphoma – subtypes 
 Mediastinal (thymic) large B cell lymphoma 
Intravascular large B cell lymphoma 
Primary effusion lymphoma in HIV patients 
Burkitt Lymphoma 
 Variant: with plasmacytoid differentiation (AIDS-associated) 
Plasmacytoma 
 Variants: Solitary Plasmacytoma of bone 
   Extramedullary plasmacytoma 
Plasma cell myeloma 
 Variant: Indolent myeloma 
   Smoldering myeloma 
   Osteosclerotic myeloma (POEMS syndrome) 
   Plasma cell leukaemia 
   Non-secretory myeloma 
   Systemic light chain disease 
   Primary amyloidosis 
204 
 
T cell neoplasias 
Precursor T cell leukaemia / lymphoma 
 T cell lymphoblastic leukaemia / lymphoma 
Peripheral BT/NK cell neoplasms – predominantly disseminated 
 T cell prolymphocytic (T-PLL) 
 T cell large granular lymphocyte leukaemia 
 NK cell leukaemia 
 Adult T cell lymphoma / leukaemia 
Peripheral T cell and NK cell neoplasms – predominantly nodal 
 AIL T cell lymphoma cell lymphoma 
ALC lymphoma 
Peripheral T cell and NK cell neoplasms – predominantly extranodal 
 Mycosis fungoides 
 Sezary syndrome 
 Primary cutaneous CD 30 positive T cell 
 Lymphoproliferative disorders 
 Primary cutaneous ALC lymphomas 
Subcutaneous panniculitic – like T cell lymphoma 
NK/T cell lymphoma – nasal type 
Enteropathy – type intestinal T cell 
Hepatosplenic T cell lymphoma 
Hodgkin Lymphoma (Hodgkin disease) 
Nodular lymphocyte-predominance Hodgkin lymphoma 
Classical Hodgkin lymphoma 
 Hodgkin lymphoma – nodular sclerosis (grades I and II) 
 Hodgkin lymphoma – mixed cellularity 
 Classical Hodgkin lymphoma – lymphocyte-rich 
 Hodgkin lymphoma – Lymphocyte-depleted 
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Appendix D: Larynx study - Tables and Figures 
D.1 Normalised spectra for individual pathology codes 
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D.2 Summary diagram for Larynx study mini models 
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D.3 Difference spectra for larynx study mini models 
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D.4 Peak data for individual study groups (SGs) 
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D.5 Mini model unique SG peaks and PIR tables for shared peaks 
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D.5.3 L2b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-10.00
-8.00
-6.00
-4.00
-2.00
0.00
2.00
4
2
2
4
5
6
6
4
3
6
6
6
7
1
8
7
5
4
7
8
3
8
2
6
8
5
3
9
3
6
1
0
0
2
1
0
2
9
1
0
8
2
1
1
2
4
1
1
5
4
1
2
4
5
1
3
0
3
1
4
4
7
1
5
7
1
1
6
5
1
Wavenumber cm
-1
P
e
a
k
 I
n
te
n
s
it
y
 R
a
ti
o
 
D
if
fe
re
n
c
e
SG3-SG10
PIRs(Controls, Normal squamous epithelium - Controls, Hyperplasia Hyperkeratosis)
229 
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D.5.11 Summary of larynx mini models multivariate analysis results. 
L1 L1-1 L2a L2b L2c L2c-1
1 300.0421 258.3151 344.7667 249.7182 213.5561 337.9797
2 2.7829 56.7493 41.6013 28.7105 29.7851 2.8279
3 150.078 25.363 19.4962 95.011 34.2954 27.5177
4 74.7436 18.7207 21.054 94.3425 32.5957 9.4957
5 13.2927 0.1891 0.3201 51.9062 0.113 93.3019
6 5.5836 219.125 268.9875 10.0596 121.6903 74.3078
7 94.0853 97.649 8.2299 2.0977 80.9551 107.7855
8 7.6865 65.9839 66.0545 4.3603 37.7285 18.9721
9 28.5302 0.0849 0.6692 4.3333 13.3636 10.5108
10 228.4783 42.9864 46.4478 0.1912 21.699 2.7146
11 135.1432 55.1824 74.5047 47.3043 54.7454 49.272
12 0.0629 14.8553 8.3755 9.2472 29.5273 5.6675
13 14.885 57.7829 33.7306 0.0019 36.3175 1.0498
14 4.458 6.9649 10.2419 5.4406 8.4914 4.8453
15 0.8887 145.989 91.7722 19.3023 74.2982 68.5529
16 1.7569 1.0229 0.0595 0.0017 26.5 27.0548
17 45.0604 61.8494 76.1229 6.7026 35.5073 11.2658
18 18.9453 2.085 0.3873 11.4611 8.7144 35.9416
19 1.5291 4.9365 10.8318 0.8854 8.8783 60.1384
20 63.6341 29.6583 1.5703 1.3593 66.5909 63.0848
21 6.7149 9.1625 1.3772 5.2367 8.0715 9.1648
22 26.6005 0.8197 27.9681 3.8515 50.1669 21.5203
23 50.0409 36.4132 22.107 3.4417 41.8755 2.7158
24 32.5562 2.4182 27.8101 0.445 2.5599 8.3516
25 71.0559 44.8853 9.9629 0.018 34.884 48.7958
Distance between Class 1 and 2 is 4.7139 8.9744 8.9188 48.8467 9.3101 16.0034
Distance between Class 1 and 3 is 4.7139 12.624 15.5775
Distance between Class 1 and 4 is 17.2031 17.9436
Distance between Class 2 and 3 is
Distance between Class 2 and 4 is 85.6455
Distance between Class 3 and 4 is 87.211
Total Distance between classes is 8.9744 8.9188 48.8467 39.1372 49.5245
Training Classfication Performance
Class 1  Percentage Correct 85.6455 95.1931 94.605 97.9472 91.8112 93.9306
Class 2  Percentage Correct 87.211 84.6284 83.4459 100 84.2905 86.5103
Class 3  Percentage Correct 77.1654 83.4646
Class 4  Percentage Correct
Training performance 86.54 91.6335 90.5521 98.8176 88.2186 91.3679
Prediction performance 86.54 91.6335 90.5521 98.8176 0 0
F Crit 10.681 10.775 10.682 10.885 10.885 7.037  
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L2c-1 L2c-2 L2c-3 L3 L4 L4_2
1 337.9797 79.9057 46.6069 53.5333 207.5909 212.2289
2 2.8279 76.6517 72.9062 16.1816 1.619 1.2787
3 27.5177 134.7785 109.3403 485.9727 25.8308 26.07
4 9.4957 35.4527 17.1352 10.5262 4.8128 5.4049
5 93.3019 9.8939 10.9579 7.2569 90.5194 90.8995
6 74.3078 51.7903 12.3766 2.5689 10.7248 10.2518
7 107.7855 9.5018 9.1142 7.7938 9.3013 9.3318
8 18.9721 4.5422 35.1909 12.3522 84.577 84.6541
9 10.5108 17.8575 5.2497 1.9706 8.5537 9.6949
10 2.7146 11.4253 37.5152 6.2579 59.4123 55.1777
11 49.272 64.6692 92.3072 0.5552 33.3613 35.3191
12 5.6675 144.8926 56.4104 0.1591 9.3678 9.3478
13 1.0498 7.3576 5.182 0.235 85.4023 88.5161
14 4.8453 0.3081 10.7124 1.9789 82.1574 81.5305
15 68.5529 14.5742 15.2854 0.1417 27.9822 26.7484
16 27.0548 87.936 47.6545 0.5976 10.6182 8.9789
17 11.2658 18.1883 35.5782 0.0509 27.72 27.8992
18 35.9416 55.0069 61.5614 0.1918 12.0315 11.5612
19 60.1384 39.9379 19.5542 0.0211 4.0865 3.8124
20 63.0848 4.2338 10.6055 0.1609 11.5576 10.68
21 9.1648 17.9414 8.3947 0.1121 43.0905 43.2298
22 21.5203 47.5714 23.1964 0.3371 16.2802 20.4906
23 2.7158 69.792 77.075 0.0537 3.1445 3.8695
24 8.3516 17.1397 7.806 0.2988 51.9213 47.7784
25 48.7958 4.1118 18.0168 0.3645 0.9454 1.2562
Distance between Class 1 and 2 is 16.0034 14.64 14.3387 56.0973 65.4779 64.12
Distance between Class 1 and 3 is 15.5775 19.5632 15.1374 96.6849 70.5998 69.18
Distance between Class 1 and 4 is 17.9436 32.8025 28.9591 78.8451 47.2946 47.35
Distance between Class 2 and 3 is 136.7591 22.7943 23.29
Distance between Class 2 and 4 is 126.4369 17.0478 17.78
Distance between Class 3 and 4 is 152.2397 13.068 13.13
Total Distance between classes is 49.5245 67.0056 58.4351 647.063 236.2823 234.86
Training Classfication Performance
Class 1  Percentage Correct 93.9306 93.738 94.7013 96.1538 97.9592 97.96
Class 2  Percentage Correct 86.5103 90.4382 94.8207 100 90.7285 90.73
Class 3  Percentage Correct 83.4646 88.9764 82.0513 100 94.1973 94.39
Class 4  Percentage Correct 100 87.2146 87.26
Training performance 91.3679 92.726 94.0015 99.2126 91.9963 92.1296
Prediction performance 0 0 0 0 0 0
F Crit 7.037 6.967 6.895 5.573 5.457 5.529  
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Appendix E: Identification Table for Characteristic Raman 
Spectral Peaks (Kendall, 2002e). 
 
Key:-   - deformational vibrations ;  - stretching vibrations; s - symmetric stretching 
vibrations; as - asymmetric stretching vibrations 
 
 Assignment Author Tissue/Substance 
207 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
275 CCC Cassanas 1991 Lactic acid 
350 Ribose, cytosine Hartman 1973  
370 CCC Cassanas 1991 Lactic acid 
385 Cytosine Hartman 1973  
400 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
424 CCC Barry 1992 Human strateum corneum 
425 CCO Cassanas 1991 Lactic acid 
429 Calcium hydroxyapatite Yu 1996  
430 Cholesterol Yu 1996  
430 δ(OPO) Wentrup-Byrne 1997a Human tooth 
435 Ribose Hartman 1973  
451 O-P-O symmetric bend Nie 1990 Chicken leg bone 
481 Glycogen Kendall C Sigma Aldrich G0885 
492 s (SiOSi) Frank 1994 silicone gel 
500 Cytosine, guanine & 
disulphide 
Hartman 1973  
500-550 Disulphide (S-S) stretch Gnaidecka 1998 Protein 
505  (S-S) Fredericks  1995 Bovine serum albumin 
507 Disulphide Schrader 1995 Nails 
509 Disulphide (S-S) Ozaki 1988  
510 Disulphide (C-S-S-C 
gauche-gauche-gauche) 
Gnaidecka 1998 Protein 
518 Glucose Goetz 1995  
525 Disulphide (C-S-S-C 
gauche-gauche-trans) 
Gnaidecka 1998 Protein 
526  (S-S) Edwards 1995 Strateum corneum 
526  (S-S) Barry 1992 Human strateum corneum 
528  (S-S) Yu 1996 Protein 
529 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
530-1  (S-S) Edwards 1995 Callus, psoriatic plaque 
533 COC deformation 
(glycosidic ring) 
Maquelin 2000  
533 Glucose Chaiken 2000 Blood 
540 Disulphide (C-S-S-C 
trans-gauche-trans) 
Gnaidecka 1998 Protein 
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540 OCO Cassanas 1991 Lactic acid 
547 Cholesterol Yu 1996 Protein 
553 Glucose Chaiken 2000 Blood 
556  (S-S) Manfait 2000  
574 Tryptophan Siebinga 1992 Eye lens 
575 Cytosine, guanine & 
disulphide 
Hartman 1973  
576 Glycogen Kendall C Sigma Aldrich G0885 
587 Calcium hydroxyapatite Yu 1996 Protein 
591 Apatite Nie 1990 Human tooth enamel 
591 δ(OPO) Wentrup-Byrne 1997a Human tooth 
600 (CH) wagging Barry 1992 Human strateum corneum 
607 Cholesterol Yu 1996 Protein 
618 Phenylalanine(amino 
acid) 
Frank 1994 Collagen 
620 Phenylalanine(amino 
acid) 
Frank 1994 Diseased breast tissue 
620 Phenylalanine Yu 1996  
620-2  (C-S) Edwards 1995 Callus, psoriatic plaque 
622 Phenylalanine Puppels 1999  
623  (C-S) Barry 1992 Human strateum corneum 
623  (C-S) Edwards 1995 Strateum corneum 
624 Adenine Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
625 Guanine in the C3' 
endo/syn form 
Mahadevan-Jansen 1996 DNA (Z) 
626 Phenylalanine Mahadevan-Jansen 1995  
626  Mahadevan-Jansen 
1998a 
Cervix tissue 
626 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
637 Ribose & disulphide Hartman 1973 Protein 
640 Guanine Mahadevan-Jansen 1996 RNA(Z) 
642 Thymine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
643  (C-S), amide IV Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
643 Tyrosine Yu 1996  
644 Tyrosine Puppels 1999  
644  (C-S), Amide IV Barry 1992 Human strateum corneum 
650 C-COH Cassanas 1991 Lactic acid 
665 Thymine Mahadevan-Jansen 1996 DNA (B) 
668 Guanine in the C3' 
endo/anti form 
Mahadevan-Jansen 1996 DNA (A), RNA (A) 
669 (C-S) Fredericks  1995 Bovine Serum albumin 
669 (C-S) Maquelin 2000  
669 Thymine Puppels 1999  
670 Breathing of aromatic 
ring of purine bases 
Mahadevan-Jansen 1996 DNA 
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(guanine  & adenine) 
670 Guanine Mahadevan-Jansen 1996 DNA (C) 
670 Guanine Hartman 1973  
670 Thymine & guanine Puppels 1991  
681 Guanine breathing ring Puppels 1991  
682 Guanine in the C2' 
endo/anti form 
Mahadevan-Jansen 1996 DNA (B) 
692 Creatine (O-C=O) 
deformation 
Dou 1996  
704 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
709 Glycogen Kendall C Sigma Aldrich G0885 
700 Cholesterol Schrader 1995 Brain 
701 Cholesterol Yu 1996  
710 Adenine Hartman 1973  
710 s (Si-C) Frank 1994 silicone gel 
720 Nucleotides Schrader 1995 Breast cancer in mouse 
720 C-N vibration Mahadevan-Jansen 1996 Phospholipid membrane 
722 Adenine Hartman 1973  
724-7 Adenine Mahadevan-Jansen 1996 DNA (A), DNA(B), 
RNA(A) 
725 C-S Siebinga 1992 Eye lens 
725 CH2 rocking Maquelin K  
727 =C-H in plane bend Frank 1994 Breast tissue, lipid 
727 C-C stretch, proline Frank 1995 Normal breast tissue 
727 =C-H in plane bend Frank 1994b  
728 C-C stretch, proline Frank 1995 Oleic acid methyl ester 
729 Adenine breathing ring Puppels 1991  
729 Adenine Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
730  Pilotto 2001 DL-Lactic acid (C3H6O3) 
742-748 O-P-O Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
743 in bovine albumin Kendall C Sigma Aldrich A2153 
746 (CH2) Barry 1992 Human strateum corneum 
748 Thymine Mahadevan-Jansen 1996 DNA (B) 
749 Thymine breathing ring Puppels 1991  
750 OCO Cassanas 1991 Lactic acid 
750 Cholesterol Feld 1995 Carotid artery 
759 Tryptophan (amino 
acid) 
Yu 1996  
759 Tryptophan (amino 
acid) 
Nie 1990 Human eye lens 
760 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea & 
Rabbit aqueous humour 
760 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
760 Tryptophan (amino 
acid) 
Hartman 1973  
760 Tryptophan (amino 
acid) 
Ozaki 1988  
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760 Tryptophan (amino 
acid) 
Miura 1995  
761 Glycogen Kendall C Sigma Aldrich G0885 
762 Collagen Kendall C Sigma Aldrich C7774 
770 Breathing of aromatic 
ring of pyrimidine bases 
(cytosine & thymine) 
Mahadevan-Jansen 1996 DNA 
777 Thymine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
780 Cytosine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
780 Nnucleotides Schrader 1995 Breast cancer in mouse 
780 Uracil ring Maquelin 2000  
782 Cytosine ring breathing Mahadevan-Jansen 1996 DNA (B) 
785 O-P-O Mahadevan-Jansen 1996 DNA (C) 
787 Cytosine & uracil Hartman 1973  
788 Thymine, cytosine, O-P-
O 
Puppels 1991 DNA 
790 s O-P-O Puppels 1999 DNA 
790 Acetone (C-C-C) stretch Dou 1996  
800  Wang 1993 pyruvate 
806-813 (809) s O-P-O Mahadevan-Jansen 1996 DNA (A) 
811 Nucleotides Schrader 1995 Breast cancer in mouse 
814 s O-P-O Manfait 2000 DNA 
814 s O-P-O Mahadevan-Jansen 1996 RNA (A) 
814 C-C stretch, backbone Frank 1995 Type I collagen (human 
placenta) 
814 C-C stretch, backbone Frank 1994a Collagen 
814 C-C stretch, backbone 
in collagen 
Kendall C Sigma Aldrich C7774 
815 Phosphate Hartman 1973  
816 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
817 C-C stretch, backbone Frank 1995 Infiltrating ductal 
carcinoma 
817 C-C stretch, backbone Frank 1994a Diseased breast tissue 
818 Haemoglobin Mahadevan-Jansen 1995  
818  Mahadevan-Jansen 
1998a 
Cervix tissue 
818 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
819 Tyrosine Liu CH 1992a  
820 Structural protein Manoharan 1998 Breast 
825-830 Tyrosine (amino acid) Mahadevan-Jansen 1996 Histones 
825-842 O-P-O Mahadevan-Jansen 1996 DNA (B) 
826 in bovine albumin Kendall C Sigma Aldrich A2153 
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827 (CCH) aliphatic Barry 1992 Human strateum corneum 
828 Tyrosine (amino acid) Kendall C Sigma Aldrich T8909 
830 C-COOH stretch Wang 1993 Lactate 
830 C-COOH stretch Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
830 C-COOH stretch Wicksted 1995 Lactate 
830 Tyrosine (amino acid) Nie 1990 Human eye lens 
830 Tyrosine (amino acid) Mahadevan-Jansen 1996  
830 Tyrosine (amino acid) Hartman 1973  
830 Tyrosine (amino acid) Miura 1995  
830 C-COOH Cassanas 1991 Lactic acid 
832 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
832 Tyrosine Puppels 1999  
832 Tyrosine Ozaki 1988  
833 as O-P-O Puppels 1999 DNA 
833 Ribose phosphate 
 
Greve 1996  
835 as O-P-O Mahadevan-Jansen 1996 DNA (B) 
840 Tyrosine (amino acid) Frank 1994a  
840 Glucose Chaiken 2000  
840-860 Polysaccharides Shim 1996  
840-860 Polysaccharides Gnaidecka 1997a  
840-880 Glucose Chaiken 2000 Blood 
846 Tyrosine (amino acid) Kendall C Sigma Aldrich T8909 
847 Glucose Mahadevan-Jansen 
1998a 
Sigma 
849  Frank 1994a Breast 
850 Proline Liu CH 1992a  
850 Tyrosine (amino acid) Mahadevan-Jansen 1996  
850 Tyrosine (amino acid) Miura 1995  
850  Kendall C Bovine albumin Sigma 
Aldrich A2153 
850 (CCH) aromatic Barry 1992 Human strateum corneum 
850-3 (CCH) aromatic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
853 Tyrosine (amino acid) Nie 1990 Human eye lens 
853 Tyrosine (amino acid) Puppels 1999 DNA 
853 Glycogen Kendall C Sigma Aldrich G0885 
854-6 Tyrosine (amino acid) Mahadevan-Jansen 1996 Histones 
855 Tyrosine Ozaki 1988  
855 C-C stretch Proline ring Frank 1994a Collagen 
855 C-C stretch, proline Frank 1995 Type I collagen (human 
placenta) 
856 Proline Nie 1990 Chicken leg bone 
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856  Mizuno 1994 Polysaccharides in glioma 
grade III (human brain 
tissue) 
856 CC strectch, COC 
stretch, 1,4 glycosidic 
link 
Maquelin 2000  
856 C-C stretch collagen 
backbone & Proline ring 
Frank 1994a Diseased breast tissue 
856 C-C stretch, proline Frank 1995 Infiltrating ductal 
carcinoma (breast) 
856 (CC) skeletal 
vibrations, keratotic 
Carter 1998 Healthy human skin 
dermis 
856 C-C stretch collagen 
backbone & Proline ring 
Lucassen 1998  
856 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
856 C-C stretch Proline ring 
in collagen 
Kendall C Sigma Aldrich C7774 
857 Tyrosine Yu 1996  
858 C-C stretch in elastin Kendall C Sigma Aldrich E1625 
859 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
860 Collagen Redd 1993 Fibrocystic human breast 
tissue 
 
860 Lactate Erckens 1997 Human aqueous humour 
865 Ribose, Tryptophan 
(amino acid) 
Hartman 1973 Protein 
866 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
868 C-C stretch, 
hydroxyproline 
Frank 1995 Oleic acid methyl ester 
870 C-C stretch, 
hydroxyproline 
Frank 1995 Normal breast tissue 
870 Proline (amino acid) Feld 1995 Malignant breast tissue 
870  Frank 1994b Breast 
872 C-C stretch of 4-
hydroxyproline in 
collagen 
Kendall C Sigma Aldrich C7774 
873 hydroxyproline Nie 1990 Chicken leg bone 
874 C-C stretch, 
hydroxyproline 
Frank 1995 Type I collagen (human 
placenta) 
874 C-C stretch of 4-
hydroxyproline 
Frank 1994a Collagen 
876 C-C stretch, 
hydroxyproline 
Frank 1995 Infiltrating ductal 
carcinoma (breast) 
876 C-C stretch of 4-
hydroxyproline 
Frank 1994a Diseased breast tissue 
879 Tryptophan (amino 
acid) 
Nie 1990 Human eye lens 
880 Tryptophan (amino 
acid) 
Ozaki 1988  
880 Tryptophan (amino Miura 1995  
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acid) 
880 Tryptophan (amino 
acid) 
Frank 1994a  
880 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea 
880 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
880 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit aqueous humour 
883 CH2 rocking, Edwards 1995 Strateum corneum, 
883 (CH2) Barry 1992 Human strateum corneum 
885 Ribose, Tryptophan 
(amino acid) 
Hartman 1973 Protein 
890 Structural protein Manoharan 1998 Breast 
890  Frank 1994b Breast 
890-1 CH2 rocking, Edwards 1995 Callus, psoriatic plaque 
892 CH2 rocking,  collagen 
hydroxyproline 
Lucassen 1998 Skin 
893  Kendall C Bovine albumin Sigma 
Aldrich A2153 
895 DNA backbone Puppels 1999 DNA 
896 Proline Kendall C Sigma Aldrich T8449 
915 Ribose Hartman 1973 Protein 
917 Deoxyribose (CH2 
deformation) 
Mahadevan-Jansen 1996 DNA (B) 
920 Glucose Mahadevan-Jansen 
1998a 
Sigma 
920 C-C stretch in elastin Kendall C Sigma Aldrich E1625 
920 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
920 C-C stretch Proline ring Frank 1994a Diseased breast tissue, 
collagen 
920 C-C Proline ring Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
920 C-C stretch Proline ring 
in collagen 
Kendall C Sigma Aldrich C7774 
921 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
921 C-C stretch Proline ring Mahadevan-Jansen 1996 Collagen 
925 DNA backbone Puppels 1999 DNA 
928 DNA backbone, α helix Puppels 1991 Protein 
928-940 C-C Proline, valine Mahadevan-Jansen 
1998a 
 
930 Tryptophan (amino 
acid) 
Hartman 1973 Protein 
930 rCH3 Cassanas 1991 Lactic acid 
931 CH3 rocking,  collagen 
proline 
Lucassen 1998 Skin 
931 (CH3), (C-C) -helix Barry 1992 Human strateum corneum 
932 Skeletal C-C, α helix Puppels 1999 DNA 
932-5 CH3 rocking,  C-C Edwards 1995 Strateum corneum, Callus, 
254 
 
stretch α helix keratin psoriatic plaque 
934 C-C stretch, backbone Frank 1994a Collagen 
934 C-C Proline ring Frank 1995 Type I collagen (human 
placenta) 
935-945 (C-C) skeletal 
vibrations, α helix 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
935 Collagen Redd 1993 Fibrocystic human breast 
tissue 
936 C-C stretch backbone, 
hydroxyproline & 
collagen 
Caspers 1998 Skin 
936 C-C stretch, backbone 
in collagen 
Kendall C Sigma Aldrich C7774 
937 Glycogen Kendall C Sigma Aldrich G0885 
937 C-C stretch, backbone Frank 1994a Diseased breast tissue 
937 C-C Proline ring Frank 1995 Infiltrating ductal 
carcinoma (breast) 
937 -helix Schrader 1995 nails 
938 (C-C) skeletal 
vibrations, 
keratotic 
Carter 1998 Healthy human skin 
dermis 
938 Peptide backbone 
stretch 
Yu 1996  
938 C-C backbone Mahadevan-Jansen 1996 Collagen 
939 C-C-N stretching Fredericks  1995 Bovine Serum albumin 
940 C-C-N stretching in 
bovine albumin 
Kendall C Sigma Aldrich A2153 
940 (C-C) of proline and 
valine 
Gniakeda 1997 Normal human skin 
940 Triple helix vibrations Fendel 1988 Collagen type I, normal 
skin dermis 
941 C-C stretch Ozaki 1988 Protein 
944 (C-C) Baraga 1992a Asian skin 
950 4-hydroxyproline Feld 1995 Malignant breast tissue 
955 Hydroxyapatite Manoharan 1992  
956 Carotenoids Mizuno 1994 Human brain tissue, 
acoustic neuroma 
956 (CH3), (CCH) 
olefinic 
Barry 1992 Human strateum corneum 
960 Calcification - 
hydroxyapatite 
Mizuno 1994 Human brain tissue, 
central neurocytoma 
960 Calcification - 
hydroxyapatite 
Clarke 1987 Aortic valve leaflets & 
coronary artery segments 
960 P-O symmetric stretch Nie 1990 Chicken leg bone 
960 P-O symmetric stretch Baraga 1992a Atherosclerotic plaque 
calcified salts 
960 Hydroxyapatite, P-O 
symmetric stretch 
Yu 1996 Calcified plaque 
960 Cholesterol Keller 1994  
961 Apatite Nie 1990 Human tooth enamel 
961 Υs(PO) of PO4
3-
in 
apatite 
Wentrup-Byrne 1997a Human tooth 
961 Phosphate groups Rava 1991 Calcified atherosclerotic 
plaque 
966 Hydroxyapatite Clarke 1987 Calcified plaque 
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966 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
966 Triple helix vibrations Fendel 1988 Collagen type I, normal 
skin dermis 
968 C-OH Manfait 2000  
972 =C-H out of plane 
deformation 
Frank 1994a Breast tissue 
972 C-C Proline ring Frank 1995 Normal breast tissue, Oleic 
acid methyl ester 
972 =C-H out of plane 
deformation 
Frank 1994b Breast 
975 Ribose Hartman 1973 Protein 
975 Deoxyribose (CH2 
deformation) 
Mahadevan Jansen 1996 DNA (B) 
978 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Phospholipids, glucose-1-
phosphate 
978 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Human cervix 
978 Phosphorylated proteins 
and nucleic acids 
Mahadevan Jansen 1995 Human cervical biopsies 
982 CH2 rocking Edwards 1995 Strateum corneum 
1000-1100 Glucose Chaiken 2000 Blood 
1000-1150 C-C skeletal vibrations Mahadevan Jansen 1996 Phospholipid membrane, 
hydrophobic chains 
1000-1250 Phosphate groups Sajid J 1997 DMPC 
(dimyristoylphosphatidych
oline), a typical lipid, brain 
1000-1200 C-C stretch – lipids Carter 1998 Healthy human skin 
1000 Phenylalanine in bovine 
Albumin 
Kendall C Sigma Aldrich A2153 
1001 Phenylalanine(amino 
acid) 
Kendall C Sigma Aldrich T8324 
1001 Phenylalanine(amino 
acid) 
Feld 1995 Malignant breast tissue 
1001  Lieber 2000 Ovary 
1001-1004 Phenyl ring breathing 
mode 
Shim 1996  
1002 υ(C-C) aromatic ring Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1002 (C-C) skeletal 
vibrations, β sheet 
Mahadevan-Jansen 1996 -sheet protein secondary 
structure 
1002 Phenylalanine(amino 
acid) 
Yu 1996  
1002 Phenylalanine(amino 
acid) 
Frank 1994a  
1002 Phenylalanine(amino 
acid) 
Frank 1994a Collagen 
1002 Hydroxyproline, 
tyrosine 
Frank 1995 Type I collagen (human 
placenta) 
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1002 (CC) aromatic ring Barry 1992 Human strateum corneum 
1003 (CC) aromatic ring 
stretch of phenylalanine 
residue in keratin 
Carter 1998 Healthy human skin 
1003 Phenylalanine(amino 
acid) breathing mode 
Mizuno 1994 Human brain tissue, 
protein 
1003 C-N stretch Erckens 1997 Urea 
1003 C-N stretch of urea Wicksted 1995 Urea 
1003 C-N stretch of urea Lucassen 1998  
1004 Phenylalanine(amino 
acid) 
Erckens 1997 Rabbit lens, aqueous 
humour, cornea & human 
cornea 
1004 Aromatic ring 
(breathing mode) 
Gniakeda 1997 Normal human skin 
1004 Phenylalanine(amino 
acid) 
Maquelin 2000  
1004 Phenylalanine(amino 
acid) 
Puppels 1999  
1004 Phenylalanine(amino 
acid) 
Puppels 1991  
1004 Phenylalanine(amino 
acid) 
Frank 1994a Diseased breast tissue 
1004 Phenylalanine(amino 
acid) 
Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1004 Phenylalanine(amino 
acid) + Trp aromatic 
ring 
Fredericks  1995 Bovine Serum albumin 
1004 Carotenoid Redd 1993a Beta carotene, Human 
breast carcinoma 
1004 
E.1 P
h
e
n
y
l
a
l
a
n
i
n
e
 
i
n
 
c
o
l
l
a
g
e
Kendall C Sigma Aldrich C7774 
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n 
1004 P-O symmetric stretch Nie 1990 Chicken leg bone 
1005 
E.2 C
a
r
o
t
e
n
o
i
d 
Redd 1993a Normal human breast 
tissue 
1005 Beta carotene Frank 1995 Breast 
1005 
E.3 C
a
r
o
t
e
n
o
i
d 
Redd 1993b Human breast tissue 
Renal cell carcinoma 
(1003) 
1005 Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1006 C-N stretch of urea Wicksted 1995 Urea, rabbit aqueous 
humour 
1006 Phenylalanine, amino 
acid 
Mahadevan-Jansen 1998 Collagen, histones 
1006 Phenylalanine, amino 
acid 
Ozaki 1988 Protein 
1006 Carotenoids Mizuno 1994 Human brain tissue, 
acoustic neuroma 
1008 C-N stretch Wang 1993 Urea NH2-CO-NH2 
1008 Carotenoids Redd 1993b Carotenoids in normal 
colon 
1010 C-N stretch Erckens 1997 Human aqueous humour 
1013 Urea N-C-N stretch Dou 1996  
1014 Tryptophan (amino 
acid) 
Mahadevan-Jansen 1998  
1015 Tryptophan (amino 
acid) 
Hartman 1973 Protein 
1016 Tryptophan – amino 
acid 
Manoharan 1995 DNA in water 
1017 DNA backbone C-O 
stretch 
Puppels 1999  
1030 Collagen Kendall C Sigma Aldrich C7774 
1031 Proline Yu 1996  
1031 (CC) skeletal cis Barry 1992 Human strateum corneum 
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conformation 
1031-32 υ(C-C) keratin Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1032 Phenylalanine(amino 
acid) 
Erckens 1997 Rabbit & human cornea 
Rabbit lens Rabbit 
aqueous humour 
1032 Phenylalanine(amino 
acid) 
Puppels 1999  
1032 proline Frank 1995 Type I collagen (human 
placenta) 
1034  Lieber 2000 Ovary 
1035 Ribose, 
Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1035 C-C skeletal cis Lucassen 1998  
1043 Proline Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1043 Formalin artefact Frank 1994a breast tissue 
1046 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1048 Glycogen Kendall C Sigma Aldrich G0885 
1050 C-CH3 Cassanas 1991 Lactic acid 
1050 CO stretch, CCC trans 
skeletal stretch 
Carter 1998 Healthy human skin 
dermis 
1057 DNA backbone C-O 
stretch 
Puppels 1999  
1060 OD Cassanas 1991 Methyl lactate 
1061 Lipid Caspers 1998 Strateum corneum 
1062 υ(C-C) skeletal trans 
conformation lipid 
Edwards 1995 Strateum corneum 
1062 (CC) skeletal trans 
conformation 
Barry 1992 Human strateum corneum 
1064 C-C stretch Sajid 1997  
1065 C-O stretch & C-O-C 
sym. stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1066 C-C stretch Frank 1994b Breast 
1066 C-C stretch Frank 1994a breast tissue 
1066 Proline Frank 1995 Normal breast tissue 
1066 C-O, C-O-C stretch Ozaki 1988 Phospholipids 
1066 Lipid Gnaidecka 1998  
1066  Lieber 2000 Ovary 
1067 Proline Frank 1995 Oleic acid methyl ester 
1069 Hydroxyapatite shifted 
due to environment 
Mahadevan Jansen A Human cervix 
1070 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Glucose -1-phosphate, 
collagen 
1070 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Human cervix 
1070 Collagen/elastin Mahadevan Jansen 1995  
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1070  Utzinger 2001 Cervix 
1070 Phosphate / carbonate Baraga 1992a Atherosclerotic plaque 
1070 Phosphate / carbonate Yu 1996  
1071 apatite Nie 1990 Human tooth enamel 
1071 Υas(PO) Wentrup-Byrne 1997a Human tooth 
1072 P-O asymmetric stretch Nie 1990 Chicken leg bone 
1074  Manoharan 1994 Adipose tissue 
1074 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1078 C-N stretch Alfano 1991 Benign breast tissue 
1078-1090 C-C, C-O stretch in 
lipids. C-C, PO2 stretch 
in nucleic acids 
Shim 1996  
1079 C-C stretch Frank 1994a Breast tissue 
1079  Frank 1995 Normal breast tissue 
1079 C-C stretch Frank 1994b Breast 
1080 C-C stretch & PO2- 
sym. stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1082 υ(C-C) skeletal random 
conformation lipid 
Edwards 1995 Strateum corneum 
1082  Frank 1995 Oleic acid methyl ester 
1082 PO2- vibration in 
phospholipids and 
nucleic acids 
Gniakeda 1997 Normal human skin 
1082 
E.4 L
i
p
i
d 
Redd 1993a Normal human breast 
tissue, Lipid (TPE) 
1082 Lipid Redd 1993 Human breast tissue 
1082 Lipid Lucassen 1998  
1082  Gnaidecka 1998 Protein 
1082 (CC) skeletal random 
conformation 
Barry 1992 Human strateum corneum 
1083 Glycogen Kendall C Sigma Aldrich G0885 
1084 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1085 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
1085 C-C stretch Yu 1996 Lipid 
1085 Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1085 Phosopholipids Feld 1995 Malignant breast tissue 
1086 C-C stretch, PO2 stretch Ozaki 1992 Phospholipids 
1087 Symmetric stretching of 
phosphate groups of the 
polynucleotide chain 
Sajid 1997 DNA 
1090 CO Cassanas 1991 Lactic acid 
1090 PO
-
2 Mahadevan-Jansen 1998 DNA (C) 
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1091 PO
-
2 Mahadevan-Jansen 1998 DNA (B) 
1094 DNA O-P-O Puppels 1999  
1094 DNA O-P-O Puppels 1991  
1095 s of two ionised 
phosphate oxygens in 
the diphosphate ester 
Mahadevan-Jansen 1998 DNA (B) 
1095 PO
-
2 Mahadevan-Jansen 1998 DNA (Z), RNA(Z) 
1095 CC stretch, COC 
deformation 1-4 
glycosidic link 
Maquelin 2000  
1099 PO
-
2 Mahadevan-Jansen 1998 DNA (A), RNA(A) 
1100 Formalin Keller 1994 Formalin 
1100 PO2 stretch Hartman 1973 Protein 
1100 s of two ionised 
phosphate oxygens in 
the diphosphate ester 
Mahadevan-Jansen 1998 DNA (A) 
1100 Lipid disorganised Gnaidecka 1998  
1100-1110 (C-C) skeletal vibrations Mahadevan-Jansen 1998 Unordered protein 
secondary structure 
1104 C-C stretch lipid Yu 1996  
1108 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
1118  Frank 1995 Normal breast tissue 
1119  Frank 1995 Oleic acid methyl ester 
1119 C-C stretch Frank 1994a Breast tissue 
1119 C-C stretch Frank 1994b Breast 
1122 C-C stretch lipid Yu 1996  
1123 Glycogen Kendall C Sigma Aldrich G0885 
1123 Glucose Mahadevan-Jansen 
1998a 
Sigma 
1125  Hartman 1973  
1125  Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1126 C-N stretch Puppels 1999 Protein 
1126 C-C stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1126 (CC) skeletal trans 
conformation 
Barry 1992 Human strateum corneum 
1127 υ(C-C) skeletal trans 
conformation lipid & 
keratin 
Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1127 Lipids Caspers 1998 Strateum corneum 
1127  Frank 1995 Type I collagen (human 
placenta) 
1128 C-C stretch Sajid 1997  
1128 Heme vibrational mode Shim 2000  
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1129 C-C stretch, lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1130 Trans C-C stretch – 
phospholipids 
Mizuno 1994 Human brain tissue, 
glioma grade III 
1130 Lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1130 C-C stretch, lipid Gnaidecka 1998  
1130 C-O stretch glucose Dou 1996  
1130 Low density 
lipoproteins 
Yu 1996  
1131 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
1135 CO, rCH3 Cassanas 1991 Lactic acid 
1150 Carotenoid Brennan 1997a Human artery 
1150 C=C Carotenoid Keller 1994 Food 
1150 Cholesterol Feld 1995 Carotid artery 
1155 C-C stretch, (COH) Lucassen 1998  
1155 (CC), (COH) Barry 1992 Human strateum corneum 
1156 CN stretch Fredericks  1995 Bovine Serum albumin 
1156 Carotenoid Frank 1994a  
1156 Carotenoid Redd 1993a Human breast carcinoma, 
Beta carotene 
1157 
E.5 C
a
r
o
t
e
n
o
i
d 
Redd 1993a Normal human breast 
tissue 
1157 Carotenoid Redd 1993b Human breast tissue 
Renal cell carcinoma 
(1155) 
1157 Carotenoid Mizuno 1994 Human brain tissue, 
acoustic neurinoma, beta 
carotene 
1158 Carotenoid Feld 1995 Carotid artery 
1158 Carotenoid Redd 1993b Carotenoids in normal 
colon 
1158 NH2 rocking vibration Wicksted 1995 Urea 
1159 C-N Siebinga 1992 Protein in eye lens 
1160 Carotenoid Larrson 1974 Blood plasma 
1162 Ribose Hartman 1973  
1166  Frank 1995 Type I collagen (human 
placenta) 
1167  Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1172 (CC) Barry 1992 Human strateum corneum 
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1175 C-O stretching Mahadevan 1995 Human cervical biopsies 
1176 Tyrosine, Phenylalanine Puppels 1999 Protein 
1180  Utzinger 2001 Cervix 
1180 Tyrosine Manoharan 1998 Breast 
1180 Tyrosine Miura 1995  
1180 Cytosine, guanine, 
adenine 
Hartman 1973  
1197 Carotenoid Frank 1994a  
1200-1700 Collagen Wentrup-Byrne 1997a Dentine 
1205 Tyrosine + 
Phenylalanine 
Kendall C Bovine albumin, Sigma 
Aldrich A2153 
1206 4-hydroxyproline 
(amino acid), tyrosine 
Frank 1994a Diseased breast tissue 
1206 4-hydroxyproline 
(amino acid) 
Frank 1994a Collagen 
1206 Hydroxyproline, 
tyrosine 
Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1207 Tyrosine Nie 1990 Human eye lens 
1207 Tyrosine + 
Phenylalanine (amino 
acid) 
Fredericks  1995 Bovine Serum albumin 
1207  Lieber 2000 Ovary 
1208 Thymine Mahadevan-Jansen 1998 DNA (B) 
1210 hydroxyproline Nie 1990 Chicken leg bone 
1210  Utzinger 2001 Cervix 
1210 Tryptophan, 
phenylalanine 
Hartman 1973  
1211 Tyrosine, 
Phenylalanine, Thymine 
Puppels 1999 Protein 
1226-1243 Amide III - (C-N) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-alanine 
1227 Heme vibrational mode Shim 2000  
1227-1247 Amide III (C-N stretch, 
N-H in plane bending) 
-sheet 
Mahadevan-Jansen 1998 -sheet protein secondary 
structure 
1230 Uracil in RNA Yazdi 1999 Cultured breast cells 
1230-1240 Amide III -sheet Carey 1982  
1230-1245 Amide III - (C-N) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-glutamate 
1234 Antisymmetric 
stretching of phosphate 
groups of the 
polynucleotide chain 
Sajid 1997 DNA 
1235-1270 Amide III (C-N stretch, 
N-H in plane bending) 
unordered 
Mahadevan-Jansen 1998  
1237 Amide III Nie 1990 Human eye lens 
1238 Amide III, random coil Erckens 1997 Rabbit & human cornea 
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1238 Amide III in elastin Kendall C Sigma Aldrich E1625 
1238 Cytosine, uracil, Amide 
III 
Hartman 1973  
1239 Thymine Mahadevan-Jansen 1998 DNA (A), RNA (A) 
1240 Amide III - (C-N) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-lysine 
1240 Vibration of pyrimidine 
bases (cytosine & 
thymine) 
Mahadevan-Jansen 1996 DNA 
1240 Amide III (C-N) Alfano 1991 Benign breast tumour 
1240 Amide III Frank 1994a  
1240 Amide III in collagen Kendall C Sigma Aldrich C7774 
1240 Amide III - (C-N) Liu CH 1992a Uterus cancer 
1240 Amide III Keller 1994 Caractous lens 
1240 Thymine Puppels 1999 Protein 
1240-1260 Amide III unordered Carey 1982  
1243 Amide III Keller 1994 Liver - collagen 
1243 Amide III Nie 1990 Chicken leg bone 
1243 Amide III Erckens 1997 Rabbit lens 
1243-48 Amide III - (C-N) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
lysine pH4 
1244 (CH2) wagging, (CN) 
amide III disordered 
Barry 1992 Human strateum corneum 
1245 CO, OH Cassanas 1991 Lactic acid 
1245 Amide III, random coil Mizuno 1994 Human brain tissue, 
glioma grade III 
1245 Keratotic Carter 1998 Healthy human skin 
dermis 
1245  Utzinger 2001 Cervix 
1245 Amide III: keratin, 
disordered collagen 
Lucassen 1998  
1245-1305 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Histones 
1246 Amide III Fredericks  1995 Bovine Serum albumin 
1246 Amide III (C-N) Mahadevan 1995 Collagen & DNA 
1246 Amide III (C-N) Mahadevan 1995 Human cervix precancer 
1246 Amide III (C-N 
stretching vibrations) 
Mahadevan 1995 Human cervical biopsies 
1246 Amide III (C-N 
stretching vibrations) 
Liu CH 1992a  
1246 Amide III (C-N 
stretching vibrations) 
Gnaidecka 1998 Protein 
1247 Amide III Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1247 Amide III Frank 1994a Diseased breast tissue 
1247  Keller 1994 Neutrogena sarcoma 
(brain) - collagen 
1247 Amide III Frank 1994a Collagen 
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1247 Amide III - (C-N) Liu CH 1992a Endometrium cancer 
1247 Collagen Redd 1993 Fibrocystic human breast 
tissue 
 
1248 Amide III Manoharan 1998 Breast 
1248 PO2- vibration in 
phospholipids and 
nucleic acids 
Gniakeda 1997 Normal human skin 
1248 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Collagen 
1249 Amide III - (C-N) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
glutamate pH 11 
1250 Cytosine, uracil, Amide 
III 
Hartman 1973  
1250 Amide III Brennan 1997a Human artery 
1250 Amide III Ozaki 1992  
1250 Cytosine Mahadevan-Jansen 1998 DNA (B) 
1250 Amide III Fendel 1988 Collagen type I, normal 
skin dermis 
1252 Amide III Baraga 1992b Aorta 
1253 Amide III random coil 
protein 
Schrader 1995 Breast cancer in mouse 
1254 Adenine Puppels 1991 Protein 
1254 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Elastin 
1255 Cytosine Puppels 1999 Protein 
1256 Glycogen Kendall C Sigma Aldrich G0885 
1258-1304 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
1260-1310 Amide III (C-N stretch, 
N-H in plane bending) 
Miura 1995 -helix protein secondary 
structure 
1259 Amide III Frank 1994a Silicone gel 
1260 Tyrosine Miura 1995 Unordered protein 
secondary structure 
1260 Structural protein Manoharan 1998 Breast 
1260 Symmetric CH3 
deformation 
Frank 1994a Silicone gel 
1260 Amide III Nie 1990 Chicken leg bone 
1260 Amide III Feld 1995 Malignant breast tissue 
1260-1280 Amide III Fredericks  1995 Bovine Serum albumin 
1261 Lipid Manoharan 1994  
1262 Amide III - (C-N) Liu CH 1992a Benign or normal cervix 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal uterus 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal 
endometrium 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal ovary 
1264 Amide III in collagen Kendall C Sigma Aldrich C7774 
1265-1300 Amide III (C-N stretch, 
N-H in plane bending) 
Carey 1982 -helix protein secondary 
structure 
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1265-1348 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
alanine 
1265 =C-H in plane 
deformation 
Frank 1994b Breast 
1265 =C-H in plane 
deformation 
Frank 1994a breast tissue 
1265 Amide III Frank 1995 Normal breast tissue 
1267 =C-H in plane 
deformation 
Keller 1994  
1267 Amide III Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1267  (=C-H) Mahadevan-Jansen 1998 Phospholipid membrane 
1267  (=C-H) Keller 1994 Coronary Artery, 
unsaturated fatty acids 
1267 Amide III Frank 1994a Lymph node 
1267 Amide III Frank 1994a Diseased breast tissue 
1267 Amide III Frank 1994a Collagen 
1268 Amide III Frank 1995 Oleic acid methyl ester 
1268 Amide III - (C-N)  and 
(NH) in bovine 
albumin 
Kendall C Sigma Aldrich A2153 
1269 Amide III Frank 1995 Type I collagen (human 
placenta) 
1269 Amide III -helix Mizuno 1994 Human brain tissue 
1270  Utzinger 2001 Cervix 
1270 Amide III - (C-N) Liu CH 1992a Endometrium cancer 
1271 Amide III - (C-N)  and 
(NH) 
Gniakeda 1997 Normal human skin 
1271 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Collagen 
1273 Amide III Fendel 1988 Collagen type I, normal 
skin dermis 
1274 (NH) wagging, (CN) 
amide III -helix 
Barry 1992 Human strateum corneum 
1280 Amide III Clarke 1993 Phospholipid membrane 
1290 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
glutamate 
1295 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
lysine 
1296 (CH2) Barry 1992 Human strateum corneum 
1296 Keratotic Carter 1998 Healthy human skin 
dermis 
1296 (CH2) Edwards 1995 Strateum corneum 
1297 Lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1300 (C-C) (C-N) Alfano 1991 Benign breast tissue 
1300 Amide III Sajid 1997 Bovine insulin 
1300 C-H bending Liu CH 1992a Lipid 
1300 Phospholipids - CH2 Mizuno 1994 Human brain tissue 
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twist and wagging 
1300 Lipids – fatty acids Manoharan 1998 Breast 
1300 CH Cassanas 1991 Lactic acid 
1300 Adenine , cytosine Hartman 1973  
1302 Lipid Redd 1993a Lipid (TPE) 
1302 Lipid Redd 1993b Human breast tissue 
1302 
E.6 L
i
p
i
d 
Redd 1993a Normal human breast 
tissue 
1302 Lipid Redd 1993 Human breast tissue 
1303 CH2 twisting Frank 1994b Breast 
1303 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1303 Adenine Puppels G  
1303  CH2 Mahadevan-Jansen 1998 Phospholipid membrane 
1303 CH2 twisting Frank 1994a Normal breast tissue 
1303 CH3CH2 twisting Frank 1994a Diseased breast tissue 
1303 CH3CH2 twisting Frank 1995 Normal breast tissue & 
infiltrating ductal 
carcinoma 
1304 CH3CH2 twisting Frank 1995 Oleic acid methyl ester 
1306 Lipid Redd 1993b Human colon 
1309 CH2 twisting & wagging 
in lipids 
Gniakeda 1997 Normal human skin 
1310-16 Δ(CH2) Edwards 1995 Callus, psoriatic plaque 
1316 Histidine Kendall C Sigma Aldrich T8776 
1316 Guanine Mahadevan-Jansen 1998 DNA (Z), RNA(Z) 
1317 CH2 twisting Redd 1993a Skin 
1318 Guanine Mahadevan-Jansen 1998 DNA (A), RNA (A) 
1319 CH3CH2 twisting Frank 1995 Type I collagen (human 
placenta) 
1319 CH3CH2 twisting Frank 1994a Collagen 
1320 Guanine Hartman 1973  
1321 in bovine albumin Kendall C Sigma Aldrich A2153 
1322 C-H Siebinga 1992  
1325 Tryptophan (amino 
acid) ring vibrations 
Liu 1992a  
1325 Nucleic acid ring 
vibrations 
Feld 1995  
1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Cervix cancer 
1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Uterus cancer 
1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Ovary cancer 
1330 C-H Mahadevan Jansen 
1998a 
Nucleic acid bases & 
DNA, phospholipids 
1330 C-H Mahadevan Jansen Human cervix precancer 
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1998a 
1330  Utzinger 2001 Cervix 
1330 DNA Yazdi 1999 Cultured breast cells 
1330 CH Cassanas 1991 Lactic acid 
1333 Glycogen Kendall C Sigma Aldrich G0885 
1333 Guanine Mahadevan Jansen 1998 DNA (B) 
1334 CH deformation Maquelin 2000  
1335 Nucleic acids Manoharan 1995 Colon 
1335 Adenine Mahadevan Jansen 1998 DNA (A), RNA (A) 
1337 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1337 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1337 Purine bases (adenine, 
guanine) 
Manoharan 1995 DNA in water 
1337 Adenylates Boustany 1999 Colon mucosa 
1338 Tryptophan, amino 
acid 
Mahadevan Jansen 1998  
1339 Adenine Mahadevan Jansen 1998 DNA (B) 
1339-41  Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1340 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea 
1340 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit aqueous humour 
1340 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1343 CH3CH2 wagging Frank 1994a Diseased breast tissue 
1343 CH3CH2 wagging Frank 1994a Collagen 
1343 CH3CH2 wag Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1343  Wicksted 1995 Rabbit aqueous humour 
1343 Adenine Hartman 1973  
1350 Glucose Mahadevan-Jansen 
1998a 
Sigma 
1358  Redd 1993 Normal renal parenchyma 
& renal cell carcinoma 
1359  Redd 1993 Hepatocellular carcinoma 
1360  Redd 1993 Normal hepatic 
parenchyma 
1360  Redd 1993a Myoglobin 
1360  Erckens 1997 Human aqueous humour 
1361 Tryptophan Mahadevan-Jansen 1998  
1365 Guanine, tryptophan Hartman 1973  
1372 Lipid Redd 1993 Human colon 
1375  Redd 1993a Myoglobin 
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1376 Thymine, guanine, 
adenine 
Puppels 1991  
1377 Glycogen Kendall C Sigma Aldrich G0885 
1380 CH3 OH Cassanas 1991 Lactic acid 
1385 (CH3) symm Barry 1992 Human strateum corneum 
1400 Uracil, adenine Hartman 1973  
1400  Utzinger 2001 Cervix 
1401 Symmetric CH3 bending 
in proteins 
Mahadevan 1995  
1410 OH Cassanas 1991 Methyl lactate 
1412 Antisymmetric CH3 
deformation 
Frank 1994a Silicone gel 
1420 OH, CO Cassanas 1991 Lactic acid 
1421 (CH3) Barry 1992 Human strateum corneum 
1421 Guanine, adenine Puppels 1991  
1438 (CH2) scissoring Barry 1992 Human strateum corneum 
1438 CH2 deformation Shim 1996  
1439 CH2 scissoring 
deformation 
Frank 1994a breast tissue 
1439 CH3, CH2 deformation Frank 1995 Normal breast tissue 
1439 CH2 deformation McCreery 1995 Human breast biopsy 
1439 CH2 deformation due to 
lipids and proteins 
Mizuno 1994 Human brain tissue 
1439 CH2 scissoring 
deformation 
Frank 1994b Breast 
1440 Lipid Manohran 1994  
1441 CH2 bending Feld 1995 Fibrous atherosclerotic 
plaque 
1441 Lipid Keller 1994 Liver 
1442 CH3, CH2 deformation Frank 1995 Oleic acid methyl ester 
1442 Lipid Redd 1993b Human breast tissue 
Colon tissue 
1442 
E.7 L
i
p
i
d 
Redd 1993a Normal human breast 
tissue 
1442 Lipids – fatty acids Manoharan 1998 Normal breast tissue 
1443 elastin Kendall C Sigma Aldrich E1625 
1444 Lipid Redd 1993a Lipid (TPE) 
1444 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1445 (CH2) or (CH3) Liu CH 1992a Cervix cancer 
1445 (CH2) or (CH3) Liu CH 1992a Uterus cancer 
1445 (CH2) or (CH3) Liu CH 1992a Benign or normal cervix 
1445 (CH2) or (CH3) Liu CH 1992a Benign or normal 
endometrium 
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1445 (CH2) or (CH3) Liu CH 1992a Benign or normal ovary 
1445 (CH2) or (CH3) Alfano 1991 Human breast tissue. 
Benign and Malignant 
tumours 
1445 CH2 deformation Frank 1994a breast tissue 
1445 CH2 bending mode Manoharan 1998 Normal breast tissue 
1445 CH3CH2 deformation in 
collagen 
Kendall C Sigma Aldrich C7774 
1447 CH3CH2  bending modes 
in bovine albumin 
Kendall C Sigma Aldrich A2153 
1448 CH2 deformation Nie 1990 Chicken leg bone 
1448 Deoxyribose Mahadevan-Jansen 1998 DNA (B) 
1448-9 Δ(CH2) scissoring Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1449 CH2 deformation Frank 1994a Lymph node 
1450 Glucose Chaiken 2000 Blood 
1450 CH bending Erckens 1997 Rabbit & human cornea 
1450 CH bending Erckens 1997 Rabbit aqueous humour 
1449 CH3CH2  bending modes Fredericks  1995 Bovine Serum albumin 
1450 CH3CH2 deformation Frank 1994a Diseased breast tissue 
1450 CH2 bending Brennan 1995 Human artery 
1450 CH2 bending mode Manoharan 1998 Diseased breast tissue 
1450 (CH2) or (CH3) Liu CH 1992a Endometrium cancer 
1450  Liu CH 1992a Elastin & collagen 
1450 CH3, CH2 deformation Frank 1995 Infiltrating ductal 
carcinoma 
1451 C-H bend Baraga 1992a Normal human aorta 
1451 CH3, CH2 deformation Frank 1995 Type I collagen (human 
placenta) 
1451 CH3CH2 deformation Frank 1994a Collagen 
1451 CH2 bending Ozaki 1988  
1451-1454 CH2 bending Mahadevan Jansen 
1998a 
Histones 
1452 Structural protein Manoharan 1998 Breast 
1452 (CH2) scissoring in 
lipids & (CH2) (CH3) 
in proteins 
Gniakeda 1997 Normal human skin 
1452 CH2 bending Feld 1995 Malignant breast tissue 
1452 CH2 in plane bending Rava 1991 Normal aorta 
1453 (CH2) or (CH3) Liu CH 1992a Ovary cancer 
1453 (CH2) or (CH3) Liu CH 1992a Benign or normal uterus 
1453 C-H bending modes Baraga 1992b Aorta 
1454 CH3 bending CH2 
scissors 
Mahadevan Jansen 
1998a 
Elastin & collagen & 
phospholipids 
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1454 CH3 bending CH2 
scissors 
Mahadevan Jansen 
1998a 
Human cervix 
1454 CH3 asymmetric 
bending of proteins 
Mahadevan 1995  
1454  Utzinger 2001 Cervix 
1455 CH3 Cassanas 1991 Lactic acid 
1455 Glycogen Kendall C Sigma Aldrich G0885 
1455 CH2 deformation Frank 1994b Breast 
1456 CH3 bending in elastin Kendall C Sigma Aldrich E1625 
1456  Lieber 2000 Ovary 
1457  Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1458 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1460 Pentose sugar vibration 
due to  CH2 
Mahadevan-Jansen 1998 DNA 
1462 Deoxyribose Mahadevan-Jansen 1998 DNA (B) 
1475 CH3 Cassanas 1991 Lactic acid 
1480 Vibration of purine 
bases (adenine & 
guanine) 
Mahadevan-Jansen 1996 DNA 
1480 DNA Yazdi 1999 Cultured breast cells 
1485 Nucleic acids Manoharan 1995 Colon 
1485 Purine bases Manoharan 1995 DNA in water 
1485 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1485 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1487 Nucleic acid Manoharan 1995 Colon 
1491 Formalin Frank 1994a  
1500-1650 Heme Ozaki 1988  
1509 Phenylalanine Fredericks 1995 Bovine Serum albumin 
1510 Adenine, guanine Puppels 1991  
1512  Lieber 2000 Ovary 
1517 Carotenoid Frank 1994b  
1520-1670 Tryptophan & tyrosine Yazdi 1999 Cultured breast cells 
1520 C=C Carotenoid Keller 1994 Food 
1520 Carotenoid Larrson 1974 Blood plasma 
1522 Carotenoid Feld 1995 Carotid artery 
1523 Carotenoid Redd 1993 Human breast tissue 
Renal cell carcinoma 
1523 
E.8 C
a
Redd 1993a Normal human breast 
tissue 
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1524 Carotenoid Mizuno 1994 Human brain tissue, 
acoustic neuroma 
1525 Carotenoid Redd 1993a Beta carotene 
1525 Carotenoid Redd 1993a TS Human breast carcinoma 
1525 Carotenoid Redd 1993a Human breast carcinoma 
1528 Carotenoid Manoharan 1994 Carotenoids in normal 
colon 
1529 Carotenoid Redd 1993b Carotenoids in normal 
colon 
1540 Amide II Sajid 1997 Bovine insulin 
1541 Tyrosine Siebinga 1992  
1547 Tryptophan Nie 1990 Human eye lens 
1550 Tryptophan Hartman 1973  
1552 (NH), (CN) Amide II Barry 1992 Human strateum corneum 
1553 Tryptophan Mahadevan-Jansen 1998  
1554  Frank 1994b Type I collagen (human 
placenta) & infiltrating 
ductal carcinoma (breast) 
1555 Tryptophan Manoharan 1995 DNA in water 
1556 Tryptophan Fredericks  1995 Bovine Serum albumin 
1570 Vibration of purine 
bases (adenine & 
guanine) 
Mahadevan-Jansen 1996 DNA 
1570 nucleotides Schrader 1995 Breast cancer in mouse 
1575 Guanine, adenine 
tryptophan 
Hartman 1973  
1576 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1577 Guanine, adenine Puppels 1991  
1580 nucleotides Schrader 1995 Breast cancer in mouse 
1580 DNA Yazdi 1999 Cultured breast cells 
1580  Utzinger 2001 Cervix 
1585 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1585 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1585 υ(C-O) olefinic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1585 (C=C) olefinic Barry 1992 Human strateum corneum 
1593 Purine bases Manoharan 1995 DNA in water 
1600  Hartman 1973  
272 
 
1602 Phenylalanine Siebinga 1992  
1602 Tyrosine Manoharan 1995 Tyrosine, colon 
adenocarcinoma 
1606 Phenylalanine Fredericks  1995 Bovine Serum albumin 
1607 Phenylalanine in bovine 
albumin 
Kendall C Sigma Aldrich A2153 
1610 Tyrosine Boustany 1999 Colon mucosa 
1610 Tyrosine Spiro 1987 Protein bands 
1612 C=C stretching Manoharan 1995 Benzene 
 
1616 Tyrosine Fredericks 1995 Bovine Serum albumin 
1617 Tyrosine, phenylalanine Puppels 1991  
1620 Tryptophan, tyrosine, 
phenylalanine, uracil 
Hartman 1973  
1620 Tryptophan Boustany 1999 Colon mucosa 
1620 Tryptophan Spiro 1987 Protein bands 
1622 Tryptophan Manoharan 1995 DNA in water 
1637 Amide I (C=O) Frank 1994a Diseased breast tissue 
1637 Amide I (C=O) Frank 1994a Collagen 
1640 OH bending Erckens 1997 Water 
1642 Amide I (C=O) Mahadevan-Jansen 1998 Collagen 
1648-1661 Amide I (C=O) Mahadevan-Jansen 1998 Histones 
1645 Bending mode  Water 
1645 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
lysine 
1645-1660 Amide I (C=O stretch) Carey 1982 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Carey 1982 -sheet protein secondary 
structure 
1660-1670 Amide I (C=O stretch) Carey 1982 Unordered protein 
secondary structure 
1645-1655 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Miura 1995 -sheet protein secondary 
structure 
1655-1665 Amide I (C=O stretch) Miura 1995 Unordered protein 
secondary structure 
1654-1662 Amide I (C=O stretch) 
-helix 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Mahadevan-Jansen 1998 -sheet protein secondary 
structure 
1654-1685 Amide I (C=O stretch) Mahadevan-Jansen 1998 Unordered protein 
secondary structure 
1650 Amide I Baraga 1992a Normal human aorta 
1650 lipid Boustany 1999 Colon mucosa 
1650 Pyrimidine bases Manoharan 1995 DNA in water 
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(cytidine, thymidine) ? 
1650 C=C lipid bands Boustany 1999 Colon 
1650 Amide I (C=O) 
 
Sajid 1997 Bovine insulin 
1650  Wang 1993 Ascorbate 
1650  Erckens 1997 Rabbit aqueous humour 
1650 Amide I (C=O stretch) 
(C=O) 
Brennan 1994 Human artery 
1650-1666 C=C vibration cis-
isomer in fatty acid 
chain 
Mahadevan-Jansen 1998 Phospholipid membrane 
1651 Amide I, (C=O) Alfano 1991 Benign breast tissue and 
malignant tumours 
1651-1664 Amide I, (C=O) Carter 1998 Healthy human skin 
1651 Amide I, (C=O) in 
collagen 
Kendall C Sigma Aldrich C7774 
1651 Amide I, (C=O stretch) Liu CH 1992a Ovarian cancer 
1651-4 υ(C-O) Amide I, α helix Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1652 Lipid Redd 1993a Zhe Chuan 
Feng, Kwok to Yue, 
Gansler TS 
Lipid (TPE) 
1652 Lipid Redd 1993 Human breast tissue 
1652 Amide I Miura 1995 -helix protein secondary 
structure in α-Poly-L-
glutamate 
1652 (C=O) Amide I -helix Barry 1992 Human strateum corneum 
1653 Lipid Redd 1993 Human breast tissue 
Human colon 
1653 
E.9 L
i
p
i
d 
Redd 1993a Normal human breast 
tissue 
1653 Amide I protein Mizuno 1994  
1653 Amide I (C=O stretch) 
in bovine albumin 
Kendall C Sigma Aldrich A2153 
1654 -helix Schrader 1995 nails 
1654 C=C stretch Olefinic McCreery 1994 Breast biopsy tissue 
1654 C=C stretch Frank 1994a Breast tissue 
1654 Amide I Frank 1995 Normal breast tissue 
1654 C=C stretch Frank 1994b Breast 
1655 C=C stretch of 
unsaturated fatty acid 
chains 
Baraga 1992b Aorta 
1655 Amide I Frank 1995 Oleic acid methyl ester 
1655 Amide I protein (C=O 
stretch) 
Keller 1994 Coronary Artery 
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1655 Amide I (C=O stretch) Frank 1994a Lymph node 
1655 Amide I (C=O stretch) Liu 1992a Endometrial cancer 
1655 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
alanine 
1656 Amide I (C=O stretch) Mahadevan Jansen 
1998a 
Collagen 
1656 Amide I (C=O stretch) Mahadevan Jansen 1996 Human cervix 
1656 Amide I (C=O stretch) Mahadevan Jansen 1995  
1656  Utzinger 2001 Cervix 
1656 Amide I (C=O stretch) Liu 1992a Benign or normal 
endometrium 
1656 Amide I (C=O stretch) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
glutamate pH 11 
1657 Amide I (C=O stretch) Liu 1992a Cervical cancer 
1657 Lipids – fatty acids Manoharan 1998 Breast 
1657 Lipids Manoharan 1995 Colon 
1657 Amide I (C=O stretch) Feld 1995 Malignant breast tissue 
1657 Amide I Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1657 Amide I (C=O stretch) Frank 1994a Diseased breast tissue 
1658 Amide I (C=O stretch) Ozaki 1992  
1658 Amide I Baraga 1992b Aorta 
1659 Amide I, (C=O) Alfano 1991 Benign breast tumours 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal ovary 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal cervix 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal uterus 
1659 Amide I (C=O stretch) Liu CH 1992a Uterus cancer 
1659 Amide I (C=O stretch) ά 
helical 
Mizuno 1994 Human brain tissue 
1659 Amide I (C=O stretch) Fredericks 1995 Bovine Serum albumin 
1659 Amide I (C=O stretch) Greve 1996  
1661 Amide I (C=O) in 
elastin 
Kendall C Sigma Aldrich E1625 
1661 Amide I (C=O) Gniakeda 1997 Normal human skin 
1662 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1662 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1662 Nucleic acids Manoharan 1996 Colon 
1664 Amide I (C=O stretch) Carter 1998 Healthy human skin 
1664  Lieber 2000 Ovary 
1665 Amide I (C=O stretch) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
lysine pH 4 
1665 Amide I (C=O stretch) Frank 1994a Collagen 
1665 Amide I Frank 1995 Type I collagen (human 
placenta) 
1665 Amide I (C=O stretch) Keller 1994 Liver - collagen 
1665 Carbonyl vibration 
mode 
Feld 1995 Fibrous atherosclerotic 
plaque 
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1666 C=O stretching modes 
of pyrimidine bases 
Sajid 1997 DNA 
1667 Structural protein Manoharan 1998 Malignant breast 
1668 Amide I (C=O stretch) Mahadevan-Jansen 1998 Elastin 
1669 Amide I (C=O stretch) Nie 1990 Human eye lens 
1669 Protein Schrader 1995 Breast cancer in mouse 
1669 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-alanine 
1669 Amide I (C=O stretch) Rava 1991 Normal aorta 
1670-1680 C=C vibration trans-
isomer in fatty acid 
chain 
Mahadevan-Jansen 1998 Phospholipid membrane 
1670 Amide I Nie 1990 Chicken leg bone 
1670 Amide I (C=O stretch) Mahadevan-Jansen 1998 Pure protein - β pleated 
sheet 
1670 Amide I (C=O stretch) Mahadevan-Jansen 1998 Collagen 
1670 Amide I (C=O stretch) Frank 1994a  
1670 Amide I (C=O stretch) Erckens 1997 Rabbit lens 
1670 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-lysine 
1672 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-glutamate 
1683 Amide I (C=O stretch) Mahadevan-Jansen 1998 Bound protein - regular 
uncharacterised secondary 
structure 
1717 C=O stretching modes 
of purine bases 
Sajid 1997 DNA 
1725  Wang 1993 Lactate 
1725 C=0 Cassanas 1991 Lactic acid 
1726 Lactate Goetz 1995  
1736 ester stretching mode 
C=O 
Sajid 1997 DMPC 
(dimyristoylphosphatidych
oline), a typical lipid 
1740 (C=O) -lipid Keller 1994 Food, coronary artery 
1743  Frank 1995 Oleic acid methyl ester, 
normal human breast tissue 
1743 C=O stretch Frank 1994a Breast tissue 
1743 C=O stretch Frank 1994b Breast 
1743 (C=O) lipid Barry 1992 Human strateum corneum 
1747 C=0 stretch Baraga 1992b Aorta 
1750 C=O Fendel 1988 Normal skin dermis 
1752 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1768 (COO) Barry 1992 Human strateum corneum 
2579 S-H stretch Erckens 1997 Rabbit lens 
2700-2880 Collagen C-H stretch Wentrup-Byrne 1997a Dentine 
2717-23 υ(CH) aliphatic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
2723 (CH) aliphatic Barry 1992 Human strateum corneum 
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2730  Frank 1994b Breast 
2800-3000 CH stretch – lipids Carter 1998 Healthy human skin 
2850-2960 CH3, CH2 stretching in 
alkyl/ acyl chains 
Sajid 1997 DMPC 
(dimyristoylphosphatidych
oline), a typical lipid 
2850 s(C-H) in (Ethylene 
CH2=CH2) 
Mahadevan-Jansen 1998 Phospholipid membrane 
(constant with 
temperature) 
2850 C-H stretching vibration Fendel 1988 Normal skin dermis 
2852 υ(CH2) symmetric Edwards 1995 Strateum corneum 
2852 s(CH2) in lipids & 
proteins 
Gniakeda 1997 Normal human skin 
2852 s(CH3) - lipid Carter 1998 Healthy human skin 
2852 (CH2) symm Barry 1992 Human strateum corneum 
2857 C-H stretch (-CH3 sym.) Frank 1994a Breast tissue 
2857 C-H stretch (-CH2 sym.) Frank 1994b Breast 
2872 υ(CH2) asymmetric Edwards 1995 Callus, psoriatic plaque 
2875 C-H stretch (-CH3 
asym.) 
Frank 1994a Breast tissue 
2875 C-H stretch (-CH2 
asym.) 
Frank 1994b Breast 
2880 as(C-H) Mahadevan-Jansen 1998 Phospholipid membrane 
2880 C-H stretch Nie 1990 Human tooth enamel 
2882 C-H stretch Nie 1990 Chicken leg bone 
2883 υ(CH2) asymmetric Edwards 1995 Strateum corneum 
2883 (CH2) sym.- lipid Carter 1998 Healthy human skin 
2883 (CH2) symm, (CH2) 
asymm 
Barry 1992 Human strateum corneum 
2885 CH3 stretch Erckens 1997 Lactate 
2886 C-H stretching vibration Fendel 1988 Normal skin dermis 
2898 C-H stretch (-CH3 sym.) Frank 1994b Breast 
2890 as(C-H) in (Ethylene 
CH2=CH2) 
Mahadevan-Jansen 1998 Phospholipid membrane 
 
2890 CH2 symmetric stretch Wicksted 1995 Glucose 
2890 CH2 stretch Erckens 1997 Rabbit & human cornea 
2890 CH2 stretch Erckens 1997 Glucose 
2890 CH stretch Erckens 1997 Rabbit & human aqueous 
humour 
2893 Glucose & lactate Wicksted 1995 Rabbit aqueous humour 
2894-5 Lactate & glucose Goetz 1995  
2898 C-H stretch (-CH3 sym.) Frank 1994a Breast tissue 
2918 C-H stretch Nie 1990 Chicken leg bone 
2929 C-H stretch (-CH3 sym.) Frank 1994a Breast tissue 
2929 C-H stretch (-CH3 sym.) Frank 1994b Breast 
2930 (CH2) – lipid Keller 1994 Coronary Artery 
2931 υ(CH3) symmetric Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
2931 (CH3) symm, (CH2) 
asymm 
Barry 1992 Human strateum corneum 
2932 C-H stretch Nie 1990 Human tooth enamel 
2935 (CH2) sym.- lipid Carter 1998 Healthy human skin 
2935 C-H stretch Erckens 1997 Rabbit lens 
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2939 Glucose & lactate Wicksted 1995 Rabbit aqueous humour 
2942 C-H Hartman 1973  
2942 as(CH3) – lipids and 
proteins 
Gniakeda 1997 Normal human skin 
2943 Glucose Goetz 1995  
2945 CH stretch Erckens 1997 Rabbit & human cornea 
2945 CH3 stretch Erckens 1997 Lactate 
2945 CH stretch Erckens 1997 Rabbit & human aqueous 
humour 
2945 Lactate Goetz 1995  
2950 CH2 anti-symmetric 
stretch 
Wicksted 1995 Glucose 
2950 CH2 stretch Erckens 1997 Glucose 
2958 (CH3) asymm Barry 1992 Human strateum corneum 
2960 C-H stretch (-CH3 
asym.) 
Frank 1994a Breast tissue 
2960 C-H stretch (-CH3 
asym.) 
Frank 1994b Breast 
2975 C-H stretch Hartman 1973  
2982 Glucose & lactate Wicksted 1995 Rabbit aqueous humour 
2983 υ(CH3) symmetric Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
2990 CH3 stretch Erckens 1997 Lactate 
2995 Lactate Goetz 1995  
3006 =C-H stretch Frank 1994a Breast tissue 
3006 C-H stretch Frank 1994b Breast 
3059-60 υ(CH) olefinic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
3060 (CH) olefinic Barry 1992 Human strateum corneum 
3063 C-H stretch Erckens 1997 Rabbit lens 
3245 OH Cassanas 1991 Methyl lactate 
3390 OH mode Erckens 1997 Rabbit lens 
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Appendix F: Glossary of Terms. 
Adenocarcinoma – Malignant tumour derived from glandular epithelial tissue. 
Adenomatous polyps – Benign tumour derived from glandular epithelial tissue. 
Aetiological factors – Factors causing or contributing to the cause of a disease or 
condition. 
Afferent - Conducting inward and in a medical context usually towards an organ, the 
opposite of efferent. 
Age standardisation– This makes allowances for the difference in the age structure of 
a population over time and between sexes. 
Allogenic - Involving, derived from, or being individuals of the same species that are 
sufficiently unlike genetically to interact antigenically. 
Angiogenesis - The formation and differentiation of blood vessels. 
Antigens - Any substance foreign to the body that evokes an immune response either 
alone or after forming a complex with a larger molecule such as a protein and that is 
capable of binding with a product of the immune response such as an antibody or T cell. 
Antioncogene – A type of tumour suppressor gene 
Anti-Stokes scattering - Radiation scattered with a frequency higher than the incident 
radiation beam and accompanied by a loss of vibrational energy by the molecule. 
Apoptosis - A form of programmed cell death in which a sequence of events leads to 
the elimination of cells without the release of harmful substances into the surrounding 
area. 
Attenuation – A decrease in the pathogenicity or vitality of a microorganism or in the 
severity of a disease. 
Autoimmune disorder – A disease caused by antibodies or T cells that attack 
molecules, cells, or tissues of the organism producing them. 
Autologous - Derived from the same individual. 
Barrett’s oesophagus – A disease diagnosed from biopsy and found in the distal 
oesophagus where intestinal metaplasia has occurred and the normal stratified 
squamous mucosa is replaced by columnar epithelial cells containing goblet cells. It is 
associated with an increased risk of developing adenocarcinoma. 
Benign - Of a mild type or character that does not threaten health or life, opposite of 
malignant. 
Carcinogens - A substance or agent causing cancer. 
Carcinoma - Malignant tumour derived from epithelial tissue 
Case-controlled study – A study which identifies and compares patients who have the 
outcome of interest (cases) and control patients who do not have the same outcome. In 
order that an assessment can be achieved as to whether the cases had an exposure of 
interest such as an environmental, behavioural factor or exposure to a drug or some 
other therapeutic intervention. 
Caudal - Situated in or directed toward the hind part of the body. 
Cell-mediated immune response - The immune response that is mediated primarily by 
T cells and especially cytotoxic T cells rather than by antibodies secreted by B cells. 
Centrosymmetric – Molecules where a reflection of any point through the centre of the 
molecule produces an identical configuration e.g. ethene (C2 H4). 
Cerebral oedema - An abnormal or excessive accumulation of serous fluid in the 
connective tissue of the brain. 
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Chemotherapy - The use of chemical agents in the treatment or control of disease. 
Clinical stage – The degree to which a disease has progressed as determined by clinical 
examination and non-surgical investigations. 
Cohort - A group of individuals having a statistical factor such as age or risk in 
common. 
Confocal – With the same foci 
Contrast enhancement - A technique by which the degree of differentiation between 
different structures as seen in certain diagnostic imaging techniques can be improved by 
the administration of a contrast agent. 
Cranial - Of or relating to the skull or cranium. 
Cryogenetics - The study of specific chromosomal translocations. 
Cytology - A branch of biology dealing with the structure, function, multiplication, 
pathology, and life history of cells. 
Cytotoxic - Toxic to cells. 
Dark current - The current produced by emission from components of the system 
itself. 
Differentiation - The sum of the developmental processes whereby apparently 
unspecialized cells, tissues, and structures attain their adult form and function. 
Dipole moment – This is the measure of the polarity of a covalent bond. 
Distal - Situated away from the point of attachment or origin or a central point.  
Ploidy - The degree of repetition of the basic number of chromosomes. 
Dysplasia – An abnormal growth or development as of organs or cells leading to an 
unequivocal neoplastic change which has the potential to further progress towards 
malignancy. 
Efferent - Conducting outward and in a medical context usually from an organ, the 
opposite of afferent. 
Electromagnetic field – This is defined as a physical field produced by electrically 
charged objects. 
Endogenous - Caused by factors within the body or arising from internal structural or 
functional causes, opposite of exogenous. 
Exogenous - Caused by factors outside the body, opposite of endogenous. 
Exophytic - Tending to grow outward beyond the surface epithelium from which it 
originates. 
Extralymphatic deposits - Lymphoma arising outside the main lympho-reticular 
system. 
Fcrit - The value over which a PC score represents true variance within a dataset. 
Fibroelastic - Consisting of both fibrous and elastic elements. 
Fibromuscular - Consisting of both fibrous and muscular elements. 
Field - The area of tissue over which these differing modalities can be practically 
applied and divided into wide field and point or narrow field. 
Fluorescence – This is an optical phenomenon in which molecular absorption of a 
photon of energy triggers the emission of a further photon which pocesses a longer 
wavelength. 
Fluorophores - Molecular species that fluoresce. 
Formalin fixed - Tissue sections preserved for histological assessment by the 
application of formalin. 
Frozen sections – Tissue section acquired by the use of a freezing microtome, avoiding 
the use of chemical agents in their preparation. 
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GASER scale – A scale used to define the depth of field of a laser. 
Genotype - All or part of the genetic constitution of an individual or group. 
Glioblastoma - A malignancy of the central nervous system derived from astrocyte 
cells. 
Glioma – A benign tumour arising from glial cells. 
Gold standard - The standard with which other tests or procedures are compared. 
Grade - The degree of severity of a disease or abnormal condition. 
Haematoxylin and Eosin (H&E) – Stains used in the histological processing of frozen 
and formalin fixed tissue for pathological analysis. 
Heterogeneous - Derived from another species or from another individual. 
Heterozygous - Having two genes at corresponding loci on homologous chromosomes 
different for one or more loci. 
Histopathology - A branch of pathology that deals with the minute structure of diseased 
tissue as discernible with the microscope. 
Humoral immune response - Part of the immune response that involves antibodies 
secreted by B cells and circulating in bodily fluids. 
Hyperkeratosis – A thickening of the strateum corneum. 
Hyperplasia - An abnormal or unusual increase in the elements composing a part of a 
tissue e.g. cells. 
Immunoassay - A technique or test used to detect the presence or quantity of a 
substance, such as a protein, which is based on its capacity to act as an antigen or 
antibody. 
Immunocompromised - Having an impaired or weakened immune system. 
Immunoglobulin – An antibody. 
Immunophenotype - The immunochemical and immunohistological characteristics of a 
cell or group of cells. 
Immunosuppression - Suppression of the natural immune responses for example by 
disease or drugs. 
Incidence – The rate of occurrence of new cases of a particular disease in a population 
being studied over a period of time. 
Inclusion bodies - Cytoplasmic or nuclear aggregates of stainable substances usually 
proteins. 
Inelastic scattering - When monochromatic radiation passes through a substance it can 
be scattered or absorbed. Most of the scattered light is elastically scattered with the 
same frequency as that of the incident light, but a small proportion of the incident light 
is inelastically scattered with the difference in energy changing the vibrational state of 
the molecule probed. Inelastic scattering is the process measured in Raman 
spectroscopy. 
Inter-observer error - The differences in interpretation by two or more individuals 
making observations of the same phenomenon. 
Ischaemia – A lack of supply of blood to a body part due to obstruction of the inflow of 
arterial blood. 
Laparotomy – A surgical technique for opening the abdominal cavity. 
Low-grade / high-grade – Terminology used to classify NHLs on the natural history of 
the diseases. 
Lycopenes – A red pigment that occurs in many fruits e.g. tomatoes. 
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Macrophages - A cell of the immune system which may be fixed or freely motile, is 
derived from a monocyte, functions in the destruction of foreign antigens, and serves as 
an antigen-presenting cell. Macrophages can also be called phagocytes. 
Meningeoma - A slow-growing, benign, encapsulated tumour arising from the 
meninges.  
Metaplasia - Abnormal replacement of cells of one type by cells of another. 
Metastatic – Spread of a cancer beyond the confines of the organ or tissue from which 
it is primarily derived. 
Modifier – A compound that acts by breaking down the surface glycoprotein layer of a 
tissue resulting in a change in the refractive index of the tissue. 
Molar concentration - This is the measure of concentration of a solute in a solution of 
a given volume and is also called molarity. 
Morbidity - The incidence of a disease in a specific population. 
Morphological - Relating to or concerned with form or structure. 
Mortality - The number of deaths in a given time or place.  
Mutagenic - A substance capable of inducing genetic mutation. 
Nasendoscopy - An endoscopic technique for examination of the pharynx and larynx. 
Neoplasia - The process of abnormal and uncontrolled growth of cell, the product of 
which is a neoplasm (a tumour). 
Normalisation - The process of removing statistical error in repeated measured data.  
Numerical aperture - This is a way of describing the collection angle of a lens and is 
related to the refractive index of the material surrounding the lens and the maximum 
angle of collection from the optical axis of the lens. 
Objective - This is the lens that receives and focuses the first light rays from the object 
being observed. 
Otolaryngology - A medical specialty concerned especially with the ear, nose, and 
throat. 
Peltier cooling – A form of thermoelectric cooling using the Peltier effect where by a 
heat pump transfers heat from one side of a device to the other side against the 
temperature gradient. 
Peyer’s patches - Isolated lymphoid follicle found in the ileum. 
Phagocytosis - The process of engulfing and usually destruction of particulate matter 
by phagocyte cells. This process is a vital bodily defence mechanism against infection 
by microorganisms and against occlusion of mucous surfaces or tissues by foreign 
particles and tissue debris.  
Phonons – These are quantised modes of vibration occurring in crystal lattices. 
Photobleaching - The photochemical destruction of a fluorophore. 
Polarisability - This is the relative tendency of a charge distribution to be distorted 
from its normal shape by the presence of an external electric field, e.g. a nearby ion or 
dipole. 
Polymorphism - The existence of a gene in several allelic forms. 
Prevalence - The number of cases of a disease or condition affecting a specific 
population at a given time. 
Pro-carcinogen - The precursor to a carcinogen. 
Prognosis - The prospect of survival and recovery from a disease as anticipated from 
the usual course of that disease or indicated by certain special features. 
Prophylactic – To guard or prevent the spread or occurrence of disease or infection. 
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Pseudostratified - Relating to or being an epithelial surface consisting of closely 
packed cells which appear to be arranged in layers but all of which are in fact attached 
to the basement membrane. 
Raman spectroscopy - An inelastic scattering technique, which exploits the frequency 
shift that occurs in incident light due to the excitation of vibrational and rotational states 
in illuminated molecules. 
Resonance - The tendency of a system to oscillate at maximum amplitude at a certain 
frequency. 
Salvage surgery – Surgery undertaken after failed treatment by a different treatment 
modality. 
Schwannoma – A tumour arising from the myelin sheaths surrounding nerve cells. 
Sensitivity - The proportion of individuals with the disease that are correctly classified 
as having the disease. 
Sessile – Attached directly by a broad base. 
Signal-to-noise ratio – This is the ratio of a signal power to the noise power corrupting 
the signal. 
Sjögren’s disease – An autoimmune disorder affecting the parotid salivary gland. 
Specificity - The proportion of individuals without the disease that are correctly 
classified as not having disease. 
Spectral resolution – A measure of the power to resolve individual feature within a 
spectrum. 
Specular reflection - The perfect reflection of light from a surface. 
Squamous - A stratified epithelium that consists at least in its outer layers of small cells 
arranged in layers. 
Staging - A process by which cancers are divided into groups which behave in a similar 
ways. 
Standard deviation – The standard deviation of a population of values is a measure of 
the spread of its values and is defined as the square root of the variance. 
Stokes scattering - Radiation scattered with a frequency lower than the incident beam 
and accompanied by a gain of vibrational energy by the molecule.  
Stratified - Arranged in layers, especially relating to an epithelium surface. 
Surgical sieve – A form of disease classification relating to pathological processes e.g. 
infective, inflammatory, neoplastic. 
Synergistic - Having the capacity to act together in a way that is greater than the sum of 
the individual processes involved.  
Transcutaneous - Passing, entering, or made by penetration through the skin. 
Tri modal spectroscopy - The combination of three spectroscopic techniques; Raman 
spectroscopy, autofluorescence and elastic scattering. 
Tumour - An abnormal benign or malignant new growth of tissue that possesses no 
physiological function and arises from uncontrolled usually rapid cellular proliferation. 
Variance – The variance of a random variable or probability distribution is a measure 
of its statistical dispersion and comprises of the averaging of the squared distance of its 
possible values from the expected value. The square root of variance is the standard 
deviation. 
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Appendix G: Nomenclature 
α  polarisability 
A  Absorbance 
AC  adenocarcinoma 
AFE   Autofluorescence endoscopy 
AFE  autofluorescence endoscopy 
AFS  autofluorescence spectroscopy 
AIDS  Acquired Immunodeficiency Syndrome 
AJCC   American Joint Committee on Cancer  
ANOVA  
APCs  antigen-presenting cells 
ATLL  adult T cell leukaemia and lymphoma  
b  cell length (cm) 
BAO-H&N  British Association of Otorhinolaryngologists-Head & Neck Surgeons 
BSA  bleomycin sensitivity assay 
C  Celsius 
c  speed of light (3x10
8
ms
-1
) 
C.B.E 
CaF2  calcium fluoride 
CARS  coherent anti-Stokes Raman spectroscopy 
CCD  charge coupled device 
CCND1 cyclin D1 gene 
CEA  carcino-embryonic antigen 
CO2  carbon dioxide 
CS  clinical stage 
CSF  cerebro-spinal fluid 
CT  computed tomography scanning 
CTVE  computer tomography virtual endoscopy 
Cu (II)  copper 
CW  continuous wave 
DNA  deoxyribose nucleic acid 
∆Ε   Change in vibrational or rotational energy of a molecule 
EBV  Epstein-Barr virus 
ENT  ear, nose and throat 
Eout / Ein  energy of the emitted and incident radiation 
ε  molar absorbtivity (Lmol-1cm-1) 
ESR   erythrocyte sedimentation rate 
C2H4  ethene 
Ev   energy of molecule in a particular vibrational state 
Evib   energy absorbed or emitted in order to alter the vibrational state 
F  force (N) 
FBC  full blood count 
FE  fluorescence endoscopy 
FNAC  fine needle aspiration cytology 
FT-IR   Fourier transform infrared spectroscopy 
FTRS  Fourier transform Raman spectroscopy 
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GMC  General Medical Council 
GNHST Gloucestershire NHS Trust 
GORD  gastro-oesophageal reflux disease 
GP  General Practitioner 
h  Planck‘s constant (6.626 x 10 -34 Js or 4.136 x 10-15 eVs) 
H&E  haematoxylin and eosin 
He-Ne  Helium-Neon 
HIV   human immunodeficiency virus 
HL  Hodgkin‘s lymphoma 
HNSCC head and neck squamous cell carcinoma  
H2O  water 
HpD   haematoporphyrin derivative 
HPV  human papilloma virus 
HRS  hyper-Raman spectroscopy 
HTLV-1 human T cell leukaemia virus 1  
IACS  Indian Association for the Cultivation of Science 
InGaAs  indium-gallium-arsenide 
IR  infrared 
K  Boltzmann constant 
K  spring constant (Nm
-1
) 
λ  wavelength 
LD  lymphocyte depleted 
LDA  linear discriminant analysis 
LDH  lactate dehydrogenase 
LIF  laser-induced fluorescence spectroscopy 
LOH   loss of heterozygosity 
LOO  leave one out (cross-validation technique) 
LP  lymphocyte-predominant 
LR  lymphocyte rich 
LSS  light scattering spectroscopy 
MPE  maximum permissible exposure 
MC  mixed cellularity 
MRI  magnetic resonance imaging 
N  Newton 
NADH 
NBI  narrow band imaging 
Nd:YAG neodymium-yttrium-aluminium-garnet laser  
NHL  non-Hodgkin‘s lymphoma 
NHS  National Health Service 
NIR  near-infrared 
NO  nitric oxide 
Non-VC Non vocal cord tissue 
No  numbers of molecules in the ground state 
NS  nodular-sclerosing 
Nv  numbers of molecules in an excited vibrational state 
O2  oxygen 
OCT  optical coherence tomography 
8-oxo-dG  8-oxo-deoxyguanosine 
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PS  pathological stage 
PC  principle component 
PCA  principle component analysis 
PET  positron emission tomography 
pH  The measure of acidity or alkalinity of a solution. 
PM  photomultiplier tubes 
PPIX   5-ALA-induced protoporphyrin IX 
REAL  Revised European American Lymphoma classification 
RNA  ribose nucleic acid 
RS  Raman spectroscopy 
SAC  Speciality Accreditation Committee 
SCC  squamous cell carcinoma 
SERRS surface enhanced resonance Raman spectroscopy 
SERS  surface enhanced Raman spectroscopy 
SNR  signal-to-noise ratio 
SPECT super-imposed dual isotope scanning 
T  absolute temperature 
T (%)  % Transmission 
T  Transmission 
TNM  tumour, node, metastasis 
TTV   transfusion transmitted virus 
UICC   Union Internationale Contre le Cancer 
UK  United Kingdom  
ULWD ultra-long-working-distance 
USA  United States of America 
USS  ultrasound scan 
UV  ultra-violet 
UV-Vis  ultraviolet-visible 
ν   frequency 
νout / νin  frequency of emitted and incident radiation 
νvib   frequency of energy absorbed or emitted in order to alter the vibrational 
state 
V  volt 
VC  vocal cord 
Vis  visible 
ώ  wavenumber (cm-1) 
WHA  World Health Assembly 
WHO  World Health Organization 
WLE  white light endoscopy 
Zn (II)  zinc 
286 
 
Appendix H: Ethical Approval 
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